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i
Abstract
Guidelines generally recommend the monitoring of serum electrolyte and creatinine
concentrations in patients treated with antihypertensive therapy in order to detect
potential adverse reactions to treatment. However, it is not well known to what extent
these guidelines are followed in primary care.
I undertook a retrospective analysis of 74096 adult patients from the General Practice
Research Database with newly diagnosed hypertension and prescribed a single
antihypertensive agent. Baseline biochemical testing was undertaken in 31 094
patients (42%) and 37 365 (50%) patients had at least one biochemical monitoring test
in the year after starting antihypertensive treatment. Monitoring was significantly
more likely in patients treated with angiotensin-converting enzyme inhibitors than
thiazide diuretics, older patients, and patients with diabetes mellitus. These patient
factors were significantly associated with monitoring when multiple imputation was
used to control for the potential bias introduced by missing data. In general, follow-up
monitoring was infrequent, irregular, and did not change in response to events such as
abnormal test results.
Patients who were monitored after the initiation of antihypertensive treatment were
significantly more likely to be admitted to hospital and discontinue therapy, which is
likely a result of reactive instead of planned monitoring. Using propensity score
methods to control for confounding, I demonstrated a decreased risk of these same
adverse outcomes in patients with baseline testing, which may be because these
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patients were less likely to have any follow-up monitoring and not the protective
effect of the baseline testing.
I described several barriers to biochemical monitoring including the lack of consensus
in published guidelines, uncertain responsibility for monitoring, patient non-
adherence, and absence of alerts or reminders to monitor. More work is needed to
improve the primary evidence base for monitoring and to improve the guidelines on
the nature and frequency of monitoring for adverse drug reactions, particularly in
patients at greater risk of drug-induced harm.
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Chapter 1
INTRODUCTION
This chapter provides a foundation for the work presented in the other chapters in this
thesis. I describe the nature of adverse drug reactions in general terms and in relation
to the use of antihypertensive therapy. I also introduce the concept of monitoring to
reduce the risk of harm due to adverse reactions to therapy. I present a summary of
the recommendations from published guidance on the monitoring of patients treated
with antihypertensive therapy for adverse drug reactions. Finally, I describe the
overall aims and objectives of the thesis.
1.1 Adverse drug reactions
Definition
An adverse drug reaction (ADR) has been defined by the World Health Organization
(WHO) as: ‘any response to a drug which is noxious, unintended and occurs at doses
used for prophylaxis, diagnosis, or therapy.’ ADRs can be divided into two types:
those reactions that are predictable and dose dependent (Type A) and those which are
unpredictable and unusual reactions (Type B). Type B reactions are less common but
can be more serious than type A reactions. This classification is simple and has been
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widely used but has also been criticized as it is sometimes difficult to assign an ADR
to only one type.
More recently, a three-dimensional classification system for the analysis of ADRs has
been suggested based on dose relatedness, timing, and patient susceptibility (DoTS)
(Aronson & Ferner, 2003). When such a classification system is used, the probability
of an ADR may vary depending on the time after drug administration, the dose of the
drug, and various patient susceptibility factors such as age, sex, genetic factors, and
exogenous factors.
Incidence of ADRs
Determining the incidence of ADRs is challenging due to several factors including:
(1) different definitions of an ADR; (2) different methods used to identify, evaluate
and document ADRs; and (3) different population groups. Several large systematic
reviews of ADRs have demonstrated that as few as 0.16% to as many as 15.7% of
hospital admissions are due to ADRs (Lazarou et al., 1998; Impicciatore et al., 2001;
Beijer & de Blaey, 2002; Wiffen et al., 2002; Davies et al., 2007; Kongkaew et al.,
2008). The incidence of fatal ADRs in patients admitted to hospital has been reported
as ranging from 0.05% to 0.44% (Pouyanne et al., 2000; Zoppi et al., 2000; Ebbesen
et al., 2001; Juntti-Patinen & Neuvonen, 2002; Mjorndal et al., 2002; Schneeweiss et
al., 2002). Although the range in the estimated incidence of ADRs does vary widely,
adverse reactions to therapeutic treatment remain a cause of significant morbidity and
mortality.
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The incidence of ADRs in the community is less well known, with fewer well-
designed studies. A small study of a single general practice demonstrated that 1.7% of
routine consultations or extra appointments were due to an ADR, the majority being
due to three common groups of drugs: antidepressants, antibiotics, and non-steroidal
anti-inflammatory drugs (Millar, 2001). Gurwitz and colleagues (2003) identified an
incidence of 50.1 adverse drug events per 1000 person-years in a group of adults in
ambulatory care, with almost a third (28%) deemed to have been ‘preventable’. A
study published in the same year reported that 25% of patients in the community had
an ADR (Gandhi et al., 2003). The incidence of fatal ADRs in a large population
study in Sweden was found to be 3%, which is higher than reported in hospital
(Wester et al., 2008).
ADRs in the UK
The largest prospective study of ADRs to be carried out in the UK determined that
6.5% of hospital admissions were related to ADRs, with the ADR directly leading to
the admission in 80% of cases (Pirmohamed et al., 2004). Almost three-quarters
(72%) of cases were classified as being preventable. The incidence of fatal ADRs in
hospitalized patients was 0.15%, similar to other reports. The impact of ADRs in the
NHS in England has been estimated to be 4 out of 100 hospital bed-days, at a cost of
about £380 million a year (Wiffen et al., 2002).
Risk factors for ADRs
ADRs tend to be more common in older adults, which may reflect the higher
prevalence of long-term disease and poly-pharmacy in this age group. Young children
are also at risk of ADRs, mainly because doses need to be calculated individually
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based on the patient’s age, weight or body surface area, and clinical condition (Wong
et al., 2004). In general, the risk of ADRs is greater in women (1.5–1.7 greater risk)
(Rademaker, 2001). ADRs may also be more common in patients with concomitant
renal, hepatic, and cardiac disease.
1.2 Adverse drug reactions associated with antihypertensive drugs
Antihypertensive drugs are used to treat patients with sustained elevation of systolic
or diastolic blood pressure. In the early 1990s there was a significant increase in the
use of newer agents such as angiotensin-converting enzyme (ACE) inhibitors and
angiotensin-II (AT-II) receptor antagonists (Psaty et al., 1995). However, thiazide
diuretics—usually considered to be more traditional agents—still remain the most
frequently used drug class (one in three patients) for the treatment of patients with
newly diagnosed hypertension (Walley et al., 2003). Indeed, thiazide diuretics, along
with calcium (Ca)-channel blockers are recommended as initial therapy in patients
aged 55 and over or in non-white patients of any age in the UK. In hypertensive
patients younger than 55, ACE inhibitors should be used as first-line therapy
(National Collaborating Centre for Chronic Conditions, 2006).
Antihypertensive drugs are generally well tolerated but are known to cause a range of
ADRs, particularly electrolyte disturbances such as hyperkalaemia, hypokalaemia,
and hyponatraemia (Olsen et al., 1999; Liamis et al., 2008a).
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1.2.1 Hyperkalaemia and antihypertensive drugs
Hyperkalaemia is a condition of excess potassium, which can lead to abnormal heart
rhythm, muscle spasm, cardiac arrest, and potentially death. Moderate hyperkalaemia
is defined as a serum potassium concentration greater than 5.5 mmol/l; severe
hyperkalaemia as a concentration greater than 6.0 mmol/l. The incidence of
hyperkalaemia in hospitalized patients varies from 1–10% depending on the definition
used (Liamis et al., 2008a).
ACE inhibitors are responsible for 10–38% of cases of hyperkalaemia in hospitalized
patients (Liamis et al., 2008a) and often cause hyperkalaemia by inducing a state of
hypoaldosteronism or by impairing renal potassium excretion (Rimmer et al., 1987).
The combination of ACE inhibitors with other potential potassium-altering
medications such as potassium-sparing diuretics can also increase the risk of
hyperkalaemia (Chiu et al., 1997; Saito et al., 2005). Hyperkalaemia is more likely to
occur in older patients, patients with impaired renal function or hypoaldosteronism,
and those with diabetes mellitus (Ramadan et al., 2005; Indermitte et al., 2007).
Potassium-sparing diuretics (e.g. amiloride, triamterene, and spironolactone) may
precipitate hyperkalaemia by diminishing potassium secretion and have been
associated with 4–19% of cases of moderate to severe hyperkalaemia (Perazella,
2000). Non-selective beta-adrenoceptor blocking drugs (beta-blockers) have also been
associated with hyperkalaemia, although the condition is rarely severe. Beta-blockers
may lead to hyperkalaemia through the suppression of catecholamine-stimulated renin
release, which decreases aldosterone synthesis; and by decreasing cellular uptake of
potassium (Perazella, 2000).
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1.2.2 Hypokalaemia and antihypertensive drugs
Hypokalaemia refers to an abnormally low serum potassium concentration and is
generally defined as a serum concentration less than 3.5 mmol/l. The most common
drug-related cause is diuretic therapy and the degree of hypokalaemia is greater with
higher doses of diuretics and increased dietary sodium intake (Gennari, 1998; Liamis
et al., 2008a).
The incidence and severity of hypokalaemia with low-dose thiazide diuretic therapy is
relatively low. One percent of patients in the large Systolic Hypertension in the
Elderly study had a serum potassium concentration less than 3.2 mmol/l (SHEP
Cooperative Research Group, 1991). Although rare, hypokalaemia can lead to
potentially dangerous cardiac arrhythmias and may also be associated with an
increased risk of cardiovascular events (Freis, 1995; Moser, 1998).
The relationship between diuretics and hypokalaemia is less well understood. The
risk is increased in patients with liver cirrhosis and in patients with severe cardiac
failure that is complicated by secondary hyperaldosteronism (Aronson, 2006). The
risk of hypokalaemia is greater in older patients, although this may reflect the
increased use of thiazide diuretics in this population group (Zuccalà et al., 2000).
Diuretic-induced hypokalaemia is usually seen in the first few weeks following
initiation of treatment (Siegel et al., 1992; Miltiadous et al., 2003).
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1.2.3 Hyponatraemia and antihypertensive drugs
Hyponatraemia is an ADR commonly associated with hospitalization and is identified
by an abnormally low serum sodium concentration. Definitions vary with some
researchers using a definition of less than 135 mmol/l, while others have used less
than or equal to 130 mmol/l. Early symptoms include nausea, headache, muscular
weakness and lethargy, and if untreated the condition can progress to seizures,
neurological damage, and death (Clayton et al., 2006a).
Diuretics are one of the most common drug classes associated with hyponatraemia
and the majority of cases are caused by thiazide diuretic or thiazide diuretic-like
agents (Spital, 1999; Chow et al., 2003; Clayton et al., 2006a; Liamis et al., 2008b).
Diuretic-induced hyponatraemia is more likely to occur in older women (Sharabi et
al., 2002), although this relationship may only reflect the high levels of diuretic
prescription in this demographic group. Cases of thiazide diuretic-induced
hyponatraemia have also been shown to develop most often within two weeks of
starting treatment (Spital, 1999; Aronson, 2006).
1.3 Monitoring patients for adverse drug reactions
Monitoring is a process of checking a system that changes with time, in order to guide
changes to the system that will maintain or improve it (Coleman et al., 2006).
Monitoring of drug treatment can have several effects including better selection of
drug therapy, better titration of treatment, and improved adherence (Glasziou et al.,
2005). Monitoring can also—perhaps most importantly—identify potential adverse
reactions to treatment. Failure to monitor renal function and electrolytes has been
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shown to be responsible for 26% of preventable drug-related hospital admissions
(Howard et al., 2003) and 36% of preventable adverse drug events in ambulatory care
(Thomsen et al., 2007).
Ideally, a test to monitor for an ADR should be safe, simple, accurate, and acceptable
to both patients and health care professionals (Pirmohamed & Ferner, 2003; Ferner et
al., 2005). The test should also be cost proportionate, in that the cost of testing should
not be greater than the cost savings associated with reducing the health burden of
adverse reactions to treatment.
If possible, monitoring instructions should provide details on:
1. The purpose of the monitoring;
2. The types of tests to be used;
3. When to start monitoring;
4. A satisfactory frequency of monitoring (although this may not necessarily be
constant);
5. An acceptable range of values;
6. Actions to be taken should the test identify a value outside of the stated
acceptable range;
7. When, if appropriate, it is safe for monitoring to cease.
Specific guidance on monitoring for ADRs available to health care professionals is
often limited. Guidelines exist from a wide variety of sources, such as publications
from government organizations, professional societies (e.g. British Hypertension
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Society), or independent researchers or research groups, but often vary in their quality
and level of detail on monitoring. Often, published guidelines do not provide clear
recommendations for the number of monitoring tests or guidance on the interpretation
of subsequent monitoring. Monitoring guidance sent to general practitioners (GPs)
when therapeutic treatment is initiated in hospital is often incomplete (Corry et al.,
2000).
Drug manufacturers also provide some information on monitoring for ADRs in the
Summary of Product Characteristics (SPC) for each drug. A SPC is presented in a
standardized format and serves as both a regulatory document and as a primary source
of information for health professionals (Waller & Evans, 2003). However, the latter
goal is often disadvantaged by the former, as the limitations placed on presentation
and the lack of flexibility imposed by the standardized format limit how information
is presented (Waller & Evans, 2003). Certainly, the information on monitoring for
ADRs in SPCs has been described as vague and inadequate in that it does not provide
enough information to carry out any monitoring or act on the results (Ferner et al.,
2005).
1.4 Monitoring guidelines for adverse reactions to drugs used in
the treatment of hypertension
Hypertension is one of the commonest conditions managed within primary care
(National Collaborating Centre for Chronic Conditions, 2006). Drugs used in the
treatment of hypertension are generally well tolerated but are known to cause a range
of ADRs (section 1.2). Specifically, renal failure can occur with ACE inhibitors, AT-
II receptor antagonists and diuretics. Hyperkalaemia is also a recognized adverse
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effect of ACE inhibitors, AT-II receptor antagonists and potassium-sparing diuretics
and hypokalaemia with thiazide and loop diuretics, which can also cause
hyponatraemia. Biochemical monitoring after the initiation of antihypertensive
therapy can consequently identify changes related to ADRs before they have caused
serious or permanent effects, and so avert them. Monitoring for ADRs that may not
necessarily manifest symptoms, such as in most cases of hypokalaemia (Gennari,
1998), is of significant importance.
In order to understand the nature of the published guidance on monitoring, I carried
out a purposeful, although not exhaustive, search to identify (1) guidelines written
with the purpose of describing the monitoring of patients treated with
antihypertensive therapy or (2) guidelines on the treatment of patients with
hypertension. In January 2010 I searched Medline using a combination of text and
MeSH terms for hypertension and drugs used in the treatment of hypertension,
limiting the results to the publication type ‘practice guideline’. I searched the National
Guideline Clearinghouse (www.guideline.gov) database using the search term
hypertension. I also searched the electronic Medicines Compendium
(http://www.medicines.org.uk/emc/), to identify monitoring recommendations listed
in SPCs for drugs licensed in the UK and used in the treatment of hypertension. I used
the following search terms to identify the recommendations: monitoring, renal
function, test or testing, creatinine, urea, potassium, sodium, or urea. I did not search
the SPCs of combination products, and all of the SPCs for a given drug were reviewed
when the drug was manufactured by multiple companies.
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I identified 23 publications that contained guidance on the monitoring of patients
treated with antihypertensive therapy, of which three were written especially for
patients with chronic kidney disease (Appendix 1). I also identified five well-cited
guidelines on the use of ACE inhibitors, AT-II receptor antagonists or spironolactone
in the treatment of heart failure. All of the guidelines provided information on what
serum concentration to monitor. I reviewed the SPCs for 58 different antihypertensive
drugs (Appendix 2).
The recommendations on the frequency of monitoring varied in their level of detail.
Some guidelines described monitoring as a ‘routine investigation’ or that laboratory
tests should be ‘measured annually’. Other guidelines were far more detailed with
recommendations for biochemical testing prior to the initiation of therapy, specific
details for the frequency of follow-up monitoring, and actions to be taken should the
laboratory tests be outside a certain range of concentrations (French Haute Autorité de
Santé, 2005; Northern Ireland Department of Health Social Services and Public
Safety, 2007; Smellie et al., 2007). The most detailed recommendations for
monitoring were provided in the guidelines for the treatment of hypertension in
patients with chronic kidney disease (National Kidney Foundation, 2002; Department
of Veterans Affairs/ Department of Defense, 2007; National Institute for Health and
Clinical Excellence, 2008). In addition to data on the frequency of monitoring and
when to stop treatment, these guidelines also provided information on how to tier the
frequency of monitoring based on the initial baseline serum concentration.
Most of the guidelines did not explicitly reference the primary evidence supporting
the recommendations, as has also been shown previously in an analysis of renal
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function monitoring guidelines in patients treated with ACE inhibitors (Coleman et
al., 2008). Indeed, monitoring guidelines for antihypertensive therapy have been
previously criticized: Sica (2006) described the guidelines for the monitoring of
serum potassium concentration in patients treated with antihypertensive drugs as ‘at
best makeshift and often drawn from the know-how of the treating physician’.
The monitoring recommendations made by the drug manufacturers in the SPCs were,
in general, rather vague and lacked detail. This is similar to the conclusions made by
Ferner and colleagues (2005), who concluded that the monitoring recommendations
for haematological reactions for non-oncological drugs were inadequate. Although
some SPCs specifically recommended monitoring in the first few weeks of treatment,
the majority were limited to statements describing ‘regular’ or ‘routine’ monitoring.
Some SPCs did suggest more vigilant monitoring in patients at increased risk of drug-
induced harm (e.g. patients with renal impairment, older patients, or patients with
diabetes mellitus). There was some additional detail on which drugs required
additional monitoring when used concomitantly with antihypertensive therapy due to
the increased risk of biochemical ADRs or renal impairment. No monitoring
recommendations were provided for alpha-blockers, beta-blockers, or calcium-
channel blockers.
The nature and detail of published guidelines and recommendations for monitoring
differs, which may be due to the lack of primary evidence. However, it is clear that a
general consensus exists: patients with newly diagnosed hypertension should have
baseline biochemical tests of renal function and electrolyte concentrations before
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treatment, monitored again after starting treatment, and at intervals following any
dose changes.
1.5 Aims and objectives of the thesis
Prior studies have demonstrated that monitoring of patients treated with
antihypertensive drugs for electrolyte disturbances is often not undertaken. Few
published studies have put their results into context with existing guidelines on
monitoring and even fewer have examined the relationships between monitoring and
patient outcomes.
The overall aim of this study is to understand the nature of monitoring for ADRs in a
population of patients newly diagnosed with hypertension and newly treated with
antihypertensive drugs using the General Practice Research Database (GPRD).
Specifically, the objectives of my research are:
1. To observe and clarify the patterns of monitoring for ADRs in patients treated
with antihypertensive drugs;
2. To determine relationships between the outcomes for patients, the patterns of
monitoring for ADRs, and other factors;
3. To compare the observed patterns of monitoring of patients after the initiation
of antihypertensive drugs for ADRs against published recommendations for
monitoring.
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1.6 Outline of the thesis
The use of the GPRD—a very large and well-validated database—will provide a large
number of patients and clinical data. This analysis will present information on the
monitoring of patients for ADRs in general practice. Patients who are newly treated
with antihypertensive drugs may be at greater risk of harm and ADRs, and will be
specifically examined. At present, this area is under-researched and the analysis will
provide important data with which to inform strategy for monitoring the safe use of
drugs in representative populations. The chapters of the thesis are as follows:
• Chapter 2 presents the results of a systematic review of studies examining
biochemical monitoring in patients treated with antihypertensive drugs;
• Chapter 3 introduces the GPRD and describes the development of the study
cohort;
• Chapter 4 describes the statistical methods used to analyze the nature of
biochemical laboratory monitoring, assessing the frequency, regularity, and
responsiveness of biochemical laboratory tests;
• Chapter 5 presents the results of the analyses described in Chapter 4;
• Chapter 6 examines the nature of biochemical monitoring and the frequency of
hyponatraemia in a sub-group of thiazide diuretic-treated patients;
• Chapter 7 describes the method of multiple imputation as a tool for dealing
with missing data and compares the results obtained using multiple imputed
data with those from a complete case analysis;
• Chapter 8 introduces propensity score methods for controlling for confounding
in observational research, which are used in addition to traditional methods to
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examine the relationship between baseline biochemical testing and adverse
patient outcomes;
• Chapter 9 describes the final conclusions and details future work.
16
Chapter 2
BIOCHEMICAL LABORATORY
MONITORING OF PATIENTS TREATED
WITH ANTIHYPERTENSIVE DRUGS: A
SYSTEMATIC REVIEW
This chapter presents the results of a systematic review of the nature of biochemical
laboratory monitoring in patients treated with antihypertensive therapy. I demonstrate
that previous research, primarily undertaken in the United States, has shown a lack of
biochemical monitoring in primary care. I discuss the strengths and weaknesses of
prior research and demonstrate the significant lack of research on the relationship
between monitoring and adverse patient outcomes.
2.1 Background and research questions
Biochemical monitoring of patients treated with antihypertensive therapy is
recommended by many guidelines (Appendix 1). Tests of serum creatinine and
electrolyte concentrations can identify adverse reactions to antihypertensive treatment
such as renal failure and hyponatraemia. However, it is not well known to what extent
these guidelines are followed in primary care. It is also unclear whether monitoring
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reduces the risk of adverse patient outcomes. Therefore I wished to identify and
summarize the literature investigating the nature of biochemical monitoring in adults
treated in primary care with antihypertensive drugs. This was undertaken by
addressing five research questions:
1. What is the proportion of patients with biochemical testing prior to the
initiation of antihypertensive therapy?
2. What is the proportion of patients with biochemical monitoring after initiation
of antihypertensive therapy?
3. What are the patient characteristics associated with biochemical monitoring?
4. What is the frequency of biochemical monitoring after the initiation of
antihypertensive therapy?
5. What is the relationship, if any, between biochemical monitoring and adverse
patient outcomes?
2.2 Selection criteria
Types of studies Randomized controlled trials or quasi-randomized
controlled trials investigating the impact of various
interventions on monitoring were included. The results
from the control arm of a randomized trial were used
when comparisons were made with other studies.
Retrospective and prospective cohort studies, cross-
sectional studies, and audits of current clinical practice
were also included. Clinical trials of drug therapy were
excluded because they do not accurately reflect
monitoring in a normal treatment setting. Case reports and
case series were also excluded.
Types of patients Male and female adults with hypertension treated with
antihypertensive therapy outside of the hospital or clinical
trial setting were included. No upper age limit was
applied.
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Types of biochemical
monitoring
The biochemical monitoring tests identified for inclusion
were tests of serum creatinine, urea, sodium, or potassium
concentration.
Types of outcome
measures
The primary outcome measure was
• The proportion of patients with any biochemical
testing prior to the start of treatment or follow-up
monitoring.
The secondary outcome measures were
• The frequency of tests (number of tests over a
period of time);
• Patient factors associated with biochemical testing
at baseline or follow-up monitoring;
• Any additional information reported on baseline
testing or biochemical monitoring.
2.3 Search strategy for the identification of studies
2.3.1 Electronic search
Two electronic databases—Medline and Embase—were searched using the OVID
interface to identify studies for potential inclusion. I used a combination of text words
and controlled vocabulary search terms for Medline (MeSH) and Embase (EMTREE)
(Appendix 3). The development of the search strategy was an iterative process where
an initial analysis of the relevant search terms was carried out. This was done in order
to identify superfluous or ineffective search terms and to create a search strategy that
was both sensitive and specific. The strategy was further tested by checking whether it
could identify relevant studies that had been previously identified. The search was
carried out with no language restrictions.
Once duplicates were removed from the combined databases, studies were selected
for inclusion based on the study title and abstract. When studies appeared to meet the
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inclusion criteria or where a decision could not be made based solely on title or
abstract, full-text copies were obtained.
Citation searching
Articles that cited or were cited by the included studies were also screened in order to
identify any further relevant studies. Additionally, reference lists from important
reviews were searched and personal files were examined in order to identify further
studies.
Identifying any unpublished literature
Google and Google Scholar were also searched in order to identify studies that had
not been published or had been published in journals not indexed by Medline or
Embase using a combination of search words:
(antihypertensive OR alpha adrenoceptor blocking OR alpha blockers OR
adrenoceptor blocking OR alpha blockers OR aldosterone antagonists OR
diuretics OR ACE inhibitors OR angiotensin converting enzyme inhibitors OR
angiotensin receptor blockers OR angiotensin II receptor antagonists OR
calcium channel blockers) AND (monitoring OR serum potassium OR serum
sodium OR serum creatinine OR serum urea OR potassium concentration OR
sodium concentration OR creatinine concentration OR urea concentration)
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2.3.2 Methods of the review
Data extraction was carried out using a standardized data extraction form (Appendix
4). A narrative summary was used to describe each study’s methods and key findings.
The primary outcome measure—the proportion of patients with any biochemical
testing or follow-up monitoring—was compared between the included studies. If data
were presented in a randomized trial examining the effect of various interventions on
monitoring, only data from the control group were extracted.
I set out a list of quality and methodological items to assess the studies identified by
the review. Using the Newcastle-Ottawa Quality Assessment Scale (NOS) (Wells et
al., 2010) and the Quality Assessment of Diagnostic Accuracy Studies tool (Whiting
et al., 2003) as guides, a list of five quality indicators was developed in order to
critically appraise the included studies. Seven additional methodological indicators
applicable to the understanding of the nature of biochemical monitoring were also
included in the appraisal process.
2.4 Results
In January 2010 I searched Medline (from 1948) and Embase (from 1980), without
any language restrictions, using a combination of medical subject headings and text
words. The initial search strategy retrieved 1223 studies. 91 studies were selected
based on their title and abstract and full-text copies were retrieved. Four studies were
identified through hand-searching (Hurley et al., 2005; Raebel et al., 2005; Feldstein
et al., 2006; Palen et al., 2006; Sauer et al., 2006; Matheny et al., 2008).
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Figure 2.1 – Flow chart of selection of studies into systematic review
Two studies that examined interventions for increasing laboratory monitoring were
excluded as they did not provide discrete data on patients treated solely with
Potentially relevant publications
N = 1223
Full-text copies retrieved for more
detailed assessment
N = 91
Publications satisfied inclusion criteria
N = 12
Publications satisfied inclusion criteria
N = 14
Publications excluded (N = 5)
2 – discrete data from patients
treated with antihypertensive
therapy not provided
3 – denominator presented was the
number of dispensed prescriptions
or patient visits and not the number
of treated patients
Publications identified through hand
searching
N = 7
Publications excluded (N = 79)
44 – review article mentioning
need for monitoring
27 – identification of an adverse
drug reaction and not monitoring
was the focus of the study
6 – small study of monitoring in the
clinical trial setting
1 – study of monitoring in other
drug class
1 – treatment for congestive heart
failure and not hypertension
Publications excluded based on title or
abstract
N = 1 132
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antihypertensive therapy (Steele et al., 2005; Feldstein et al., 2006). Three studies
were also later excluded as they presented only data on the proportion of dispensed
prescriptions or patient visits with biochemical monitoring, and not the proportion of
patients (Raebel et al., 2005; Palen et al., 2006; Matheny et al., 2008). Fourteen
studies were included in the final review (Figure 2.1). A detailed summary of the
studies selected for inclusion is provided in Appendix 5 and each study is considered
individually below. The excluded studies are described in Appendix 6.
2.4.1 Narrative review of included studies
An early cross-sectional study was carried out in a UK general practice of 330
patients treated with diuretics (Rhodes, 1992). Almost one quarter (23%) of patients
had no record of any monitoring of urea and electrolyte concentrations. 36 patients
(11%) had a record of urea and electrolyte monitoring prior to the initiation of diuretic
treatment but not subsequently.
A postal questionnaire of 277 British GPs was carried out to determine the proportion
of GPs who regularly monitored renal function in patients treated with ACE
inhibitors. 85% of the GPs reported that they checked renal function prior to initiation
of treatment, and fewer GPs (34%) monitored after treatment (Kalra et al., 1999). An
audit of the laboratory records from 122 patients in one GP practice by the same
authors revealed that GPs tended to overestimate how often they carried out any
monitoring: only 45% of patients had their renal function monitored before ACE
inhibitor treatment and 29% had any monitoring subsequent to treatment initiation.
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A large study of an Israeli computerized patient record system identified
approximately 35 000 patients who were treated with a diuretic (Hoch et al., 2003).
Almost 22% of patients did not have a record of a serum potassium concentration test
within one year of the start of treatment. This value decreased significantly to 18%
after the initiation of a computer alert sent to physicians indicating that a patient had
not had a monitoring test.
The large retrospective analysis of data from a US Health Maintenance Organization
(HMO) by Hurley and colleagues (2005) examined the rates of missed laboratory tests
in patients treated with ACE inhibitors and diuretics from 1999 to 2001.
Approximately a third of patients (35%) did not have any creatinine or potassium
monitoring within one year of starting treatment with an ACE inhibitor. Similar rates
were observed with patients treated with diuretics. The rates of monitoring were
shown to improve over the three-year period.
A cross-sectional analysis of patients from the United States aged over 65 years
examined the proportion of patients treated with cardiovascular medications who did
not have any baseline testing (defined as a creatinine or potassium test in the 180 days
before and 14 days after the start of treatment) (Simon et al., 2005). Approximately
one third of patients had no evidence of any baseline testing. In patients treated with
diuretics, biochemical testing was less likely to occur in women and patients with
fewer co-morbidities. No sex difference was observed in patients treated with ACE
inhibitors or AT-II receptor antagonists.
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Clayton and colleagues (2006b) undertook a large, retrospective analysis of electronic
prescribing and laboratory records of patients who were treated with at least one
thiazide diuretic from six UK GP practices. 17% of patients had at least a sodium or
potassium concentration test in the two years before initiation of thiazide diuretic
treatment. Almost a third of patients had at least one follow-up monitoring test of
sodium or potassium within two years of the start of treatment. Male sex, increasing
age, and more concomitant prescriptions were shown to be statistically significantly
associated with electrolyte monitoring in the two years after the initiation of
antihypertensive treatment.
An analysis of records from a large veterans database in the United States reported
that 81% of patients had at least one baseline potassium or creatinine test prior to the
initiation of ACE inhibitor or AT-II receptor antagonist treatment (Sauer et al., 2006).
Half of the cohort had both baseline testing and follow-up monitoring within 12
weeks. However, over two thirds of the cohort (67%) did not have a baseline test and
follow-up monitoring within four weeks of treatment. Patients with fewer outpatient
encounters (OR 1.9, 95% CI 1.5–2.3), and those travelling longer distances to receive
treatment (OR 1.19, 95% CI 1.03–1.4) were significantly more likely not to have
follow-up monitoring.
Lafata and colleagues (2007) undertook a cluster-randomized study in primary care
practices to examine the effect of an academic detailing intervention with
performance feedback on baseline testing in patients newly treated with
antihypertensive therapy and continuing users of the treatment. The intervention
involved two face-to-face visits where the primary care providers received feedback
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on their current rates of laboratory monitoring, research evidence supporting the need
for monitoring, and strategies to improve monitoring within their practice. Pre-
intervention, 59% of patients in the control cohort treated with an ACE inhibitor or
AT-II receptor antagonist had both a baseline serum creatinine and potassium test.
55% of patients treated with a thiazide diuretic had any baseline potassium testing.
The very large study by McAlister and colleagues (2007) examined administrative
drug databases from one Canadian province for 164 413 patients aged 66 years and
older who were newly treated with antihypertensive monotherapy. Overall, 41% of
patients had at least one laboratory test in the six months before initiation of treatment
and 49% of patients had at least one laboratory test during one year of follow-up.
Patients prescribed thiazide diuretics were more likely to have their serum electrolytes
measured at least once during follow-up, compared with newer agents (ACE
inhibitors, AT-II receptor antagonists, and Ca-channel blockers). Thiazide diuretic-
treated patients were less likely to have any renal function monitoring than patients
treated with newer agents.
Raebel and colleagues (2007a) undertook a retrospective analysis of data from 10
HMO databases of patients treated with spironolactone. Almost three quarters of
patients had both serum creatinine and potassium tests within one year of treatment.
Male sex, increasing age, and diabetes mellitus were some of the patient covariates
associated with monitoring.
Another large retrospective analysis of over 50 000 patients treated with ACE
inhibitors or AT-II receptor antagonists was carried out using data from 10 HMOs
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(Raebel et al., 2007b). 64% of the cohort had at least one creatinine and one
potassium concentration test within one year of continuing therapy. Patient factors
such as increasing age, male sex and co-morbidities such as diabetes mellitus and
chronic renal failure were significantly associated with laboratory monitoring.
Besançon and colleagues (2008) undertook a review of computerized patient records
from a French health insurance database for 3620 patients treated with a
spironolactone-ACE inhibitor combination. In the six months prior to the initiation of
treatment, 1083 patients (30%) had evidence of at least one record of both serum
potassium and creatinine measurements.
A retrospective study analyzed of records from older adults in a French national
insurance database who were treated with diuretics (Gérardin-Marais et al., 2008).
70% of the population had at least one serum chemistry monitoring test within one
year of treatment. Older age, female sex and serious disease were significantly
associated with monitoring.
The most recent study was an analysis of data from diabetic patients treated with an
ACE inhibitor, an angiotensin-II receptor antagonist or spironolactone (Raebel et al.,
2010). 71% of the cohort had at least one serum potassium concentration measured
during treatment. Patients who were monitored were more likely to be older, female,
and have more chronic disease. Serum potassium monitoring was associated with a
decreased risk (adjusted RR 0.50, 95% CI 0.37–0.66) of hyperkalaemia and
hyperkalaemia-associated adverse events such as emergency department visits,
hospitalization and death. The risk of adverse events further decreased with
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monitoring in a sub-group of patients with chronic kidney disease (adjusted RR 0.19,
95% CI 0.11–0.36).
2.4.2 Summary of studies
The UK, France, and the USA provided the majority of the studies and all but two of
the studies were cross-sectional or retrospective analyses of monitoring (Hoch et al.,
2003; Lafata et al., 2007). All of the studies used databases of electronic prescription
records to identify the patients treated with antihypertensive therapy. The majority of
studies (79%) used electronic records to identify laboratory tests, with only one study
undertaking an assessment of the ability of the administrative data to identify
monitoring (Raebel et al., 2007b).
Most studies (71%) were undertaken using insurance databases to identify a range of
patients typically treated with antihypertensive therapy in primary care. Some studies
focused on specific sub-groups of patients, such as the elderly (Simon et al., 2005;
Gérardin-Marais et al., 2008) or those with diabetes (Raebel et al., 2010). Three
studies were carried out in patients newly treated with antihypertensive therapy
(Lafata et al., 2007; McAlister et al., 2007; Raebel et al., 2010). The majority of
studies focused on follow-up monitoring, with three studies examining only baseline
testing (Simon et al., 2005; Lafata et al., 2007; Besançon et al., 2008). Six studies
(Rhodes, 1992; Kalra et al., 1999; Clayton et al., 2006b; Sauer et al., 2006; McAlister
et al., 2007; Raebel et al., 2010) reported data on the both the proportion of patients
with baseline biochemical testing and follow-up monitoring therapy, of which one
(Clayton et al., 2006b) presented data on the proportion of patients with testing before
and monitoring after the initiation of antihypertensive therapy.
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2.4.3 Summary of the primary outcome measure
The proportion of patients with biochemical testing prior to the initiation of therapy
varied by the time frame used, the antihypertensive drug class, and the serum
concentration measured. From 17 to 81% of patients treated with antihypertensive
drugs had a baseline biochemical test (Table 2.1). There was also a four-fold range in
the proportion of patients with follow-up monitoring (20–79%) (Table 2.2). In five of
the eleven studies examining follow-up monitoring, fewer than half the patients had
any evidence of biochemical monitoring.
Table 2.1 – Proportion of patients with baseline testing (grouped by the
definition of baseline testing)
Study Antihypertensivedrug treatment What to test?
% of patients with
baseline testing
3 months prior
Kalra (1999) ACE inhibitors Creatinine 45%
6 months prior to and 14 days after
Simon (2005) ACE inhibitors Creatinine or potassium 67%
Simon (2005) AT-II receptor
antagonists
Creatinine or potassium 72%
Simon (2005) Diuretics Creatinine or potassium 67%
Lafata (2007)† ACE inhibitors,
AT-II receptor
antagonists
Creatinine and
potassium
59%
Lafata (2007) † Diuretics Potassium 55%
6 months prior
McAlister (2007) Thiazide diuretics Sodium or potassium 21%
McAlister (2007) Thiazide diuretics Creatinine 32%
McAlister (2007) ACE inhibitor, AT-
II receptor
antagonist, beta-
blocker, calcium-
channel blocker
Sodium or potassium 23%
McAlister (2007) ACE inhibitor, AT-
II receptor
antagonist, beta-
blocker, calcium-
channel blocker
Creatinine 36%
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Study Antihypertensivedrug treatment What to test?
% of patients with
baseline testing
Besançon (2008) Spironolactone and
ACE inhibitors
Potassium and
creatinine
30%
2 years prior
Clayton (2006) Thiazide diuretics Sodium and/or
potassium
17%
No definition
Rhodes (1992) Diuretics Urea or electrolytes 11%
Kalra (1999) ACE inhibitors Creatinine 49%
Sauer (2006) ACE inhibitors or
AT-II receptor
antagonist
Potassium and
creatinine
81%
†Only data from the control arm in patients who are new medication users are presented
Table 2.2 – Proportion of patients with follow-up monitoring (grouped by the
definition of follow-up monitoring)
Study Antihypertensivedrug treatment What to test?
% of patients
with follow-up
monitoring
2 weeks after
Sauer (2006) ACE inhibitor or
AT-II receptor
antagonist
Potassium and creatinine 27%
4 weeks after
Sauer (2006) ACE inhibitor or
AT-II receptor
antagonist
Potassium and creatinine 33%
3 months after
Kalra (1999) ACE inhibitors Creatinine 29%
Sauer (2006) ACE inhibitors or
AT-II receptor
antagonist
Potassium and creatinine 50%
1 year after
Hurley (2005) ACE inhibitors Creatinine 65%
Hurley (2005) ACE inhibitors Potassium 60%
Raebel (2007b) ACE inhibitors Creatinine and potassium 68%
Raebel (2007b) AT-II receptor
antagonists
Creatinine and potassium 74%
Géradin-Marais
(2008)
Diuretics Serum chemistry
monitoring
75%
Hurley (2005) Diuretics Creatinine 64%
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Study Antihypertensivedrug treatment What to test?
% of patients
with follow-up
monitoring
Hoch (2003) Diuretics Potassium 79%
Hurley (2005) Diuretics Potassium 66%
Rhodes (1992) Diuretics Urea or electrolytes 20%
Raebel (2007a) Spironolactone Creatinine and potassium 72%
McAlister (2007) Thiazide diuretics Sodium or potassium 38%
McAlister (2007) Thiazide diuretics Creatinine 41%
McAlister (2007) ACE inhibitor, AT-
II receptor
antagonist, beta-
blocker, calcium-
channel blocker
Sodium or potassium 31%
McAlister (2007) ACE inhibitor, AT-
II receptor
antagonist, beta-
blocker, calcium-
channel blocker
Creatinine 42%
2 years after
Clayton (2006) Thiazide diuretics Sodium and/or potassium 32%
No definition
Kalra (1999) ACE inhibitors Creatinine 62%
Raebel (2010) ACE-inhibitors,
angiotensin-II
receptor blockers,
spironolactone
Potassium 71%
2.4.4 Summary of secondary outcomes measures
Eight studies presented information on patient characteristics associated with either
baseline testing or follow-up monitoring. Biochemical testing prior to the initiation of
treatment was less likely to occur in women and in patients with fewer co-morbidities
(Simon et al., 2005). Few studies presented additional information besides the
proportion of patients with baseline testing or follow-up monitoring.
Increasing age (Clayton et al., 2006b; Raebel et al., 2007a; Raebel et al., 2007b;
Gérardin-Marais et al., 2008; Raebel et al., 2010), more concomitant prescriptions
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(Clayton et al., 2006b; Raebel et al., 2010), and increasing number of co-morbidities
such as diabetes mellitus (Raebel et al., 2007a; Raebel et al., 2007b) or chronic renal
failure (Raebel et al., 2007b; Raebel et al., 2010) have been shown to be significantly
associated with follow-up monitoring. One study demonstrated that patients
prescribed thiazide diuretics were more likely to have their serum electrolytes
monitored than those prescribed angiotensin-converting enzyme (ACE) inhibitors,
angiotensin-II (AT-II) receptor antagonists, or calcium-channel blockers (McAlister et
al., 2007). Patients with fewer outpatient encounters and those travelling longer
distances to receive treatment were significantly less likely to have follow-up
monitoring (Sauer et al., 2006). Some studies have demonstrated that male patients
were significantly more likely to have follow-up monitoring (Clayton et al., 2006b;
Raebel et al., 2007a; Raebel et al., 2007b). However, two studies found that female
patients were likely to be monitored (Gérardin-Marais et al., 2008; Raebel et al.,
2010).
Two studies presented additional information on the number of monitoring tests,
demonstrating a low frequency of monitoring subsequent to the initial first test.
Clayton and colleagues (2006b) provided data on the number of follow-up electrolyte
tests, in addition to data on the proportion of patients with follow-up monitoring.
McAlister and colleagues (2007) presented the test density (number of tests per 100
patients per 6 months) by drug class, with elderly patients treated with thiazide
diuretics having the greatest density of tests.
One study examined the relationship between monitoring and adverse patient
outcomes. In a sub-group of diabetic patients treated with antihypertensive therapy,
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serum potassium monitoring was associated with a decreased risk of hyperkalaemia
and hyperkalaemia-associated adverse events such as emergency department visits,
hospitalization and death (Raebel et al., 2010).
2.5 Critical appraisal of prior studies of monitoring of patients
treated with antihypertensive drugs
This systematic review identified a range of studies examining the nature of
monitoring for ADRs in patients treated with antihypertensive drugs. The estimated
rate of baseline biochemical testing in primary care varied markedly, ranging from
17% to 81% (Rhodes, 1992; Kalra et al., 1999; Simon et al., 2005; Clayton et al.,
2006b; Sauer et al., 2006; Lafata et al., 2007; McAlister et al., 2007; Besançon et al.,
2008). Similarly, the proportion of patients with follow-up monitoring ranged from
20% to 79% (Rhodes, 1992; Kalra et al., 1999; Hurley et al., 2005; Clayton et al.,
2006b; Sauer et al., 2006; McAlister et al., 2007; Raebel et al., 2007a; Raebel et al.,
2007b; Raebel et al., 2010). The wide range in the proportion of patients with baseline
testing or follow-up monitoring may reflect differences in monitoring rates between
studies, but may also be a result of differences in the methods and definitions of
monitoring used by the various studies. These differences, and the various study
populations, make comparison between studies challenging. Each study was assessed
against several quality and methodological indicators, which are presented in Table
2.3 and summarized in Figure 2.2.
33

Ta
bl
e
2.
3
–

Su
m
m
a
ry

o
fq
u
a
lit
y
a
n
d
m
et
ho
do
lo
gi
ca
li
n
di
ca
to
rs

 St
u
dy

Representativenessof
thecohort?
Ascertainmentof
exposuretotreatment?
Assessmentof
laboratory
monitoring?
Validationof
laboratory
monitoring?
Lengthoffollow-up
sufficient?
Referencemadeto
publishedmonitoring
guideline?
Monitoringassessed
usinginsurance
database?
Cohortofnewly
treatedpatients?
Baselinetestingand
follow-upmonitoring
presented?
Frequencyof
monitoringpresented?
Patientfactors
associatedwith
monitoringpresented?
Relationshipbetween
monitoringand
adverseoutcomes
presented?
R
ho
de
s
(19
92
)
 
 
 
 
 

 
 
 



K
al
ra

(19
99
)
 
 
 
 
 

 
 

 
 
 
H
o
ch

(20
03
)
 
 
 
 
 

 
 
 
 
 
 
H
u
rle
y
(20
05
)
 
 
 
 
 

 
 
 
 
 
 
Si
m
o
n

(20
05
)
 
 
 
 
 

 
 
 
 
 
 
Cl
ay
to
n

(20
06
b)
 
 
 
 
 

 
 
 
 
 
 
Sa
u
er

(20
06
)
 
 
 
 
 

 
 
 
 
 
 
La
fa
ta

(20
07
)
 
 
 
 
 
 
 
 
 
 
 
 
M
cA
lis
te
r
(20
07
)
 
 
 
 
 

 
 
 
 
 
 
−

+

+

+

+

+

+

+

−

+

+

−

−

−

−

−

+

+

+

+

−

+

+

+

−

+

−

+

−

+

+

+

−

?
+

?
−

+

−

+

−

−

−

+

−

+

+

+

−

+

−

−

−

+

+

+

−

+

+

−

−

−

−

−

−

+

−

+

−

+

+

+

−

−

−

−

−

−

−

+

−

+

+

?
−

−

−

+

−

−

+

+

−

?
+

+

−

−

−

+

−

−

−

+

−

−

+

+

34

St
u
dy

Representativenessof
thecohort?
Ascertainmentof
exposuretotreatment?
Assessmentof
laboratory
monitoring?
Validationof
laboratory
monitoring?
Lengthoffollow-up
sufficient?
Referencemadeto
publishedmonitoring
guideline?
Monitoringassessed
usinginsurance
database?
Cohortofnewly
treatedpatients?
Baselinetestingand
follow-upmonitoring
presented?
Frequencyof
monitoringpresented?
Patientfactors
associatedwith
monitoringpresented?
Relationshipbetween
monitoringand
adverseoutcomes
presented?
R
ae
be
l(
20
07
a)
 
 
 
 
 

 
 
 
 
 
 
R
ae
be
l(
20
07
b)
 
 
 
 
 

 
 
 
 
 
 
Be
sa
n
ço
n

(20
08
)
 
 
 
 
 

 
 
 
 
 
 
G
ér
ad
in
-
M
ar
ai
s
(20
08
)
 
 
 
 
 

 
 
 
 
 
 
R
ae
be
l(
20
10
)
 
 
 
 
 

 
 
 
 
 
 

Y
es


N
o


U
n
cl
ea
r
(in
su
ffi
ci
en
ti
n
fo
rm
at
io
n

av
ai
la
bl
e
to

m
ak
e
a
jud
ge
m
en
t)
?
–

+

+

+

−

+

+

+

+

?
−

+

+

−

−

+

−

−

−

+

+

+

−

+

+

−

−

−

−

−

−

+

+

+

−

+

+

+

−

+

−

−

−

+

+

+

+

+

+

+

−

+

−

−

−

+

+

+

−

+

+

+

35
Figure 2.2 – Percentage of included studies where information for the
methodological indicators are presented
Patients identified by the review differed in the extent to which they were
representative of the patients who would receive biochemical monitoring due to
treatment with antihypertensive therapy. While the majority of studies included
patients as young as 18 years old, three were carried out exclusively in older patients
(Simon et al., 2005; McAlister et al., 2007; Gérardin-Marais et al., 2008). These three
studies demonstrated high rates of monitoring, which may be due to doctors targetting
monitoring to patients at higher risk of ADRs as adverse reactions to drug treatment
have been shown to be more frequent in older patients. Three studies (Lafata et al.,
2007; McAlister et al., 2007; Raebel et al., 2010) presented data on monitoring in
newly treated patients, who may present with different characteristics (e.g. co-
morbidities, severity of hypertension, demographics) than patients who have been
treated for some time. This has important implications for monitoring as patients who
are newly treated may be particularly vulnerable to ADRs as they are drug-naïve and
some ADRs, such as hyponatraemia, have been shown to occur very soon after the
0% 25% 50% 75% 100%
Relationship with adverse…
Patient factors presented?
Monitoring frequency…
Baseline and follow-up…
Newly treated patients?
Monitoring assessed using…
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Length of follow-up sufficient?
Validation of laboratory…
Assessment of laboratory…
Ascertainment of exposure to…
Representativeness of the cohort?
Information presented No information presented Unclear
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initiation of treatment (Spital, 1999; Aronson, 2006). The sample size of the different
studies also differed considerably. Although one study was carried out in over 160 000
patients (McAlister et al., 2007), the majority of studies examined fewer than 10 000
patients.
All of the studies used electronic prescription records to identify patients exposed to
treatment with antihypertensive therapy. Electronic patient records were also used to
identify both baseline testing and follow-up monitoring in the majority of the studies.
However, one study only used a retrospective chart review (Rhodes, 1992) and two
studies (Kalra et al., 1999; Sauer et al., 2006) did not provide clear descriptions on the
methods used to identify biochemical monitoring. Only Raebel and colleagues
(2007b) validated the ability of the electronic records to identify monitoring. They
considered the actual patients records to be the gold standard, and compared the
monitoring results obtained from the electronic records with the patient records for a
random sample of patients, to determine the sensitivity and predictive values of the
administrative data.
The majority of the studies identified by the review assessed the nature of monitoring
using large insurance or administrative databases. The nature of laboratory monitoring
in these large organizations may be significantly different from monitoring carried out
in other countries and in other healthcare organizations.
All of the studies described biochemical monitoring as an important tool for
identifying adverse reactions to treatment. However, over a quarter of the studies
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made no reference to a published guideline on monitoring patients for adverse
reactions to antihypertensive therapy.
Most of the studies focused exclusively either on baseline testing or follow-up
monitoring. Therefore very few studies were able to examine the important
relationship between baseline testing and monitoring following the initiation of
treatment. The majority of studies only treated monitoring (either baseline testing or
follow-up monitoring) as a binary outcome. Indeed, only two studies provided any
additional information on the number of monitoring tests (Clayton et al., 2006b;
McAlister et al., 2007), which limits any analysis on the nature of monitoring.
Several studies only presented the prevalence of monitoring and did not provide any
information on the patient factors associated with monitoring, which limits the
interpretation of their results (Hoch et al., 2003; Hurley et al., 2005). Finally, only one
study (Raebel et al., 2010) examined any relationships between the monitoring of
patients and adverse outcomes. Monitoring is advocated as a way of preventing
patient harm but little to no information was presented in previous studies on the
relationship between monitoring and adverse patient outcomes.
Barriers to monitoring
Monitoring is recommended as a tool for the identification of potential adverse
reactions to therapy. Evidence obtained from the studies identified by this systematic
review suggests that as many as one in five patients do not obtain any follow-up
monitoring during treatment with antihypertensive therapy. Doctors have described
monitoring as a critical, albeit time-consuming, component of their practice (Goldman
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et al., 2010). Several barriers to monitoring have been described including: lack of
consensus in the guidelines, uncertain responsibility for monitoring, patient non-
adherence, and absence of alerts or reminders to monitor.
Strategies for improving monitoring
Several initiatives have been recently developed to encourage biochemical
monitoring, which sometimes apply to the healthcare practitioner and sometimes to
the patient. Electronic laboratory monitoring alerts aimed at reminding doctors to
undertake monitoring have been examined within a computerized medical records
system (Hoch et al., 2003; Feldstein et al., 2006; Palen et al., 2006; Matheny et al.,
2008; Lo et al., 2009). Academic detailing, where doctors go through a face-to-face
educational process on the importance of monitoring, has also been investigated as a
tool to improve monitoring (Lafata et al., 2007). Additional research has investigated
the impact of an automated voice message to the patient (Feldstein et al., 2006), and a
pharmacy team outreach to the patient (Feldstein et al., 2006) on monitoring.
Although some slight improvement in the rates of appropriate biochemical monitoring
have been observed following the introduction of the interventions, most were not
statistically significant. Certainly electronic alerts may not alter physician behaviour
due to issues relating to alert fatigue. The results obtained from the studies
investigating the various interventions is also limited as the majority of these studies
have been undertaken in American healthcare systems and the results may not be
generalizable to other environments.
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2.6 Conclusions
This systematic review identified several large, well planned studies that examined
the prevalence of monitoring and identified patient factors associated with greater
rates of monitoring. However, very few studies examined both baseline testing and
follow-up monitoring. The majority of studies demonstrated that monitoring is not
being carried out in accordance with published guidelines. In only 45% of the studies
examining follow-up monitoring did more than half of the patients have any
monitoring. There also remains a significant gap in knowledge with respect to the
patterns of monitoring of antihypertensive drugs for ADRs in newly diagnosed and
newly treated hypertensive patients. Further research that accurately examines
potential relationships between monitoring and adverse patient outcomes is important
in order to determine the effectiveness and value of monitoring.
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Chapter 3
DESCRIPTION OF THE STUDY
COHORT
In this chapter I introduce the General Practice Research Database (GPRD) and
describe its use in pharmacoepidemiological research. I explain the process by which
the cohort of patients who were newly diagnosed with hypertension and newly treated
with antihypertensive therapy was identified from the GPRD. Finally, I define the
various patient covariates and outcomes that were used in the analysis of the database.
3.1 The use of large databases in pharmacoepidemiology
Pharmacoepidemiology has been defined as the study of the use of and the effects of
drugs in large numbers of people (Strom, 2005). It is a relatively new applied field
that provides a link between epidemiology and clinical pharmacology.
Pharmacoepidemiological methods are often applied to large automated databases or
routine data sources such as MediPlus (Germany, UK, France), GPRD (UK),
Saskatchewan Health (Canada), Medicaid (US), and PHARMO (The Netherlands).
These databases provide a way to link patient records with drug therapy and outcomes
for large populations in both a time- and cost-effective manner. Because they have the
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potential to provide very large sample sizes, automated databases are particularly
useful when looking for outcomes such as uncommon (fewer than 1 in 100 patients)
or rare (fewer than 1 in 1 000 patients) ADRs. The size and nature of these databases
is advantageous compared with clinical trials, which are most often carried out in
small, pre-selected groups of patients over short periods of time. Clinical studies are
usually not specifically designed to identify ADRs, instead focusing on drug efficacy,
and are often too small or too short in follow-up time to detect rare, or late or delayed
ADRs. Finally, the therapy used in the treatment of patients and the way in which the
therapy is administered and monitored differs significantly between clinical trials and
‘real life’ clinical practice. Therefore automated databases can provide both a large
sample size to identify rarer or delayed outcomes and a more comprehensive
understanding of drug treatment usage in clinical practice.
The use of such databases in pharmacoepidemiology has, however, been criticized.
Information on important confounding patient characteristics is often not recorded and
because exposure is usually defined as a prescription record, misclassification of
exposure may occur. The majority of these large databases do not contain direct
linkage to hospital databases containing information on discharge diagnoses and
procedures performed, which would be extremely useful (Garcia Rodriguez & Perez
Gutthann, 1998).
3.2 The General Practice Research Database
The General Practice Research Database (GPRD) is the world’s largest computerized
database of anonymized longitudinal patient records from general practice (General
Practice Research Database, 2007). The GPRD was established in 1987 and contains
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information on over 3.5 million patients, providing approximately 39 million person-
years of data. The GPRD contains approximately 5.5% of the UK population and is
broadly representative of the general UK population in terms of age, sex, and
geographic distributions (Gelfand et al., 2005). The database is currently operated and
maintained by the Medicines and Healthcare products Regulatory Agency (MHRA).
Over 460 practices currently contribute to the GPRD and contributing GPs are
provided with guidelines that define what information should be recorded
electronically for GPRD purposes, including: demographic and lifestyle information
(e.g. smoking status); medical diagnoses; all prescriptions; events leading to
withdrawal of a drug or treatment; referrals to hospitals; treatment outcomes; and
laboratory test results (General Practice Research Database, 2007).
The GPRD uses Read terminology, which is a structured hierarchy of both medical
and non-medical terms. The codes include categories for observations, symptoms,
diagnoses, investigations, occupations, and administrative processes. In 1994 the
Read system of coding replaced the Oxford Medical Information System (OXMIS)
medical codes, which were loosely based on the eighth revision of the International
Classification of Diseases. OXMIS codes still remain in historical records in the
GPRD.
The GPRD collects information on medications prescribed in general practice. Data
collected for each prescription include generic name, formulation, strength, GPRD
drug dictionary code, and codes relating to the British National Formulary (BNF)
classification system.
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The GPRD provides flat text files—plain text files that usually contain one record per
line—for patient demographic, consultation, test, immunization, referral, and therapy
data, which are all linked through the use of a unique patient identification number.
The practices are regularly checked for data quality and data duplication, and
referential integrity (i.e. that references between data are valid and intact). Patients
must have registration, event recording, age, and sex data to a certain standard.
Practices that meet the GPRD data quality standards are considered up-to-standard
(UTS). A UTS date is generated, which indicates when data coding by the practice
complied with specific quality measures.
3.2.1 Validation of the General Practice Research Database
The quality and the completeness of the data recorded in the GPRD have a direct
impact on the validity of any research undertaken using the database. Internal
methods (e.g. validating a diagnosis by the presence of codes indicating specific
symptoms/signs, prescriptions for disease-specific drugs or test results) and external
methods (e.g. questionnaires sent to GPs; comparison with other national databases or
statistics) have been used to assess the validity of diagnoses recorded in the GPRD.
The majority of validation occurred through requests to GPs for further information.
Several studies have demonstrated good agreement between the medical diagnoses
recorded using the Read/OXMIS coding systems and the diagnosis in the patient’s
medical record (Herrett et al., 2010; Khan et al., 2010). Outcomes such as myocardial
infarction (Jick et al., 1996), chronic obstructive pulmonary disease (Soriano et al.,
2001), inflammatory bowel disease (Lewis et al., 2002), and venous
thromboembolism (Lawrenson et al., 2000) have been well validated. The
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completeness of data from referrals to specialists and information related to such
visits has been also well established (Jick et al., 1991; Jick et al., 1992).
3.2.2 Limitations of the General Practice Research Database
The GPRD provides a rich source of well-validated data, but there are some
limitations to the database. Research has demonstrated that data from many
specialists, as well as events that occur in hospital, may not be fully captured in the
patient’s electronic record. Treatments given in hospital may also not be recorded.
The information on important confounding factors such as smoking, alcohol use,
weight, and height is also limited (Gelfand et al., 2005). Other factors such as socio-
economic status are not implicitly recorded, although a patient’s socio-economic
status can be inferred from the level of deprivation of the post code of the GP
practice. Finally, GPs do not routinely collect information on each encounter, only
consultations. Therefore there is less complete information for minor sequelae of
chronic diseases (like an episode of breathing problems in asthma), although the
presence of the disease itself is usually very well recorded (Lawrenson et al., 1999).
3.3 Development of the study cohort
3.3.1 Ethics approval
The study protocol was approved by the Independent Scientific Advisory Committee
(ISAC) for Medicines and Healthcare products Regulatory Agency (MHRA) database
research [study reference number 06_096, issued 24 Jul 2007].
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3.3.2 Database development
3.3.2.1 Inclusion criteria
Data were requested from the MHRA using the following inclusion criteria:
1. Patients with a recorded first prescription of one of the nine following drug
classes in general practice between 1 January 2000 and 31 December 2003
(first prescription was defined as no prior prescription of any drug from the
nine drug classes within the preceding year);
I. Angiotensin-converting enzyme (ACE) inhibitors
II. Angiotensin-II (AT-II) receptor antagonists
III. Calcium-channel blockers (Ca-channel blockers)
IV. Thiazide diuretics
V. Potassium-sparing or loop diuretics
VI. Alpha-adrenoceptor antagonists (alpha-blockers)
VII. Beta-adrenoceptor antagonists (beta-blockers)
VIII. Aldosterone antagonists/potassium-sparing diuretics
IX. Mixed class (e.g. beta-blocker and thiazide diuretic
combination)
2. Patients with a diagnosis of hypertension, as identified by a Read/OXMIS
code of hypertension (Appendix 7) or with three blood pressure measurements
of greater than 160/100 (the threshold for initiation of antihypertensive
treatment without other patient factors at the time) on or in the 365 days before
the date of the first antihypertensive prescription;
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3. Patients must have at least one year of available data prior to the first
prescription of an antihypertensive drug;
4. Patients must be aged 18 years and older on the day of the first prescription.
The day of the first prescription of the antihypertensive drug is referred to as the index
date.
Data were obtained from the MHRA as 38 flat text tiles linked by a unique patient
identification number. Look-up files were also provided to allow for the linkage
between data files (Table 3.1). Not all of the text files were deemed to be relevant to
the aims of the study including those relating to asthma, diet, exercise, immunization,
passive smoking, residence, and sleeping habits.
Table 3.1 – GPRD data and look-up files obtained from the MHRA
File name Data description
Data files
ADR Allergy and intolerance information
Agencies Information about health agency involvement
Alcohol Details relating to alcohol use including the number of units
of alcohol per week
Asthma Data recorded via the asthma disease management structured
data area
Blood pressure Current and historic blood pressure records
BMI Historic measurements of height, weight, and BMI
Clinical All the medical history data entered on the GP practice
system, including systems, signs, and diagnoses (split into 3
files due to size of data set)
Consultation Data relating to the type of consultation as entered by the GP
(split into 2 files due to size of data set)
Death administration Death data
Diabetes Data entered via the diabetes disease management structured
data area
Diet Data relating to the patient’s diet
Exercise Data relating to the patient’s exercise pattern
Height Patient height data
Historical registration Current and historical registration details
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File name Data description
Immunization Data on patient immunizations.
Maternity Data entered via the maternity structure data area
Passive smoking Information about whether the patient is exposed to passive
smoking
Patient Basic patient demographics and patient registration details
Practice Practice registration details
Referral Information involving patient referrals to external care
centres such as hospitals
Residence Information about the patient’s residential arrangements
Sleeping patterns Data about the patient’s sleeping habits
Smoking Current and historic smoking details
Status Current and historic records for the patient health status
Test Data on the type of test (e.g. biochemical investigation) and
results (split into 3 files due to size of data set)
Therapy Data relating to all prescriptions issued by the GP (split into
6 files due to size of data set)
Treatment compliance Data for which level the patient complies with the treatment
issued
Weight Weight data
Look-up files
Medical codes Read/OXMIS codes and associated code name
Product codes Product codes for treatments including drug name, dose, and
British National Formulary chapter and header
Test codes Test codes and associated test name
Dose conversion table Data that convert the dose provided to a numeric dose (e.g.
one tablet per day converted to 1)
3.3.2.2 Data cleaning
The GPRD is a large and well-validated database, but extreme and implausible values
can still exist within the database. When determining the patient baseline covariates
described below in section 3.3.3, the recorded values were assessed for plausibility.
Impossible values (such as a weight of 1000 kg) were recoded as an error or excluded.
In determining baseline values, if the implausible value was the value recorded closest
to the index date, this record was excluded and the next closest record was used as the
baseline value.
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The test file was examined in order to identify biochemical laboratory tests that were
not clinically possible. In consultation with clinicians, decisions were made to exclude
implausible laboratory test results. For example, a record of a creatinine serum
concentration of 1800 µmol/l was excluded from the analysis, because such a
concentration would not have been clinically possible.
3.3.2.3 Exclusion of pregnant women
Hypertension may be diagnosed during pregnancy as a result of the pregnancy or
following pre-existing hypertension. Women who were pregnant during the study
period were excluded because of possible differences in the condition, the treatment
of the patient, and how the GP monitors the patient for both drug efficacy and drug
safety.
An algorithm was developed based on the work suggested by Hardy and colleagues
(2004) for identifying pregnant women using Read/OXMIS codes. The algorithm was
based on the Read/OXMIS codes that were representative of a pregnancy marker or a
pregnancy outcome.
Types of pregnancy markers included:
1. Lab tests and procedures;
2. GP practice visits related to pregnancy;
3. Threatened abortion;
4. Abortion referral;
5. Obstetric hospitalization.
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Types of pregnancy outcomes included:
1. Elective termination;
2. Fetal death;
3. Hydatiform mole/blighted ovum;
4. Live births;
5. Delivery outcome unclear;
6. Delivery booking;
7. Multi-fetus delivery.
The algorithm developed by Hardy and colleagues (2004) was designed to identify
definite pregnancies and to accurately determine dates of conception. My goal was to
identify women who possibly could have been pregnant during the study time period
and therefore 804 women were excluded from my analysis because they had any one
of the following conditions:
1. A pregnancy marker from 01/04/1999 to 31/12/2003;
2. A pregnancy outcome from 01/01/2000 to 30/09/2004;
3. An expected date of delivery in the maternity file from 01/01/2000 to
30/09/2004.
Patients who had a pregnancy marker from 01/01/2004 to 30/09/2004 and no
pregnancy outcome were also examined. The decision was taken to exclude these 339
patients on the basis that they were potentially pregnant during the study time period.
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Therefore 1143 women, who represented 3.0% of the female population, were
excluded from subsequent analyses.
3.3.3 Baseline patient covariates
A variety of demographic, lifestyle, and clinical covariates for all patients were
identified and are described below. GPs are encouraged to record ‘lifestyle factors’
such as smoking status, alcohol intake, and weight at least once every three years.
Therefore a five-year tolerance was considered suitable in order to include the
maximum amount of relevant data.
Some covariates such as diabetes mellitus were identified through the use of
Read/OXMIS codes. The development of a list of appropriate Read/OXMIS codes for
relevant patient characteristics was carried out under the guidance of Dr P S Gill, a
GP with considerable experience in disease coding in general practice; and Dr J J
Coleman and Prof R E Ferner, who both have significant clinical experience and
expertise.
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Table 3.2 – Baseline patient covariates extracted from the GPRD
Patient covariate Description Category (if used)
Demographics
Age Ages were recorded as the age in
years on the day of the index
date
<40 years
40–49 years
50–59 years
60–69 years
70–79 years
80–89 years
90–100 years
Sex Male or female
Socio-economic
status (SES)
A socio-economic status score
(scored out of 100) is defined by
the GPRD using the Index of
Multiple Deprivation, which is
based on the GP practice
postcode
SES score quintiles
(0= least deprived; 4=most
deprived)
Lifestyle factors
Smoking Patients had their smoking status
classified using the ‘smoking
summary’ table provided by the
GPRD or through the use of
relevant Read/OXMIS codes
(Appendix 8). The smoking
status closest to index date,
within 5 years of the index date,
was used.
Never smoker
Ever smoker (current or ex-
smoker)
Alcohol use The number of units of alcohol
per week recorded closest to the
index date (within 5 years) was
used as the measure of alcohol
intake.
Alcohol use was categorized
using quartiles, which generally
fit into recommended guidelines
by sex.
Male Female
0–3 units/week 0–2 units/week
4–14 3–7
15–21 8–13
>21 >14
Height Single height measurements
where available were recorded;
for patients with 3 or more
height measurements, the
median height measurement was
taken; for 2 measurements, the
mean was taken.
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Patient covariate Description Category (if used)
Weight Weight in kilograms closest to
the index date (± 5 years) was
used
Body mass index
(BMI)
BMI was defined as the above
weight (in kg) divided by the
square of the height (in metres)
(kg/m2)
BMI was categorized using
recognized WHO definitions
Category Range (kg/m2)
Underweight <18 kg/m2
Normal 18–24.9
Overweight 25–29.9
Obese ≥30
Co-morbidities
Diabetes Any record of a Read/OXMIS
code of diabetes (Appendix 9) on
or the index date was indicative
of the presence of diabetes
mellitus.
Baseline blood
pressure
Systolic blood pressure (SBP)
and diastolic blood pressure
(DBP) readings recorded closest
to the index date (within 365
days) were used. Where 3 values
were recorded on the same day
the average of the last two
readings was used.
Blood pressure categories were
created using guidelines from
the British Hypertension Society
(Williams et al., 2004)*
SBP
(mmHg)
DBP
(mmHg)
Normal <140 <90
Mild 140–159 90–99
Moderate 160–179 100–109
Severe ≥180 ≥110
*If the SBP and DBP fell into different
categories, the higher value was taken for
classification
3.3.4 Assessment of biochemical serum concentrations
It is important to differentiate between biochemical tests recorded prior to the start of
treatment and those tests started after the patient has been treated with
antihypertensive therapy. Tests prior to the initiation of therapy can discover
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secondary causes of hypertension, while tests taken during treatment can identify
changes in serum concentration resulting from adverse reactions to the therapy.
I defined baseline biochemical testing as a measurement of one or more of serum
creatinine, urea, potassium or sodium concentrations between six months prior to the
index date and two days following it, to allow for any delays in the uploading of
laboratory test results to the GP practice computer (prior to 2003 the majority of
laboratory data entry was not automated). Biochemical monitoring was defined as a
measurement of one or more of these serum concentrations between three days and
one year after the index date.
Abnormal serum concentrations were determined using standardized (95%) reference
ranges provided with the tests. Standardized reference ranges were 56–122 µmol/l for
creatinine, 2.6–7.2 mmol/l for urea, 135–146 mmol/l for sodium, and 3.5–5.1 mmol/l
for potassium. Where such ranges were missing, they were inferred from the patient’s
sex and age. Concentrations outside the reference ranges for sodium or potassium
concentrations, and above the reference ranges for creatinine or urea, were classified
as abnormal.
3.3.5 Changes or alterations to antihypertensive treatment
I identified several changes to patients’ antihypertensive treatment using the methods
described below.
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3.3.5.1 Dose changes
Changes in the dose of the initial antihypertensive therapy were identified using the
dose conversion look-up file provided by the GPRD. This file allows for the
conversion of the text codes to a numeric dose (e.g. ‘take tablet BD’ is converted to
the value of 2). The identification of a dose change was carried out as more vigilant
monitoring of biochemical serum concentrations and renal function after an increase
in the dose of antihypertensive therapy has been suggested (Eccles et al., 1998;
Chobanian et al., 2003; North East Essex Medicines Management Committee, 2007;
Smellie et al., 2007).
3.3.5.2 Co-prescription of drug therapies
Additional antihypertensive therapies are often added after first-line therapy has
demonstrated limited effectiveness. However, the use of two or more drug therapies at
the same time can create the risk of a potential drug interaction. For example, the use
of an ACE inhibitor and spironolactone at the same time can increase the risk of
hyperkalaemia and close laboratory monitoring of serum potassium concentrations
has been recommended (Juurlink et al., 2004). I defined co-prescription of two drug
therapies as a record for the second drug prior to the expiry of the prescription for the
first drug (Figure 3.1). The day the second therapy was initiated was used as the day
of co-prescription. The three drug groups identified, and the potential adverse
reactions associated with their co-prescription, are described in Table 3.3.
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Table 3.3 – Drug classes examined for co-prescription
Co-prescription of drug therapies Potential ADR Serum concentration test
ACE inhibitor & spironolactone Hyperkalaemia Potassium
ACE inhibitor & AT-II receptor
antagonist
Hyperkalaemia Potassium
Thiazide diuretic & loop diuretic Hyperkalaemia Potassium
Figure 3.1 – Co-prescription was defined as the prescription of a second drug
prior to the expiry of the prescription of the first drug
Spironolactone
(duration of 28 days)
42 56 70 84 98 112 126 140
ACE inhibitor
(duration of 56 days)
No evidence of co-prescription of potentially interacting drugs
42 56 70 84 98 112 126 140
ACE inhibitor
(duration of 28 days)
Spironolactone
(duration of 28 days)
Co-prescription of potentially interacting drugs
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3.3.6 Patient outcomes
I identified four patient outcomes within one year of the first antihypertensive drug
prescription, which are described below.
3.3.6.1 Persistence with antihypertensive drug treatment
Discontinuation of drug therapy is a common problem in clinical practice. Adherence
to treatment is a term used to describe whether a patient has taken the prescribed
treatment according to schedule, while persistence refers to whether a patient stays on
therapy (Andrade et al., 2006). Non-persistence can inhibit the treatment of certain
chronic conditions and may lead to increased morbidity and mortality (van Wijk et
al., 2006). The lack of persistence may also suggest an adverse reaction that
necessitated the cessation of treatment.
Several methods have been proposed for determining persistence with medication and
there is no consensus about the best method for determining non-persistence in large
automated databases (Caetano et al., 2006). Some authors have used the medication
possession ratio (MPR)—the proportion of days’ supply obtained during a specific
time period—to determine persistence. Persistence has also been defined using an
‘anniversary’ model; a patient is considered to be persistent with treatment for one
year if they have a record of a prescription within a specified interval around the one-
year anniversary of their first prescription. A minimum refill algorithm has also been
used to defined persistence where records of a specified minimum number of
prescriptions per year is indicative of persistence, although no consideration is given
to the length or dates of the prescriptions. Finally, other papers have generally defined
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discontinuation based on gaps or ‘grace periods’ between one dispensing of a drug
and a subsequent prescription. Some studies have allowed for grace periods from 30–
90 days after exhausting the drug supply from the prior prescription to define
discontinuation (Bourgault et al., 2005; Perreault et al., 2005; Burke et al., 2006;
Elliott et al., 2007).
I defined drug discontinuation as no subsequent prescription in the 30 days after the
expiry of the prescription. The delay of 30 days was to allow for alternative supply
and less than perfect dosing compliance (Figure 3.2). The discontinuation date was
defined as the day when the previous prescription would have expired. Sensitivity
analyses using alternative 60-day and 90-day periods (following the expiration of the
most recent prescription) were carried out to determine the effect of different
definitions of discontinuation.
I did not, however, take into account any drug stockpiling when determining the drug
discontinuation date. The oversupply of therapy or ‘stockpiling’ can occur when a
patient collects a prescription for later use (Greevy et al., 2010), and this may have an
impact on the calculation of drug discontinuation dates.
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Figure 3.2 – Persistence with antihypertensive drug therapy. Discontinuation
(non-persistence) was defined as no subsequent prescription in the 30 days after
the expiry of the prescription
3.3.6.2 Biochemical adverse drug reactions
Biochemical ADRs (hyperkalaemia, hypokalaemia, and hyponatraemia) were
identified using three methods: (1) a record of the ADR in the ADR database; (2) a
Read/OXMIS ADR code (Appendix 10); or (3) a biochemical lab test above or below
a certain concentration. Hyperkalaemia was defined as a serum potassium
concentration greater than or equal to 5.5 mmol/l; hypokalaemia was defined as a
Persistence with treatment
Gap in treatment (12 days)
0 14 28 42 56 70 84 98
First antihypertensive drug
prescription (day = 0)
New prescription of same
drug (day = 68)
Gap in treatment (49 days)
0 14 28 42 56 70 84 98
First antihypertensive drug
prescription (day = 0)
Discontinuation of treatment (non-persistence)
Permitted margin of delay (30 days)
New prescription of same
drug (day = 77)
Permitted margin of delay (30 days)
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serum potassium concentration less than 3.5 mmol/l; and hyponatraemia was defined
as a serum sodium concentration less than 135 mmol/l. The date closest to the index
date was taken as the date of occurrence of the ADR.
The majority of cases of biochemical ADRs were identified solely on the basis of
abnormal serum electrolyte concentrations: 87.8% of the hyponatraemia cases; 93.8%
of the hypokalaemia cases; and 96.1% of the hyperkalaemia cases. A small proportion
of the biochemical ADRs had both a record of an abnormal serum concentration and a
Read/OXMIS code (2.5–6.8%) recorded within 28 days of each other.
3.3.6.3 Death
Death was identified through a combination of three methods suggested by
researchers at the GPRD: (1) a Read/OXMIS code of death or suicide (Appendix 11);
(2) a record of transfer out of the practice where the reason for transfer was death; or
(3) a record in the GPRD ‘Death administration’ table.
During the data cleaning process, 19 patients who had been identified as dead within
one year of antihypertensive treatment using the method described above, were found
to have records after the recorded death date. A check was made of the clinical and
therapy records for each of the 19 patients. All of these patients had clinical or therapy
records after the reported date of death, which would suggest that the patients were
indeed alive and the Read/OXMIS code had been entered in error. This may have
been due to a death Read/OXMIS code being used for the description of the death of a
spouse or family member and not death of the patient. Alternatively, some patients
may have attempted suicide, which was recorded as a death in error. The decision was
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made to recode these 19 patients as alive within one year of antihypertensive
treatment.
3.3.6.4 Hospital admission
I wished to only identify admission to hospital and not simply hospital attendance.
Therefore only Read/OXMIS codes where admission to hospital was clearly the
outcome were included (Appendix 12). When two codes from the same patient were
recorded within seven days of each other, the codes were treated as one single
hospital admission, with the earlier date being used as the date of admission.
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Chapter 4
BIOCHEMICAL LABORATORY
MONITORING IN A COHORT OF
PATIENTS TREATED WITH
ANTIHYPERTENSIVE DRUGS:
STATISTICAL METHODS
In this chapter I describe the statistical methods used to analyze the nature of
biochemical laboratory monitoring in a cohort of patients treated with
antihypertensive therapy. The results of these analyses are presented in Chapter 5. I
characterize monitoring using the frequency, regularity, and responsiveness of
biochemical laboratory tests. I introduce the concept of immortal time bias and how it
can impact on the results of a study. Finally, I describe the statistical methods I have
used to control for this type of bias.
4.1 Descriptive analyses
Descriptive analyses of the data were carried out to describe the patient cohort and to
characterize biochemical laboratory monitoring. Comparisons were made between
data using the Chi-squared test for categorical data, the independent t-test (for data
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where parametric tests could be used), and the Mann-Whitney U test (for data where
parametric tests were not appropriate) for continuous data.
I analyzed the data to determine the nature of biochemical monitoring by assessing
the frequency, regularity, and responsiveness of laboratory testing, which are
explained later. The analyses were based upon (1) the number of tests, (2) the
calculated time intervals (∆t) between tests of serum concentration of creatinine, urea,
sodium, and potassium, and (3) the density of tests (defined as the number of tests
within 28 days). The density of tests was calculated in order to take into account the
time that the patient had been in the study. For example, a patient who only had one
test but had only been registered in the GP practice for two months would have
approximately the same density of tests as someone who had six tests and had been
registered in the practice for an entire year.
I assessed the frequency of biochemical monitoring by examining the number of tests,
the density of tests, and the time intervals between the tests. Sparse monitoring occurs
when there is a low number of biochemical tests, a low density of tests, or wide time
intervals between individual tests. Conversely, frequent monitoring occurs when there
is a high number of tests, a high density of tests, or a narrow separation in the time
between tests (i.e. ∆t is small).
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I investigated the regularity of monitoring by examining the absolute first and second
differences in the time intervals between biochemical tests (Figure 4.1).
Figure 4.1 – First and second differences in the number of days between
biochemical monitoring
Regular monitoring is characterized by approximately equal time intervals between
biochemical tests (i.e. ∆t1 ≈ ∆t2 ≈ ∆t3 ≈ ∆t4), while variable time intervals between
tests is suggestive of irregular monitoring. The standard deviation for the time
intervals between tests also provides an indication of the regularity of monitoring. A
narrow standard deviation suggests a regular monitoring pattern, while a wide
standard deviation in ∆t suggests an irregular pattern of monitoring.
Regular monitoring can also be characterized through the examination of second
differences. A second difference of 0 would indicate exactly regular monitoring.
However, I chose to define regular monitoring as an average absolute second
difference of 0 to 3 days, which would allow for any delays in uploading of the results
or weekends. An average second difference of 0 to 7 days would suggest reasonably
regular monitoring, while a value of greater than 7 days would suggest irregular
First differences
42
Index
date
Date of
Test 1
Date of
Test 2
Second differences
∆t1 ∆t2 ∆t3
∆∆t12 ∆∆t23
Date of
Test 3
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monitoring. Figure 4.2 demonstrates how the first and second differences were
calculated and also provides an example of regular and irregular monitoring.
Figure 4.2 – Examples of regular and irregular monitoring based on first and
second differences in the time intervals between biochemical monitoring
I assessed the responsiveness of monitoring to three events where guidelines have
recommended an increase in the level of monitoring. First, I examined the nature of
monitoring in patients where laboratory test results were outside the standardized 95%
reference ranges provided with the test. Second, I looked at the relationship between
monitoring and the co-prescription of other drugs that could lead to potentially
harmful drug-drug interactions. Concomitant treatment with an ACE inhibitor and
spironolactone can increase the risk of hyperkalaemia and close laboratory monitoring
42
0
9
25Day 7 14 34
7 7 11
0 4 2|∆∆t|
|∆t|
30Day
|∆∆t|
Regular monitoring
50 8 23
71535
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Irregular monitoring
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of serum potassium concentrations has been recommended when the two drugs are
used at the same time (Juurlink et al., 2004). Finally, I assessed the responsiveness of
monitoring to dose changes as some guidelines have specifically recommended more
vigilant monitoring of serum electrolytes and renal function after an increase in the
dosage of antihypertensive therapy.
4.2 Statistical analyses
4.2.1 Logistic regression modelling
I used Microsoft Access® to initially arrange and manipulate the data, and Stata®
10.0 to perform the statistical analyses. I determined the relationships between
baseline patient characteristics and the probability of any monitoring within six
months and one year in univariable logistic regression analyses. The methods by
which the patient covariates were determined were described in Table 3.2. Alcohol
use was excluded prior to undertaking any analyses due to the significant proportion
of missing data. Baseline characteristics that were statistically significant at the
P<0.05 level or were biologically plausible were then entered into a multivariable
logistic regression model using backwards stepwise variable selection. The patient
variable of sex was forced into the model a priori.
4.2.2 Time-to-event analyses
I used the Cox proportional hazards model to model the relationship between
biochemical monitoring and patient outcomes (Cox, 1972). The Cox proportional
hazards model is the most frequently used model for analyzing time-to-event data.
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The Cox model is a regression method that provides an estimate of the ratio of the
hazard function in treated patients compared with untreated patients. The hazard
function is the probability that a patient experiences an event or outcome, conditional
on the fact that they have not had an event or outcome to a certain time point. There
are several advantages to using the Cox model including: (1) the ability to censor
patients who fail to complete a study or do not reach the study endpoint; (2) the ability
to incorporate time-varying patient covariates; and (3) the absence of any assumptions
about the shape of the hazard over time (Cox & Oakes, 2001).
I modelled the relationship between biochemical monitoring and three patient
outcomes described in section 3.3.6: death, hospital admission, and drug
discontinuation. I also used the Cox proportional hazards model to model the
relationship between evidence of hyponatraemia, hypokalaemia or hyperkalaemia and
the same three outcomes.
Patients who were transferred out of the GP practice or who died were censored and
the date of the censoring event was used as the follow-up time in the time-to-event
analyses. A multivariable model using backwards stepwise variable selection was
used, where patient characteristics that were statistically significant at the P<0.05
level or were biologically plausible were entered into the model. The patient variable
of sex was also forced into the model a priori.
4.3 Immortal time bias
Biochemical follow-up monitoring was treated as a time-dependent covariate in the
time-to-event analyses in order to avoid immortal time bias. This bias can occur when
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an exposure or treatment of interest occurs within the same time period where an
outcome can occur. Immortal time is the period of follow-up or observation time,
during which an outcome (such as death) cannot occur (Suissa, 2007; Lévesque et al.,
2010). Immortal time bias has also been referred to as ‘survivor treatment bias’
(Austin & Platt, 2010), ‘time-dependent bias’(Beyersmann et al., 2008b), ‘survival
treatment selection bias’ (Glesby & Hoover, 1996), or ‘survival bias’ (Zhou et al.,
2005).
This bias was first described in the early 1970s, when it was demonstrated in two
cohort studies examining the benefit of heart transplantation (Messmer et al., 1969;
Clark et al., 1971). Patients who received a heart transplant were shown to live longer
than those who did not receive a heart transplant. A subsequent analysis demonstrated
that the previous studies had included the time from when the transplant was
approved to when the transplant was actually carried out in the total survival time for
those patients who received a heart transplant (Gail, 1972). Therefore the time waiting
for the transplantation had been incorrectly classified as time exposed to
transplantation. This resulted in the time patients spent on the waiting list being
incorrectly credited to the transplant and created an artificial decrease in the rate of
death in the group of patients that did have a heart transplant.
4.3.1 The effect of immortal time bias
The effect of immortal time bias on the results of analyzes can be significant. A
simulation study demonstrated that immortal time bias induced a negative or
downward bias, which causes exposures or treatments to appear more protective than
they really are (Austin et al., 2006). Additional work by Beyersmann and colleagues
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(2008a) showed that a log-hazard ratio that is biased due to immortal time bias will
always be smaller than the true log-hazard ratio.
Several observational studies have demonstrated findings that have not been
suggested or seen in randomized trials because of the failure to control for immortal
time bias. For example, Rochon and colleagues (2000) demonstrated a 43% reduction
in the rate of admission for heart failure following the use of low-dose beta-blockers
while a 29% decrease in all-cause mortality was seen after treatment with inhaled
corticosteroids (Sin & Tu, 2001).
Suissa (2007) clearly illustrated how immortal time bias can create an artificial
protective effect when he examined the association between two drug classes with no
plausible beneficial effect in the treatment of cardiovascular disease and the reduction
in mortality. He found that when immortal time (the length of time from cohort entry
to treatment) was excluded or misclassified, a 27% decrease in mortality was
observed. When the immortal time was correctly classified, no significant difference
in the association was found (Rate Ratio 0.94, 95% CI 0.73–1.20).
The effect of immortal time bias towards inducing a negative bias towards exposure
or treatments has been further illustrated by studies that have re-analyzed published
work that failed to account for immortal time bias. For example, Yee and colleagues
(2004) presented the surprising result that treatment with 3-Hydroxy-3-
methylglutaryl-coenzyme A (HMG Co-A) reductase inhibitors (‘statins’) reduced the
risk of diabetes mellitus by 26%. Lévesque and colleagues (2010) re-analyzed the
same data and correctly classified the time from cohort entry until prescription of a
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statin as unexposed. They found an opposite effect, where exposure to a statin was in
fact associated with a 53% increased risk of diabetes mellitus.
Another example focused on the study by Martin and colleagues (2006), which
demonstrated a 51% reduction in the risk of all-cause mortality in patients with
diabetes who performed self-monitoring of blood glucose. Hoffmann and Andersohn
(2011) recently re-analyzed the same data set and correctly classified the immortal
person-time as unexposed. They determined that self-monitoring of blood glucose
was associated with a 95% increased risk of all-cause mortality, suggesting that the
protective effect of monitoring was due entirely to immortal time bias.
A final example can be found in the study by Redelmeier and Singh (2001), which
suggested that OSCAR® winners lived significantly longer (almost 4 years) than their
less-recognized peers. A re-analysis of the study corrected for the winners’ immortal
time demonstrated that winner an Academy Award® conveyed an average advantage
of only 0.7 years (95% CI −0.3 to 1.6 years) (Sylvestre et al., 2006).
In summary, both simulation work and several re-analyses of published studies have
demonstrated that the failure to control for immortal time can bias results and create
the illusion of treatment effectiveness. When immortal time is misclassified, the event
rate in the exposed group (the number of events per person-years) will be lower
because the number of person-years in the exposed group is artificially increased.
This will cause the rate of the event in the exposed group to be lowered. Therefore, a
comparison between exposed and unexposed patients will be biased downwards and
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exposed patients will be artificially protected until they are exposed to the treatment
or intervention.
4.3.2 The extent of immortal time bias in the literature
Two studies have demonstrated that the failure to control for immortal time bias is
prevalent in the medical literature. The review by van Walraven and colleagues
(2004) examined 682 observational studies published in medical journals that used
survival analysis. They identified 52 articles susceptible to immortal time bias and
reported that in 44% of these studies, the use of analyses that corrected for this bias
could have changed the study’s conclusion.
A later paper identified twenty recently published studies, that all failed to take into
account the risk of immortal time bias by either misclassifying or excluding the
immortal time (Suissa, 2007). The majority of the studies used existing, large
computerised databases and demonstrated significant decreases in the rates of adverse
patient outcomes associated with treatment with various drug therapies.
4.3.3 Controlling for immortal time bias in the analysis of follow-up
biochemical monitoring
A patient with follow-up biochemical monitoring was defined as any patient with a
biochemical measurement in the 365 days following the start of antihypertensive
treatment. The period from first antihypertensive prescription to the time of the first
biochemical monitoring was considered to be event-free and thus ‘immortal’ (Figure
4.3).
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Figure 4.3 – Illustration of immortal time bias, using the adverse outcome of
death as an example
For the patient to have been monitored, they would have needed to have survived this
period of time. The failure to account for this time in the data analysis can lead to
immortal time bias, which would bias the results in favour of those who were
monitored.
Specifically, when an adverse patient outcome occurred shortly after the start of
antihypertensive treatment, a patient was less likely to be classified as having
biochemical monitoring because the opportunity for having a biochemical test was
lower. Therefore a majority of outcomes that occurred shortly after antihypertensive
treatment was initiated would have been classified as not monitored because there
would have been fewer opportunities to receive biochemical monitoring. If the
immortal time was not accounted for correctly, this would lead to a higher rate of the
outcomes in the patients that did not have monitoring and would cause an artificial
decrease in the rate of the outcome among patients that had biochemical monitoring.
Immortal time
42
First
antihypertensive
drug prescription
First biochemical
monitoring
Monitored
Death
Unmonitored
DeathFirst
antihypertensive
drug prescription
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Therefore, in order to control for immortal time bias I needed to model follow-up
biochemical monitoring as a time-dependent covariate, which is illustrated in Figure
4.4. In this example, patient 3 had a record of follow-up monitoring on day 115 and
experienced the outcome on day 211. The time from day 0 to day 115 is considered as
‘immortal’ and therefore was classified as unmonitored, while the time from day 115
to day 211 was classified as monitored.
Figure 4.4 – An illustration of how time was coded in order to control for
immortal time bias
Finally, I wished to quantify the extent of misclassified immortal time bias and to
estimate the effect of this bias on the relationship between biochemical monitoring
and adverse patient outcomes. This was achieved through the use of a simple Poisson
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rate approach, which assumed a constant rate of the various patient outcomes over
follow-up time. I also used a Cox proportional hazards model to calculate hazard
ratios adjusted for potentially confounding factors, but where the time to monitoring
was time fixed (not time varying). Therefore the person days between entry into the
cohort and biochemical monitoring were classified as monitored.
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Chapter 5
BIOCHEMICAL LABORATORY
MONITORING IN A COHORT OF
PATIENTS TREATED WITH
ANTIHYPERTENSIVE DRUGS:
RESULTS
This chapter presents the results of the analysis investigating the nature and frequency
of biochemical laboratory monitoring. I describe the frequency of both baseline
testing and follow-up monitoring and make comparisons between patients with and
without baseline biochemical testing. I demonstrate that follow-up monitoring, when
carried out, is sparse and infrequent. I also show that few patients have both baseline
biochemical testing and follow-up monitoring. Finally, I demonstrate that multiple
patient characteristics are associated with follow-up monitoring and examine the
relationships between monitoring and adverse patient outcomes.
5.1 Identification of the study cohort
I identified 77 905 patients from 401 GP practices who were newly diagnosed with
hypertension and newly treated with an antihypertensive drug between January 2000
and December 2003. The majority of patients (69%) were identified based solely on a
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recorded OXMIS/Read code for hypertension, while almost one third (28%) were
selected for inclusion because they had both a code for hypertension and blood
pressure measurements indicating hypertension. Only 3% of patients were identified
solely on blood pressure measurements. 1143 women were excluded from the analysis
because they could have been pregnant during the treatment period (Figure 5.1).
Figure 5.1 – Flowchart of patients treated with antihypertensive drugs
Adult UK population treated with
antihypertensive drugs†
N = 7 173 282
Adult patients in the GPRD who
were newly diagnosed with
hypertension and newly treated
between 1/1/2000 and 31/12/2003
N = 77 905
Final cohort of adult patients for
analysis
N = 76 762
Adult patients in GPRD started on
only 1 antihypertensive drug
N = 74 096
Women who could have been
pregnant
N = 1 143
† based upon population data from the Office of National Statistics and British
Heart Foundation Statistics
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74 096 patients, 48% male, were first prescribed a single antihypertensive agent (the
index prescription) between January 2000 and December 2003. Patients most often
began treatment with a thiazide diuretic (48.1%), beta-blocker (24.3%), or an ACE
inhibitor (15.2%). Although the majority of patients were treated with a thiazide
diuretic, this proportion decreased from 2000 to 2002 and later increased in 2003
(Table 5.1). The opposite trend was found with ACE-inhibitor treatment where there
was an increase in the proportion of patients treated from 2000 to 2002, followed by a
significant decrease.
Table 5.1 – Choice of antihypertensive drug class by year of first prescription
†Test for linear trend by year
Drug class Total(N=74 096)
Year of first antihypertensive prescription
2000
(N=16 508)
2001
(N=17 927)
2002
(N=19 532)
2003
(N=20 129)
P
value†
ACE inhibitor 11245 (15.2) 2 168 (13.1) 2 682 (15.0) 3 319 (17.0) 3 076 (15.3) <0.0005
Alpha-blocker 753 (1.0) 200 (1.2) 233 (1.3) 177 (0.9) 143 (0.7) <0.0005
AT-II receptor
antagonist 1630 (2.2) 254 (1.5) 349 (2.0) 512 (2.6) 515 (2.6) <0.0005
Beta-blocker 17 977 (24.3) 4 332 (26.2) 4 657 (26.0) 4 856 (24.9) 4 132 (20.5) <0.0005
Ca-channel
blocker 5651 (7.6) 1 454 (8.8) 1 407 (7.9) 1 417 (7.3) 1 373 (6.8) <0.0005
Combination 771 (1.0) 196 (1.2) 196 (1.1) 198 (1.0) 181 (0.9) 0.046
Loop or K-
sparing diuretic 416 (0.6) 121 (0.7) 107 (0.6) 97 (0.5) 91 (0.5) 0.002
Thiazide
diuretic 35653 (48.1) 7 783 (47.2) 8 296 (46.3) 8 956 (45.9) 10 618 (52.8) <0.0005
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There were also some substantial differences in the prescription of antihypertensive
therapy by age group (Table 5.2). The prescription of ACE inhibitors declined with
age, while the prescription of all of the diuretic classes increased with age. Some
classes of drugs demonstrated a more complex pattern, where there was an initial
increase with age, followed by a decline in the oldest age group.
5.2 Describing the nature of baseline biochemical testing
31 094 patients (42%) had evidence of any baseline biochemical testing, which was
defined as one or more laboratory tests in the six months prior to the index date. The
majority of patients (76.2%) with baseline testing had all four baseline tests, while
2090 (6.7%) patients had only one test. Almost 12% of the baseline tests were outside
of the standardized 95% reference range and were therefore abnormal (Table 5.3;
Figure 5.2). A large number of patients had a record of serum urea concentration of
2.5, which is most likely a reflection of a tendency to record concentrations at the
lower limit of normal.
Table 5.3 – Summary of baseline biochemical tests
Baseline biochemical test
Number of patients
with a baseline
biochemical test
Number of patients
with an abnormal
baseline test
Creatinine, n (%) 30 258 (40.8) 1 222/30 258 (4.0)
Urea, n (%) 25 263 (34.1) 93/25 263 (0.3)
Sodium, n (%) 28 262 (38.1) 969/28 262 (3.4)
Potassium, n (%) 28 061 (37.8) 1 627/28 061 (5.8)
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There were significant differences between patients with and without baseline testing.
Patients with baseline testing were more likely to be male, younger, have diabetes
mellitus, and be a smoker (Table 5.4).
Table 5.4 – Baseline patient characteristics in those patients with baseline
biochemical testing compared with those with no baseline biochemical testing
Baseline patient characteristic Total(N = 74096)
Any
baseline
testing
(N=31 094)
No baseline
testing
(N=43 002)
P value
Male, n (%) 35345 (47.7) 15 513 (49.9) 19 832 (46.1) <0.0005
Age, mean (SD) 61.1 (12.8) 60.8(12.4) 61.2 (13.0) 0.0001
<40, n (%) 3 492 (4.7) 1 384 (4.5) 2 108 (4.9) <0.0005†
40–49, n (%) 10 388 (14.0) 4 396 (14.1) 5 992 (13.9)
50–59, n (%) 20 360 (27.5) 8 664 (27.9) 11 696 (27.2)
60–69, n (%) 19 312 (26.1) 8 429 (27.1) 10 883 (25.3)
70–79, n (%) 14 971 (20.2) 6 231 (20.2) 8 740 (20.0)
80–89, n (%) 5 190 (7.0) 1 875 (6.0) 3 315 (7.7)
90–100, n (%) 383 (0.52) 115 (0.37) 268 (0.62)
BMI (kg/m2), mean (SD) 28.5 (5.4) 28.6 (5.4) 28.4 (5.4) 0.0001
Underweight, n (%) 654 (1.0) 264 (1.0) 390 (1.1) <0.0005†
Normal, n (%) 16039 (25.6) 6 641 (24.6) 9 398 (26.3)
Overweight, n (%) 25392 (40.5) 11 067 (41.0) 14 325 (40.1)
Obese, n (%) 20606 (32.9) 9 004 (33.4) 11 602 (32.5)
Current or ex-smoker, n (%) 33118 (46.4) 14 513 (48.1) 18 605 (45.3) <0.0005
Presence of diabetes mellitus, n (%) 6437 (8.7) 3 876 (12.5) 2 561 (6.0) <0.0005
SES quintile, n (%)
0 (least deprived) 15660 (21.1) 6 132 (19.7) 9 528 (22.2) <0.0005†
1 13205 (17.8) 5 875 (18.9) 7 330 (17.1)
2 15005 (20.3) 6 121 (19.7) 8 884 (20.7)
3 14154 (19.1) 5 311 (17.1) 8 843 (20.6)
4 (most deprived) 16072 (21.7) 7 655 (24.6) 8 417 (19.6)
Blood pressure mmHg (SD)
Mean systolic blood pressure 170.9 (20.1) 170.9 (19.5) 170.7 (20.5) 0.67
Mean diastolic blood pressure 97.2 (11.3) 97.2 (11.3) 97.2 (11.4) 0.62
Drug therapy
81
Baseline patient characteristic Total(N = 74096)
Any
baseline
testing
(N=31 094)
No baseline
testing
(N=43 002)
P value
ACE inhibitor 11 245 (15.2) 5 835 (18.8) 5 410 (12.6) <0.0005
Alpha-blocker 753 (1.0) 299 (1.0) 454 (1.1) 0.21
AT-II receptor antagonist 1 630 (2.2) 668 (2.2) 962 (2.2) 0.42
Beta-blocker 17 977 (24.3) 7 123 (22.9) 10 854 (25.2) <0.0005
Ca-channel blocker 5 651 (7.6) 2 229 (7.2) 3 422 (8.0) <0.0005
Loop or K- sparing diuretic 416 (0.6) 151 (0.49) 265 (0.62) 0.02
Combination preparation 771 (1.0) 246 (0.79) 525 (1.2) <0.0005
Thiazide diuretic 35 653 (48.1) 14 543 (46.8) 21 110 (49.1) <0.0005
†Chi-squared test for trend
5.3 Follow-up monitoring
5.3.1 What is the nature of follow-up monitoring?
In the year after the date of first prescription half of the patients (37 365) had at least
one biochemical measurement (Table 5.5; Figure 5.3). Over a third of patients
(26 946; 36.4%) had at least one measurement within six months and 16.3% had at
least one measurement within 28 days. Of those patients who were monitored at least
once within one year, 29 753 (79.6%) had all four tests of potassium, sodium,
creatinine, and urea; 2045 (5.5%) of those who were monitored had only one type of
serum concentration test.
Almost 40% of those patients who were monitored had at least a second biochemical
serum concentration measurement. The majority of patients tended to have ‘sparse’
monitoring in that they had few, if any, biochemical tests and a low density of tests.
8790 (23.5%) patients with any monitoring had at least one serum concentration that
82
was abnormal and 6589 (74.9%) of these abnormal serum concentrations were
recorded on the first follow-up monitoring test.
Table 5.5 – Summary of the biochemical serum concentrations measured in the
year after the start of antihypertensive treatment
Creatinine Urea Sodium Potassium
Number of patients with at least 1 test
Within 1 year, n (%) 36 558 (49.3) 31 318 (42.3) 34 595 (46.7) 34 606 (46.7)
Within 6 months, n (%) 26 282 (35.5) 22 456 (30.3) 24 804 (33.5) 24 853 (33.5)
Within 1 month, n (%) 11 709 (15.8) 10 124 (13.7) 11 134 (15.0) 11 222 (15.2)
Number of patients with
1 test, n (%) 21 899 (29.6) 19 030 (25.6) 20 819 (28.1) 20 947 (28.3)
2 tests, n (%) 8 840 (11.9) 7 466 (10.1) 8 338 (11.3) 8 288 (11.2)
3 tests, n (%) 3 454 (4.7) 2 870 (3.9) 3 260 (4.4) 3 228 (4.4)
4 tests, n (%) 1 370 (1.8) 1 132 (1.5) 1 258 (1.7) 1 253 (1.7)
≥5 tests, n (%) 995 (1.3) 820 (1.1) 920 (1.2) 890 (1.2)
Number of tests per patient (in patients with at least 1 test) (mean; mode; range)
Within 1 year 1.68 (1) 1–30 1.67 (1) 1–18 1.68 (1) 1–30 1.67 (1) 1–30
Within 6 months 1.39 (1) 1–15 1.38 (1) 1–15 1.39 (1) 1–15 1.38 (1) 1–15
Within 1 month 1.04 (1) 1–4 1.05 (1) 1–4 1.05 (1) 1–4 1.05 (1) 1–4
Density of tests per month,
mean (SD) 0.064 (0.090) 0.054 (0.084) 0.060 (0.088) 0.060 (0.089)
Density of tests per month
(in pts with at least one
test), mean (SD)
0.129 (0.090) 0.128 (0.087) 0.129 (0.089) 0.128 (0.089)
Number of patients with
abnormal test, n (%)
2 654/36 558
(7.3)
5 098/31 318
(16.3)
2 894/34 595
(8.4)
4 547/34 606
(13.1)
Number of patients with
abnormal first test, n (%)
2 220/36 558
(6.1)
4 397/31 318
(14.0)
2 115/34 595
(6.1)
2 898/34 606
(8.4)
In the 1995 patients who had a potassium test subsequent to an abnormal test, 71%
(1420) of the patients’ serum potassium concentrations returned to normal. This was
more than the 55% (750/1368), 36% (640/1794), and 36% (1312/3618) of patients
whose sodium, creatinine, and urea tests returned to normal.
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The percentage of patients who had any biochemical monitoring in the first year of
antihypertensive treatment increased from 37.5% in patients whose first prescription
was in 2000 to 63.4% in patients whose first prescription was in 2003 (test for trend
P<0.0005) (Figure 5.4).
Figure 5.4 – Proportion of patients who had at least one biochemical monitoring
test in the succeeding one year, by year of starting treatment
Over the time period examined, the proportion of patients within each GP practice
with follow-up biochemical monitoring differed significantly (Figure 5.5). Some GP
practices did not undertake any follow-up biochemical monitoring, while some
practices monitored almost 9 in 10 of their patients treated with antihypertensive
therapy.
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Figure 5.5 – Distribution of the proportion of patients with any monitoring
within 1 year of index date by GP practice
The proportion of patients within a GP practice with follow-up biochemical
monitoring increased significantly over time (Figure 5.6). In 2000, 13.6 % of practices
undertook no biochemical monitoring of patients started antihypertensive therapy,
compared with only 1.0% in 2003.
The mean number of repeat follow-up monitoring tests within one year in patients
with at least one test was 1.68 (Table 5.6). The number of follow-up tests varied by
drug class. Patients treated with ACE inhibitors and potassium-sparing or loop
diuretics had a larger mean number of follow-up tests.
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A graph of time from index date to all of the biochemical follow-up monitoring tests
reveals a sinusoidal pattern in the tail of the distribution, with peaks seen at seven-day
intervals. All of the creatinine serum concentration measurements one month before
and six months after initiation of antihypertensive therapy are presented in Figure 5.7
as an example. There was a large proportion of tests prior to the initiation of therapy
and on days 0 to 2, indicating baseline testing. There also was a large initial peak of
follow-up monitoring at day seven after the start of antihypertensive treatment and
peaks are seen at seven-day intervals, which would suggest that monitoring tends to
occurs at a certain number of weeks following the patient is started on therapy.
Figure 5.7 – Serum creatinine concentration tests in the one month before and
six months after the index date (grey represents baseline testing)
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The median interval between first antihypertensive prescription and first biochemical
monitoring test within one year was 75 days, and the modal interval was seven days.
The median interval between first antihypertensive prescription and first GP
consultation within one year was 24 days, and the modal interval was 28 days (Figure
5.8).
Figure 5.8 – Time to first biochemical monitoring test and first GP consultation
in the twelve months after the first antihypertensive prescription
5.3.2 What is the regularity of follow-up monitoring?
In patients with any biochemical monitoring, the first differences varied considerably
(Table 5.7). The time between tests was positively skewed with a mean value of 112
days and median value of 76 days. The second differences [see Figure 4.1 for a
definition] between tests also varied widely and were positively skewed with a mean
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value of 91 days and a median value of 63 days (Figure 5.9). Less than 2% of the
patients with two or more tests had a mean second difference of 0 to 3 days, which
would have suggested regular monitoring. Therefore very few patients had
biochemical monitoring where the time intervals between tests were approximately
equal.
Table 5.7 – First and second differences in the number of days between
biochemical laboratory tests
Creatinine Urea Sodium Potassium
First differences (t)
Mean (SD) 111.5 (102.6) 111.6 (103.1) 111.3 (102.9) 111.9 (103.1)
Median 76 76 76 76
Range 1–365 1–365 1–365 1–365
Interquartile range 26–178 26–180 25–179 26–180
Second differences (t)
Mean (SD) 90.8 (85.2) 91.5 (85.6) 91.1 (85.4) 91.1 (85.5)
Median 63 63 63 63
Range 0–358 0–358 0–358 0–358
Interquartile range 22–138 22–139 22–139 22–139
Number of patients with mean second difference between:
0–3 days, n (%) 211/14659
(1.4)
178/12288
(1.4)
217/13776
(1.6)
215/13659
(1.6)
0–7 days, n (%) 474/14659
(3.2)
409/12288
(3.3)
471/13776
(3.4)
467/13659
(3.4)
Mean is the group mean and not the mean intra patient value, SD = standard deviation
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Figure 5.9 – Second differences in time between follow-up monitoring
5.3.3 How responsive is follow-up monitoring?
5.3.3.1 The responsiveness of follow-up monitoring to abnormal tests
When an abnormal serum concentration was identified, a record for a subsequent
follow-up test was significantly more likely to be recorded (Table 5.8). However, the
density of serum concentration tests was significantly lower after an abnormal test for
all tests except for potassium (Table 5.9). Therefore when an abnormal laboratory test
was recorded, a patient was significantly more likely to have a follow-up test,
although not a significantly higher number of tests per month after the abnormal test.
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Table 5.8 – Proportion of laboratory tests with a subsequent follow-up test
Abnormal serum
concentration with
follow-up, n (%)
Normal serum
concentration with
follow-up, n (%)
P value
Creatinine 3 037/5 973 (50.9) 22 065/55 687 (39.6) <0.0005
Urea 5 606/12 802 (43.8) 15 258/39 380 (38.8) <0.0005
Sodium 2 023/4 091 (49.5) 21 429/53 956 (39.7) <0.0005
Potassium 2 608/5 116 (51.0) 20 581/52 679 (39.1) <0.0005
Table 5.9 – Density of serum concentration tests prior to and after an abnormal
test result
Density of tests (no. of tests per 28 days), mean (SD)
Prior to abnormal test After abnormal test P value†
Creatinine 0.189 (0.32) 0.157 (0.30) <0.0005
Urea 0.157 (0.32) 0.122 (0.29) <0.0005
Sodium 0.179 (0.33) 0.153 (0.53) <0.0005
Potassium 0.170 (0.35) 0.158 (0.33) 0.61
† Wilcoxon matched paired signed-rank test
5.3.3.2 The responsiveness of follow-up monitoring to co-prescription of
antihypertensive therapies
Very few patients had records of co-prescription of two drugs that could lead to
potential ADRs. When spironolactone or an AT-II receptor antagonist was prescribed
at the same time as an ACE inhibitor, there was a significant decrease in the density
of serum potassium concentration tests after the date of co-prescription (Table 5.10).
No statistically significant difference was observed in the number of tests prior to or
after the concomitant treatment with a thiazide diuretic and a loop diuretic.
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Table 5.10 – Density of serum concentration tests prior to and after the co-
prescription of potentially interacting drugs.
Concomitant
therapy Potential ADR
Number of
patients
with
concomitant
therapy
Biochemical
Test
Density of tests (no. of tests
per 28 days), mean (SD)
Prior After P value†
ACE inhibitor &
spironolactone
Hyperkalaemia 62 Potassium 0.197
(0.26)
0.147
(0.26)
0.0003
ACE inhibitor &
AT-II receptor
antagonist
Hyperkalaemia 2 913 Potassium 0.185
(0.32)
0.088
(0.18)
<0.0005
Thiazide diuretic
& loop diuretic
Hyperkalaemia 451 Potassium 0.113
(0.30)
0.172
(0.74)
0.25
† Wilcoxon matched paired signed-rank test
5.3.3.3 The responsiveness of follow-up monitoring to changes in treatment dose
Almost 40% (29 550) of patients had a change in the dose of the first antihypertensive
drug. 83% of the 56 247 dose changes involved an increase in the prescribed daily
dose. The density of tests was significantly smaller after a change in drug dose (Table
5.11).
Table 5.11 – Density of serum concentration tests prior to and after a dose
change
Density of tests (no. of tests per 28 days), mean (SD)
Prior to dose change After dose change P value†
Creatinine 0.173 (0.35) 0.089 (0.22) <0.0005
Urea 0.169 (0.5) 0.086 (0.22) <0.0005
Sodium 0.167 (0.35) 0.085 (0.22) <0.0005
Potassium 0.167 (0.35) 0.085 (0.21) <0.0005
† Wilcoxon matched paired signed-rank test
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5.4 What proportion of patients had both baseline testing and
follow-up monitoring?
In 17 445/74 096 patients (23.5%), both baseline testing and follow-up monitoring
within one year were performed. Over a third of patients treated with an ACE
inhibitor had both baseline testing and follow-up monitoring, compared with only
14% of patients started on combination antihypertensive treatment (Table 5.12).
Table 5.12 – Proportion of patients with records of both baseline and follow-up
monitoring, by drug class
The proportion of patients with at least one abnormal result increased from 13% at
baseline to 24% with treatment (Table 5.13). Of the 15 215 patients with normal
results at baseline, 2883 (18.9%) developed an abnormal test within one year of
starting treatment (Figure 5.10).
Drug class No. of patientstreated with drug
Creatinine
n (%)
Sodium
n (%)
Potassium
n (%)
ACE inhibitor 11 245 4 375 (38.9) 3 925 (34.9) 3 892 (34.6)
Alpha-blocker 753 156 (20.7) 138 (18.3) 135 (17.9)
AT-II receptor
antagonist 1 630 373 (22.9) 342 (21.0) 340 (20.9)
Beta-blocker 17 977 3 136 (17.4) 2 941 (16.4) 2 907 (16.2)
Ca-channel blocker 5 651 1 106 (19.6) 1 020 (18.1) 1 014 (17.9)
Combination 771 116 (15.1) 109 (14.1) 109 (14.1)
Loop or K-sparing
diuretic 416 83 (20.0) 77 (18.5) 77 (18.5)
Thiazide diuretic 35 653 7 571 (21.2) 7 096 (19.9) 7 031 (19.7)
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Table 5.13 – Proportion of patients with an abnormal biochemical test in those
patients with both baseline testing and follow-up monitoring within one year
Any test
(N=17 445)
Creatinine
(N=16 916)
Sodium
(N=15 648)
Potassium
(N=15 505)
Abnormal baseline
serum concentration,
n (%)
2 230 (12.8) 803 (4.8) 584 (3.7) 908 (5.9)
Any abnormal serum
concentration within
one year of
treatment, n (%)
4 188 (24.0) 1 302 (7.7) 1 324 (8.5) 2 039 (13.2)
Figure 5.10 – Distribution of abnormal tests in patients who had both baseline
testing and follow-up monitoring
Normal
values
(87%)
Abnormal
values
(13%)
Baseline testing
1 305
2 883
925
12 332
Normal
values
(76%)
Abnormal
values
(24%)
Follow-up monitoring
15 215
2 230
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5.5 What are the patient factors associated with biochemical
monitoring?
The patient factors associated with monitoring within six months and one year are
shown in Table 5.14 and Table 5.15. Patients with pre-existing diabetes, patients
started on ACE inhibitors at baseline, and those with a first antihypertensive
prescription in 2003 were more likely to be monitored. In the multivariable model,
monitoring was again significantly associated the presence of diabetes, first-line
antihypertensive therapy with ACE inhibitors, and year of first prescription.
Monitoring within one year was also significantly associated with increasing age,
baseline testing, and with socio-economic status, although the magnitude of these
associations was slight.
Table 5.14 – Logistic regression model of any monitoring in six months following
first prescription (n is the number of patients who exhibit the characteristic from
N, the total population assessed for this characteristic)
Baseline patient
characteristic n/N
Unadjusted OR
95% CI P value
Adjusted OR*
95% CI P value
Sex
Female 13 768/38 751 1 1
Male 13 178/35 345 1.08 1.05–1.11 <0.0005 1.00 0.97–1.04 0.91
Age
<40 1 112/3 492 1 1
40–49 3 599/10 388 1.12 1.03–1.22 0.007 1.09 0.99–1.19 0.09
50–59 7 118/20 360 1.14 1.05–1.23 0.001 1.12 1.03–1.22 0.009
60–69 7 214/19 312 1.26 1.17–1.36 <0.0005 1.24 1.14–1.36 <0.0005
70–79 5 830/14 971 1.35 1.25–1.46 <0.0005 1.35 1.23–1.48 <0.0005
80–89 1 936/5 190 1.26 1.15–1.38 <0.0005 1.26 1.13–1.41 <0.0005
90–100 127/383 1.05 0.84–1.31 0.683 1.17 0.84–1.63 0.34
Smoking status
Never 13 710/38 166 1 1
Ever 12 537/33 118 1.09 1.05–1.12 <0.0005 1.08 1.04–1.12 <0.0005
Diabetes status
No 23 271/67 659 1 1
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Baseline patient
characteristic n/N
Unadjusted OR
95% CI P value
Adjusted OR*
95% CI P value
Yes 3 675/6 437 2.54 2.41–2.67 <0.0005 2.03 1.91–2.16 <0.0005
SES quintile (0=least deprived)
0 5 823/15 660 1 1
1 5 011/13 205 1.03 0.98–1.08 0.182 1.06 1.00–1.12 0.04
2 5 318/15 005 0.93 0.89–0.97 0.002 0.92 0.87–0.97 0.002
3 4 760/14 154 0.86 0.82–0.90 <0.0005 0.88 0.83–0.93 <0.0005
4 6 034/16 072 1.02 0.97–1.06 0.508 1.06 1.00–1.12 0.02
Hypertension
Normal or mild 4 147/11 373 1 1
Moderate 10 836/30 241 0.97 0.93–1.02 0.232 1.07 1.02–1.13 0.005
Severe 11 098/28 529 1.11 1.06–1.16 <0.0005 1.31 1.25–1.38 <0.0005
BMI
Underweight 243/654 1.01 0.86–1.19 0.860 1.01 0.85–1.21 0.88
Normal 5 905/16 039 1 1
Overweight 9 334/25 392 0.98 0.96–1.03 0.907 0.98 0.94–1.03 0.42
Obese 7 840/20 606 1.05 1.00–1.10 0.016 1.02 0.97–1.07 0.37
Drug Therapy
Thiazide
diuretic 12 492/35 653 1 1
ACE inhibitor 6 049/11 245 2.16 2.07–2.25 <0.0005 1.93 1.82–2.03 <0.0005
Alpha-blocker 220/753 0.93 0.77–0.90 0.001 0.76 0.63–0.91 0.003
AT-II receptor
antagonist 576/1 630 1.01 0.91–1.12 0.804 0.99 0.87–1.11 0.81
Beta-blocker 5 441/17 977 0.80 0.77–0.84 <0.0005 0.87 0.83–0.91 <0.0005
Ca-channel
blocker 1 808/5 651 0.87 0.82–0.93 <0.0005 0.89 0.83–0.96 0.001
Loop or K-
sparing diuretic 149/416 1.03 0.85–1.27 0.740 1.41 1.10–1.81 0.006
Combination
preparation 211/771 0.70 0.60–0.82 <0.0005 0.79 0.66–0.95 0.01
Any baseline testing
No 15 419/43 002 1
Yes 11 527/31 094 1.05 1.02–1.09 0.001 0.80 0.77–0.83 <0.0005
Year of first prescription
2000 4 251/16 508 1 1
2001 5 742/17 927 1.36 1.30–1.42 <0.0005 1.35 1.28–1.43 <0.0005
2002 7 543/19 532 1.81 1.73–1.90 <0.0005 1.77 1.68–1.87 <0.0005
2003 9 410/20 129 2.53 2.42–2.64 <0.0005 2.56 2.43–2.69 <0.0005
* adjusted for sex, age, smoking status, diabetes, socio-economic status (SES), BMI, hypertension,
drug therapy, any baseline testing, and year of first prescription
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Table 5.15 – Logistic regression model of any monitoring in one year following
first prescription (n is the number of patients who exhibit the characteristic from
N, the total population assessed for this characteristic)
Baseline patient
characteristic n/N
Unadjusted OR
95% CI P value
Adjusted OR*
95% CI P value
Sex
Female 19 151/38 751 1 1
Male 18 214/35 345 1.09 1.06–1.12 <0.0005 1.02 0.98–1.05 0.32
Age
<40 1 486/3 492 1 1
40–49 4 882/10 388 1.19 1.11–1.29 <0.0005 1.19 1.09–1.30 <0.0005
50–59 9 811/20 360 1.26 1.17–1.35 <0.0005 1.27 1.17–1.38 <0.0005
60–69 10 122/19 312 1.49 1.38–1.60 <0.0005 1.52 1.39–1.65 <0.0005
70–79 8 180/14 971 1.63 1.51–1.75 <0.0005 1.71 1.56–1.87 <0.0005
80–89 2 701/5 190 1.46 1.34–1.60 <0.0005 1.57 1.41–1.75 <0.0005
90–100 183/383 1.24 1.00–1.53 0.050 1.52 1.10–2.11 0.01
Smoking status
Never 19 149/38 166 1 1
Ever 17 274/33 118 1.08 1.05–1.12 <0.0005 1.06 1.02–1.10 0.001
Diabetes status
No 32 491/67 659 1 1
Yes 4 874/6 437 3.38 3.18–3.58 <0.0005 2.77 2.58–2.97 <0.0005
SES quintile (0=least deprived)
0 7 843/15 660 1 1
1 6 891/13 205 1.09 1.04–1.14 <0.0005 1.11 1.05–1.17 <0.0005
2 7 377/15 005 0.96 0.92–1.00 0.107 0.95 0.90–1.00 0.06
3 6 731/14 154 0.90 0.86–0.95 <0.0005 0.94 0.89–0.99 0.02
4 8 523/16 072 1.13 1.08–1.18 <0.0005 1.17 1.11–1.24 <0.0005
Hypertension
Normal or mild 5 829/11 373 1 1
Moderate 15 334/30 241 0.98 0.94–1.02 0.320 1.07 1.02–1.12 0.007
Severe 14 975/28 529 1.05 1.00–1.10 0.026 1.22 1.16–1.28 <0.0005
BMI
Underweight 342/654 1.04 0.89–1.22 0.586 1.02 0.86–1.21 0.81
Normal 8 213/16 039 1 1
Overweight 13 125/25 392 1.02 0.98–1.06 0.338 1.01 0.97–1.05 0.67
Obese 10 817/20 606 1.05 1.01–1.10 0.014 1.05 1.00–1.10 0.03
Drug Therapy
Thiazide
diuretic 17 706/35 653 1 1
ACE inhibitor 7 473/11 245 2.00 1.92–2.10 <0.0005 1.62 1.53–1.71 <0.0005
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Baseline patient
characteristic n/N
Unadjusted OR
95% CI P value
Adjusted OR*
95% CI P value
Alpha-blocker 360/753 0.93 0.80–1.07 0.314 0.93 0.79–1.11 0.43
AT-II receptor
antagonist 783/1 630 0.94 0.85–1.03 0.199 0.89 0.79–0.99 0.05
Beta-blocker 7 874/17 977 0.78 0.76–0.82 <0.0005 0.89 0.85–0.92 <0.0005
Ca-channel
blocker 2 643/5 651 0.89 0.84–0.94 <0.0005 0.91 0.85–0.97 0.005
Loop or K-
sparing diuretic 213/416 1.05 0.87–1.28 0.598 1.32 1.02–1.69 0.03
Combination
preparation 314/771 0.70 0.60–0.81 <0.0005 0.83 0.70–0.99 0.03
Any baseline testing
No 19 920/43 002 1
Yes 17 445/31 094 1.48 1.44–1.53 <0.0005 1.15 1.11–1.19 <0.0005
Year of first prescription
2000 6 189/16 508 1 1
2001 8 008/17 927 1.34 1.29–1.41 <0.0005 1.31 1.25–1.38 <0.0005
2002 10 401/19 532 1.90 1.82–1.98 <0.0005 1.83 1.74–1.92 <0.0005
2003 12 767/20 129 2.89 2.77–3.01 <0.0005 2.80 2.66–2.94 <0.0005
* adjusted for sex, age, smoking status, diabetes, socio-economic status (SES), BMI, hypertension,
drug therapy, any baseline testing, and year of first prescription
5.6 What is the association between follow-up monitoring and
adverse patient outcomes?
Overall, the rate of biochemical ADRs within six months and one year of starting
treatment was low and varied by drug class (Table 5.16). Patients treated with ACE
inhibitors or thiazide diuretics had a higher rate of hyponatraemia. Hyperkalaemia
was more frequently detected in patients treated with ACE inhibitors and
hypokalaemia was most often seen in patients treated with thiazide diuretics.
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657 patients (0.9%) died within one year of beginning antihypertensive treatment. The
death rate was significantly higher in those who had any biochemical monitoring than
in those patients who did not. This increase was not explained by confounding as
adjustment for potential confounding factors did not reduce the magnitude of
association (adjusted hazard ratio 1.37, 95% CI 1.12–1.67) (Table 5.17).
2499 patients (3.4%) were admitted to hospital at least once within one year of
starting antihypertensive treatment. 456 patients had more than one admission (range
1–7). Patients were more likely to be admitted to hospital if their biochemistry had
been monitored after beginning treatment, even when allowance was made for sex,
age, smoking, presence of diabetes, socio-economic status, and first-line drug therapy
(adjusted hazard ratio 1.27, 95% CI 1.16–1.39) (Table 5.18).
Table 5.17 – Hazard ratios (with 95% confidence intervals) for death in the one
year following first antihypertensive prescription
Unadjusted HR P value Adjusted HR* P valueHR 95% CI HR 95% CI
Any monitoring on or before event
No 1 1
Yes 1.28 1.09–1.50 0.003 1.37 1.12–1.67 0.002
Sex
Female 1 1
Male 1.26 1.08–1.47 0.003 1.51 1.24–1.85 <0.0005
Age
<50 1 1
50–59 3.02 1.81–5.04 <0.0005 3.69 1.94–7.01 <0.0005
60–69 5.21 3.19–8.54 <0.0005 5.83 3.12–10.9 <0.0005
70–79 11.8 7.30–19.1 <0.0005 12.0 6.49–22.3 <0.0005
80–89 24.9 15.3–40.6 <0.0005 29.1 15.6–54.5 <0.0005
90–100 69.7 39.3–123 <0.0005 71.9 32.4–159 <0.0005
Smoking
Never 1 1
Ever 2.15 1.76–2.62 <0.0005 2.15 1.75–2.64 <0.0005
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Unadjusted HR P value Adjusted HR* P valueHR 95% CI HR 95% CI
Diabetes status
No 1 1
Yes 1.59 1.26–1.99 <0.0005 1.82 1.35–2.45 <0.0005
SES quintile
0 (least deprived) 1 1
1 1.35 1.05–1.72 0.019 1.80 1.31–2.47 <0.0005
2 1.18 0.92–1.51 0.199 1.48 1.07–2.04 0.02
3 1.17 0.91–1.51 0.217 1.44 1.04–1.99 0.03
4 1.21 0.95–1.55 0.116 1.45 1.05–1.99 0.02
Hypertension
Normal or mild 1 -
Moderate 0.82 0.65–1.05 0.118 -
Severe 1.22 0.97–1.54 0.089 -
Drug therapy
Thiazide diuretic 1 1
ACE inhibitor 0.89 0.70–1.13 0.345 0.87 0.63–1.20 0.38
Alpha-blocker 1.22 0.61–2.47 0.573 0.37 0.09–1.50 0.16
AT-II receptor
antagonist 0.63 0.33–1.23 0.179 0.27 0.07–1.10 0.07
Beta-blocker 0.74 0.60–0.92 0.006 1.24 0.96–1.60 0.10
Ca-channel blocker 1.54 1.19–1.98 0.001 1.34 0.98–1.84 0.07
Loop/K-sparing diuretic 9.63 6.72–13.8 <0.0005 4.40 2.64–7.34 <0.0005
Combination
preparation 2.88 1.81–4.58 <0.0005 2.57 1.36–4.84 0.004
* adjusted for any monitoring, age, sex, smoking status, diabetes, SES, and first antihypertensive therapy
103
Table 5.18 – Hazard ratios (with 95% confidence intervals) for first hospital
admission in the one year following antihypertensive prescription
Unadjusted HR P value Adjusted HR* P valueHR 95% CI HR 95% CI
Any monitoring on or before event
No 1
Yes 1.30 1.20–1.42 <0.0005 1.27 1.16–1.39 <0.0005
Sex
Female 1
Male 1.03 0.96–1.12 0.391 1.06 0.97–1.15 0.21
Age
<50 1 1
50–59 1.00 0.96–1.15 0.957 1.05 0.91–1.21 0.50
60–69 1.33 1.17–1.51 <0.0005 1.33 1.16–1.52 <0.0005
70–79 1.71 1.50–1.95 <0.0005 1.77 1.54–2.03 <0.0005
80–89 2.15 1.84–2.51 <0.0005 2.12 1.78–2.52 <0.0005
90–100 2.14 1.36–3.36 0.001 2.11 1.23–3.62 0.01
Smoking
Never 1 1
Ever 1.14 1.05–1.23 0.002 1.12 1.03–1.22 0.01
Diabetes status
No 1 1
Yes 1.17 1.03–1.34 0.017 1.11 0.96–1.18 0.17
SES quintile
0 (least deprived) 1 1
1 0.95 0.83–1.10 0.520 0.95 0.82–1.11 0.55
2 1.19 1.04–1.36 0.010 1.20 1.05–1.38 0.01
3 1.79 1.58–2.02 <0.0005 1.82 1.61–2.08 <0.0005
4 1.42 1.25–1.61 <0.0005 1.38 1.21–1.58 <0.0005
Hypertension
Normal or mild 1 1
Moderate 0.87 0.78–0.98 0.024 0.86 0.76–0.97 0.02
Severe 1.07 0.95–1.20 0.272 0.95 0.84–1.08 0.44
Drug therapy
Thiazide diuretic 1 1
ACE inhibitor 1.03 0.91–1.16 0.620 1.03 0.90–1.18 0.67
Alpha-blocker 1.29 0.90–1.86 0.163 1.00 0.65–1.54 0.99
AT-II receptor
antagonist 1.01 0.76–1.34 0.941 1.04 0.77–1.41 0.80
Beta-blocker 1.12 1.01–1.23 0.209 1.25 1.12–1.39 <0.0005
Ca-channel blocker 1.63 1.43–1.85 <0.0005 1.52 1.32–1.75 <0.0005
Loop/K-sparing diuretic 2.94 2.10–4.11 <0.0005 2.02 1.35–3.05 0.001
Combination preparation 0.98 0.64–1.48 0.922 0.85 0.52–1.37 0.50
* adjusted for any monitoring, age, sex, smoking status, diabetes, SES, hypertension and first antihypertensive
therapy
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Over half (52.7%) of patients discontinued the antihypertensive drug initiated on the
index date within one year. The mean time to discontinuation was 120 days (median
86). Of the 39 019 patients who discontinued treatment, 7316 (18.7%) had a
discontinuation date of 28 days. This would suggest that a significant proportion of
patients discontinued their antihypertensive treatment after one course of therapy.
Any biochemical monitoring was significantly associated with a small increase in the
risk of discontinuation of the first antihypertensive prescription (adjusted HR 1.05,
95% CI 1.03–1.08) (Table 5.19).
Table 5.19 – Hazard ratios (with 95% confidence intervals) for discontinuation
of the first antihypertensive prescription in the one year following the start of
treatment
Unadjusted HR P value Adjusted HR* P valueHR 95% CI HR 95% CI
Any monitoring on or before event
No 1 1
Yes 1.02 0.99–1.04 0.087 1.05 1.03–1.08 <0.0005
Sex
Female 1 1
Male 1.00 0.98–1.02 0.687 1.01 0.99–1.03 0.300
Age
<50 1 1
50–59 0.83 0.81–0.85 <0.0005 0.83 0.80–0.86 <0.0005
60–69 0.77 0.75–0.79 <0.0005 0.76 0.73–0.78 <0.0005
70–79 0.80 0.77–0.82 <0.0005 0.78 0.75–0.81 <0.0005
80–89 0.94 0.90–0.98 <0.0005 0.89 0.85–0.94 <0.0005
90–100 1.08 0.95–1.22 0.262 1.03 0.88–1.20 0.71
Smoking
Never 1 1
Ever 1.02 0.99–1.04 0.057 1.02 1.00–1.04 0.05
Diabetes status
No 1 1
Yes 0.86 0.83–0.89 <0.0005 0.89 0.85–0.94 <0.0005
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Unadjusted HR P value Adjusted HR* P valueHR 95% CI HR 95% CI
SES quintile
0 (least deprived) 1 1
1 1.02 0.99–1.05 0.244 0.99 0.96–1.03 0.82
2 1.02 0.99–1.06 0.136 1.02 0.99–1.05 0.26
3 1.10 1.07–1.14 <0.0005 1.08 1.05–1.12 <0.0005
4 1.13 1.09–1.16 <0.0005 1.10 1.06–1.13 <0.0005
Hypertension
Normal or mild 1 1
Moderate 0.92 0.89–0.95 <0.0005 0.92 0.89–0.95 <0.0005
Severe 0.93 0.90–0.96 <0.0005 0.93 0.90–0.96 <0.0005
Drug therapy
Thiazide diuretic 1 1
ACE inhibitor 0.91 0.88–0.93 <0.0005 0.90 0.87–0.93 <0.0005
Alpha-blocker 1.00 0.91–1.11 0.883 1.00 0.90–1.12 0.94
AT-II receptor
antagonist
0.83 0.77–0.90 <0.0005 0.80 0.74–0.86 <0.0005
Beta-blocker 0.97 0.95–0.99 0.016 0.94 0.92–0.97 <0.0005
Ca-channel blocker 1.11 1.07–1.15 <0.0005 1.10 1.06–1.15 <0.0005
Loop/K-sparing diuretic 2.30 2.05–2.57 <0.0005 2.30 2.03–2.60 <0.0005
Combination
preparation 1.11 1.00–1.22 0.031 1.06 0.96–1.18 0.27
* adjusted for any monitoring, age, sex, smoking status, diabetes, SES, hypertension and first
antihypertensive therapy
I defined drug discontinuation as no subsequent prescription 30 days after the expiry
of the prescription. The delay of 30 days was to allow for alternative supply and less
than perfect dosing compliance (section 3.3.6.1). The use of an alternative 60-day
definition of discontinuation decreased the proportion of patients discontinuing the
first-ever antihypertensive therapy within one year to 40.4% (Table 5.20). The use of
a 90-day definition further decreased the proportion of patients who discontinued their
first course of treatment to 35.7%. The predictive relationships of other patient factors
in the multivariable models remained similar when the different discontinuation
definitions were examined.
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Table 5.20 – Sensitivity analysis comparing different discontinuation definitions
Discontinuation
definition
Patients
discontinuing
treatment
within 1 year,
n (%)
Any monitoring on or before the day of discontinuation of
the first antihypertensive prescription within 1 year
Unadjusted HR
(95% CI)
P value Adjusted HR*
(95% CI)
P value
30-day definition 39 019 (52.7) 1.02 0.99–1.04 0.087 1.05 1.03–1.08 <0.0005
60-day definition 29 909 (40.4) 1.05 1.02–1.08 <0.0005 1.09 1.06–1.12 <0.0005
90-day definition 26 467 (35.7) 1.07 1.04–1.10 <0.0005 1.11 1.09–1.15 <0.0005
* adjusted for any monitoring, age, sex, smoking status, diabetes, SES, hypertension and first
antihypertensive therapy
Within the cohort of patients who had a serum concentration test within one year, a
serum concentration test indicative of a biochemical ADR was significantly
associated with an increased risk of death, hospital admission, and discontinuation of
first antihypertensive treatment (Table 5.21).
Table 5.21 – Hazard ratios (with 95% confidence intervals) for adverse patient
outcomes after a serum concentration test indicating a biochemical ADR
Death Hospital admission Discontinuation of first
antihypertensive treatment
Adjusted HR*
(95% CI)
Adjusted HR*
(95% CI)
Adjusted HR*
(95% CI)
Hyponatraemia 5.71 (3.61–9.04) 2.16 (1.53–3.03) 2.24 (1.99–2.52)
Hyperkalaemia 2.93 (1.65–5.18) 1.77 (1.26–2.50) 1.24 (1.09–1.40)
Hypokalaemia 4.34 (2.63–7.16) 1.54 (1.12–2.13) 1.39 (1.26–1.52)
* adjusted for age, sex, smoking status, diabetes, SES, hypertension and first antihypertensive therapy
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5.7 Assessing the impact of the definition of baseline testing and
follow-up monitoring
Baseline testing was defined as any record of a serum concentration in the six months
before and up to and including two days after the start of treatment, while follow-up
monitoring was defined as any record of a serum concentration from three days after
the start of treatment. The decision was made to use this definition primarily because
of potential delays in the uploading of laboratory test results as prior to 2003 the
majority of laboratory data entry was not automated. This decision is supported by
Figure 5.7, which demonstrates a large number of tests on days 0 and 1, followed by a
significant drop in the number of tests.
If the definition of baseline testing is changed to include the first seven days after the
initiation of antihypertensive therapy, the number of patients with baseline testing is
increased from 31 094 (42%) to 35 388 (48%). The corollary of the change in
definition is that the number of patients with follow-up monitoring within one year
decreases from 37 365 (50%) to 33 071 (45%). Almost 14% (576) of the 4294 patients
with a biochemical test on days three to seven had a record of baseline testing.
Changing the definitions of baseline testing and follow-up monitoring would also
increase the number of patients who had both baseline testing and follow-up
monitoring from 17 445 (23.5%) to 19 550 (26.4%). Certainly there is a difference
depending on the definition used, however this change is not very large and does not
greatly affect the results.
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5.8 Investigating the impact of immortal time bias on the results
5.8.1 Quantifying the impact of immortal time bias
The estimates for the association between biochemical monitoring and adverse patient
outcomes presented in previous sections were adjusted for immortal time bias. This
bias can arise when immortal time is misclassified and can create an artificial
protective effect for an exposure (described previously in section 4.3.3).
I wished to illustrate the nature of immortal time bias through the use of a Poisson
regression model. The rate ratios of the various adverse events associated with
biochemical monitoring were estimated using the number of events and person-time.
When data were unadjusted for immortal time, a decreased mortality rate with
biochemical monitoring was observed (crude rate ratio 0.67, 95% CI 0.66–0.69)
(Table 5.22). I also used a time-fixed Cox proportional hazards model where
monitoring was not treated as a time-dependent covariate and immortal time was not
correctly classified. A similar adjusted hazard ratio to the crude rate ratio was
obtained (0.67, 95% CI 0.55–0.81). Therefore, this analysis, which did not take into
account immortal time, suggested that biochemical monitoring had a protective effect.
There were 12 013 person-years of follow-up during which patients were yet to have
biochemical monitoring, which should have been ascribed to the unmonitored group.
This accounted for approximately 32% of total follow-up time allocated to patients
with monitoring. This immortal time, when correctly classified, resulted in a corrected
crude rate ratio of 1.33 (95% CI 1.30–1.36), suggesting an increased risk of death in
patients with biochemical monitoring. This result is similar to the adjusted hazard
109
ratio from the time-to-event analyses presented previously (1.37, 95% CI 1.12–1.67).
Similar differences in results were obtained when the failure to control for immortal
time bias in the analysis of biochemical monitoring and hospital admission and drug
discontinuation was examined.
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5.8.2 Dealing with immortal time bias
I have demonstrated that the person time that was incorrectly allocated to the
monitoring group represented over one third of the follow-up time for patients with
monitoring. This caused a falsely low rate of events in the patients with monitoring
and created an artificial protective effect of monitoring for all three adverse patient
outcomes. This tendency for immortal time bias to create an artificial benefit for an
exposure has been demonstrated by other authors (Suissa, 2007; Lévesque et al.,
2010).
Treating the exposure of interest as time-dependent or time-varying is one method
that can be used to control for immortal time bias, and is the method I have used in
this analysis. Several additional techniques for dealing with immortal time have been
suggested including: (1) using a time matched, nested case-control analysis; (2)
prescription time-distribution matching (where the start of follow-up time for treated
patients is moved to the end of the immortal period and the follow-up time for
untreated patients is assigned according to the distribution of the treated patients’ time
to start of treatment) ; and (3) classifying the exposure as a binary value (where use
takes the value of 1 for those who started treatment within 90 days of cohort entry and
0 for those who did not). Exposed and unexposed patients are then followed until the
event. This therefore follows only 90-day survivors from the same point in time
(Suissa, 2005; Zhou et al., 2005; Lévesque et al., 2010).
Immortal time bias is not restricted to studies of drug therapies, but has also been
shown to artificially increase the benefit of other interventions. Given the widespread
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nature of this bias in published studies, there is a need for increased awareness and
improved vigilance in order to control and restrict its effect.
5.9 Discussion
In a large cohort of patients with newly diagnosed hypertension, most patients began
treatment with either thiazide diuretics or beta-blockers, consistent with
contemporaneous guidelines (Ramsay et al., 1999) and as previously demonstrated in
the UK (Walley et al., 2003). In addition, an increase in the proportion of patients
treated with thiazide diuretics was observed in 2003, which is similar to the trend seen
in North America. Stafford and colleagues (2006) demonstrated an increase in the
prescription of thiazide diuretics following the publication of the ALLHAT trial in
December 2002, which demonstrated clinical equivalence of thiazide diuretics to
ACE inhibitors and calcium channel blockers (The ALLHAT Officers and
Coordinators, 2002).
Only 310 94 patients (42%) had any baseline biochemical test in the six months prior
to beginning antihypertensive treatment, despite guideline recommendations. The
absence of baseline testing is inconsistent with standard guidelines. Even older
hypertension guidelines state that the measurement of serum electrolyte and urea or
creatinine concentrations is ‘essential’ (Sever et al., 1993). These and other simple
baseline investigations allow the detection of some causes of secondary hypertension,
associated cardiovascular risk factors, evidence of target organ damage, and co-
morbid diseases, all of which can influence treatment decisions. Absence of baseline
testing also makes assessment of changes in renal function and electrolyte
concentrations after the initiation of treatment more difficult.
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Half of the cohort had follow-up laboratory monitoring in the year after the initiation
of drug therapy; monitoring occurred within six months of starting treatment in a
minority (36%) of patients. These rates compare with similar poor rates of follow-up
monitoring seen in other studies of antihypertensive drugs used in primary care
(Hurley et al., 2005; Clayton et al., 2006b; McAlister et al., 2007; Raebel et al.,
2007b) and in hospitalized patients (Uijtendaal et al., 2011). Low levels of monitoring
have also been demonstrated in other drugs such as statins (Abookire et al., 2001;
Tragni et al., 2007), thiazolidinediones (Graham et al., 2001), and allopurinol (Raebel
et al., 2006). A GP practice consultation was recorded within 24 days of treatment for
half of the cohort, so the lack of follow-up monitoring was most likely not due to non-
attendance but because only a small proportion of patients was monitored.
Overall, less than a quarter of patients had both baseline testing and subsequent
follow-up monitoring, depriving their doctors of the opportunity to assess intra-
individual changes within the reference range. Also, for those patients who had
baseline monitoring alone, this deprives the doctors of the assurance that treatment
had caused no biochemical ADR. Guidelines have specifically recommended that all
hypertensive patients given an ACE inhibitor should have their renal function
measured before and after one week of treatment (Smellie et al., 2007). This is
because a rise in previously normal serum creatinine concentration of ≥30% after
starting treatment with an ACE inhibitor may suggest renovascular disease. Although
more patients treated with an ACE inhibitor had both baseline testing and follow-up
monitoring of their serum creatinine concentrations than patients treated with other
drug classes, over 60% of those patients did not have their renal function (either
creatinine or urea concentration) measured before and after the start of treatment. In
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general, only forty percent of patients who did have at least one follow-up monitoring
test had a second follow-up test within one year. This lack of additional monitoring
limits the ability of GPs to judge sequential changes in serum concentrations.
The proportion of patients monitored after starting treatment increased over the four-
year period that I examined. This improvement was similar to the pattern
demonstrated in the proportion of patients with a record for weight and smoking in the
GPRD, and may reflect a general improvement in standards in general practice
(Campbell et al., 2005), or in the way guidelines are implemented. This improvement
may have also been as a result of the trend towards the use of incentive schemes
targetted at GPs. The Quality and Outcomes Framework (QoF) was introduced as part
of the General Medical Services Contract, as a scheme to reward GPs in the UK for
how well they care for patients (NHS Employers, 2011). Although QoF was not
introduced until after the time period examined in this study—April 2004—the
improvement seen in the level of monitoring may have been a reflection of the general
trend towards the use of these types of incentive schemes.
Older patients and those with diabetes mellitus were more likely to have either
baseline testing or follow-up monitoring, which is consistent with the results of other
smaller studies (Hurley et al., 2005; Raebel et al., 2007b). Although patients treated
with diuretic drugs and those acting on the angiotensin system were more likely to be
monitored than those treated with drugs such as calcium antagonists that have fewer
biochemical adverse effects, many patients treated with drugs with a potential to
cause biochemical harm went unmonitored.
Patient outcomes
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Biochemical ADRs within one year of the start of antihypertensive treatment were
rare and the majority of the ADRs were identified solely based on a serum
concentration below a certain value and not by a clinical code. Certainly, many
patients suffering biochemical disturbances will be asymptomatic and therefore
detected only on monitoring. If the patient had not been monitored, the ADR would
not have been identified, which may have caused further harm to the patient.
Patients who had any monitoring within the one year of their first prescription were
slightly but significantly more likely to be admitted to hospital within that time. This
might be explained by admission as a consequence of the results of monitoring tests
that showed, for example, hyperkalaemia or important renal impairment. It might also
be explained by doctors being more ready to arrange biochemical tests in patients
with conditions, such as heart failure, that will themselves require admission to
hospital. Alternatively, doctors may be ordering laboratory tests when patients present
with an illness that will then progress to a hospital admission. This may be an
example of more reactive monitoring or monitoring by indication, rather than a more
proactive monitoring approach.
A small proportion of patients died within one year of starting antihypertensive
treatment. Patients that were monitored demonstrated a small, although statistically
significant, increase in the risk of death compared with those who had no monitoring.
However, because of the small number of deaths used in the modelling there is greater
uncertainty to the results, and therefore it is difficult to make generalizations to other
populations.
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Discontinuation of drug therapy is a common problem in clinical practice and
constitutes a significant challenge to patients and healthcare providers. Over half of
the patients discontinued their first antihypertensive treatment within one year. This
proportion is higher than in other studies (Hasford et al., 2002; Burke et al., 2006;
Elliott et al., 2007), although this may be due to differences in the distribution or
sequence of antihypertensive treatment, the patient population, or the more stringent
definition of discontinuation. Of those patients who discontinued first
antihypertensive treatment, almost 20% discontinued at 28 days. This would suggest
that a large proportion of patients discontinued treatment after one course of
treatment. My analysis did not attempt to consider discontinuation rate or its
definition as the primary focus. The different discontinuation rates do, however,
highlight problems in intermittent compliance during presumed chronic therapy. The
discontinuation rate may therefore only be a loose proxy for intolerance to treatment.
Monitoring was associated with an increased risk of discontinuation, which may be
associated with several factors including increased patient contact, lack of drug
efficacy or the serum concentration test detecting an adverse effect of the treatment
that would warrant discontinuation.
When I explored the relationship between monitoring and the three outcomes
described above, monitoring was treated as a time-dependent covariate in order to
control for immortal time bias. The extent of this type of bias is directly dependent on
the amount of immortal time that is misclassified (Suissa, 2007). A patient with
biochemical monitoring was defined as any patient with a biochemical measurement
in the 365 days following the start of antihypertensive treatment. Patients that
experienced an outcome shortly after the start of treatment were less likely to be
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classified as monitored because the opportunity for having a biochemical test was
lower. Likewise, a patient that had biochemical monitoring later (e.g. on the 100th day
after starting antihypertensive treatment) would have been free from any outcomes
during the first 100 days (thus immortal time). Therefore a majority of events that
occurred soon after the start of antihypertensive treatment would have been classified
as not monitored as there would have been fewer opportunities to receive biochemical
monitoring (Suissa, 2003). This results in a higher rate of the outcomes in the patients
that did not have monitoring and artificially decreased the rate of the outcome among
patients that had biochemical monitoring, which was seen when I did not model
monitoring as a time-dependent covariate.
5.10 Strengths and weaknesses of this analysis
5.10.1 Strengths
This work has examined the nature and frequency of biochemical monitoring using a
very large and well-validated database. Most previous studies of monitoring have
been carried out using data from American Health Maintenance Organizations, where
monitoring is often protocol-driven, and therefore the results of such studies are not as
relevant to the UK. The analysis was carried out on a significantly larger population
than any of the three previous studies examining monitoring in primary care in the
UK (Rhodes, 1992; Kalra et al., 1999; Clayton et al., 2006b). My analysis also looked
at both baseline testing and follow-up monitoring and investigated the changes in
serum sodium concentrations before and after treatment, which has not been
previously carried out in other studies. I undertook modelling to identify patient
factors associated with monitoring which importantly adjusted for immortal time bias;
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a bias that I have clearly shown can create the illusion of a real benefit in an
intervention like biochemical monitoring. Finally, this was the first study that, to the
best of my knowledge, examined monitoring not only as a binary outcome, but also
explored the frequency and regularity of monitoring.
5.10.2 Weaknesses
There were some limitations and weaknesses to my study. It was impossible to
determine the exact context in which monitoring occurred and therefore I cannot be
sure that the laboratory tests were undertaken specifically because the patient was
being treated with an antihypertensive drug. I was not able to determine from the
database whether the GP had undertaken planned or reactive monitoring, in that I
could not tease out whether the record of a serum potassium concentration was an
indication of a planned monitoring test because the patient was newly treated with an
ACE inhibitor, or because the patient presented with an illness that the GP felt
required some laboratory tests. Furthermore, I could not determine whether the GP
had intended to monitor only potassium, only sodium or both serum electrolyte
concentrations, as these tests can generally only be ordered at the same time. Finally,
it was impossible to differentiate between GPs failing to undertake biochemical
monitoring and patients failing to attend for monitoring.
The GP practice records may not have captured monitoring that may have occured in
secondary care. However, most patients with hypertension, especially those with
‘simple’ hypertension requiring therapy with a single agent, are treated in the
community. The GP who initiated treatment would usually be responsible for
monitoring.
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Inevitability, decisions of treatment and monitoring differ amongst GPs. The GPRD
does not provide specific information on GPs (e.g. gender, age) or the GP practice
itself (e.g. whether it was a group or a single-handed practice). Therefore I was
unfortunately unable to make adjustments for potential differences between GPs in
their decision and ability to carry out biochemical monitoring due to the lack of
available data on GP characteristics.
The majority of patients were included in the cohort based on a code for hypertension
and coding for hypertension may not have been consistent across the different
practices. Although I used the the threshold for initiation of antihypertensive
treatment that was in place at the time, I may also have missed patients treated with
antihypertensive agents at blood pressures lower than we defined.
I relied on records of issued prescriptions, and therefore I do not know that the patient
collected, or most importantly took, the medicine prescribed (Vrijens et al., 2008). I
might therefore have over-estimated the number of patients taking medicines, and so
over-estimated the ‘non-monitoring’ rate.
The proportion of patients who had at least one monitoring test increased significantly
during the survey period. This is most likely due to an increase in the number of
practices becoming linked electronically to laboratories where tests results are
incorporated automatically into the GP practice’s electronic records. Without this
direct link to the laboratory, it would have been up to the practice to record paper-
based laboratory results in their electronic records, which may have caused an under-
reporting of monitoring. In addition, the data were collected during a time of change
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in United Kingdom general practice that resulted in improvements in the management
of hypertension as judged by the increased recording of blood pressure measurements
(Ashworth et al., 2008). Although I cannot be sure the data reflect current practice in
biochemical monitoring, the differences in monitoring between drug classes and
amongst patients are likely to persist.
I chose not to include renal function at baseline as a potential predictor of subsequent
monitoring in the models. Although a GP may base their decisions to monitor serum
concentrations on a patient’s renal function, the inclusion of this variable in the
statistical models would have required a measurement of serum creatinine or urea
concentration and biased the results by restricting the analyses to patients who already
had a laboratory test and might be more likely to be monitored.
Finally, I did not consider potential bias associated with missing data in the study
cohort. A significant number of patients were excluded from multivariable analyses
examining the patient factors associated with biochemical monitoring due to missing
data such as body mass index, which may have led to the introduction of bias into the
results. The issue of missing data will be addressed in Chapter 7.
5.11 Conclusions
Just over half over the study cohort had any biochemical monitoring within one year
of antihypertensive therapy. Monitoring tended to be sparse and did not tend to follow
any regular patterns of testing. The elderly, those with diabetes, and those on ACE
inhibitors were more likely to be monitored. Few patients had both baseline tests and
subsequent monitoring, but almost one in four of those developed an abnormal test
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within one year of starting treatment. The majority of abnormal tests were recorded on
the first monitoring test. Despite this, those who were untested were less likely to be
admitted to hospital, discontinue treatment or die. The laboratory testing identified a
small proportion of patients with evidence of a biochemical ADR. Biochemical
laboratory monitoring was therefore able to identify patients who developed an ADR
during antihypertensive treatment, as had been supposed. The results suggest,
however, that the benefits of monitoring as practiced are slight. It is unclear whether
more frequent or more assiduous monitoring in general practice would reduce serious
harm from ADRs. There is a need for rational schemes for monitoring ADRs, based
on good evidence.
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Chapter 6
A SUB-GROUP ANALYSIS OF
BIOCHEMICAL ELECTROLYTE
MONITORING IN THIAZIDE
DIURETIC-TREATED PATIENTS
This chapter presents results from thiazide diuretic-treated patients, who represent the
largest sub-group of patients from the initial cohort of patients newly diagnosed with
hypertension and newly treated with antihypertensive therapy. Using this sub-group
of patients, I further evaluate the nature of sodium and potassium monitoring. I also
investigate the frequency of thiazide diuretic-induced hyponatraemia, which is an
adverse reaction to treatment that is not well characterized in primary care.
6.1 Introduction
Thiazide diuretics are clinically effective and cost-effective drugs for the treatment of
essential hypertension, and are recommended as initial therapy for patients in
numerous published guidelines (Chobanian et al., 2003; Guidelines Committee, 2003;
National Collaborating Centre for Chronic Conditions, 2006). After the publication of
the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
(ALLHAT), which recommended the thiazide diuretic class as the first-choice
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antihypertensive medication (The ALLHAT Officers and Coordinators, 2002), this
class of drugs became more widely used (Xie et al., 2005). As described previously
(chapter 1, sections 1.2.2 and 1.2.3), thiazide diuretics can cause several metabolic
ADRs such as hyponatraemia and hypokalaemia.
Hyponatraemia is identified by an abnormally low serum sodium concentration,
generally defined as less than 135 mmol/l. Diuretics are the most common cause of
drug-induced hyponatraemia, the majority being thiazide diuretics or thiazide diuretic-
like agents (Liamis et al., 2008a). Thiazide diuretic-induced hyponatraemia is
considered to be of rapid onset, with 50–90% of cases occurring within two weeks of
thiazide diuretic use (Spital, 1999; Aronson, 2006; Mann, 2008). Several mechanisms
for hyponatraemia due to thiazide diuretics have been postulated including, (1) a
positive water balance; (2) negative sodium and/or potassium balance; or (3) a shift of
sodium from the extracellular to the intracellular space (Spital, 1999). Mild
hyponatraemia is usually asymptomatic, but severe hyponatraemia often requires
hospitalization and is associated with symptoms including vomiting, nausea, and
lethargy (Sharabi et al., 2002).
Hypokalaemia is often defined as a serum potassium concentration less than 3.5 mmol
and has been shown to occur in 10–40% of patients treated with thiazide diuretics
(Gennari, 1998). The degree of hypokalaemia due to thiazide diuretic therapy has
been shown to be dose-dependent (Ben Salem et al., 2009). In two large randomized
controlled trials of low-dose thiazide diuretic treatment, the incidence of
hypokalaemia was low (Franse et al., 2000; The ALLHAT Officers and Coordinators,
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2002). Patients with low serum potassium concentrations are generally asymptomatic,
but the condition can be life threatening when severe.
Hypokalaemia and hyponatraemia can occur concurrently. Indeed, several studies
have demonstrated that low potassium concentrations are common in patients with
hyponatraemia (Ashraf et al., 1981; Sterns, 1987; Dorup et al., 1988). Potassium
deficiency may predispose patients to hyponatraemia because serum sodium
concentrations are dependent on the relationship between exchangeable sodium and
potassium (Fichman et al., 1971). Hypokalaemia may also increase the risk of serious
neurological impairment caused by hyponatraemia (Lohr, 1994).
Most research examining these thiazide diuretic-induced hyponatraemia has been
carried out in controlled trials of hospitalized patients, who frequently have significant
co-morbidities. The nature and frequency of this ADR is not very well characterized
in primary care, where the majority of thiazide diuretics are prescribed (Clayton et al.,
2006b). Therefore the aims of this analysis were:
1. To use a large electronic database to examine the nature of electrolyte
monitoring in patients treated with thiazide diuretics in primary care;
2. To estimate the frequency of hyponatraemia and concurrent hypokalaemia in
this sub-group of patients.
6.2 Methods
Thiazide diuretic-treated patients were identified from the cohort of patients who were
newly diagnosed with hypertension and newly treated with a single antihypertensive
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agent (described in detail in chapter 3). 1143 women who could have been pregnant at
the time of the study were excluded because of potential differences in clinical course,
treatment, and monitoring of pregnancy-associated hypertension.
The sub-group analysis focused on the patients who were prescribed a thiazide
diuretic alone as their first course of treatment. The same baseline patient covariates
described in section 3.3.3 were used in this sub-group analysis. Smoking status, the
presence of diabetes mellitus, and body mass index (BMI) were used in the analysis if
recorded within five years of the index date, and systolic blood pressure and diastolic
blood pressure were used if recorded in the year prior to the index date. I also
examined prescription records to see whether carbamazepine or selective serotonin re-
uptake inhibitors (SSRIs) were used concomitantly with a thiazide diuretic (within 90
days of starting treatment), or at the time of test for serum sodium concentration.
These drugs have been shown to cause hyponatraemia when used concomitantly with
thiazide diuretics.
6.2.1 Assessment of electrolyte monitoring and biochemical ADRs
As defined previously in section 3.3.4, I defined baseline sodium or potassium testing
as a measurement of one or more serum concentrations between six months prior to
the index date and two days following it, to allow for any delays in the uploading of
laboratory test results to the GP practice (prior to 2003 most laboratory data entry
were entered manually). Biochemical monitoring was defined as a measurement of
one or more of these serum concentrations between three days and one year after the
index date.
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In this sub-group analysis, the occurrence of hyponatraemia or hypokalaemia within
one year of thiazide diuretic treatment was identified solely through the use of
laboratory tests. Hyponatraemia was defined as a serum sodium concentration less
than 135 mmol/l and concurrent hypokalaemia was defined as a record of a serum
potassium concentration less than 3.5 mmol/l on same day as the sodium
concentration .
6.2.2 Statistical methods
Statistical analyses were carried out using Stata® 10.0. Comparisons were made
between data using the Chi-squared test for categorical data, the independent t-test
(for data were parametric tests could be used), and the Mann-Whitney U test (for data
where parametric tests were not appropriate) for continuous data. I determined the
relationships between patient variables and the probability of hyponatraemia within
one year in univariable analyses, and then entered the baseline characteristics that
were statistically significant at the P<0.05 level, or were biologically plausible into a
backwards stepwise multivariable logistic regression model.
6.3 Results
In the cohort of 74 096 patients who were prescribed a single antihypertensive agent
between January 2000 and December 2003, thiazide diuretics was the most commonly
used drug class. Almost half of the patients (48%) were newly treated with a thiazide
diuretic, of whom 34 877 (97.8%) were treated with bendroflumethiazide—low dose
bendroflumethiazide (2.5 mg) was used in the majority of patients (34 472; 98.8%). A
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small number of patients were prescribed indapamide (688), chlortalidone (43), and
other thiazide diuretics (45).
Almost 40% (13 318) of thiazide diuretic-treated patients had a baseline sodium test,
with the serum sodium concentration ranging from 117 to 157 mmol/l, (median 140).
A similar number of patients (13 217) had a baseline potassium test, with a serum
potassium concentration ranging from 2.5 to 11.8 mmol/l, (median 4.4). Patients with
baseline testing for serum sodium and potassium concentration tended to be male,
older, a smoker, and were more likely to have diabetes mellitus (Table 6.1). Of those
patients with baseline electrolyte testing, 300 (2.2%) and 218 (1.7%) had evidence of
hyponatraemia or hypokalaemia prior to initiation of thiazide diuretic treatment.
Almost one third (11 566) of thiazide diuretic-treated patients had at least one sodium
concentration measurement in the six months and a one half (16 463) in one year
following their first thiazide diuretic prescription. Similar rates of potassium
monitoring were observed. Men, older and thinner patients, smokers, those with
diabetes mellitus, and those that had baseline testing were significantly more likely to
have follow-up electrolyte monitoring (Table 6.2).
In those patients with at least one sodium test, the number of tests ranged from 1 to 30
(median = 1 test) (Table 6.3). The time to first follow-up test was highly skewed with
a modal time of seven days and a median time of 84 days. Patients with baseline
sodium testing had a significantly longer length of time until the first follow-up test
and more follow-up tests. Similar results were obtained for potassium monitoring.
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In the 16 463 patients with a follow-up sodium monitoring test, 9.1% of patients
(1505) and 8.4% of the tests (2232/26 728) had evidence of hyponatraemia. For the
majority of patients (1168/1505; 77.6%), the lowest recorded sodium serum
concentration was indicative of mild hyponatraemia (130–134 mmol/l) (Table 6.4). Of
those 1505 patients with hyponatraemia, 1410 (93.7%) also had a serum potassium
test recorded on the same day. Patients with evidence of severe hyponatraemia had a
greater likelihood of being hypokalaemic.
Table 6.4 – Lowest serum sodium concentration recorded within one year and
concomitant potassium monitoring in patients with follow-up sodium monitoring
Serum sodium concentration range Serum potassium
concentration test on
same day, n (%)
Evidence of
hypokalaemia, n (%)Range n (%)
≥135 mmol/l 14 958 (90.9) 14703/14958 (98.3) 618/14703 (4.2)
130–134 mmol/l 1 168 (7.1) 1096/1168 (93.4) 62/1096 (5.7)
125–129 mmol/l 290 (1.8) 273/290 (94.1) 31/273 (11.4)
120–124 mmol/l 37 (0.22) 33/37 (89.1) 5/33 (15.2)
<120 mmol/l 10 (0.06) 8/10 (80.0) 4/8 (50.0)
Ten patients had evidence of very severe hyponatraemia (<120 mmol/l) within one
year of thiazide diuretic treatment and their characteristics and electrolyte monitoring
are presented in Table 6.5.
133
Table 6.5 – Characteristics and electrolyte monitoring in patients with severe
hyponatraemia within one year of thiazide diuretic treatment
Sex Age(years)
Baseline
Na+ value
Thiazide ,
dose
(in mg)
Severe hyponatraemia
Monitoring
before severe
hyponatraemia
Monitoring
after severe
hyponatraemia
Time
(days)
Na+
value
K+
value
Time
(days)
Na+
value
Time
(days)
Na+
value
Male 71 - BDZ, 2.5 233 113 4.4 118
176
130
131
236
239
124
130
Female 74 140 BDZ, 2.5 221 114 - - - 225
232
239
267
351
127
131
130
138
132
Male 83 - BDZ, 2.5 111 114 2.1 72 132 139
310
137
137
Female 70 117 BDZ, 2.5 8 116 4.5 - - 19
38
123
123
Male 66 138 CHL, 50 95 118 3.0 - - 109
129
207
139
141
138
Male 81 137 BDZ, 2.5 48 118 - - - 49
128
139
188
247
132
132
129
130
132
Male 81 - BDZ, 2.5 105 118 5.2 10 127 124
147
120
121
Male 60 - BDZ, 2.5 7 119 2.7 - - 14 130
Male 86 - BDZ, 2.5 12 119 3.3 - - 335 127
Female 80 142 BDZ, 2.5 151 119 4.0 - - - -
BDZ = bendroflumethiazide; CHL = chlortalidone
The time to the first case of hyponatraemia was highly skewed (Figure 6.1), with a
mean number of days of 140, a median time of 113 days, and a modal time of one
week. The proportion of sodium tests recorded within 28 days of the first thiazide
diuretic prescription that indicated hyponatraemia was 6.9%, which was significantly
smaller than the 8.7% of tests carried out later than 28 days after first treatment
(P<0.0005). Similarly, 6.9% of the tests recorded within 14 days indicated
hyponatraemia compared with 8.9% of tests recorded after 14 days of treatment
(P<0.0005).
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Figure 6.1 – Time until first case of hyponatraemia within one year of thiazide
diuretic treatment
The majority of the hyponatraemia cases (1181) were identified on the first serum
sodium concentration test. The further sodium monitoring of these patients is
described in Table 6.6. A greater proportion of patients with severe hyponatraemia
(<125 mmol/l) had a subsequent serum sodium test. The serum sodium concentration
normalized in the majority of patients who demonstrated mild hyponatraemia (130–
134 mmol/l) on initial testing.
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Table 6.6 – Further sodium monitoring and concomitant potassium monitoring
in patients with evidence of hyponatraemia on initial testing
Serum sodium
concentration on
initial testing
No. with a
repeat test
(%)
Repeat serum sodium
concentration
No. with a
concomitant
K test (%)
Serum potassium
concentration
Range n (%) Range n (%) Value n (%)
130–134 955 (80.9) 437 (45.8) ≥135 214 (49.0) 888 (92.9) ≥3.5 835 (94.0)
130–134 166 (38.0) 3.0–3.4 48 (5.4)
125–129 50 (11.4) <3.0 5 (0.56)
<125 7 (1.6)
125–129 201 (17.0) 132 (65.7) ≥135 32 (24.2) 185 (92.0) ≥3.5 165 (89.2)
130–134 68 (51.5) 3.0–3.4 16 (8.6)
125–129 26 (19.7) <3.0 4 (2.2)
<125 6 (4.5)
<125 25 (2.1) 17 (68.0) ≥135 4 (23.5) 22 (88.0) ≥3.5 16 (64.0)
130–134 8 (47.1) 3.0–3.4 3 (8.0)
125–129 3 (17.6) <3.0 3 (8.0)
<125 2 (11.7)
6.3.1 What are the patient factors associated with hyponatraemia?
Women, thinner, older patients, smokers, and those who were prescribed concomitant
carbamazepine were significantly more likely to develop hyponatraemia (Table 6.7).
Table 6.7 – Logistic regression model of hyponatraemia within one year of the
start of thiazide diuretic treatment
n/N Unadjusted OR P value Adjusted OR* P value
Sex
Male 489/6 608 1 1
Female 1 016/9 855 1.44 1.29–1.61 <0.0005 1.34 1.17–1.53 <0.0005
Age range
<50 70/2 121 1 1
50–59 156/3 870 1.23 0.92–1.64 0.156 1.11 0.81–1.52 <0.0005†
60–69 355/4 554 2.48 1.91–3.22 <0.0005 2.09 1.57–2.79
70–79 548/4 258 4.33 3.36–5.59 <0.0005 3.12 2.34–4.14
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n/N Unadjusted OR P value Adjusted OR* P value
80–89 341/1 547 8.28 6.34–10.8 <0.0005 5.16 3.80–7.00
90–100 35/118 12.4 7.79–19.6 <0.0005 6.13 3.26–11.5
Smoking
Never 737/8 662 1 1
Ever 700/7 413 1.12 1.00–1.25 0.039 1.25 1.10–1.42 0.001
Diabetes mellitus
No 1 416/15 831 1 1
Yes 89/632 1.67 1.32–2.10 <0.0005 1.99 1.55–2.55 <0.0005
BMI
Underweight 61/191 2.91 2.12–4.00 <0.0005 2.24 1.60–3.14 <0.0005
Normal 554/3 990 1 1
Overweight 406/5 648 0.48 0.42–0.55 <0.0005 0.55 0.48–0.63 <0.0005
Obese 162/4 273 0.24 0.20–0.29 <0.0005 0.33 0.27–0.40 <0.0005
SSRI treatment at time of test
No 1 453/15 889 1 -
Yes 52/574 0.99 0.74–1.32 0.944 - - -
Carbamazepine treatment at time of test
No 1 473/16 379 1 1
Yes 32/84 6.23 4.00–9.70 <0.0005 8.79 5.09–15.2 <0.0005
* Adjusted for sex, age, smoking status, presence of diabetes mellitus, BMI, and concomitant
carbamazepine treatment at time of test; † Chi-squared test for trend
6.3.2 Patients with baseline testing and follow-up monitoring
A smaller group of 7096 (19.9%) patients had both a baseline serum sodium test and
evidence of follow-up sodium monitoring. A similar number of patients (7031;
19.7%) had both a baseline potassium test and at least one record of follow-up serum
potassium concentration within one year. Patients with evidence of hyponatraemia at
baseline (191; 2.7%) had a smaller mean percentage change from baseline to the first
sodium monitoring test and to the lowest recorded serum sodium concentration (Table
6.8). However, 64.9% (124) of patients with hyponatraemia at baseline had a serum
sodium concentration test below 135 mmol/l during follow-up, compared with 8.0%
(549) of patients that had a normal baseline serum sodium test (P<0.005).
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Table 6.8 – Mean percentage change in serum sodium concentration from
baseline to first sodium monitoring test and lowest sodium monitoring test
All patients
(N=7 096)
Hyponatraemic
at baseline
(N=191)
Normal sodium
at baseline
(N=6 905)
P value
% change in serum sodium concentration from baseline to first monitoring test
Mean −0.55 (2.11) +0.27 (3.0) −0.57 (2.07) <0.0005
Range −18.5 to 9.16 −7.52 to 9.16 −18.5 to 7.19
Median −0.70 0.75 −0.70
% change in serum sodium concentration from baseline test to monitoring test with
lowest serum concentration
Mean −0.95 (2.20) −0.19 (3.18) −0.97 (2.16) <0.0005
Range −18.5 to 9.16 −7.52 to 9.16 −18.6 to 6.67
Median −0.71 0.0 −0.71
Both the mean percentage change from baseline to the first monitoring test and
baseline to the monitoring test with the lowest serum concentrations were
significantly correlated with age (P<0.0005; P<0.0005) and gender (P=0.0019;
P=0.0283) (Figure 6.2 and Figure 6.3).
Figure 6.2 – Mean percentage change in serum sodium concentration from
baseline to first sodium monitoring test and lowest sodium monitoring test by
age group (95% confidence intervals shown) (P<0.0005; P<0.0005)
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Figure 6.3 – Mean percentage change in serum sodium concentration from
baseline to first sodium monitoring test and lowest sodium monitoring test by sex
(95% confidence intervals shown) (P=0.0019; P=0.0283)
6.4 Discussion
This analysis of patients newly diagnosed with hypertension confirmed a high level of
thiazide diuretic prescribing in UK primary care during the time period studied (48%
of patients newly diagnosed with hypertension were treated with a thiazide diuretic).
The majority of patients were treated with a low-dose thiazide diuretic—most often
bendroflumethiazide 2.5 mg—which was in accordance with published guidelines
(Williams et al., 2004).
An examination of thiazide diuretic-treated patients provided specific insight into the
nature of electrolyte monitoring and the development of hyponatraemia in a cohort of
patients treated with the most common type of antihypertensive therapy. Thiazide
diuretics are known to be associated with important biochemical ADRs. Only 37%
0
-
0.
4
-
0.
6
-
0.
8
-
1.
0
-
0.
2
M
e
a
n

pe
rc
e
n
ta
ge

ch
a
n
ge

fro
m

ba
se
lin
e
Female Male
To first sodium test To lowest sodium test
139
had electrolyte testing prior to the initiation of thiazide diuretic treatment and 46%
had any electrolyte monitoring during one year of treatment. Patients with baseline
electrolyte testing were significantly more likely to have any follow-up monitoring, so
too were men, older patients, those with diabetes mellitus, smokers, and those with a
lower BMI.
I demonstrated that 9% of patients with serum sodium monitoring had evidence of
hyponatraemia during thiazide diuretic treatment. The majority of cases of
hyponatraemia following thiazide diuretic treatment were mild. Only 2% of
monitored patients demonstrated moderate (125–129 mmol/l) or severe (<125
mmol/l) hyponatraemia. An analysis of subsequent monitoring demonstrated that the
majority of cases of mild hyponatraemia normalized on the subsequent serum sodium
concentration test. A relationship between hyponatraemia and hypokalaemia was
demonstrated as patients with evidence of severe hyponatraemia were significantly
more likely to have a serum potassium test indicating hypokalaemia. A small
proportion of patients had both baseline testing and follow-up monitoring. Most of
these patients (65%) with hyponatraemia at baseline remained hyponatraemic upon
subsequent testing in the year following thiazide diuretic prescription, a finding that
should perhaps encourage more baseline testing.
The increased risk of hyponatraemia identified in older patients is consistent with the
findings of other studies, which have demonstrated that age is an independent risk
factor for hyponatraemia (Gross & Palm, 2005; Jiang et al., 2009). This may be
related to the decreased ability in older adults to excrete free water as efficiently as
younger adults (Clark et al., 1994).
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There was an increased risk of thiazide diuretic-induced hyponatraemia in patients
who were underweight, although the relationship between low body mass index and
hyponatraemia is unclear. Chow and colleagues (2003) suggested that sodium
concentration may change more in patients with smaller body size, because they have
smaller extra-cellular volume. It is also possible that there is an interaction between
smoking, body mass index, and serum sodium concentration: patients with
renovascular disease are more likely to be smokers (Mackay et al., 1979; Nicholson et
al., 1983), and renal artery stenosis is associated with hyponatraemia (McAreavey et
al., 1983).
The increased risk of thiazide diuretic-induced hyponatraemia seen in women is
consistent with results from the study of hospitalized patients presented by Sharabi
and colleagues (2002), showing that women had a three-fold higher risk of developing
thiazide diuretic-induced hyponatraemia. However, this may be due to multiple
factors such as a smaller body size, older age, or a lower dietary intake of sodium.
The relationship may also be due to an over-representation of women in thiazide
diuretic-treated cohorts, instead of an inherent susceptibility to low serum sodium
concentrations (Chow et al., 2003; Clayton et al., 2006b).
Patients who were taking carbamazepine were also significantly more likely to
develop hyponatraemia. The interaction between thiazide diuretics and carbamazepine
to cause hyponatraemia is recognized (Joint Formulary Committee, 2010) and it
seems prudent to caution prescribers that monitoring is especially important in
patients taking thiazide diuretics with carbamazepine.
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Thiazide diuretic-induced hyponatraemia has been shown to occur within 2 to 14 days
after the start of treatment (Aronson, 2006). However, the current analysis, like that of
Chow and colleagues (2003), failed to demonstrate that hyponatraemia occurs early in
thiazide diuretic treatment. Evidence of hyponatraemia was recorded as early as 3
days to as late as 365 days from the start of thiazide diuretic treatment and the
proportion of tests with evidence of hyponatraemia was not significantly lower in the
first month of treatment.
Limitations
The main limitation of this analysis is the same as those presented in Chapter 5, in
that the nature of electrolyte monitoring in this cohort of patients may have been
slightly underestimated. This may have occurred due to some monitoring that may
have been undertaken in secondary care or that may not have been successfully
uploaded into the GP practice’s database. There is also the issue of what constitutes a
normalized range for serum sodium or potassium concentrations, as the range of
concentrations was rather high. GP samples often take hours to reach the laboratory
and the ‘normal’ range is probably different for GPs than for hospital samples.
Another limitation is concerned with the estimation of the frequency and nature of
hyponatraemia. The burden of this adverse drug reaction was estimated exclusively
using records of laboratory tests. In order to estimate the frequency of hyponatraemia
I used the number of patients with serum sodium concentration testing as the
denominator and not the number of patients treated with a thiazide diuretic. This may
have overestimated the frequency of hyponatraemia seen in thiazide diuretic-treated
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patients. It is impossible to determine whether hyponatraemia was missed because the
patient did not have a serum sodium concentration test that would have identified the
adverse reaction to thiazide diuretic treatment. In addition, because hyponatraemia
was identified through laboratory testing it is impossible to disentangle the
relationship between testing and the hyponatraemia. In other words, it is impossible to
know whether the time to hyponatraemia is an accurate reflection of the time to the
event occurring, or simply the time taken for a GP to request a laboratory
measurement.
I also presented results that demonstrated significant differences in the patient
characteristics between patients with and without baseline sodium testing. The P
values showed that the differences were statistically significant and were likely to be
real but the magnitude of the absolute differences themselves were very small, and
therefore potentially not as clinically important.
Finally, prior research has demonstrated a dose-dependent relationship between
thiazide diuretic use and the risk of hyponatraemia. This association could not be
explored in this analysis because the majority of patients were treated with the same
low dose of bendroflumethiazide.
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6.5 Conclusions
The risk of hyponatraemia in thiazide diuretic-treated hypertensive patients is
generally low: 9% of the patients with serum sodium concentration monitoring had
evidence of hyponatraemia in the first year, of whom only one in five hundred had
serum sodium concentrations below 125 mmol/l. Individuals at increased risk of
hyponatraemia included women, older patients, patients with a low BMI or diabetes,
smokers, and patients taking carbamazepine.
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Chapter 7
USING MULTIPLE IMPUTATION IN
THE ANALYSIS OF THE GENERAL
PRACTICE RESEARCH DATABASE
This chapter describes the problem of missing data in observational research and the
biases that can arise when analyses are restricted to patients with complete data. I
detail various methods used to deal with missing data and discuss the benefits and
limitations of the different methods. I introduce the method of multiple imputation as
a tool for dealing with missing data that can reduce the risk of bias. I describe the
development of an imputed data set and contrast the range of imputed values with the
recorded values. Finally, I compare the results obtained using multiple imputed data
with those from a complete case analysis.
7.1 Missing data
Most epidemiological studies contain missing data. Determining whether the missing
data will be a problem requires a consideration of the mechanism that caused the
missingness. Data can be missing completely at random (MCAR), as in the case
where measurement equipment simply malfunctioned in an unpredictable way. When
data are MCAR there are no systematic differences between missing values and
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observed values. Data can also be missing at random (MAR) where the probability of
being missing is not related to the value of the variable that is missing, but may be
related to other observed variables (Gorelick, 2006). Finally, data can be missing not
at random (MNAR), where the missingness of the data is related to the variable itself
and other observed or missing covariates. For example, blood pressure data are MAR
if older individuals are more likely to have their blood pressure recorded (and age is
included in the analysis), but they are MNAR if individuals with high blood pressure
(the variable itself) are more likely to have their blood pressure recorded than other
individuals of the same age (White et al., 2010). It is not possible to test whether data
are indeed MNAR, as this missing data mechanism depends on unobserved variables.
The assumption that data are MAR becomes more likely when more explanatory
variables are collected and included in the analysis (White et al., 2010).
7.1.1 Approaches used to determine the mechanism of missing data
One way to determine the missing data mechanism is to create a missing data dummy
variable (i.e. data are missing = 0, data are not missing = 1). A significant correlation
between the dummy variable and other variables in the data set indicates that missing
data are related to other variable(s) and that the data cannot be MCAR. Alternatively,
a t-test (for continuous variables) and a Chi-squared test (for categorical variables)
can be used to determine if there are any significant differences in the variables
between patients who did or did not have missing data. Univariable logistic regression
models, where the missing data dummy variable is the outcome variable, can also be
used to determine if there is a significant association between patient covariates and
data missingness.
146
7.1.2 Commonly used techniques for handling missing data
The easiest way to deal with missing data is to exclude observations with missing
data, which is often called ‘complete case analysis’. This is the default for the
majority of statistical packages, and is the method I have used in the analyses
presented in Chapter 5. This method may result in a large number of cases being
discarded, which reduces the study sample size and decreases statistical power.
Furthermore, case deletion is also only appropriate when data are MCAR. If the cases
that are deleted are systematically different from the rest of the sample, the results of
the analysis can be seriously biased (Schafer, 1999).
A method that is commonly used to handle missing data is the indicator method where
a new dummy or indicator binary variable for each independent variable is created
with 1 indicating a missing value and 0 indicating an observed value. The missing
values are recoded as 0 in the original variable. The new indicator variable is then
used, together with the original (now recoded) variable, in a multivariable analysis to
determine the association between the independent variable and the outcome. If the
independent variable with missing data is categorical, an additional category
classified as missing is added. This method has greater precision than complete case
analysis as no patients are discarded due to missing data. It has been recommended
for dealing with incomplete covariate data in randomized control trials because the
covariates are not potential confounders due to randomization (White & Thompson,
2005). However, in observational research, this technique will lead to biased
associations between the original variables and the outcome, even when the data are
missing completely at random (Donders et al., 2006). Furthermore, one cannot adjust
for confounding if data from a known confounder are missing.
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7.1.3 Simple imputation methods for handling missing data
Simple imputation methods, where a single value for the missing observations is
obtained, can also be used to deal with missing data. One such method is mean
substitution where each missing data point for a given covariate is replaced by the
observed mean value for that patient covariate. Analyses are then carried out in the
complete imputed data set. This method has several limitations including the
assumption that the data are MAR. Also, the mean substitution will have a mean
variance of zero, which may lead to an overestimate in the level of confidence in the
imputed data set compared with the observed data set.
Linear regression methods can also be used to fill in or predict the missing data
conditional on the basis of other variables. This method allows for the distribution of
the variables used in the regression model to be maintained but the variability
introduced through the imputation is still ignored as it treats the imputed data as real
observed data. This may lead to biased associations and over-precise results.
7.1.4 Multiple imputation for handling missing data
Multiple imputation has been developed and further refined as a method for more
appropriately dealing with missing data that uses the distribution of the observed data
to estimate a range of plausible values for the missing data. It also adds random
components into the model in order to allow for uncertainty from the imputed data.
This is repeated several times to created multiple data sets. The estimates are then
combined in a way that takes into account the variability of the imputations to obtain
the overall estimates, variances, and confidence intervals.
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Multiple imputation is a three-stage process. First, m values are imputed for each
missing data. Missing values are replaced by imputed values that have been sampled
from their predictive distribution based on the observed data (Sterne et al., 2009).
Imputations are generally undertaken using Markov Chain Monte Carlo or multiple
imputation through chained equation techniques. Secondly, the m complete data sets
are treated as a real complete data set. Each data set will differ because the missing
values have been replaced by different imputations. Thirdly, the results of the m
analyses are combined using Rubin’s rules to create a single inference about the
parameter of interest that includes a measure of uncertainty from the missing data
(Rubin, 1987; Zhou et al., 2001).
Multiple imputation has been shown to perform well when the proportion of the
overall missing data is less than 61% (Barzi & Woodward, 2004). The underlying
assumption of multiple imputation is that missing data are MAR, and therefore
missing values may depend on the observed data but not on the unobserved data.
Even if the assumption that the data are MAR does not hold, multiple imputation is
less biased than methods such as complete case analysis.
7.1.4.1 Methods for imputing values for the missing data
Markov Chain Monte Carlo technique
Multiple imputations can be created from a multivariate normal model using Markov
Chain Monte Carlo (MCMC) techniques. The MCMC method involves simulating
draws from a multivariate normal distribution of all of the variables in the imputation
model. This method generates predicted values based on the linear regressions and
then random draws are made from the simulated error distribution for each regression
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equation. The imputed values are created through the addition of the random errors to
the predicted values for each individual (Allison, 2009).
Multiple imputations by chained equations
Multiple imputations can also be created through multiple imputation by chained
equations (MICE). MICE is a recently developed sequential method where instead of
assuming a single multivariate model for all of the data, uses a separate regression
model to impute each variable with missing data. MICE cycles through all of the
variables, and models each variable conditional on the others (Stuart et al., 2009).
Logistic regression is used for incomplete binary variables and linear regression for
continuous data.
Therefore unlike MCMC techniques, where values imputed for one variable are never
used as predictors to impute other variables, MICE methods use a sequential process
so that the values that were imputed in the previous round are then used as predictors
for imputing other variables (Allison, 2009). The variable with the least missingness
is imputed first, followed by the variable with the second lowest amount of missing
data, and so on. Variables with the same amount of missingness are processed in a
random order, but the same order is always used (Royston, 2005b). One iteration is
complete after all of the variables have been cycled through (Stuart et al., 2009) and
the process repeats, imputing missing values until the process reaches convergence
(i.e. more iterations will not produce significant changes in the parameter estimates)
(Horton & Kleinman, 2007).
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MICE techniques may be preferable in certain data sets because MCMC methods
assume normality and linearity, and therefore are not well suited for the imputation of
categorical variables. MCMC methods are often slow to converge and it is difficult in
practice to assess convergence. However, the MCMC approach has stronger statistical
underpinnings and there is no theoretical guarantee that the MICE method will
converge to the correct distribution for the missing values (Allison, 2009). Recent
work by Lee and Carlin (2010) demonstrated that both methods are less biased than
complete case analyses and that the results obtained from the two methods are similar.
7.1.4.2 Determining the number of imputations
Some simulation studies have demonstrated that three imputed data sets are sufficient
for data where less than 20% are missing (van Buuren et al., 1999). Where rates of
missing data are high, more than five to ten imputations tend to have little or no
practical benefit (Schafer, 1999). However, more recent research has questioned the
claims that more than ten imputed data values are seldom needed. Work by Bodner
(2008) has suggested that precision is improved through the use of increasing
numbers of imputations. A recent publication has conservatively suggested that the
number of imputations should be greater than or equal to the percentage of incomplete
cases (i.e. if a data set had 13% incomplete cases, an appropriate number of
imputations would be approximately 15) (White et al., 2010).
7.1.4.3 Methods for combining the complete data sets (Rubin’s rules)
Once the complete data sets are created, they are then combined using a set of rules in
order to obtain the overall estimates, variances, and confidence intervals. This
incorporates both within-imputation variability (uncertainty about the results from one
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imputed data set) and between-imputation variability (the uncertainty due to the
missing data) (White et al., 2010).
The overall multiple imputation point estimate for the parameter of interest is the
average of the m estimates of the variable Q from the imputed data sets:
i
m
i
Q
m
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1
∑
=
= (7.1)
The variability of variable Q has two components: (1) the estimated within-imputation
variance (Ū),
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and (2) the between-imputation variance (B).
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The between-imputation variance is the additional variance created by the uncertainty
around the missing values. The total variance for the overall multiple imputation
estimate is defined as T.
B
m
UT )( 11 ++= (7.4)
7.1.4.4 Selection of variables to include in the imputation model
In general, the selection of all available covariates produces multiple imputations with
minimal bias and maximal certainty (van Buuren et al., 1999). However, due to
computational limitations or problems with multicollinearity, it is often neither
feasible nor appropriate to use all variables. A stepwise process for the selection of
variables for inclusion into a multiple imputation model using either MCMC or MICE
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has been suggested by van Buuren and colleagues (1999). First, one should include all
of the patient variables with missing data, the outcome variables and important
observed covariates. Failure to include the outcome variable in the imputation of a
missing covariate leads to an increase in the risk of bias when determining the
association between covariates and the outcome (Moons et al., 2006). Specifically,
there is an increased risk of underestimating the covariate-outcome association
because there is no covariate-outcome association in the imputed data. Secondly, the
variables that are associated with the missingness of the data should be included in the
model. Thirdly, variables that are highly correlated with the variables with missing
data should be included. Finally, variables that have a very high proportion of missing
data should be removed from the imputation model if MCMC methods are being
used. Because MICE imputes data variable by variable, one can use different
variables that may have been excluded due to a very high proportion of missing data
to impute each variable, and therefore MICE can be more advantageous than MCMC
methods. The selection of appropriate variables is crucial to providing accurate
imputed values.
7.1.4.5 Monitoring convergence
Attempts should be made to determine whether the MICE algorithm has reached
convergence or when the chain reaches equilibrium, although no definite method
exists. The goal is to have a sufficient number of iterations to stabilize the distribution
of the parameters. In general MICE requires fewer iterations than the MCMC
methods, which can often require thousands of iterations (van Buuren & Oudshoorn,
1999). Simulation studies have demonstrated that the imputations using a MICE
algorithm have stabilized after 10 to 20 iterations, and as few as five (Brand, 1999),
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such that the order in which the variables are imputed is no longer an issue (Stuart et
al., 2009). One method for assessing convergence of the MICE algorithm is to
increase the number of iterations/cycles and examine the data for any noticeable
differences. This can be carried out in Stata® by plotting the mean value of each
imputed variable against the iteration number (Royston, 2005b). The model has
converged when no trend—just random jumps up and down—is apparent in each plot.
7.1.4.6 Imputation diagnostics
After imputed data have been created, one should check to see whether data from the
imputations are plausible and whether they differ from the observed data. Differences
can arise from the model used to generate the imputations or may indicate that the
missingness assumption has been violated, which is a more serious concern (Abayomi
et al., 2008). Although there are no agreed tests, statistical and visual diagnostic tests
can be used to identify potential problems with the imputed data. A simple graphical
method can be to plot the density distribution of observed and imputed values (i.e.
only those values actually imputed and not all values in the imputed data sets)
(Royston, 2005a; Abayomi et al., 2008). These plots are useful for detecting
important differences between the observed and imputed data. Another graphical
method is to use bivariate scatter plots, which compare the internal consistency of the
imputed and observed observations with respect to a continuous variable. Finally, a
significant result from a Kolmogorov–Smirnov test may signal potential differences
between observed and imputed values.
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7.1.4.7 Assessing the impact of multiple imputation
Finally, one needs to make an assessment of the impact of the multiple imputation.
Often comparisons are made between the results obtained using complete case
analysis and analyses that have used multiple imputed data.
7.1.4.8 The use of multiple imputation in the literature
The number of publications that have used multiple imputation has increased
significantly, although the details of the imputation procedures are often severely
lacking (Sterne et al., 2009). Guidelines on the reporting of information on missing
data and the implementation of multiple imputation have been suggested by Sterne
and colleagues (2009) (Table 7.1).
Table 7.1 – Guidelines for reporting any analysis potentially affected by missing
data (from Sterne and colleagues 2009)
• Report the number of missing values for each variable of interest, or the number of cases with
complete data for each important component of the analysis
• Clarify whether there are important differences between individuals with complete and incomplete
data
• Describe the type of analysis used to account for missing data and the assumptions that were made
For analyses based on multiple imputation
• Provide details of the imputation modelling:
- Report details of the software used and of key settings for the imputation modelling
- Report the number of imputed data sets that were created
- What variables were included in the imputation procedure?
- How were non-normally distributed and binary/categorical variables dealt with?
- If statistical interactions were included in the final analyses, were they also included in
imputation models?
• If a large fraction of the data is imputed, compare observed and imputed values
• Where possible, provide results from analyses restricted to complete cases, for comparison with
results based on multiple imputation.
• Discuss whether the variables included in the imputation model make the MAR assumption
plausible
• It is also desirable to investigate the robustness of key inferences to possible departures from the
missing at random assumption, by assuming a range of MNAR mechanisms in sensitivity analyses.
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7.1.4.9 Software for the application of multiple imputation procedures
Several widely used statistical packages provide methods for the development and
analysis of imputed data sets (Harel & Zhou, 2007; Horton & Kleinman, 2007).
• SAS – the PROC MI procedure generates imputed data sets through different
methods including MCMC techniques, regression, and propensity score
methods. The MIANALYZE procedure combines the results of analyses of
imputations.
• Stata® – the ice procedure implements multiple imputation by chained
equations. The newest version of Stata® 11.0 now has an embedded mi
procedure that does not implement MI through chained equations. Instead,
imputations can be generated through various methods included MCMC
techniques.
• R and S-Plus – implement multiple imputation through chained equations
Freely available, stand-alone programmes also exist for undertaking multiple
imputation including NORM and MLWin, which use MCMC techniques for the
generation of imputed values.
7.1.5 Handling missing data in the General Practice Research Database
The way in which authors have handled the presence of missing data in the GPRD has
varied. Often, authors have acknowledged the issue of missing data (Meier et al.,
2000; Opatrny et al., 2008), but little work has been done to address potential bias that
the significant amount of missing data can introduce to the results. Authors have
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sometimes used the indicator method where a missing data indicator was created for
each variable with missing data and is then used in regression models (Solaymani-
Dodaran et al., 2004; Souverein et al., 2004; Osborn et al., 2007). This method can
yield estimates with reduced standard errors relative to a complete case analysis but it
can still produce biased estimates (Greenland & Finkle, 1995; Jones, 1996). When
data were missing on the length of drug treatment, several authors have also imputed
the missing data using the median value from the entire population (Watson et al.,
2002; van Staa et al., 2005). This method can also yield biased results.
Very few authors have used multiple imputation with the GPRD, even though the
occurrence of missing data, particularly with respect to patient weight and blood
pressure, has been widely acknowledged (Gelfand et al., 2005). Five published
studies using the GPRD have used multiple imputation to control for potential bias
associated with missing data (Delaney et al., 2007; Tannen et al., 2007a; Tannen et
al., 2007b; Delaney et al., 2008; Delaney et al., 2009). Delaney and colleagues (2007;
2008; 2009) undertook multiple imputation with MCMC techniques using SAS
software. A description of how multiple imputation modelling was undertaken was
not provided in either of the studies by Tannen and colleagues (2007a; 2007b).
7.2 Using multiple imputation in the analysis of the GPRD
7.2.1 Introduction
The GPRD, like most other large clinical databases, is prone to missing information.
Several methods exist to deal with the missing data, but multiple imputation has been
shown to be superior in reducing the risk of biased estimates of effect that can occur
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when data are not missing at random. Although the problems caused by missing data
and the value of multiple imputation have been previously acknowledged by other
authors, the use of this method in the GPRD has been limited.
I have previously examined the relationship between patient factors and biochemical
monitoring for ADRs in Chapter 5 using a complete case analysis. However this type
of analysis may have biased the estimate of effect. Indeed, one potentially important
patient covariate (alcohol use) was excluded entirely from the primary analysis before
any regression modelling was undertaken due to the high proportion of missing data.
Therefore the aims of this analysis were:
1. To examine the nature of the missingness of the data in the cohort of patients
newly diagnosed with hypertension and newly treated with antihypertensive
therapy;
2. To determine if there are important differences between patients with
complete and incomplete data;
3. To determine the patient factors associated with biochemical monitoring in a
multivariable analysis using multiple imputed data.
7.2.2 Methods
Prior to undertaking multiple imputation, the missing data mechanism was examined.
Dummy binary variables were created for each variable with missing data (missing
data = 0; non-missing data = 1). The proportion of missing data for each covariate
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was also plotted against the year the patient entered the cohort to determine time
trends in the measurement of baseline patient covariates.
Multiple imputation was carried out using the Stata® command ice (Royston, 2005b),
which is an implementation of MICE regression switching algorithm (van Buuren et
al., 1999). I did not consider using the MCMC technique to impute the missing data
for the practical reason that multiple imputation using chained equations is the method
used in Stata® 10.0. A random number seed of 123456 was used to allow for the
reproduction of the sets of imputations. Binary variables were imputed using logistic
regression and continuous variables using linear regression.
Normality was assumed and was checked prior to undertaking multiple imputation.
Continuous variables that did not have a normal distribution were transformed using
the nscore command (Lunt, 2008), which transformed the data to normality, so that
they could be imputed. The invnscore command was then used to convert the
normally distributed imputed variables back to the distributions of the original
variables. The invnscore command guarantees that the imputed values cannot lie
outside the observed data range. The final step involved rounding the continuous
imputed values to the nearest integer.
As a sensitivity analysis, a second method was used to transform continuous variables
that did not have a normal distribution. The lnskew0 command was also used, which
created a new variable equal to ln(± skewed variable − Κ). The command chooses a
sign of the variable and a constant Κ so that the skewness of the new variable is zero.
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A back-transformation of the transformed variables was then carried out after multiple
imputation, followed by a check to ensure the range of imputed values was valid.
All the patient variables with missing data, the outcome variable and important
covariates such as age and sex were selected for inclusion in the imputation model
(Table 7.2). Variables that were associated with the missingness of the data, as well as
those that were highly correlated with the variables with the missing data, were
included in the model. The outcome variable of interest was any biochemical
monitoring within one year of antihypertensive and was defined in section 3.3.4. The
patient variables were described previously in section 3.3.3.
Table 7.2 – Patient variables used in the development of the imputation model
Variables in the imputation model Type of variable
Incomplete and outcome variables
BMI Continuous
Systolic blood pressure Continuous
Diastolic blood pressure Continuous
Smoking status Binary
Units of alcohol per week Continuous
Any monitoring within one year Binary
Covariates
Age Continuous
Sex Binary
Variables related to missingness
SES quintile Ordinal
Year of treatment Ordinal
Drug class Categorical
8 or more GP visits in year prior Binary
Any baseline testing Binary
Prediction variables
Diabetes status Binary
PVD Binary
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Ten cycles of regression switching (iterations) were used. For diagnostic purposes, the
mean of each imputed variable was plotted against a large number of cycles (e.g.
100). A random pattern would indicate that convergence has occurred. Ten
imputations were carried out and the imputed data sets were combined using the
Stata® command mim (Carlin et al., 2008; Royston et al., 2009). This command can
be used to fit regression models in several imputed data sets and can apply Rubin’s
rules to combine estimates across imputations, as well as calculating the appropriate
standard errors for the estimates.
7.2.3 Results
7.2.3.1 Investigating the nature of the missing data
In the cohort of 74 096 patients who were newly diagnosed with hypertension and
newly treated with a single antihypertensive medication, smoking status was recorded
in 96% of patients, blood pressure in 95% of patients, BMI in 85% of patients, and the
number of units of alcohol per week in 59% of patients (Table 7.3). 38 917 (53%)
patients were ‘complete cases’ and had complete data for all the demographic data
described below.
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Table 7.3 – Amount of missing data in entire cohort
Covariates Number of records % missing
Age 74 096 0%
Sex 74 096 0%
Diabetes status 74 096 0%
SES score 74 096 0%
Smoking status 71 284 4%
Blood pressure 70 143 5%
BMI 62 691 15%
Units of alcohol per week 43 586 41%
Plots of the proportion of missing data by year of first antihypertensive prescription
demonstrate that the proportions of missing data for smoking status, blood pressure,
BMI, and units of alcohol per week decreased over time (Figure 7.1). The largest
absolute decrease was in the proportion of missing blood pressure data, which
decreased from 10% to 3% between 2000 and 2003. The decrease in the proportion of
missing data was statistically significant for all four variables (P<0.0005, Chi-squared
test for trend).
The units of alcohol and blood pressure variables did not have a normal distribution
and required transformation in order to approximate normality. The number of units
of alcohol per week was a semi-continuous variable, in that there was a mixture of
zeros and continuously distributed positive values. The zeroes represented actual valid
data and were not proxies for negative or missing responses (Schafer & Olsen, 1999).
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Figure 7.1 – Missingness of baseline patient covariate data by year of first
antihypertensive prescription
Univariable logistic regressions demonstrated the presence of relationships between
the missingness of the data and several prognostic variables (Table 7.4).
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Table 7.4 – Associations between missing data and other patient covariates, and
biochemical monitoring
Missingness of
Smoking Blood
pressure
BMI Units of alcohol
per week
Patient covariates    
Age 
—
 
Sex    
SES score 
—
 
Diabetes status   
—
Year    
Outcomes
Any monitoring
within 6 months
   
Any monitoring
within 1 year
   
 = an association (P<0.05) was found between missingness of the baseline characteristic and the patient covariate
using a univariable logistic regression model; — = no association was found;  = patients with missing data were
significantly less likely to have any biochemical laboratory monitoring
Women with missing data for their smoking status were significantly older, were less
likely to suffer from diabetes, consumed more units of alcohol per week, had higher
systolic and diastolic blood pressures, and had a higher SES score (Table 7.5). A
similar pattern was evident in men, although no difference was noted in the SES
score.
Significant differences were also observed in patients with missing blood pressure
data (Table 7.6). Both men and women with missing blood pressure data were older
and less likely to have diabetes. No differences were observed in SES score, BMI, or
the recorded number of units of alcohol per week. Male patients with no record of
BMI were significantly different in a range of characteristics (Table 7.7). Female
patients were only different in their age, diabetes status, SES score, and systolic blood
pressure.
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Patients with alcohol data were significantly different from those patients who did not
have a record of a baseline alcohol use (Table 7.8). Individuals with alcohol data
tended to be younger, less likely to have diabetes, more likely to be a smoker and
more likely to have a lower SES score.
Table 7.5 – Comparison between patients with and without smoking status
recorded
Male Female
Missing
(n=1 240)
Not missing
(n=34 105) P value
Missing
(n=1 572)
Not missing
(n=37 179) P value
Age,
mean (SD)
61.2 (14.9) 59.4 (12.3) <0.0005 67.0 (14.4) 62.3 (12.9) <0.0005
Diabetes,
n (%)
82 (6.6) 3780 (11.1) <0.0005 53 (3.4) 2 522 (6.8) <0.0005
SES score,
mean (SD)
22.6 (16.8) 22.0 (16.6) 0.21 23.7 (17.1) 22.2 (16.7) 0.0006
Systolic BP,
mean (SD)
170.8 (21.1) 169.4 (19.6) 0.03 175.2 (22.2) 172.2 (20.2) <0.0005
Diastolic BP,
mean (SD)
98.5 (11.6) 98.1 (11.6) 0.36 96.9 (11.5) 96.3 (11.0) 0.07
BMI,
mean (SD)
29.1 (5.2) 28.5 (4.7) 0.01 28.7 (6.6) 28.4 (5.9) 0.12
Units
alcohol/week,
mean (SD)
25.0 (25.4) 15.5 (17.0) <0.0005† 12.3 (21.2) 6.3 (8.8) 0.0003†
Any
monitoring
within 6
months, n (%)
299 (24.1) 12 879 (37.8) <0.0005 400 (25.5) 13 368 (36.0) <0.0005
Any
monitoring
within 1 year,
n (%)
404 (32.6) 17 810 (52.2) <0.0005 538 (34.2) 18 613 (50.1) <0.0005
† Mann-Whitney test for non-parametric data
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Table 7.6 – Comparison between patients with and without blood pressure
recorded
Male Female
Missing
(n=1 942)
Not missing
(n=33 403) P value
Missing
(n=2 011)
Not missing
(n=36 740) P value
Age,
mean (SD)
58.7 (12.9) 59.5 (12.4) 0.008 63.2 (14.0) 62.5 (12.9) 0.01
Diabetes,
n (%)
151 (7.8) 3 711 (11.1) <0.0005 99 (4.9) 2 476 (6.7) 0.001
SES score,
mean (SD)
22.1 (15.9) 22.0 (16.7) 0.77 22.9 (16.4) 22.2 (16.7) 0.09
Smoking
status, n (%)
925 (52.5) 18 106 (56.0) 0.004 685 (37.3) 13 402 (37.9) 0.61
BMI,
mean (SD)
28.7 (4.9) 28.5 (4.7) 0.19 28.7 (6.7) 28.4 (5.9) 0.07
Units
alcohol/week,
mean (SD)
14.7 (16.0) 15.6 (17.1) 0.16† 6.4 (9.6) 6.3 (8.9) 0.51†
Any
monitoring
within 6
months, n (%)
453 (23.3) 12 725 (38.1) <0.0005 412 (20.5) 13 356 (36.4) <0.0005
Any
monitoring
within 1 year,
n (%)
641 (33.0) 17 573 (52.6) <0.0005 586 (29.1) 18 565 (50.6) <0.0005
† Mann-Whitney test for non-parametric data
Table 7.7 – Comparison between patients with and without BMI recorded
Male Female
Missing
(n=5 252)
Not missing
(n=30 093)
P value Missing
(n=6 153)
Not missing
(n=32 598)
P value
Age,
mean (SD)
60.7 (13.5) 59.3 (12.2) <0.0005 66.6 (13.5) 61.7 (12.7) <0.0005
Diabetes,
n (%)
88 (1.7) 3 774 (12.5) <0.0005 84 (1.4) 2 491 (7.6) <0.0005
SES score,
mean (SD)
21.0 (17.0) 22.2 (16.5) <0.0005 21.5 (17.4) 22.4 (16.7) <0.0005
Smoking
status, n (%)
2 373 (53.3) 16 658 (56.2) <0.0005 1 904 (36.8) 12 183 (38.1) 0.08
Systolic BP,
mean (SD)
171.7 (20.7) 169.1 (19.4) <0.0005 175.5 (21.5) 171.7 (20.0) <0.0005
Diastolic BP,
mean (SD)
98.9 (11.9) 98.0 (11.6) <0.0005 96.2 (11.6) 96.3 (10.9) 0.39
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Male Female
Missing
(n=5 252)
Not missing
(n=30 093)
P value Missing
(n=6 153)
Not missing
(n=32 598)
P value
Units
alcohol/week,
mean (SD)
19.7 (21.1) 15.2 (16.6) <0.0005
†
8.3 (11.8) 6.2 (8.6) <0.0005
†
Any
monitoring
within 6
months, n (%)
1 674 (31.9) 11 504 (38.2) <0.0005 1 950 (31.7) 11 818 (36.3) <0.0005
Any
monitoring
within 1 year,
n (%)
2 229 (42.4) 15 985 (53.1) <0.0005 2 639 (42.9) 16 512 (50.7) <0.0005
† Mann-Whitney test for non-parametric data
Table 7.8 – Comparison between patients with and without number of units of
alcohol per week recorded
Male Female
Missing
(n=11 373)
Not missing
(n=23 972)
P value Missing
(n=19 137)
Not missing
(n=19 614)
P value
Age,
mean (SD)
60.9 (13.0) 58.8 (12.0) <0.0005 64.1 (13.3) 61.0 (12.5) <0.0005
Diabetes,
n (%)
1 297 (11.4) 2 565 (10.7) 0.05 1 414 (7.4) 1 161 (5.9) <0.0005
SES score,
mean (SD)
22.0 (16.7) 22.0 (16.6) 0.68 22.9 (17.0) 21.6 (16.4) <0.0005
Smoking
status, n (%)
5 287 (51.6) 13 744 (57.6) <0.0005 6 007 (34.1) 8 080 (41.3) <0.0005
Systolic BP,
mean (SD)
170.3 (20.3) 169.1 (19.3) <0.0005 173.3 (20.7) 171.3 (19.9) <0.0005
Diastolic BP,
mean (SD)
97.8 (11.8) 98.3 (11.5) 0.0006 96.0 (11.2) 96.7 (10.8) <0.0005
BMI,
mean (SD)
28.7 (5.1) 28.5 (4.6) 0.0073 28.8 (6.3) 28.1 (5.7) <0.0005
Any
monitoring
within 6
months, n (%)
3 963 (34.9) 9 215 (38.4) <0.0005 6 528 (34.1) 7 240 (36.9) <0.0005
Any
monitoring
within 1 year,
n (%)
5 458 (48.0) 12 756 (53.2) <0.0005 9 105 (47.6) 10 046 (51.2) <0.0005
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The significant differences in the characteristics of the patients with and without
missing data suggest that the data are not MCAR. However, it is not possible to test
whether data are MNAR as this missing data mechanism depends on unobserved
variables.
7.2.3.2 Imputation diagnostics
When the mean of each continuous imputed variable was plotted against a very large
number of cycles, no tendency for oscillation was observed, which suggested that
convergence was achieved and that the ten iterations or cycles were sufficient. The
traces of the first 100 cycles of the MICE algorithm are presented in Figure 7.2 to
Figure 7.5.
Figure 7.2 – Trace of the first 100 cycles of the MICE algorithm imputing
systolic blood pressure (the horizontal line indicates the mean value of the
original observations)
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Figure 7.3 – Trace of the first 100 cycles of the MICE algorithm imputing
diastolic blood pressure (the horizontal line indicates the mean value of the
original observations)
Figure 7.4 – Trace of the first 100 cycles of the MICE algorithm imputing BMI
(the horizontal line indicates the mean value of the original observations)
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Figure 7.5 – Trace of the first 100 cycles of the MICE algorithm imputing units
of alcohol per week (the horizontal line indicates the mean value of the original
observations)
7.2.3.3 Comparing observed and imputed values
The summary statistics of the observed and imputed values are shown in Table 7.9.
[The term ‘imputed values’ refers to only those values that were actually imputed and
not all values in the imputed data sets, which include both observed and imputed
values]. The values of the imputed data were very similar to those from the original
data. The summary statistics of the observed data and the complete imputation data
sets are presented in Table 7.10.
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Figure 7.6 and Figure 7.7 show the density plots and the quintile-quintile plots for the
four imputed variables. The distributions of the observed and imputed variables are
similar, especially for systolic and diastolic blood pressure, which provides support
that the multiple imputation generated values with similar distributions to the
observed values.
Figure 7.6 – Density plots of observed and imputed variables for four patient
variables. For each variable, the solid line shows the density plot of observed
values and the dashed line the density plot of the imputed variables.
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0 20 40 60 80
BMI
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Figure 7.7 – Quantile-quantile plots comparing the distribution of observed
values (x-axis) and imputed values (y-axis) for four patient variables
7.2.3.4 What are the patient factors associated with biochemical monitoring using
multiple imputed data?
I have previously investigated the patient factors associated with biochemical
monitoring, however the analysis was restricted to those patients with complete data
and alcohol use was excluded from the outset due to the high proportion of missing
data.
Multiple imputation created a complete data set with 74 096 patients; 15 194 more
patients than the model using complete case analysis presented in chapter 5 (Table
7.11). Univariable analyses using data from multiple imputation demonstrated the
same results as presented in chapter 5: patients with pre-existing diabetes, patients
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started on ACE inhibitors at baseline, and those with a first antihypertensive
prescription in 2003 were more likely to be monitored. Alcohol use significantly
decreased the likelihood of biochemical monitoring. In the multivariable model,
monitoring was again significantly associated the presence of diabetes, first-line
antihypertensive therapy with ACE inhibitors, and year of first prescription.
The results from the multiple imputed data tended to have narrower confidence
intervals compared with the results from the complete case analysis. Differences in
the effect size between the results obtained from multiple imputed data and the
complete case analysis were seen in some patient factors including older age groups,
baseline testing, severe hypertension, and year of initiation of antihypertensive
treatment.
As a comparison, a second complete case analysis was also undertaken where alcohol
was introduced into the model. This reduced the sample size even more to 38 917
patients. The effect size of diabetes mellitus was greater in this data set, while the
relationship between hypertension and follow-up monitoring was reduced. Wider
confidence intervals were demonstrated in this model, as was expected with the
smaller sample size.
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7.2.3.5 Sensitivity analysis of the transformation of continuous variables
I used a user-written Stata® command (nscore) to transform the variables that did not
approximate a normal distribution. As a sensitivity analysis, I used another Stata®
command (lnskew0) to transform the continuous variables. Density plots
demonstrated that the distributions of the observed and imputed variables generated
using the lnskew0 function were similar (Figure 7.8).
Figure 7.8 – Density plots of observed and imputed variables for four patient
variables using the lnskew0 function. For each variable, the solid line shows the
density plot of observed values and the dashed line the density plot of the
imputed variables.
The imputed values generated by both the nscore and lnskew0 Stata® commands
generated similar results. The multiple imputed data generated by the lnskew0
command also generated similar results in the multivariable analysis investigating the
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patient factors associated with monitoring as those data generated by the nscore
command.
7.3 Discussion
Primary care databases such as the GPRD are recognized as rich data sources, which
provide for opportunities to analyse various exposures and populations that would
potentially be impossible or unethical in clinical trials (e.g. studies of the elderly or in
pregnant women). These databases often provide a good number of important patient
covariates such as blood pressure, height, and weight. However, the proportion of
missing values for these variables can be significant, which can lead to potential
issues in the analysis and the significant potential for bias.
Complete case analysis, where records with missing data are discarded, is an easy
method for dealing with the problem of missing data and is the method used in the
analyses I presented in chapter 5. This method does, however, exclude variables with
large quantities of missing data (e.g. alcohol use), which does not allow for the ability
to adjust for potential confounding by these variables. Complete case analysis also
reduces the precision of the effect estimates and can introduce significant bias if the
assumption that the data are missing completely at random does not hold. Indeed,
upon examination of the missingness of the data, I found that there were significant
differences in the patients with and without missing data, and therefore demonstrated
that the data were not missing completely at random.
Multiple imputation is a powerful technique that is used to deal with missing data,
that does not require data to be missing completely at random. The use of this
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technique has increased significantly, with several statistical packages providing
options to both create and to later analyze the multiple imputed data. Multiple
imputation has been shown to be successful in accounting for missing data on weight,
height, and blood pressure in primacy care databases (Marston et al., 2010). Although
the same authors cautioned that multiple imputation may not be suitable for imputing
alcohol use or smoking status as the assumptions used in multiple imputation may be
violated.
I used multiple imputation by chained equations to create a data set with an additional
15 194 patients and use all of the information in the incomplete records. This method
prevented the loss in power from having to exclude a patient that is missing only one
variable. Multiple imputation by chained equations specifies different regression
models for each incomplete variable, which is beneficial because it does not assume a
specific form for the multivariate distribution. This method does assume that the
regression models converge to the joint multivariate distribution. Convergence was
achieved, which suggested that the number of iterations used was satisfactory.
I was able to create a range of imputed values with distributions that were similar to
the observed values using multiple imputation. The results from the analysis using
imputed data were similar to those from the complete case analysis, with some
differences in the magnitude of the effect of some patient factors on monitoring. For
example, the absolute difference in the association between age and biochemical
monitoring in the multiple imputed data set was 12% lower than in the complete case
analysis. This may have been caused by differences in how data were recorded in
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these older age groups, which may have led to data being missing and the subsequent
exclusion of these patients from the complete case analysis.
Multiple imputation is based on the assumption that the data are MAR, and departures
from MAR, which tend to occur with large amounts of missing data, can affect the
results. This can be reduced through the inclusion of many variables in the imputation
model in order to make MAR more plausible. The selection of the variables into the
imputation model was based on practical and theoretical considerations in that
variables that predicted the missingness of a missing variable or were correlated with
a missing variable were selected. The database consisted of hundreds of variables that
may have been used in the imputation model. However, the inclusion of all of the
variables would not have been computationally feasible and may have led to
instability of the model.
7.4 Conclusions
Imputed data will never be a substitute for observed data, and steps should be taken
by researchers to minimize the proportion of data that are missing. However, multiple
imputation by chained equations was able to generate plausible values for variables
with missing data that were similar to the observed values. When I examined the
patient factors associated with biochemical monitoring using multiple imputed data,
similar results were obtained to those from the previous complete case analysis. This
does not provide clear evidence that the complete case analysis is more appropriate.
Indeed, the results using the multiple imputed data had narrower confidence intervals
and more precision.
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Chapter 8
ESTIMATING THE RELATIONSHIP
BETWEEN BASELINE BIOCHEMICAL
TESTING AND ADVERSE PATIENT
OUTCOMES USING PROPENSITY
SCORE METHODS
In this chapter I introduce the propensity score as a tool for controlling confounding in
observational research. I discuss the increase in the use of propensity score methods
and their potential benefits and risks. I describe the development of a propensity score
to estimate the probability of baseline biochemical testing, which is then used to
examine the relationship between biochemical testing and adverse patient outcomes.
Finally, I compare the results obtained using propensity score methods and traditional
multivariable models.
8.1 Controlling for confounding in observational research
8.1.1 Comparing randomized controlled trials with observational studies
Randomized controlled trials (RCTs) are viewed as the gold standard for estimating
treatment effects. Randomization in RCTs ensures that measured and unmeasured
patient covariates are balanced in both treatment arms, which reduces the risk of
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confounding. However, RCTs can sometimes be unnecessary, inappropriate,
impossible, or inadequate (Black, 1996). For example, a RCT may be unethical or
unfeasible when one wishes to study the effects of treatment in certain patient groups
such as pregnant women or children. RCTs are also often too small to identify rare
adverse events; a limitation that is addressed through the use of post marketing
surveillance schemes to identify adverse drug reactions such as the Yellow Card
Scheme in the UK (Davis et al., 2007). RCTs also commonly enrol a sample of
patients that may not be representative of the population of interest due to restrictive
selection criteria. Patients enrolled in a RCT tend to be healthier, younger, and more
likely to be male (Hennekens & Buring, 1987). RCTs are also limited by their short
length of duration, which can limit the ability to detect delayed adverse reactions to
treatment. Finally, a randomized experiment may not be appropriate if randomization
itself will reduce the effectiveness of an intervention. This will occur if the
participation of the patient was dependent on the patient’s own preferences (e.g.
health promotion or disease prevention programmes) (Black, 1996).
Because RCTs are often impossible due to ethical, logistical, or practical limitations
described above, observational studies are required. Observational studies can provide
an assessment of real world practices with regards to the behaviours of both
physicians and patients. Observational studies, particularly those that are retrospective
in design, allow for the timely and cost-effective assessment of treatments. They also
can provide opportunities to analyze long-term follow-up data that would have not
been feasible with a RCT.
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The main source of potential bias in observational studies is selection bias, where the
treatment groups may differ systematically at baseline (Deeks et al., 2003). In a
randomized experiment, patients are allocated to treatment groups through chance.
For observational research, allocation to treatment will be influenced by a range of
factors including a doctor’s experience and various patient factors. This tendency can
result in treatment groups that are systematically different and impossible to compare.
Confounding by indication—where differences between two groups originate from
differences in the indication for treatment such as the presence of various risk
factors—is of specific concern. The decision to treat a patient with a certain
intervention can be influenced by some factor that is associated with the outcome of
interest. Confounding by indication can lead to an overestimation or underestimation
of the true association between a treatment or exposure and an outcome (Rothman &
Greenland, 1998).
Observational studies are also at risk of (1) attrition bias, which is associated with the
completeness of follow-up; (2) detection bias if the assessment of the events of
interest is not blinded; and (3) performance bias if there are systematic differences in
the way that an intervention is allocated, applied, and recorded (Deeks et al., 2003).
8.1.2 Controlling for confounding in observational studies
Various methods have been suggested for controlling for measured confounding in
observational studies (Rothman & Greenland, 1998; Greenland & Morgenstern,
2001). One method is restriction, where analyses are carried out in a sub-sample of
patients that are alike with regards to the confounding variable. For example, if
smoking is thought to be a confounder then the analysis can be carried out solely in
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non-smokers. This method removes the potential for confounding based on smoking,
but can significantly decrease the sample size and limit how one extrapolates the
results to other groups.
Matching based on one or more of the suspected confounders can also be carried out
to control for confounding. Exposed patients are matched with unexposed patients (in
the case of a cohort study) based on the suspected confounding factor (e.g. age or
sex). Matching can control for confounding more efficiently with less random error in
the statistical analysis (Greenland & Morgenstern, 2001). However, it may become
difficult to obtain matches if attempts are made to match on more than one
confounding factor.
Standardization is a method of data analysis that combines information over strata
using a specified system of weights. Weights from a standard population are used to
determine the number of events that would have been expected if the two populations
being compared had had identical distributions of the potential confounding factor
(Hennekens & Buring, 1987). When rates adjusted for a particular factor are
compared, any remaining observed difference between the groups cannot be attributed
to confounding by that factor.
Stratification is another data analysis method that can control for measured
confounding. The results are stratified by levels of one or more confounding factors
and the effect of the exposure is estimated with a given stratum. Because the
confounding factor is homogeneous within each stratum, it cannot act as a
confounder. The effect is then summarized across all of the strata through a pooled
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estimate. The method is limited to one or two potential confounders and can lead to
problems with sparse data as few strata may have both treated and untreated patients
with all of the confounding factors. Another disadvantage is that continuous variables
will have to be classified into strata using potentially arbitrary criteria (Martens,
2007).
Finally, multivariable regression modelling examines the relationship between an
exposure and an outcome while simultaneously controlling for multiple confounding
factors. The exposure is treated as the independent variable of interest and the analysis
adjusts for the treatment effect of all of the confounders added into the model. This
method adjusts for significantly more confounders than stratification, but there is a
limit to the number of potential confounders that can be modelled and still generate
stable estimates. A rough rule of thumb of no fewer than ten events or outcomes per
variable has been suggested in order to maintain the validity of the model and reduce
the occurrence of biased estimates (Peduzzi et al., 1995; Harrell et al., 1996; Peduzzi
et al., 1996), although this ‘rule of ten’ may be too strict (Vittinghoff & McCulloch,
2007). The ease of use of multivariable modelling has increased substantially with
improvements in computing systems and statistical software. However, the ability of
multivariable modelling to control for confounding is only as good as the model itself.
Indeed, Rothman (1986; p. 285) stated that:
‘The first experience with multivariate analysis is apt to leave the impression
that a miracle in the technology of data analysis has been revealed; the method
permits control for confounding and evaluation of interactions for a host of
variables with great statistical efficiency. Even better, a computer does all the
arithmetic and neatly prints out the results. The heady experience of
commanding a computer to accomplish all these analytic goals and the simply
gathering and publishing the sophisticated ‘output’ with barely a pause for
retyping is undeniably alluring... However useful it may be, multivariate
analysis is not a panacea...Multivariate analysis provides a way to preserve
precision while controlling many variables, by postulating a mathematical
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model that allows the data to be used more efficiently to estimate many effects
simultaneously. The extent to which this process represents improved
efficiency rather than just bias depends on the adequacy of the assumptions
built into the mathematical model.’
8.2 A summary of propensity score methods
Propensity score methods have also been suggested as a way of controlling for
measured confounding. The propensity score is a single, unidimensional multivariate
score calculated for each patient within a given cohort that estimates the patient’s
chance of receiving treatment according to their characteristics. The use of a
multivariate score to control for measured confounding was first suggested by
Miettinen (1976) over thirty years ago. He described an approach where confounding
factors are summarizing using a single, unidimensional score. Rosenbaum and Rubin
(1983; 1984) built upon Miettinen’s work, coining the term ‘propensity score’, and
advocating the use of propensity score methods as a way of controlling for
confounding in observational studies. The use of propensity score methods to estimate
treatment effects using observational data has increased significantly, with a dramatic
increase in the past few years (Weitzen et al., 2004; Stürmer et al., 2005; Stürmer et
al., 2006a; Austin, 2008b).
8.2.1 Estimating the propensity score
The propensity score is defined as the conditional probability of an event—usually the
treatment—given an individual’s observed covariates (D'Agostino, 1998). A
propensity score captures how differences in these observed covariates contribute to
the probability of a patient receiving a given treatment. The score has a value between
zero and one, so each patient has a non-zero probability of receiving treatment. The
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goal of the propensity score model is not to predict patient allocation into treatment
groups accurately but to create a score that will create a balance on covariates over
groups within propensity score strata (Brookhart et al., 2006). For a given propensity
score, the distribution of the covariates defining the propensity score is on average the
same in the treated and the untreated groups, thus creating a quasi-randomized
experiment, at least with respect to these covariates (Stuart & Rubin, 2008).
The propensity score is most often estimated from a logistic regression model where
the event (most often drug treatment) is a binary outcome (yes/no; 0/1) regressed on
measured baseline patient covariates. The selection of the covariates used in the
development of the propensity score requires careful consideration as the variance of
the estimated exposure effect can be strongly influenced by the selection of the
variables and how such variables are categorized and made to interact with each other
(Brookhart et al., 2006).
The process of selection of variables to include in the propensity score model is a
topic of some debate (Austin et al., 2007). Early research suggested using variables
associated specifically with treatment allocation (Rosenbaum & Rubin, 1983), while
authors have more recently suggested that all variables associated with both treatment
allocation and outcome should be included in the propensity score model (Perkins et
al., 2000). Rubin suggested that a broad range of variables should be included when
building the propensity score. He did, however, warn against the use of variables ‘that
are effectively known to have no possible connection to the outcomes, such as random
numbers, or five-way interactions, or the weather half-way around the world’ (Rubin,
2007; p.29). Simulations have demonstrated that the inclusion of variables associated
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with the treatment allocation but not the outcome can increase the variance of the
treatment effect (Brookhart et al., 2006) and can also reduce the ability to carry out
matching based on the propensity score (Austin et al., 2007).
Unlike traditional regression modelling, the propensity score model does not need to
be parsimonious and can include numerous covariates, interactions, and nonlinear
terms. The propensity score model should be estimated using the structured, iterative
process described Rosenbaum and Rubin (1984). First, the initial propensity score
should be estimated using the variables as main effects that were identified for
inclusion in the model. Balance between these variables should then be assessed. Each
potential confounder is regressed on treatment, propensity score quintile, and the
treatment and quintile interaction using analysis of variance. If there is evidence of
imbalance the propensity score model should be modified by using the square of the
variable and through the addition of interactions with other clinically important
variables. Higher order terms can be added to further refine the model. This iterative
process is repeated until balance is achieved between the potential confounders or
when repeating the process is no longer practical. Indeed, the liberal use of
interactions and transformations is encouraged in order to create balance between the
two treatment groups and therefore better adjust for bias (Shah et al., 2005).
8.2.2 Common support of the propensity score model
The distribution of the estimated propensity score for treated and untreated patients
should be plotted to allow for the examination of overlap in the propensity scores of
the two treatment groups (Figure 8.1). This can, for example, identify untreated
patients with very low propensity scores for whom there would be no treated patients
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with whom to match on the propensity score. These patients may not be comparable
and their inclusion may lead to a biased estimate of the treatment effect (Rosenbaum
& Rubin, 1985; Heckman et al., 1998). This bias can be reduced by enforcing
common support, that is, by restricting the analysis to the range of propensity scores
that overlap. Enforcing common support excludes untreated patients with a propensity
score lower than the lowest propensity score from the treated patients, as well as
excluding treated patients whose propensity score are higher than the highest value in
the untreated patients.
Figure 8.1 – The propensity score distribution demonstrating the area of over-
lap between treated and untreated patients. Patients with very low propensity
scores are never treated and patients with very high propensity scores are always
treated (adapted from Schneeweiss & Avorn, 2005).
8.2.3 Propensity score methods
Once estimated, the propensity score can then be used in several ways in order to
control for confounding. Some of the commonly used methods are described below.
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8.2.3.1 Covariate adjustment using the propensity score
Propensity score can be used as a covariate, in addition to the treatment variable, in a
regression model to adjust for the estimate of the treatment effect. Both treatment and
the propensity scores are regarded as independent variables in the analysis and it is
assumed that the relationship between the propensity score and the outcome is linear.
Additional covariates may be included in the regression model.
8.2.3.2 Matching on the propensity score
Matching on the propensity score is an intuitive method to adjust for confounding that
does not impose linearity restrictions on the relationship between an outcome and the
patient covariates (Zhou, 2005). Matching treated and untreated patients on the
propensity score is most commonly carried out through nearest neighbour matching,
where an algorithm matches treated patients with the nearest untreated patient based
on their similar propensity scores. The majority of studies use one-to-one matching,
although one-to-many and many-to-one matches can be made. There is a risk of poor
matches using nearest neighbour matching if the nearest neighbour is numerically
distant.
Two types of nearest neighbour matching algorithms exist. The more commonly used
is the greedy matching algorithm, which randomly selects a treated patient and
matches them with the nearest untreated patient, even if that untreated patient could
serve as a better match for another treated patient. The other type of algorithm is
optimal matching, where the algorithm finds pairs with the smallest average absolute
distance between each pair. Pairs that were previously formed can be unmatched if
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another pair would have a smaller distance. Optimal matching is difficult to achieve in
large data sets for computational reasons (Austin, 2009a).
Greedy nearest-neighbour matching is most often undertaken within a given interval
of the treated patient’s propensity score (the caliper width) (Austin, 2009c). A treated
patient is matched with the nearest untreated patient within a fixed caliper width,
which is used to reduce the risk of bad matches by imposing a maximum numerical
distance between matches. Deciding on the appropriate caliper width a priori is
difficult and various calipers have been used in the medical literature. Some authors
have carried out matching on the logit of the propensity score, using caliper widths of
0.6 times (Ayanian et al., 2002) and 0.2 times (Austin et al., 2007) the standard
deviation of the logit of the propensity score. Other authors have matched on the
propensity score using caliper widths ranging from 0.005 (Cole et al., 2002); to 0.01
(Seeger et al., 2003); to 0.1 (Moss et al., 2003). Cochran and Rubin (1973)
demonstrated that matching using calipers of width of 0.2 of the standard deviation of
the logit of the propensity score eliminated between 98 and 99% of the bias of the
confounding variable, assuming that this variable was normally distributed.
A more recent Monte Carlo simulation by Austin (2009c) examined the performance
of matching methods using different caliper widths. Using a caliper width of 0.6 times
the standard deviation of the logit of the propensity score resulted in the greatest
number of matches but also generated estimates with the greatest bias. Austin
recommended the use of calipers with width of 0.2 standard deviation of the logit of
the propensity score or using calipers of width 0.02 or 0.03 on the propensity score
scale.
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Nearest neighbour matching on the propensity score can be undertaken with or
without replacement. Matching without replacement is most commonly used, where
an untreated patient who has been matched with a treated patient is removed from the
matching pool and can no longer act as a potential match for other treated patients.
Poor matching can occur when there is limited overlap in the distribution of
propensity scores of the treated and untreated patients. In matching with replacement,
each treated patient is matched with the closest untreated patient, which allows more
exposed patients to be used and improves the performance of the match (Lunt et al.,
2009). This method does, however, increase the potential for a small number of
untreated patients to be used multiple times and can therefore influence the results
significantly.
The various matching techniques and algorithms represent a trade-off between bias
and efficiency and careful consideration must be given to their application (Table
8.1).
Table 8.1 – The trade-off between decreased bias and improved efficiency in
matching techniques (adapted from Hebert, 2010)
Matching techniques Bias Inefficiency
1-to-1 matching  
1-to-N matching
Matching with replacement
Matching without replacement
Matching with calipers
Matching without calipers
193
Nearest neighbour matching can also be undertaken using five-to-one (5→1) digit
matching. This method matches treated and untreated patients on the first five digits
of the propensity score. If this cannot be achieved for a treated patient, then matching
is attempted on the first four digits. If a suitable match cannot be found for a treated
patient, attempts to find suitable matches on the first three, first two, and finally the
first digit of the propensity score are then made.
8.2.3.3 Stratification on the propensity score
In this method, patients are grouped into strata based upon the propensity score and
the exposed and unexposed patients are compared within each stratum. The strata are
usually equal sized groups created using the quintiles or deciles of the estimated
propensity score. Within each stratum of the propensity score the treated and
untreated patients are more likely to be directly comparable, similar to a randomized
trial (Weitzen et al., 2005). Stratification based on the quintiles of a propensity score
has been shown to decrease 90% of bias due to imbalance of potential confounders
(Rosenbaum & Rubin, 1984). However, residual imbalance between treated and
untreated patients in the upper and lower strata has been demonstrated (Austin et al.,
2007), and stratification can lead to greater bias when compared with matching on the
estimated propensity score (Austin, 2008d).
8.2.3.4 Weighting by the inverse of the propensity score
Weighting is another method of using propensity scores to estimate treatment effects,
although it is used less frequently than other methods. In propensity score weighting,
the treated and control observations are re-weighted in order to make them more
representative of the population. The weight of a treated patient is defined as the
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inverse of its propensity score, while the weight of an untreated patient is defined as
the inverse of one minus its propensity score. This method does have potential for
serious bias as the procedure can give a high weight to a small number of patients
who may not be representative of the population as a whole.
8.2.3.5 Other propensity score and similar methods
Another method that has been suggested but is used infrequently is matching on the
Mahalanobis distance between a treated patient and an untreated patient. The
Mahalanobis distance d(i,j) is defined as
( ) ( ) ( )jiTji vuvujid C −−= −1, (8.1)
where u and v are values of the matching variables for treated patient i and untreated
patient j, and C is the sample covariance matrix of the matching variables from the
full set of control subjects (D'Agostino, 1998). The Mahalanobis distance scales the
distance in variance based on the covariance matrix so that if , for example, the
variance of u is twice the variance of v, then an observation needs to be twice as far in
order to be equidistant in the Mahalanobis distance (Posner & Ash, 2006). Patients are
randomly ordered and the Mahalanobis distance is calculated between the first treated
patient and all of the untreated patients. The untreated patient with the smallest
Mahalanobis distance is chosen as a match and both the treated and untreated patients
are removed from the selection pool. The process is repeated until matches are found
for all treated patients. Mahalanobis metric matching can also be carried out including
the estimated propensity score and where the logit of the estimated propensity score is
used in the calculation of the Mahalanobis distance. Finally, nearest available
Mahalanobis metric matching can also be implemented within set calipers that are
defined by the estimated propensity score.
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Finally, kernel weighting can be used to match every treated patient with the weighted
average of the untreated patients. The weights are inversely proportional to the
distance between the treated and untreated patients’ propensity scores (Baser, 2006).
This method results in lower variance as all of the treated patients contribute to the
weights.
8.2.4 A comparison of propensity score methods
There is an inherent relationship among the different propensity score methods and
they often can generate similar results. For example, matching on the propensity score
can be likened to stratification where one is using very small stratum. However, each
method has benefits and limitations, which must be considered and acknowledged.
Covariate adjustment using the propensity score is a useful method because no data
are lost due to poor overlap or lack of common support between treated and untreated
patients, which increases the generalizability of the results. However, this method can
be significantly affected by errors in estimation of the propensity score. Regression
using the estimated propensity score also assumes a linear relationship between the
propensity score and the outcome, which is not assumed with matching or stratifying
on the propensity score.
The method of weighting by the inverse of the propensity score is less frequently used
and is limited because it attaches more importance to observations at the tail-end of
the propensity score distributions. This has potential for serious bias as a small
number of patients can be weighted heavily who may not be representative of the
entire study cohort. Furthermore, if there is an error in the measurement of the
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outcome, treated patients will tend to have smaller propensity scores or treated
patients will have larger propensity scores, which will lead to an estimated treatment
effect with very large variance.
Several studies have used multiple propensity score methods with the specific goal of
making comparisons among the different methods and traditional regression models.
Stürmer and colleagues (2005) used various methods including stratification and
matching on the propensity score, covariate adjustment using the propensity score,
weighting by the inverse of the propensity score and a traditional multivariable model
to investigate the effect of non-steroidal anti-inflammatory drug use on mortality. All
of the methods produced estimates of the treatment effect that were comparable with
the results obtained from prior randomized trials.
A second study examined the effect of statin therapy on mortality following acute
myocardial infarction using various propensity score methods, all of which gave
similar estimates of treatment effect (Austin & Mamdani, 2006). Covariate adjustment
including the propensity score had the lowest variance, but the estimate produced by
matching on the propensity score was identical to one obtained from a meta-analysis
of trials. The authors also demonstrated that matching and stratifying on the
propensity score both improved balance in the baseline characteristics between treated
and untreated patients, although greater balance was achieved by matching. This
study illustrated the trade-off between matching and stratification on the propensity
score: matching improves balance and reduces bias, but may result in a reduction in
the sample size if a match cannot be found, which can decrease the precision of the
results. Stratification on the propensity score may result in greater bias due to the
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strata being heterogeneous in the propensity score—referred to as residual
confounding—but results in estimates with greater precision (Austin et al., 2007;
Austin, 2008d).
Austin (2009b) used an empirical case study and a simulation study to compare the
four main propensity score methods. He demonstrated that matching on the propensity
score removed almost all of the systematic differences between treated and untreated
patients. Weighting using the inverse of the propensity score was comparable to
matching, while stratification on the propensity score and covariate adjustment using
the propensity score resulted in greater residual differences in baseline characteristics
between treated and untreated patients.
There is some evidence that the various propensity score methods can perform
differently depending on which method is used and the context in which it is used.
Kurth and colleagues (2006) analyzed the effect of tissue plasminogen activator on
mortality and demonstrated that the different propensity score methods can have
significantly divergent results. They found that covariate adjustment and stratification
on the propensity score tended to overestimate the treatment effect while weighting by
the inverse of the propensity score overestimated the treatment effect by a factor of
approximately 10 because of many very small propensity score values. The
differences were most likely due to the inclusion of patients with low propensity
scores who were uncommon in the treated group, common in the untreated group, and
significantly different from the rest of the patients in their risk of death. This was
demonstrated when the analyses were limited to patients with a propensity score of
greater than 0.05; all of the propensity score methods gave fairly similar results. The
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authors argued that the variation in the results obtained by the different methods does
not suggest that one of the methods is better for controlling confounding. Instead, one
must investigate the potential causes of the divergent results.
The different propensity score methods have their advantages and disadvantages and
can produce different results, which may be valid but depend on the research question
implied by the adjustment method. Matching is often chosen because it can generate
an easier, more transparent analysis, but this method is limited by the loss in the
sample size due to incomplete matching. Stratification on the propensity score
improves precision but may result in greater bias due heterogeneous strata. Weighting
by the inverse of the propensity score is not very often used, primarily because in
cases with extreme propensity score values, the variance of the weighted estimator
can be very large. Generally, it is not apparent whether any of various propensity
score methods is superior to the others. Neither is it certain whether propensity score
methods are preferable to traditional regression models.
8.2.5 Diagnostics of propensity score matching methods
Balance diagnostic tests determine whether the propensity score model has been
adequately specified by identifying whether balance has been achieved between the
treated and untreated patients with respect to the covariates used to define the
propensity score (Austin, 2009a). Balance diagnostics differ depending on how the
propensity score was used to adjust for confounding, although all of the diagnostics
use a method based on the standardized difference to compare the balance in
measured baseline covariates between treated and untreated patients. The use of
standardized differences is preferable to significance testing and probability values
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because they are not influenced by sample size and are less sensitive to bias. The
standardized difference (d) for continuous variables is defined as
2
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where x¯ represents the sample mean and s the sample variance of the covariate in
treated and untreated patients. For dichotomous variables, the standardized difference
(d) is defined as
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where pˆ is the prevalence of the dichotomous variable in treated and untreated
patients. The standardized difference allows for the comparison of the relative balance
between different covariates measured in different units (Austin, 2008e). A
standardized difference of 10 percent or greater has been demonstrated to indicate
significant imbalance in the patient characteristic (Normand et al., 2001).
In addition to the standardized differences of the potential confounders in the matched
sample, means of continuous covariates and the frequency distribution of categorical
variables between treated and untreated patients should be reported (Austin, 2009a).
The adequacy of matching can further be assessed by calculating the percent bias
reduction, which is defined as
( )
( )





−=
d
d
unmatched
matched
reductionbias 1% (8.4)
where d is the standardized difference obtained in either equation (8.2) or (8.3) .
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When many-to-one matching has been carried out, a weighted standardized difference
should be used, using the inverse of the number of untreated subjects within a given
matched set as the weight for each untreated patient (Austin, 2008a). When
stratification on the propensity score is used, within-strata standardized differences
are used to compare the distribution of baseline confounders between treated and
untreated patients within the same propensity score stratum. A mean standardized
difference can then be combined across the strata (Austin, 2009b).
Two balance diagnostics have been suggested when covariate adjustment with the
propensity score is used. A weighted conditional standardized difference can be
computed, which compares the conditional difference in baseline covariates between
the two treatment groups. A qualitative method using a quantile regression model
conditional on the propensity score can compare the distribution of continuous
baseline covariates between treated and untreated patients (Austin, 2008c).
Some authors have used the Hosmer–Lemeshow test to assess the goodness of fit
(GoF) of the propensity score model. The GoF assesses how well the model describes
the data and whether differences between observed values from the data and the
values predicted from the model are small and random. Lack-of-fit may occur due to
the misspecification of continuous variables, the use of inappropriate interaction
terms, or through the omission of important confounders (Hosmer et al., 1997).
Another diagnostic test that is often presented is the area under the receiver operator
characteristic (ROC) curve (also called the c-statistic). The c-statistic assesses the
discrimination of the propensity score model, or how well the estimated propensity
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score classifies patients into treated or untreated groups. A value of 0.5 would suggest
that the propensity score model was as effective as tossing a coin, compared with a
value of 1.0 that suggested that the model perfectly predicted whether a patient was
treated or untreated (Weitzen et al., 2005).
Although both the GoF test and c-statistic are often reported (Weitzen et al., 2004),
several authors have warned against the use of these tests of model discrimination and
specification. Previous simulation studies have demonstrated that both tests of GoF
and the c-statistic fail to identify whether an important confounding variable has been
omitted from the propensity score model or when a model is misspecified (Weitzen et
al., 2005; Austin et al., 2007; Austin, 2009a). Indeed, no association has been
demonstrated between the c-statistic and the ability of the propensity score model to
balance potential confounders between treated and untreated patients (Austin et al.,
2007). A propensity score with a high c-statistic (e.g. 0.90) can have significant levels
of non-overlap in the distributions of propensity scores in treated and untreated
patients, which can lead to significant bias in the estimation of the treatment effect.
Other statistical tests, in addition to the calculation of standardized differences, have
also been suggested to ensure that balance has been achieved between the two
treatment groups on potential confounding factors in matched cohorts. The variance
of variables can also be compared between treated and untreated patients (Imai et al.,
2008; Austin, 2009a). Austin demonstrated in a simulation study that incorrectly
specified propensity models can be identified by comparing the ratios of variances
(Austin, 2009a). Ho and colleagues (2007) and Austin (2009a) have both suggested
comparing the means of interactions of pairs between treated and untreated patients,
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which can determine if covariances are similar between the two treatment groups.
Austin’s simulation study demonstrated that a large standardized difference indicated
an incorrectly specified propensity score model.
Graphical methods have also been suggested as a way to assess balance, including the
use of quantile-quantile plots and side-by-side box plots (Ho et al., 2007; Imai et al.,
2008). These graphs can be used to compare the distribution of baseline covariates
between treated and untreated groups, and help to provide additional evidence that the
propensity model has been correctly specified.
8.2.6 The use of propensity score methods
Although propensity score methods were first fully described in 1983 (Rosenbaum &
Rubin) as a tool to reduce confounding, it has only been in recent years where an
increase in their use has been observed (Austin, 2008b). Indeed, the National Library
of Medicine did not introduce the medical subject heading (MeSH) ‘propensity score’
until July 2009.
A search of Medline (via OVID) on 1 January 2011 using the text words propensity
score$ or propensity match$ or the propensity score MeSH term identified 2279
publications. A dramatic increase in the number of publications and the proportion of
Medline citations referencing propensity score methods over time is evident (Figure
8.2).
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Figure 8.2 – Total number of citations and number of citations per 10,000
publications in Medline referencing propensity score (PS) methods by year of
publication
Several systematic reviews have been carried out over the past six years examining
the nature and quality of medical studies using propensity score methods (Table 8.2).
An early systematic review by Weitzen and colleagues (2004) examined 47 studies
published in 2001 that used propensity score methods. The majority of studies (25)
adjusted the model using the propensity score, 7 used matching based on the
estimated propensity score, and 13 studies stratified on the propensity score. Two
studies provided no clear description of the method used.
Shah and colleagues (2005) reviewed 43 studies that published results using both
traditional regression and propensity score methods to control for confounding. The
majority of studies (22) used the propensity score as a covariate in a regression model,
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13 studies matched on the propensity score, and 8 studies used stratification on the
propensity score. Fewer than half (19) of the studies reported whether balance had
been achieved in the confounders used to estimate the propensity score. The estimates
generated by propensity score methods tended to be more conservative than those
from traditional regression analyses.
A large review examined 177 studies published until the end of 2003 that used
propensity score methods (Stürmer et al., 2006a). Fifty-one studies used matching on
the propensity score. Of the 69 studies that presented the results of both propensity
score methods and traditional methods, only 9 (13%) had an effect estimate that
differed by more than 20%. Seventy-three studies (41%) reported the discrimination
of the propensity score model using the area under the ROC curve, which ranged from
0.56 to 0.93.
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A systematic review examined studies that were published in the medical literature
between 1996 and 2003 that carried out matching on the propensity score (Austin,
2008b). Forty-seven studies were identified, of whom 15 (32%) did not report how
matched pairs were formed. Eight studies did not assess whether matching on the
propensity score resulted in balance between potential confounders in the treated and
untreated patients. Analytic methods to estimate the treatment effect did not take into
account the matched nature of the cohort in 26 studies.
Another systematic review had a more narrow scope and examined studies published
from 2004 to 2006 from the cardiovascular surgery literature (Austin, 2007). Austin
identified 60 studies that carried out matching using an estimated propensity score.
Almost 30% (17) of the papers did not report how the matched pairs were created.
There was poor reporting of whether balance on the potential confounders had been
achieved between treated and untreated patients, as 18% of the studies did not report
this information. Over two-thirds (39) of the studies used statistical methods to
estimate the treatment effect that did not take into account the matched nature of the
cohort.
Austin (2008e) reported a second similar systematic review of studies undertaking
propensity score matching published within the same time frame (2004 to 2006), but
which were reported in the cardiology literature. There was no overlap in the studies
from his other review. Austin identified 44 studies of which 24 (55%) reported how
matches were formed. Fourteen studies did not assess balance in the confounders
between treated and untreated patients. Almost half of the studies (21) used statistical
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techniques to assess the statistical significance of the treatment effect that were
inappropriate given the matched cohort.
The most recent systematic review was carried out by Gayat and colleagues (2010),
who examined studies published in intensive care and anaesthesiology journals from
2006 to 2009. The average number of covariates used to estimate the propensity score
was 15 (range 9–22) in the 47 studies reviewed. The majority of studies (26) carried
out matching on the propensity score, of which 23 (79%) presented data on balance
between confounders. Nine articles used stratification of the propensity score and 12
used the propensity score in a regression model. No studies used weighting on the
propensity score.
The seven systematic reviews identified several common themes. First, reviewers
called for greater clarity and transparency in how the propensity score was estimated,
with a clearer description of covariate selection and how these covariates were
chosen. Secondly, when propensity score matching techniques are used, authors
should explicitly state how the pairs were created and whether sampling was carried
out with or without replacement. Thirdly, the distribution of baseline characteristics
should be compared. This should be carried out using standardized differences and
most authors discouraged the use of GoF tests and the c-statistic. Weitzen and
colleagues (2004) did not explicitly discourage the use of these tests of goodness of fit
and model discrimination but later the same authors published a study demonstrating
that these tests failed to detect missing confounders in a propensity score model
(Weitzen et al., 2005). Finally, appropriate statistical methods that take into the
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account the lack of independence due to matching should be used when analyzing a
matched cohort.
The most recently published systematic review by Gayat and colleagues (2010)
described an improvement in the use of more robust methods to assess balance
between confounders (e.g. the use of standardized differences) and a general turn
towards the use of matching as the primary propensity score technique. The authors
did, however, describe continued failings in how the propensity score was estimated
and in the statistical methods used to determine the treatment effect.
The use of propensity score methods is not restricted to the medical literature. These
methods have also been used in observational research investigating other
‘treatments’ that have been non-randomly allocated such as the exposure to different
educational (Yanovitzky et al., 2005; Zanutto et al., 2005) or economic programmes
(Dehejia & Wahba, 2002).
8.2.7 Benefits and limitations of propensity score methods
Propensity score methods have been shown to be robust and although they may
slightly decrease the strength of the association between treatment and outcome, they
do not tend to give significantly different results than those obtained from traditional
regression models (Shah et al., 2005; Stürmer et al., 2006a). They may also provide
additional benefit by restricting the analysis to groups that overlap with respect to
potential confounders and therefore are more readily comparable (Hill et al., 2004).
The lack of sufficient overlap cannot be detected in traditional multivariable
modelling.
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Another advantage of propensity score methods is that they have been shown to
perform particularly well when there are few events per potential confounding
variable. When an outcome is rare and the drug treatment is relatively common—such
as rhabdomyolysis with statins—there may be too few data with which to model the
relationship between an outcome and patient covariates. For example, if several
thousand patients are assigned to one of two drug treatments and only thirty outcomes
are observed, standard logistic regression with multiple covariates would not be
possible as ten events per covariate is usually considered to be the minimum
requirement for stable, unbiased estimates (Peduzzi et al., 1996; Stürmer et al.,
2006a). When treatment is common, there are sufficient data with which to model the
relationship between treatment and patient outcomes and therefore calculate a
propensity score. The use of a single propensity score, which has been estimated with
many patient covariates, can therefore control simultaneously for many measured
covariates, even when there are too many covariates to model their relationships with
the rare outcome (Braitman & Rosenbaum, 2002).
A simulation study by Cepeda and colleagues (2003) demonstrated that when there
were seven or fewer events per confounder, propensity score estimates were less
biased, more robust and more precise than logistic regression methods. This has
important implications for pharmacoepidemiological research, where studies often
examine rare outcomes (Glynn et al., 2006).
There is also some evidence that stratification on the propensity score may have some
benefit over traditional methods when effect modification is present, because a
summary measure is calculated over the strata. This has particular relevance to
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pharmacoepidemiology where one can infer the relationship between drug and an
outcome for an entire treated population (Stürmer et al., 2006b).
Propensity score methods can adjust for selection bias in observational studies and
can perform well when modelling rare outcomes. They are not, however, ‘magic
bullets’ that can eliminate all bias in observational studies (Shah et al., 2005). Some
authors have noted the ‘perceived opacity of the statistical process’, which can cause
propensity score methods to have a ‘very black box feeling’(Nuttall & Houle, 2008).
Propensity score methods cannot control for confounding by unmeasured factors, and
it is these unmeasured confounders that can still lead to biased results. This is the
main limitation of observational research because, compared with randomized studies,
the lack of randomization cannot balance the distribution of all covariates, observed
or unobserved. Residual confounding bias cannot be excluded, particularly when one
is carrying out research in databases where information on confounders is limited.
Although sensitivity analyses techniques have been suggested as methods to
quantitatively assess the degree of residual confounding, these methods are not often
used (Schneeweiss, 2006).
There can also be errors in the model used to estimate the propensity score, and these
can result in bias. Although the model need not be parsimonious, the addition of
extraneous variables into the model should be avoided as they may not bias the results
but can increase the variance (Heckman et al., 1998).
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Propensity score methods also work better in large samples as substantial imbalance
has been demonstrated in small samples due to an increase in the variance of
estimated effects (Rubin, 1997). The study sample size needs to be sufficiently large,
particularly if stratification is used, in order to ensure that there are sufficient numbers
in each stratum. Comparison between treatment groups may be impossible if a
stratum only contains patients that belong exclusively to one treatment group. A large
sample size is also important if one uses the propensity score to match treated with
untreated patients, as there is potential for a significant decrease in the patient
population due to incomplete matching, particularly when common support—
restricting the analysis to the range of propensity scores that overlap—is enforced.
When working with propensity scores, the distribution of the propensity scores
between the treated and untreated patients should overlap. A significant lack of over-
lap, or propensity score distributions that are very dissimilar, may introduce
significant error.
Finally, propensity score methods can be limited by missing data values. Because
propensity scores are estimated using a wide range of covariates, many patients are
likely to be excluded from the analysis as a significant proportion of patients often
have missing values for at least one covariate.
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8.3 Application of propensity score methods to the GPRD
8.3.1 Introduction
Biochemical testing of patients treated with antihypertensive drugs is not randomly
allocated and therefore there are systematic differences between patients who are
tested and those who are not. This may confound any relationship between testing and
adverse patient outcomes. I will therefore use both propensity score methods and
multivariable regression modelling to adjust for potential bias due to the non-random
nature of baseline biochemical testing. Some of the adverse outcomes are rare and the
propensity score methods may generate estimates that are more precise and less
biased than the traditional methods when the number of events per confounder is low.
The aims of this analysis were:
1. To examine the relationship between baseline biochemical testing and adverse
patient outcomes;
2. To use propensity score methods to adjust for potential confounding in
baseline testing;
3. To make comparisons between the results obtained from propensity score
methods and traditional multivariable regression models.
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8.3.2 Methods
8.3.2.1 Propensity score development
I wished to develop a propensity score model that determined the probability of each
patient having any baseline laboratory test (creatinine, potassium, sodium, or urea) in
the six months before the start of antihypertensive treatment. The propensity score
was estimated using a logistic regression model where the binary outcome was any
baseline biochemical test regressed on measured baseline patient covariates.
The development of the propensity score model was an iterative process (Figure 8.3).
Twenty-one patient characteristics that were considered to be clinically relevant and
associated with baseline testing or the outcomes a priori were used in the
development of the initial propensity score. These characteristics include: age, sex,
socioeconomic status (SES) score, body mass index (BMI), number of units of
alcohol per week, systolic blood pressure, diastolic blood pressure, diabetes, smoking
status, hypothyroidism, peripheral vascular disease (PVD), antihypertensive drug
treatment, concomitant treatment with carbamazepine, concomitant treatment with
non-steroidal anti-inflammatory drugs (NSAID), concomitant treatment with selective
serotonin re-uptake inhibitors (SSRI), concomitant treatment with tricyclic
antidepressants, concomitant treatment with trimethoprim, year of cohort entry, ten or
more prescriptions in the year prior to starting antihypertensive treatment, prior
evidence of electrolyte ADRs, and eight or more GP practice visits in the year prior to
starting antihypertensive treatment.
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Once the initial propensity score was determined, patients were then stratified into
quintiles of the estimated propensity score. Each potential confounder was then
regressed on baseline testing, propensity score quintile and the baseline testing and
quintile interaction using analysis of variance. A P value of <0.05 for either the
baseline testing effect or the baseline testing and propensity score quintile interaction
suggested imbalance between the patients with and without baseline testing for that
specific confounder. When there was evidence of imbalance, interactions with other
variables in the model or higher order terms for continuous variables were added.
This process was repeated until there was no evidence of imbalance between the
potential confounders or where it was evident that repeating the process was no longer
practical. Once the propensity score was determined for each patient, the common
support condition was imposed by deleting patients with no baseline testing with
lower estimated propensity scores than patients with any baseline testing and deleting
patients with baseline testing with higher propensity scores than patients with no
baseline testing.
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Figure 8.3 – Flow chart describing the estimation of the propensity score
A histogram and a kernel density estimate were used to examine the distribution of
the estimated propensity score and make comparisons between patients with and
without baseline testing. Two-sample Kolmogorov–Smirnov tests were used to assess
differences between the propensity score distributions. Boxplots and quantile-quantile
Enter patient characteristics into model to
estimate initial PS
Stratify estimated PS into quintiles
Use ANOVA model to regress each
confounder on baseline testing, PS quintile,
and the baseline testing × PS quintile
interaction
e.g. anova age testing psquintile
testing*psquintile
Assess P values for either the baseline
testing or the baseline testing*PS quintile
interaction for each patient characteristic
Evidence of imbalance
between patients with and
without baseline testing on the
characteristic
Add interactions with other
variables in the model or
higher order terms (e.g. age2)
Patients with and without
baseline testing are balanced
on the characteristic
Is the P value
< 0.05?No Yes
No changes are required to
the patient characteristic in
the PS model
Re-estimate the
PS with
interactions
and/or higher
order terms
PS = propensity score
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plots were also used to graphically examine the distribution of the propensity score
within quintiles.
8.3.2.2 Assessment of balance between confounders
Differences in patient characteristics between the two groups were examined using
two methods: (1) Chi-squared tests were used to compare binary characteristics and t-
tests were used for continuous variables; and (2) standardized differences for each
patient characteristic. The percentage reduction in bias was also calculated.
8.3.2.3 Relationship between baseline monitoring and patient outcomes
Several methods were used to determine the relationship between baseline monitoring
and four patient outcomes within six months of starting antihypertensive treatment:
antihypertensive drug discontinuation, hospital admission, death, and any adverse
drug reaction. These outcomes were identified using methods described in section
3.3.6.
One-to-one matching using the propensity score
Matched pairs were created using a greedy matching algorithm without replacement,
using a caliper of 0.001 of the estimated propensity score. Various caliper widths of
0.01, 0.02, 0.03, 0.1, and 0.2 times the standard deviation of the logit propensity score
were also used to assess the impact of different widths on the number of matches and
the reduction in bias. The psmatch2 programme written for Stata® (Leuven &
Sianesi, 2003) was used to carry out one-to-one matching. This programme can
implement different kinds of matching and has the ability to graph common support
(psgraph) and carry out covariate imbalance testing (pstest). Conditional logistic
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regression modelling was then used to estimate the relationship between baseline
testing and adverse patient outcomes in the matched cohort of patients.
Adjustment using the propensity score
The estimated propensity score was used as an independent covariate in a univariable
logistic regression model.
Stratification using propensity score quintiles
The propensity score quintile was used as covariate in a univariable logistic regression
model.
Standard/traditional multivariable regression modelling
Traditional logistic regression modelling was used to estimate the relationship
between baseline testing and patient outcomes. Patient characteristics that were
statistically significant at the P<0.05 level or were biologically plausible were entered
into a multivariable model using backwards stepwise variable selection.
The coding used in Stata® for the analyses described above is presented in Appendix
13.
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8.3.3 Results
8.3.3.1 Cohort characteristics
I identified 38 600 patients with complete data for all of the covariates who were
started on antihypertensive treatment between 2000 and 2003. 17 777 (46.1%) had any
baseline testing in the six months prior to the initiation of antihypertensive treatment.
The propensity score model included 21 main effects and three two-way interactions
(age × sex, age × diabetes, diabetes × sex).
The distribution of patient characteristics between patients with and without baseline
testing is presented in Table 8.3. Patients who did have baseline testing were
significantly more likely to be male, to have a higher BMI, to drink a greater number
of units of alcohol per week, to have diabetes mellitus, to be smokers, to have
evidence of PVD, to be started on an ACE inhibitor as part of their antihypertensive
treatment, and to have a greater number of GP practice consultations in the year prior
to the start of antihypertensive treatment.
Table 8.3 – Patient characteristics at baseline
Characteristics Any baselinetesting (N=17 777)
No baseline
testing (N=20 823) P value
Demographics
Age 59.7 (11.9) 59.8 (12.4) 0.550
Male sex 10 088 (56.8) 10 985 (52.8) <0.0005
SES score 22.7 (17.2) 21.2 (15.8) <0.0005
BMI 28.5 (5.2) 28.2 (5.0) <0.0005
Number of units of
alcohol per week
11.4 (14.3) 10.9 (14.3) 0.002†
Vital signs
Systolic blood pressure 169.9 (19.0) 170.0 (19.9) 0.497
Diastolic blood pressure 97.5 (11.2) 97.5 (11.1) 0.613
Co-morbidities
Diabetes 2 293 (12.9) 1 253 (6.0) <0.0005
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Characteristics Any baselinetesting (N=17 777)
No baseline
testing (N=20 823) P value
Smoking 9 177 (51.6) 10 223 (49.1) <0.0005
Hypothyroidism 92 (0.52) 115 (0.54) 0.641
PVD 140 (0.79) 117 (0.56) 0.007
Antihypertensive treatment
ACE inhibitor 3 433 (19.3) 2 753 (13.2) <0.0005
Alpha-blocker 183 (1.0) 211 (1.0) 0.875
AT-II receptor
antagonist
363 (2.0) 418 (2.0) 0.810
Beta-blocker 4 180 (23.5) 5 353 (25.7) <0.0005
Ca-channel blocker 1 176 (6.6) 1 518 (7.3) 0.010
Combination 135 (0.76) 231 (1.1) <0.0005
Loop diuretic 62 (0.35) 93 (0.45) 0.130
Thiazide diuretic 8 245 (46.4) 10 246 (49.2) <0.0005
Concomitant medications
Carbamazepine 75 (0.42) 96 (0.46) 0.564
NSAIDs 2 498 (14.1) 2 806 (13.5) 0.101
SSRIs 565 (3.2) 736 (3.5) 0.053
Tricyclic antidepressants 655 (3.7) 807 (3.9) 0.327
Trimethoprim 297 (1.7) 306 (1.5) 0.112
Year of study entry
2000 2 820 (15.9) 5 122 (24.6) <0.0005
2001 3 917 (22.0) 5 202 (25.0) <0.0005
2002 5 017 (28.2) 5 528 (26.6) <0.0005
2003 6 023 (33.9) 4 971 (23.9) <0.0005
10 or more prior
prescriptions
8 021 (45.1) 9 298 (44.7) 0.357
Prior electrolyte ADRs 34 (0.19) 29 (0.14) 0.207
8 or more GP consultations 5 329 (30.0) 5 636 (27.1) <0.0005
* Binary variables are presented as proportions (%), continuous variables are presented as mean
(standard deviation); † Mann-Whitney test for non-parametric data
8.3.3.2 Distribution of the estimated propensity score
Imposing common support led to the deletion of 150 patients. Figure 8.4 demonstrates
the histogram and the kernel density estimate of the estimated propensity score, which
ranged from 0.009 to 0.946. The estimated propensity score distribution in patients
with and without baseline testing differed significantly (Kolmogorov–Smirnov
P<0.0005). Patients who did have baseline testing tended to have a higher propensity
score.
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Figure 8.4 – Histogram and kernel density estimate of the estimated propensity
score
Figure 8.5 presents box plots of the estimated propensity scores for patients with and
without baseline testing within each quintile. The distribution of the propensity scores
within each quintile is generally similar. There is, however, some evidence of a
significant difference in the median propensity score in quintile 1 between patients
with and without baseline testing.
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Figure 8.5 – Comparison of propensity score by propensity score quintile and
baseline testing
The distribution of the propensity scores was also examined using quantile-quantile
plots (Figure 8.6). Again, these plots demonstrated that there is evidence of residual
imbalance in the first quintile.
Table 8.4 compares the patients with and without baseline testing by propensity score
quintile for each patient characteristic. In general, within each quintile, patients with
and without baseline testing are similar. There is some evidence of residual imbalance
in patient characteristics within some quintiles, particularly in quintiles 1 and 5. For
example, patients with baseline testing had a lower diastolic blood pressure
measurement and drank more units of alcohol per week in quintile 1.
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Figure 8.6 – Distribution of propensity score in patients with and without
baseline testing by propensity score quintile. The 45° line indicates identical
distributions.
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8.3.3.3 Matching on the propensity score
Standardized differences before and after matching using a caliper width of 0.001 are
depicted in Figure 8.7 and presented in Table 8.5. Large standardized differences
were observed in diabetes status, year of monitoring, SES score, sex, and
antihypertensive treatment between patients with and without baseline testing prior to
matching on the propensity score. After matching, there were no significant
differences in the covariates between patients with and without baseline testing who
were matched on the propensity score. The largest absolute standardized difference
was 2.3%, suggesting good balance on the various covariates between patients with
and without baseline testing in the matched sample.
Figure 8.7 – Absolute standardized differences between patients with and
without baseline testing before and after matching on the propensity score using
a caliper width of 0.001
Units alcohol/week
Diabetes
2003
2000
ACE-inhibitor
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Male sex
2001
>= 8 GP visits/year
Thiazide diuretic
BMI
Smoking
Beta-blocker
2002
Combination
PVD
Ca-channel blocker
SSRI
NSAID
Loop diuretic
Trimethoprim
Prior biochemical ADR
Tricyclic antidepressant
>=10 prescriptions/year
Systolic BP
Age
Carbamazepine
Diastolic BP
Hypothyroidism
Alpha-blocker
AT-II receptor antagonist
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Table 8.5 – Standardized differences between patients with and without baseline
testing before and after matching on the propensity score using a caliper width
of 0.001
Characteristics Before
matching
After
matching
% reduction in
bias
Demographics
Age −0.6 −0.2 62.9
Male sex 8.0 0.9 89.4
SES score 8.8 0.2 98.2
BMI 5.4 0.5 90.2
Number of units of
alcohol per week
3.1 0.4 88.1
Vital signs
Systolic blood pressure −0.7 −1.5 116.2
Diastolic blood pressure −0.5 −0.9 66.3
Co-morbidities
Diabetes 23.7 2.3 90.3
Smoking 5.1 0.5 90.3
Hypothyroidism −0.5 0.8 70.8
PVD 2.8 0.0 100.0
Antihypertensive treatment
ACE inhibitor 16.6 2.1 87.6
Alpha-blocker 0.2 0.1 47.4
AT-II receptor
antagonist
0.2 −0.2 26.4
Beta-blocker −5.1 −1.0 81.1
Ca-channel blocker −2.7 −0.4 86.2
Combination −3.6 −0.2 95.2
Loop diuretic −1.6 0.0 100.0
Thiazide diuretic −5.7 −0.4 92.5
Concomitant medications
Carbamazepine −0.6 0.6 -8.3
NSAIDs 1.7 0.1 94.1
SSRIs −2.0 −0.4 78.6
Tricyclic antidepressants −1.0 −0.7 33.4
Trimethoprim 1.6 1.0 36.8
Year of cohort entry
2000 −21.9 −0.8 96.5
2001 −7.0 −1.2 82.7
2002 3.8 1.2 69.1
2003 22.2 0.7 97.0
10 or more prior
prescriptions
0.9 −0.4 60.1
Prior electrolyte ADRs 1.3 1.0 18.5
8 or more GP consultations 6.4 1.2 81.4
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A quantile-quantile plot (Figure 8.8) compares the propensity score distributions
between patients with and without baseline testing before and after matching on the
propensity score. Figure 8.9 presents the estimated propensity score distribution in
patients with and without baseline testing in the unmatched and matched samples. A
two-sample Kolmogorov–Smirnov test indicates that there is no significant difference
in the distribution of propensity scores between patients with and without baseline
testing in the matched sample (P=1.000).
Figure 8.8 – Distribution of propensity score in patients with and without
baseline testing before and after matching. The 45° line indicates identical
distributions.
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Figure 8.9 – Kernel density estimates of the propensity score in patients with and
without baseline testing before and after matching on the propensity score
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Patient characteristics in patients with and without baseline testing in the matched
cohort are presented in Table 8.6. No significant differences between the two groups
of patients were observed. In the matched sample, the largest absolute standardized
difference was 2.3% (presented in Table 8.5), which also suggests good balance
between patients with and without baseline testing.
Table 8.6 – Patient characteristics at baseline after propensity score matching
Characteristics Any baselinetesting (N=11 795)
No baseline
testing (N=11 795) P value
Demographics
Age 59.8 (12.4) 59.8 (12.0) 0.862
Male sex 6 489 (55.0) 6 439 (54.6) 0.513
SES score 22.1 (16.6) 22.1 (16.6) 0.906
BMI 28.3 (5.1) 28.3 (5.1) 0.687
Number of units of
alcohol per week
11.2 (14.4) 11.1 (14.5) 0.776†
Vital signs
Systolic blood pressure 169.9 (19.1) 170.2 (20.1) 0.253
Diastolic blood pressure 97.5 (11.4) 97.6 (11.4) 0.512
Co-morbidities
Diabetes 1 001 (8.5) 922 (7.8) 0.060
Smoking 6 023 (51.1) 5 994 (50.8) 0.706
Hypothyroidism 67 (0.57) 60 (0.51) 0.533
PVD 76 (0.64) 76 (0.64) 1.000
Antihypertensive treatment
ACE inhibitor 1 833 (15.5) 1 744 (14.8) 0.106
Alpha-blocker 126 (1.1) 125 (1.1) 0.949
AT-II receptor
antagonist
235 (2.0) 238 (2.0) 0.889
Beta-blocker 2 968 (25.2) 3 017 (25.6) 0.463
Ca-channel blocker 832 (7.1) 843 (7.2) 0.780
Combination 109 (0.92) 111 (0.94) 0.892
Loop diuretic 43 (0.36) 43 (0.36) 1.000
Thiazide diuretic 5 649 (47.9) 5 674 (48.1) 0.745
Concomitant medications
Carbamazepine 58 (0.49) 53 (0.45) 0.634
NSAIDs 1 627 (13.8) 1 623 (13.8) 0.940
SSRIs 390 (3.3) 399 (3.4) 0.744
Tricyclic antidepressants 442 (3.8) 457 (3.9) 0.610
Trimethoprim 195 (1.7) 180 (1.5) 0.435
Year of study entry
2000 2 238 (19.0) 2 274 (19.3) 0.551
2001 2 727 (23.1) 2 787 (23.6) 0.356
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Characteristics Any baselinetesting (N=11 795)
No baseline
testing (N=11 795) P value
2002 3 324 (28.2) 3 263 (27.7) 0.376
2003 3 506 (29.7) 3 471 (29.4) 0.618
10 or more prior
prescriptions
5 240 (44.4) 5 262 (44.6) 0.773
Prior electrolyte ADRs 22 (0.19) 17 (0.14) 0.423
8 or more GP consultations 3 359 (28.5) 3 295 (27.9) 0.354
* Binary variables are presented as proportions (%), continuous variables are presented as means
(standard deviation); † Mann-Whitney test for non-parametric data
Matching using the greedy algorithm and a caliper width of 0.001 created 11 795 pairs
of patients with and without baseline testing. Therefore, there were 5982 patients with
baseline testing where no match could be found. These unmatched patients differed
significantly from those patients with baseline testing who were matched successfully
(Table 8.7). The unmatched group had a higher propensity score, and were more
likely to be male, have a higher SES, a higher BMI, and consume more units of
alcohol per week.
Table 8.7 – Baseline characteristics of matched versus unmatched patients with
baseline testing
Characteristics Matched patients(N=11 795)
Unmatched
patients (N=5 982) P value
Propensity score 0.512 (0.17) 0.704 (0.11) <0.0005
Demographics
Age 59.8 (12.0) 59.6 (11.7) 0.530
Male sex 6 489 (55.0) 3 599 (60.2) <0.0005
SES score 22.1 (16.6) 23.8 (18.3) <0.0005
BMI 28.3 (5.1) 28.7 (5.2) <0.005
Number of units of
alcohol per week
11.2 (14.4) 11.7 (14.1) 0.016†
Vital signs
Systolic blood pressure 169.9 (19.1) 169.7 (18.8) 0.381
Diastolic blood pressure 97.5 (11.1) 97.3 (11.4) 0.213
Co-morbidities
Diabetes 1 001 (8.5) 1 292 (21.6) <0.0005
Smoking 6 023 (51.1) 3 154 (52.7) 0.036
Hypothyroidism 67 (0.57) 25 (0.42) 0.187
PVD 76 (0.64) 64 (1.1) 0.002
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Characteristics Matched patients(N=11 795)
Unmatched
patients (N=5 982) P value
Antihypertensive treatment
ACE inhibitor 1 833 (15.5) 1 600 (26.7) <0.0005
Alpha-blocker 126 (1.1) 57 (0.95) 0.471
AT-II receptor
antagonist
235 (2.0) 128 (2.1) 0.511
Beta-blocker 2 968 (25.2) 1 212 (20.3) <0.0005
Ca-channel blocker 832 (7.1) 344 (5.8) 0.001
Combination 109 (0.92) 26 (0.43) <0.0005
Loop diuretic 43 (0.36) 19 (0.32) 0.616
Thiazide diuretic 5 649 (47.9) 2 596 (43.4) <0.0005
Concomitant medications
Carbamazepine 58 (0.49) 17 (0.28) 0.044
NSAIDs 1 627 (13.8) 871 (14.6) 0.165
SSRIs 390 (3.3) 175 (2.9) 0.171
Tricyclic antidepressants 442 (3.8) 213 (3.6) 0.532
Trimethoprim 195 (1.7) 102 (1.7) 0.799
Year of study entry
2000 2 238 (19.0) 582 (9.7) <0.0005
2001 2 727 (23.1) 1 190 (19.9) <0.0005
2002 3 324 (28.2) 1 693 (28.3) 0.866
2003 3 506 (29.7) 2 517 (42.1) <0.0005
10 or more prior
prescriptions
5 240 (44.4) 2 781 (46.5) 0.009
Prior electrolyte ADRs 22 (0.19) 12 (0.20) 0.839
8 or more GP consultations 3 359 (28.5) 1970 (32.9) <0.0005
* Binary variables are presented as proportions (%), continuous variables are presented as mean
(standard deviation); † Mann-Whitney test for non-parametric data
8.3.3.4 Effect of baseline testing
In the cohort of 38 600 patients, only 76 patients (0.2%) died within six months of
treatment. A greater proportion of patients discontinued their initial antihypertensive
treatment (51%), was admitted to hospital (1.7%), or experienced an ADR (2.6%)
(Table 8.8).
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Table 8.8 – Adverse patient outcomes within six months of starting
antihypertensive treatment
Adverse outcome, n (%) Any baselinetesting (N=17 777)
No baseline
testing (N=20 823) P value
Antihypertensive drug
discontinuation 8 714 (49.0) 11 008(52.9) <0.0005
Hospital admission 271 (1.5) 382 (1.8) 0.019
Death 32 (0.18) 44 (0.21) 0.489
Any ADR 464 (2.6) 536 (2.6) 0.824
A crude univariable analysis indicated that baseline testing was associated with a 17%
decrease in the odds of hospital admission. No statistically significant association was
demonstrated between baseline testing and death or baseline testing and any ADR
(Table 8.9). Adjustment for potential confounding variables using multivariable
logistic regression models suggested a larger decrease in the risk of hospital
admission (OR 0.76, 95% CI 0.66–0.93) and a 28% decrease in the odds of the patient
experiencing an ADR.
Methods using the estimated propensity score gave very similar results to those
obtained from multivariable methods. Matching on the propensity score suggested
that patients with baseline testing were significantly less likely to be admitted to
hospital (OR 0.76, 95% CI 0.63–0.92) or suffer from an ADR (OR 0.70, 95% CI
0.60–0.81). When the regression model used the estimated propensity score as either a
continuous variable or as a quintile, a significant decrease in the risk of hospital
admission or developing an ADR within six months was demonstrated.
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Increasing the caliper widths increased the number of a patients with baseline testing
that could be matched (Table 8.10). The corollary of this increase in sample size was
that the decrease in the percentage bias achieved through matching was significantly
diminished.
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8.4 Discussion
Patients who received baseline testing of serum electrolytes or renal function prior to
the initiation of antihypertensive therapy were younger, more likely to be male, and
more likely to have diabetes. Both traditional multivariable regression methods and
propensity score methods demonstrated a decreased risk of hospital admission and
any ADR in patients who had a record of any baseline testing. Similarly, both
methods indicated that there was no association between baseline testing and death.
I chose to use propensity score methods as they may generate estimates that are more
precise and less biased than traditional multivariable methods when the number of
events per confounder is low (Cepeda et al., 2003). These methods can control for
measured confounding in observational research and allow for the assessment whether
balance has been achieved between patients with and without the treatment of interest.
Propensity score methods may also provide additional benefit by restricting the
analysis to groups that overlap on potential confounders, making the groups more
comparable (Hill et al., 2004).
The imbalance in the observed covariates was reduced between patients with and
without baseline testing using both stratification and matching on the propensity
score. Stratification using propensity score quintiles, which used the entire sample,
did not yield very different results from one-to-one matching on the propensity score.
Matching allowed for the reduction in the imbalance in patient covariates between
patients, although this process decreased the sample size from which an estimate of
the effect of baseline testing on adverse patient outcomes could be measured. I
initially used a caliper of 0.001 for matching, which is narrower than the caliper
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widths recommended elsewhere (Austin, 2009c). The tighter caliper allowed for
improved balance between potential confounding variables, such as diabetes mellitus,
but further decreased the sample size. As a sensitivity analysis, various caliper widths
were used to examine the effect of the using wider widths on the results. Wider
caliper widths increased the sample size, decreased the balance in the patient
covariates between the two groups, but did not cause a very large difference in the
results.
The development of the propensity score was done using an iterative method.
Variables were selected a priori if they were believed to be associated with baseline
testing but also if they were thought to be associated with the adverse outcome. The
inclusion of variables that are related to the outcome, irrespective of their relationship
between the exposure, has been previously suggested (Rubin, 1997). Brookhart and
colleagues (2006) demonstrated that the inclusion of variables that are related to the
exposure but not to the outcome increases the variance of the estimated exposure
effect.
The propensity score was evaluated using graphical methods and standardized
differences to assess the ability of the score to achieve balance on potential
confounders. The graphical methods indicated that the estimated propensity score
achieved good balance on measured confounders, although there was evidence of
some residual imbalance in the extreme quintiles of the propensity score. Although
some authors have previously used the Hosmer–Lemeshow goodness-of-fit (GoF) test
or the area under the receiver operator characteristic (ROC) curve (the c-statistic) as a
way to measure the adequacy of the propensity score (Weitzen et al., 2004), these
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tests were not used for several reasons. The GoF test and the c-statistic do not provide
any information on detecting important missing confounders in a propensity score
model (Weitzen et al., 2005). Moreover, Austin (2009a) demonstrated using a
simulated data set that the c-statistic could not differentiate between a propensity
score model that had been misspecified and one that had been correctly specified.
Propensity score methods have been shown to be robust and perform well when the
outcome of interest is rare. However, they may slightly decrease the strength of the
association between treatment and outcome. Although there has been a significant
increase in the use of propensity score methods over the past several years, research
has demonstrated that they continue to generate similar results to those obtained from
traditional regression models (Shah et al., 2005; Stürmer et al., 2006a), as was
observed in my analysis. In this case, this may have been due to the relatively large
sample size and a sufficient number of adverse patient outcomes that were not rare.
8.4.1 Limitations
Matching based on the propensity score created excellent balance between patients
with and without baseline testing on potentially confounding variables. However,
matching significantly reduced the sample size as 5982 patients with baseline testing
were lost because no match could be found. These patients were significantly
different from patients for whom a match could be found, which may have introduced
some bias into the results. The use of propensity scores, as well as traditional
multivariable modelling, is also limited by the fact that they cannot control for
confounding due to unmeasured variables.
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Finally, the analysis was restricted to patients with complete data on patient
covariates. Because propensity scores are estimated using a wide range of covariates,
a number of patients may have been excluded from the analysis as a significant
proportion of patients often have missing values for at least one covariate. Patients
with missing data may have therefore differed from those patients with complete data,
which may have introduced bias into the results. Two methods have been suggested
for implementing propensity scores methods with multiple imputed data, although
few studies have undertaken this work (Hill, 2004). In the first method, propensity
scores are calculated for each imputed data set and the propensity scores are then
combined across the imputed data sets. A matched control group is then selected
allowing for the calculation of the effect estimate. In the second method, the
propensity scores are again calculated for each imputed data set but in this method the
matched control group is selected within the imputed data set and the effect estimate
is calculated. The effect estimates are then combined across all of the imputed data
sets.
8.4.2 Potential further statistical analysis using propensity score methods
I used propensity score methods to control for confounding by indication in my
analysis of baseline testing and adverse patient outcomes. However little work has
been carried out to investigate how propensity score methods should be used when
there is potential for immortal time bias (which has been described in detail in section
4.3 ). This would have been required if I had modelled the propensity of receiving
follow-up monitoring.
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Several approaches have been suggested for using propensity score methods with
time-dependent exposures. A Cox proportional hazards model where survival time is
regressed on the propensity score and treatment status has been used, where treatment
is modelled as a time-varying covariate (Tleyjeh et al., 2010). A second approach has
been to use the follow-up time as a matching variable, which ensures that treated
patients are matched with untreated patients who survived at least as long as the time
to the event in a matched, treated patient (Kumar et al., 2010; Lalani et al., 2010;
Tleyjeh et al., 2010). A third approach that has been used to deal with both selection
bias and immortal time bias is to restrict the analysis to patients who experienced the
time-dependent event at baseline or time of study entry (e.g. restricting an analysis
that examines the relationship between treatment and an outcome to patients who had
the treatment on the day of hospital admission) (Lindenauer et al., 2010).
8.4.3 Conclusion
I examined the relationship between baseline testing and adverse patient outcomes
using different propensity score methods and a traditional multivariable regression
technique. Both techniques found that patients with baseline testing had a
significantly decreased risk of hospital admission or the development of an ADR
within six months of starting antihypertensive treatment.
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Chapter 9
CONCLUSIONS AND FUTURE WORK
This chapter summarises the important study findings and describes the important
strengths and limitations, and generalizability of the results. I also describe future
research opportunities that need to be addressed.
9.1 Background to the research
The monitoring of drug treatment has been suggested as a way to improve therapy
decisions, allow for better titration of treatment, improve adherence to therapy, and
identify potential adverse reactions to treatment. Monitoring for ADRs that may not
necessarily manifest symptoms is of particular importance.
Antihypertensive therapy is commonly used in general practice but is known to cause
a range of ADRs, particularly electrolyte disturbances. Published guidelines
recommend that patients treated with antihypertensive therapy should have tests of
their renal function and electrolyte concentration in order to identify biochemical
ADRs. It is not well known to what extent these guidelines are followed in primary
care.
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As a consequence, a systematic review was undertaken in order to identify studies
examining the nature of monitoring for ADRs. I identified several large, well-planned
studies that examined the prevalence of monitoring in patients treated with
antihypertensive drugs and identified patient factors associated with greater rates of
monitoring. The estimated rate of baseline biochemical testing in primary care
differed markedly, ranging across studies from 17% to 81%. The proportion of
patients with follow-up monitoring also differed, from 20% to 79%. These wide
ranges may reflect differences in the rates of monitoring, differences in the methods
and definitions of monitoring used by the studies, or random error. In addition, very
few studies examined both baseline testing and follow-up monitoring, and only one
previous study examined relationships between monitoring and adverse patient
outcomes.
9.2 Summary of the findings
I used data from the GPRD—the world’s largest database from primary care— to
provide specific insight into the nature of monitoring for biochemical ADRs in a
cohort of over 74 000 patients newly treated with antihypertensive therapy. The main
findings from this thesis are summarized in relation to the original aims of the study.
1. To observe and clarify the patterns of monitoring for ADRs in patients treated with
antihypertensive drugs;
The study demonstrated that monitoring for ADRs in patients treated with
antihypertensive drugs in primary care often did not occur. Baseline biochemical
testing, which was defined as any test in the six months prior to the initiation of
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antihypertensive therapy, was recorded in 42% of the cohort. Only half of the patients
had any laboratory test within one year of starting antihypertensive treatment, and
36% had any laboratory test within six months. Few patients—only 1 in 5—had more
than one follow-up laboratory test. The scarcity of tests must limit the ability of GPs
to monitor changes in renal function or electrolyte concentration during
antihypertensive treatment. Less than one quarter of patients had both baseline testing
and follow-up monitoring. This too must limit the ability of clinicians to assess intra-
individual changes in serum concentrations after the initiation of treatment.
Similar low levels of monitoring where observed when I examined a sub-group of
thiazide diuretic-treated patients to provide specific insight into electrolyte monitoring
and the development of hyponatraemia in a cohort of patients treated with the most
common type of antihypertensive therapy. Only 37% had electrolyte testing prior to
the initiation of thiazide diuretic treatment and 46% had any electrolyte monitoring
during one year of treatment.
In patients with records of any biochemical monitoring, the time between laboratory
tests varied significantly and very few patients demonstrated ‘regular’ monitoring,
where the time intervals between tests were approximately equal. Follow-up
monitoring did not increase after an abnormal test result, dose change, or co-
prescription of other drugs that could lead to potentially harmful drug-drug
interactions – events where guideline have recommended increased levels of
monitoring. Indeed, a decrease in the density of follow-up laboratory tests (the
number of tests over time) was observed.
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2. To determine relationships between the outcomes for patients, the patterns of
monitoring for ADRs, and other factors;
Patient factors such as treatment with an ACE-inhibitor, increasing age, the year of
initiation of antihypertensive treatment, and diabetes mellitus were shown to be
strongly associated with follow-up biochemical monitoring. These same factors were
shown to be associated with follow-up monitoring when allowances were made to
deal with potential bias introduced by missing data on important patient covariates.
The increase in monitoring with patient age and disease may suggest that GPs tend to
adhere to monitoring guidelines for certain patients to whom they may attribute a
greater risk of harm.
I modelled the relationship between follow-up monitoring and three adverse patient
outcomes: antihypertensive drug discontinuation, hospital admission, and death.
Follow-up monitoring was treated as a time-varying covariate in order to control for
immortal time bias. Patients who had any follow-up monitoring were slightly but
significantly more likely to experience all three outcomes. Death was rare and only a
small proportion of patients died within one year of starting antihypertensive
treatment. Patients with follow-up monitoring were statistically more likely to die,
although the small numbers of death implies a greater uncertainly in the results. Less
than 4% of patients were hospitalized within one year of treatment. Patients with
follow-up monitoring may have been more likely to be admitted to hospital for
several reasons: the doctors ordered some follow-up monitoring when the patient
presented with an illness that would later progress to hospital admission, patients were
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admitted to hospital as a consequence of the results of a test, or patients had a test as
prelude to admission to hospital for another reason.
Discontinuation of antihypertensive treatment was common, with over half of the
patients stopping treatment within one year. Indeed almost one in five patients had a
discontinuation date of 28 days, suggesting that a large proportion of patients
discontinued treatment after one course of therapy. Monitoring was associated with an
increased risk of antihypertensive discontinuation, which may have been associated
with increased contact with the GP that allowed for the further discussion on the
nature of the treatment, lack of drug efficacy, or a serum concentration value that
warranted discontinuation of treatment.
I also determined the rate of biochemical ADRs in the year following the initiation of
treatment. Fewer than 1 in 20 patients had a record of a biochemical ADR. The
majority of the ADRs were identified only through the use of a certain serum
concentration value outside of a given range and not by a clinical code.
I undertook a sub-group analysis of thiazide diuretic-treated patients—the most
commonly used antihypertensive therapy—to examine the development of
hyponatraemia. I demonstrated that one in ten patients with serum sodium monitoring
had evidence of hyponatraemia during thiazide diuretic treatment. The majority of
cases of hyponatraemia were mild and most often normalized on the subsequent
serum sodium concentration test. A relationship between hyponatraemia and
hypokalaemia was demonstrated as patients with evidence of severe hyponatraemia
were significantly more likely to have a serum potassium concentration test indicating
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hypokalaemia. Patients with evidence of hyponatraemia at baseline remained
hyponatraemic upon subsequent monitoring after initiation of thiazide diuretic
treatment, which should perhaps encourage more baseline testing. An increased risk
of hyponatraemia was identified in older patients, those with a low body mass index,
female patients, and those taking concomitant carbamazepine. The increased risk in
women may be due to several factors including smaller BMI, increasing age, a lower
dietary intake of sodium, an over-representation of women in the thiazide diuretic-
treated cohort, or because women are known to have more ADRs than men.
3. To compare the observed patterns of monitoring of patients after the initiation of
antihypertensive drugs for ADRs against published recommendations for
monitoring;
It was difficult to make comparisons between the patterns of monitoring in the GPRD
and published recommendations for monitoring because of the varied nature of the
recommendations. The majority of published guidelines identified recommended
baseline testing prior to starting antihypertensive therapy and at least some follow-up
monitoring after the start of treatment. However, some guidelines specifically stated
that follow-up monitoring should be undertaken one week and one month after
starting treatment, and at intervals following any dose changes. Even when the less
frequent of recommendations was used as reference, the patterns of testing and
monitoring by UK GPs in this cohort of patients did not follow these guidelines.
Indeed, only half of patients and 16% of patients had any monitoring in the year and
one month after initiation of antihypertensive therapy. A change in dose was not
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associated with increased monitoring; indeed, the density of follow-up laboratory tests
was significantly smaller after an increase in the dose of antihypertensive therapy.
4. Additional findings supplementary to the original aims;
It became clear after the original aims of the thesis were envisioned that further work
using more advanced statistical and pharmacoepidemiological techniques was
desirable. The proportion of missing data was a significant concern, because of the
potential for bias if the data were not missing completely at random. I demonstrated
that several patient factors such as age and sex were associated with the missingness
of different patient covariates, which suggested that an analysis restricted to patients
with complete data may have been biased. When the primary analysis investigating
the patient factors associated with follow-up monitoring was carried out using
multiple imputed data, similar results were obtained with those from the complete
case analysis. However, the results using the multiple imputed data had narrower
confidence intervals and more precision.
The issue of confounding and how one can control for confounding in observational
research was another concern. I chose to use propensity score methods to control for
confounding in the analysis of the potential relationship between baseline biochemical
testing and adverse patient outcomes within six months of treatment. Propensity score
methods were first fully described in 1983 but have been used more widely in recent
years. Their use in pharmacoepidemiological research has grown substantially, mainly
because they have been shown to perform particularly well when there are few events
per potential confounding variable.
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Patients with evidence of serum electrolyte or creatinine tests prior to
antihypertensive treatment (baseline testing) were at lower risk of discontinuation of
antihypertensive therapy or a biochemical adverse drug reaction within six months of
starting antihypertensive treatment, than patients who had no evidence of baseline
biochemical tests. Propensity score methods generated more precise although still
similar results compared with those from traditional multivariable methods.
5. Examining the different findings from chapters 5 and 8 investigating the
association between adverse patient outcomes and baseline biochemical testing
and follow-up biochemical monitoring.
I differentiated between biochemical tests recorded prior to the start of treatment
(baseline testing) and tests started after the patient has been treated with
antihypertensive therapy (biochemical monitoring). Tests prior to the initiation of
therapy can discover secondary causes of hypertension and coincidental baseline
abnormalities; and act as a benchmark against which to assess change, while tests
taken during treatment can identify changes in serum concentration resulting from
adverse reactions to the therapy. I investigated the potential association between
adverse patient outcomes and follow-up biochemical monitoring (Chapter 5) and
again between adverse patient outcomes and baseline testing (Chapter 8).
The risk of adverse patient outcomes was significantly lower in patients with any
record of biochemical tests in the six months prior to the initiation of antihypertensive
therapy than in those with none. These results are the converse of those presented in
Chapter 5 where follow-up monitoring after the start of treatment was associated with
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an increased risk of adverse outcomes. This relationship between baseline testing and
decreased risk of adverse outcomes may, in fact, be an artefact of the way the data
were modelled and not represent a true association. Indeed, I demonstrated that
patients with baseline biochemical testing were significantly less likely to have any
follow-up monitoring in the six months after the initiation of antihypertensive therapy
(adjusted OR 0.80 (95% CI 0.77–0.83)). This suggests that patients with baseline
testing may have been seen less frequently by their GP, thus reducing the number of
opportunities to undertake reactive monitoring (i.e. where the patient presented to the
practice with an illness requiring monitoring that would lead to the adverse outcome).
The lack of follow-up monitoring in patients with baseline testing may have led to a
decrease in contact with the GP and concomitant decrease in the adverse patient
outcomes that I examined, therefore causing a potentially inverse association between
baseline testing and the outcomes.
Intuitively, monitoring should be beneficial. However, the retrospective analysis of
electronic health records does not allow the true relationship between monitoring and
adverse patient outcomes to be unravelled; that will require prospective studies, as I
discuss in section 9.4.1.
9.3 Strengths and limitations of the thesis
I have presented the strength and weaknesses of the various analyses in the previous
chapters. Here, I describe the overall strengths and limitations of the thesis. This study
is strengthened by its large sample size and access to a range of baseline patient
covariates. Earlier work in the UK has been carried out in significantly smaller
populations. In addition, the majority of previous research on biochemical monitoring
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using large scale studies has been limited primarily to HMOs in the United States,
where monitoring is often driven by targets, and therefore the results of such studies
may not be relevant to the UK.
Missing data are a common problem in studies of primary care databases and I
demonstrated that there were significant associations between patient factors and the
missingness of the data. This is one of the few studies using the GPRD to undertake
multiple imputation to control for the potential bias that can occur when complete
case analyses are carried out.
Finally, this is only the second study to investigate the relationship between follow-up
monitoring and adverse patient outcomes. The data were analysed in such a way as to
control for immortal time bias and I demonstrated how failure to control for this bias
created an artificial protective effect.
Certainly, the main limitation of this thesis lies in the assumption that a record of a
laboratory test was evidence of monitoring for an ADR. Because the data were
obtained from a retrospective analysis of the GPRD, there was no way of knowing
what the impetus was for ordering the laboratory test or the context in which
monitoring occurred. I demonstrated an increased risk of adverse patient outcomes in
patients with monitoring, which I have interpreted to mean that monitoring was
actually reactive instead of being planned (i.e. carried out in accordance with
published guidelines). However, this conclusion is only an assumption as the results
are based on a retrospective analysis of records, and it is impossible to precisely
determine whether the monitoring itself was truly planned or reactive. In addition, I
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cannot be sure whether the laboratory test was ordered specifically because the patient
was being treated with an antihypertensive drug. Finally, it was impossible to
differentiate between GPs failing to undertake biochemical monitoring and patients
failing to attend for laboratory testing.
The results may also be limited by the time frame of the analysis. I demonstrated that
follow-up monitoring improved over time, with 63% of patients who started
antihypertensive treatment in 2003 having any monitoring compared with only 38%
of patients started treatment in 2000. This is most likely due to an increase in the
number of practices becoming linked electronically to laboratories. This electronic
link allows test results to be incorporated automatically into the GP practice’s
electronic records. Without this direct link to the laboratory, it would have been up to
the practice to record paper-based laboratory results in their electronic records, which
may have caused an under-reporting of monitoring. This increase in the level of
monitoring may also reflect, to a lesser extent, the general trend in United Kingdom
general practice towards improving quality standards and recording. Because the data
were obtained from an earlier time period, it is impossible to determine whether the
data presented in this thesis reflect current practice in biochemical monitoring.
However, the differences in monitoring between drug classes and among patients are
likely to persist.
Finally, I did not attempt to assess any potential effect of clustering based on the GP
practice. The mean number of patients each practice contributed to the cohort was
185, but the results were skewed with five practices contributing fewer than ten
patients and six practices contributing more than 500 patients. Differences between
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GP practices can exist due to different standards, staffing levels and general
practitioner characteristics, which can impact upon the extent of laboratory
monitoring that is undertaken. Indeed, previous research has demonstrated significant
differences in the demographic and professional characteristics of GPs in the number
and type of laboratory tests ordered (Vinker et al., 2007). Matching patients on the GP
practice would have, in theory, decreased this risk of confounding. However,
significant information would have been lost if no match was found.
9.4 Should we really monitor for ADRs to antihypertensive
therapy?
Monitoring tests have become a major element of primary care and intuitively,
monitoring should be beneficial (Glasziou, 2007). Indeed, doctors have described
monitoring as a critical component of their practice, although they also view it as a
time-consuming process (Goldman et al., 2010). It is therefore necessary to determine
whether the benefits of monitoring outweigh any harms such as inconvenience and
cost, and the potential impact that false positive or false negative results may have on
treatment (Glasziou et al., 2005). Certainly, false positive results can lead to the
potentially harmful ‘ping-pong’ effect [referred to as ‘hunting’ in control theory],
where changes in treatment in response to a test are too large and can increase with
the variation in the monitored variable (Glasziou & Aronson, 2008). This effect may
not be as important in the monitoring for adverse reactions to antihypertensive
treatment as it would be in the therapeutic monitoring of a patient’s INR during
warfarin treatment, but still is a potential cause for concern in a monitoring strategy.
One also doesn’t want to measure too often, as apparent changes in test results may
only be the result of short-term biological variation and analytical variation.
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I used a retrospective analysis of observational data to investigate the nature,
frequency, and responsiveness of biochemical monitoring in clinical practice. I
demonstrated that only half of patients had any follow-up monitoring within one year
of antihypertensive treatment. Few patients had more than one monitoring test, which
may suggest that GPs used a ‘hit and run’ type of monitoring, where the patient was
tested once—usually to assess the initial response to therapy—and not again
(Glasziou & Aronson, 2008). I also demonstrated an increased risk of adverse patient
outcomes in patients who were monitored, which may simply be a reflection of a
more reactive approach to monitoring whereby GPs order tests when a patient
presents with a condition that requires hospital admission or discontinuation of
treatment.
I was also able to demonstrate that 9% of serum concentration tests recorded within
one year of antihypertensive treatment were outside of the standardized reference
ranges. These tests identified patients that may have been experiencing ADRs that
may not have manifested any symptoms and prevented drug-induced harm. However,
the corollary of this is that a large proportion of tests (91%) were normal. In addition,
even though it was not possible to determine the false positive rate, a large proportion
of the patients with an abnormal serum concentration had a subsequent test that
returned to normal. Specifically, almost three quarters of patients with an abnormal
potassium test had a subsequent normal potassium test, which would suggest that
either the tests of serum concentration generate a number of false positive results or
that there is considerable within-patient variance in the serum concentrations.
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This retrospective analysis of observational data was able to characterize and describe
the nature of biochemical monitoring for ADRs, and provide specific insight into
monitoring in primary care in the UK. However, it cannot be used to answer the
question of whether doctors should monitor at all for ADRs. Furthermore, this type of
analysis can neither be used to estimate the benefit of monitoring nor to create a
definitive evidence-based monitoring strategy for ADRs in patients treated with
antihypertensive therapy. Instead, randomized controlled trials or prospective studies
of monitoring are required to determine whether monitoring for adverse reactions to
antihypertensive therapy itself is a rational and useful exercise.
9.4.1 What types of studies can be used to determine whether we should
monitor at all for ADRs?
In general, randomized controlled trials or prospective studies of monitoring are
limited, although there have been some randomized trials examining the benefits of
therapeutic drug monitoring. For example, Jannuzzi and colleagues (2000)
demonstrated in a study of patients with epilepsy that the mean serum concentrations
of antiepileptic drugs outside the target range was significantly lower in the monitored
group compared with the control group (8% vs. 25%), but the proportion remaining
free of seizures did not change (38% vs. 41%). Another small randomized trial
investigated the monitoring of plasma concentrations of HIV protease inhibitors and
demonstrated that monitoring improved the number of patients with a low viral load
(Burger et al., 2003). There have also been modelling studies that have investigated
the benefits of monitoring the effects of treatment such as monitoring blood pressure
during ACE inhibitors treatment (Bell et al., 2010) or monitoring bone mineral
density with bisphosphonate treatment (Bell et al., 2009).
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No prospective observational studies or randomized trials of monitoring for
biochemical ADRs in patients treated with antihypertensive therapy have been
undertaken. The majority of studies examining monitoring for ADRs, like the one
presented in this thesis, have been retrospective in design. Certainly data on adverse
reactions to treatment from clinical trials exist and these provide the evidence on the
epidemiology of ADRs and how they are manifest in terms of dose, time, and various
susceptibility factors. However, these types of studies were primarily designed to
evaluate the efficacy and safety—although perhaps to a lesser extent—of
antihypertensive therapy. Monitoring was not the focus of these clinical trials and the
data on ADRs are often applied to monitoring guidelines, without consideration to the
context of the monitoring.
There is limited knowledge of the signal-to-noise ratio of the laboratory tests for renal
function and electrolyte concentration. Ideally, one would want a monitoring test with
a high signal-to-noise ratio, where the test is able to differentiate changes due to an
ADR from background measurement variability caused by short-term biological
fluctuations and technical measurement error (Mant, 2008). The average long-term
change in the serum concentration (the signal) and the short-term within-person
variation (the noise) need to be understood in order to determine whether the
monitoring tests are appropriate and to better inform the development of a monitoring
strategy. Certainly, there was some indication in the analysis of the GPRD data that
the serum concentration tests may have a low signal-to-noise ratio as a large number
of the abnormal serum potassium tests returned to normal. This may be due to
problems with validity of the tests or due to other considerations such as problems
with storage and how the tests were obtained. For example, a serum potassium
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concentration can be artificially increased if fist clenching or pumping is used to
obtain the blood sample or if the blood sample is stored for a longer period of time.
It is therefore necessary to determine the number of monitoring tests that are true
positives and to then model the proportion of tests that need to be true positives before
monitoring can be regarded as worthwhile.
It is also necessary to determine the appropriate timing and frequency of monitoring
tests. Deciding on the test frequency, particularly at the initiation of treatment,
requires an understanding of the dose of treatment and speed at which changes in the
serum concentrations may develop (Coleman et al., 2006).
I propose two types of studies to develop the primary evidence base for the
monitoring of adverse reactions to antihypertensive therapy and to better address the
question of whether doctors should monitor at all for ADRs. The first study would be
an experimental trial where biochemical monitoring of patients occurred as frequently
as practically and ethically feasible (e.g. once a week or once a fortnight) in order to
identify potential ADRs. Observations could then be deleted in order to compare the
specificity or specificity of the different monitoring regimens (e.g. monitoring every
week versus monitoring every four weeks). For example, if 90% of all pre-specified
ADRs were identified by monitoring every week, compared with 87% of ADRs that
were identified by monitoring every month, this would suggest that the benefit from
monitoring every week compared with every month would be slight.
The second study would be a modelling exercise using trial data and analogous to the
study by Glasziou and colleagues (2008), who investigated serum cholesterol
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concentration monitoring in patients treated with pravastatin. Data would be obtained
from a randomized trial where antihypertensive therapy was compared with placebo
and where tests of renal function or electrolyte concentrations were taken before the
initiation of treatment and at regular intervals subsequently. For example, the HOPE
study—a large RCT of ramipril—measured both creatinine and potassium pre-
randomization, at one month after the start of treatment, and at yearly intervals (Yusuf
et al., 2000). The analysis would need to estimate several parameters. First, the
variation in the change in serum concentration from baseline to initial monitoring (e.g.
one month or three months) would be estimated. Second, the extent to which the long-
term change varies within and among patients can be estimated. Finally, the signal-to-
noise ratio for the serum concentration test would be calculated. The average long-
term change in the serum concentration between treated and untreated patients (the
signal) would be compared with the short-term within-person variation (the noise),
which can be calculated using the pre-treatment measures of the serum
concentrations.
This type of modelling exercise would allow for a comparison between treated and
untreated patients in the variation in the initial response, long term changes in the
serum concentrations and perhaps most importantly, the ratio of the long term
changes to the within-person variation. These parameters would generate a better
estimate of the frequency of monitoring required to identify true changes in serum
concentrations and the potential risk of biochemical ADRs.
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9.5 What are the barriers to monitoring?
9.5.1 Lack of consensus in monitoring guidelines
One of the barriers to monitoring is the lack of consensus between expert and national
hypertension societies in the guidelines for monitoring, which is likely due to the poor
evidence base for monitoring. Some published guidelines are vague and describe
monitoring as a ‘routine investigation’ (Williams et al., 2004), while only a small
number of guidelines provide detailed recommendations for biochemical testing prior
to the initiation of therapy, specific details for the frequency of follow-up monitoring,
and actions to be taken should the laboratory tests be outside a certain range of values
(French Haute Autorité de Santé, 2005; Smellie et al., 2007). Indeed, monitoring
guidelines tend to be subjective and based solely on expert opinion (McAlister et al.,
2007). When Eccles and colleagues (1998) developed a monitoring guidelines for
ACE inhibitors used in the treatment of heart failure they stated that they ‘could find
no basis for recommending one monitoring interval over another in long term
treatment, and felt that monitoring at least once a year was appropriate’. This
uncertainty can lead doctors to making decisions on monitoring based on their clinical
experience rather than evidence, which may in turn create opportunities for adverse
events (Goldman et al., 2010).
9.5.2 Absence of alerts or reminders to monitor
Another potential barrier to monitoring is the lack of well-designed and
implementable electronic alerts to remind the practitioner of the need to undertake
monitoring both pre- and post-initiation of therapy, as well as alerts to indicate that a
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patient had not attended for monitoring. Considerable recent research has been carried
out to examine the impact of electronic alerts and reminders to improve biochemical
monitoring in primary care, which reflects the increasing use of information
technology in healthcare. Health information technology (HIT), including electronic
prescribing and clinical decision support, has been shown to improve patient safety
and reduce medication errors (Bates et al., 1999; Garg et al., 2005). In general,
primary care is highly computerized and was an early adopter of HIT (Bryan &
Boren, 2008; Ludwick & Doucette, 2009). Within the UK, general practice has the
highest level of computer use and literacy in the NHS (BMA General Practitioners
Committee, 2010). Therefore, there exists the necessary electronic infrastructure in
which to introduce electronic alerts to remind the prescriber to undertake laboratory
monitoring for patients treated with specific drugs. Indeed, when respondents to an
electronic Delphi survey were asked to form a consensus on the most important
features of GP computer systems for the improvement of patient safety, all agreed on
the importance that ‘it should be possible to set up the [computer] system so that
patients can be automatically recalled for blood tests and other forms of monitoring’
(Avery et al., 2005).
Two systematic reviews have synthesized the literature on the use of HIT
interventions to improve laboratory monitoring in primary care (Hayward et al., 2009;
Fischer et al., 2010). Both reviews identified the same studies, which used various
study designs and interventions. The systematic reviews both concluded that the
literature demonstrated conflicting results. Hayward and colleagues (2009) stated that
the studies that incorporated an intervention at a point in time outside of the GP visit
(e.g. involvement of a clinical pharmacist team to arrange for patients to have a
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laboratory test) led to increased monitoring, while the other health technology
interventions (e.g. if monitoring was due, the electronic prescribing system generated
a non-interruptive alert to recommend a laboratory test when a drug was prescribed)
showed no improvement in laboratory monitoring. Fischer and colleagues (2010)
summarized that although there was some improvement following the interventions to
improve laboratory monitoring, when the analysis was restricted to the well-designed,
higher quality studies, little improvement was seen with HIT interventions that only
targetted doctors.
The use of electronic alerts and reminders targetted at GPs using information
technology in daily practice may go some way towards improving laboratory
monitoring, but there is the possibility that the problem of alert fatigue may reduce the
effect of the reminders. Alert fatigue can occur when the alerts recommending
monitoring do not relate to serious enough outcomes, are irrelevant, or because a
given alert appears repeatedly and can therefore lead to the alert being overridden or
simply ignored (Shah et al., 2006; van der Sijs et al., 2006; van der Sijs et al., 2008;
Isaac et al., 2009).
There have been no efficient developments in electronic systems to alert GPs when a
patient has not had a laboratory test that the doctor had recommended. Goldman
(2010) presented results of interviews of doctors who described their annoyance that
there were no efficient electronic systems in place to track whether patients had
fulfilled the laboratory tests that had been ordered. This desire to have an electronic
system to assist in the tracking of biochemical tests to completion has also been
echoed by doctors in the secondary care setting (Poon et al., 2004).
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9.5.3 Patient factors
No work has been undertaken to investigate patients’ perceptions on laboratory
monitoring. There is a need for this type of research in order to identify other potential
barriers to follow-up monitoring. Certainly the reason why such a large proportion of
patients did not have follow-up monitoring following the initiation of their
antihypertensive treatment may have been due to patients failing to attend for
laboratory testing and not because GPs were failing to order the tests. Goldman and
colleagues (2010) suggested that further work should investigate how doctors
communicate the need for laboratory monitoring to patients and how patients perceive
the role of monitoring in the detection and potential prevention of harm. As described
earlier, interventions to improve laboratory monitoring using information technology
have focused primarily on addressing issues in the work systems used by GPs. There
is some evidence that interventions which involve the patients in the monitoring
process (e.g. through the use of automated phone calls to patients due for drug
monitoring) show significant improvement in the frequency of follow-up monitoring
(Feldstein et al., 2006). Future work should also be carried out to investigate the
impact of interventions focussed specifically on improving the awareness of the
importance of recommended monitoring in patients.
9.5.4 Uncertain responsibility for monitoring
Finally, an uncertain responsibility for monitoring has also been identified as a
potential barrier to monitoring (Goldman et al., 2010). Most patients with
hypertension, especially those with ‘simple’ hypertension, are treated in the
community and the general practitioner who initiated treatment would usually be
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responsible for monitoring. However, in instances where treatment is initiated by
specialist prescribers outside of primary care, it may be difficult to determine where
the responsibility for monitoring lies.
9.6 Evaluating the cost-effectiveness of monitoring
Monitoring of patients for adverse reactions to treatment should be cost proportionate,
in that the cost of testing should not be greater than the cost savings associated with
reducing the health burden of adverse reactions to therapy. Doctors working in the
American fee-for-service setting have stated that monitoring ‘requires an inordinate
amount of unreimbursed time (Goldman et al., 2010).
Little to no work had been undertaken to evaluate the cost-effectiveness or cost-
benefit of laboratory monitoring. Some research has been undertaken to determine the
cost-effectiveness of therapeutic drug monitoring, which differs from monitoring for
adverse reactions to treatment. The aim of therapeutic drug monitoring is to maximise
therapeutic efficacy and prevent patient harm due to treatment with drugs with a
narrow therapeutic range. This is achieved through regular blood measurements in
order to maintain a relatively constant concentration of the drug in the bloodstream.
Therapeutic drug monitoring has been demonstrated to be cost-effective for
aminoglycosides and to a lesser extent for vancomycin, anti-epileptics, and
immunosuppressant therapy (Touw et al., 2005).
Only one study has focused specifically on the cost-effectiveness of laboratory
monitoring of patients treated with antihypertensive therapy. The recent study by
Smith and colleagues (Smith et al., 2011) used a probabilistic decision model to
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compare the cost of laboratory monitoring programme for patients treated with ACE
inhibitors or AT-II receptor antagonists with the cost of the adverse outcomes of
hyperkalaemia and acute renal failure. The programme involved a telephone call,
followed by a letter, to a patient if they had not had a test of serum creatinine and
potassium within five days of starting treatment. In the whole patient population, the
per patient cost of adverse events was $119 with a monitoring programme, compared
with $94 without the programme. Therefore, on average, the programme cost was $24
extra per person, per year. Cost savings were only observed when the analysis was
restricted to the monitoring programme was targetted to patients with chronic kidney
disease – patients who are higher risk of adverse events. Although the results are not
generalizable outside of the system within which the analysis was undertaken—an
American HMO with an established electronic health record system—the results do
suggest that for laboratory monitoring of patients treated with antihypertensive
therapy to be cost-effective, the monitoring needs to be carried out in a population
with a high risk of adverse events.
9.7 Concluding observations
Monitoring of drug treatment can lead to better selection of drug therapy, better
titration of treatment, improved adherence, and perhaps most importantly—identify
potential adverse reactions to treatment before causing harm. I used a retrospective
analysis of a large primary care database to examine the nature of biochemical
monitoring in a cohort of patients newly treated with antihypertensive therapy.
Although monitoring of renal function and electrolyte concentrations is recommended
in published guidance, only half of patients newly treated with antihypertensive
therapy had any follow-up monitoring within one year of treatment.
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The benefits of monitoring as practiced in this cohort were slight to non-existent.
Indeed, when monitoring was undertaken it was associated with increased risk of drug
discontinuation, hospital admission and even death, although it is likely that this
association was only a reflection of the clinician’s willingness to reactively monitor
patients who were already at greater risk of these events or who presented with
symptoms requiring hospital admission or discontinuation of therapy.
The GPRD was able to show how monitoring was undertaken in primary care, but it
could not demonstrate or develop the ideal monitoring strategy for adverse reactions
to antihypertensive treatment. Indeed, there is a significant lack of primary evidence
upon which to base rational monitoring strategies, which can only be addressed
through the use of prospective observational or clinical trials of monitoring.
Several barriers to monitoring have been identified including the lack of systems in
place to remind GPs to undertake monitoring. There is also a limited understanding of
non-adherence to monitoring by patients, as the lack of monitoring may be as a result
of the patient not attending for laboratory testing and not because the clinician did not
order a test. More work needs to be carried out in order to determine patients’
perceptions on the need for monitoring and research needs to be undertaken to
evaluate the impact of interventions directed specifically to patients on the uptake of
monitoring. Finally, more work is needed to understand the cost-effectiveness of
monitoring by comparing the cost of monitoring with the cost of harm caused by the
adverse reactions to antihypertensive treatment.
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Future studies are necessary in order to determine whether more frequent or more
assiduous biochemical monitoring in hypertensive patients in general practice would
reduce harm from adverse drug reactions. Results from such studies would help to
devise rational, evidence-based monitoring strategies.
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Appendices
Appendix 1 – Monitoring guidelines for patients treated with antihypertensive drugs
Guideline Drug class Monitoring test(s) Monitoring recommendations
Treatment for hypertension
SIGN (2001) ACE inhibitors Creatinine, potassium - Serum creatinine and potassium must be checked within 1–2 weeks of commencing therapy
AT-II receptor
antagonists
Creatinine, potassium - Serum potassium and creatinine should be checked within 1–2 weeks of commencing therapy
Thiazide diuretic Potassium - Serum potassium levels should be checked within 4–6 weeks of starting low-dose therapy
Knight and
Avorn (2001)
ACE inhibitors
Thiazide diuretics
Creatinine, potassium
Potassium
- Serum potassium and creatinine levels should be checked within 1 week of initiation of therapy
because this may prevent the development of renal insufficiency and hyperkalaemia
- Serum potassium should be checked within 1 week after initiation and at least yearly because of
the risk for hypokalaemia due to diuretic therapy
Joint National
Committee 7
(2003)
Antihypertensive
therapy
Creatinine, potassium - Serum potassium and creatinine tests are recommended before initiating therapy and should be
monitored at least one to two times per year
- Co-morbidities such as heart failure, associated diseases such as diabetes should influence the
frequency of laboratory testing
- With ACE inhibitors or AT-II receptor antagonist serum creatinine and potassium should be
monitored 1–2 weeks following initiation or escalation in therapy in patients with renal
transplantation
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Palmer (2003) ACE inhibitor or AT-
II receptor antagonist
Potassium - Serum potassium should be checked within 1–2 weeks of starting treatment in patients with
chronic renal disease
- If the potassium concentration increases to a value >5.6 mEq/l then another class of
antihypertensive therapy will need to be utilized
Palmer (2004) ACE inhibitor or AT-
II receptor antagonist
Potassium - Serum potassium concentration should be checked within one week after the drug has started
- With each increase in the dose, the serum potassium concentration should be measured again one
week later
British
Hypertension
Society (2004)
Antihypertensive
drugs in general
Creatinine - Creatinine monitoring is described as a routine investigation
Electrolytes - Potassium monitoring is described as a routine investigation
French Haute
Autorité de Santé
(2005)
Antihypertensive
drugs
Biochemical tests - Serum creatinine, sodium, and potassium should be measured before initiation of treatment
- If an ACE inhibitor or AT-II receptor antagonist is prescribed, tests for serum potassium and
creatinine should be done within 7–15 days of starting treatment
- If serum creatinine rises by more than 20–30% while on an ACE inhibitor or AT-II receptor
antagonist, treatment should be discontinued and the patient referred to a specialist
- Serum creatinine, sodium, and potassium should then be confirmed at least twice a year and in the
event of intercurrent disease
- Serum creatinine should be specifically monitored in elderly patients treated with diuretics, ACE
inhibitors and AT-II receptor antagonists, and/or prescribed in combination with potentially
nephrotoxic drugs
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South African
Medical
Association
(2006)
Antihypertensive
drugs
Creatinine and potassium - Tests of creatinine and potassium are described as routine investigations and should be undertaken
yearly if normal
ESH/ESC (2007) Antihypertensive
drugs
Creatinine and potassium - Tests of creatinine and potassium are described as routine investigations
Additional information:
- The combination of ACE inhibitors and AT-II receptor antagonists in combination or of high doses
of angiotensin receptor antagonists may be used if careful attention is paid to possible rises in
serum creatinine and potassium.
Smellie (2007) ACE inhibitors; AT-
II receptor
antagonists
Creatinine, electrolytes - Before initiating treatment
- 1 week after starting treatment or any subsequent dose increase
- At 4 and 10 days after starting treatment or increase in dose in patients at higher risk of developing
hyperkalaemia or deteriorating renal function (e.g., peripheral vascular disease, diabetes mellitus,
pre-existing renal impairment and older patients)
Consider seeking further advice if a patient has:
- Renal impairment (serum creatinine >200 mmol/l or eGFR <30 ml/min) or confirmed/suspected
renovascular disease before initiating ACE inhibitor/AT-II receptor antagonist
- Marked creatinine rise (>30%) with large fall in blood pressure after starting ACE inhibitor or AT-
II receptor antagonist may suggest renovascular disease that should be investigated
Thiazide or loop
diuretic
Creatinine, electrolytes - Within 4–6 weeks of starting low-dose thiazide diuretic treatment or loop diuretic treatment
- thereafter, in all patients every 6–12 months
- or if a person’s clinical condition changes or a potentially interacting drug is added
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Spironolactone or
potassium-sparing
diuretics
Creatinine, electrolytes - before initiation of treatment (it should not be initiated if the potassium values >5 mmol/l)
- after 5–7 days with dose titration if required
- every 5–7 days until the potassium values are stable
- 1–2 times/year up to every 4–8 weeks during chronic treatment, depending on risk factors (older
patients, renal or cardiac dysfunction)
- If potassium rises to >6 mmol/l, spironolactone or potassium-sparing diuretics should be stopped
and specialist advice sought
Northern Ireland
Department of
Health, Social
Services and
Public Safety
(2007)
ACE inhibitors, AT-
II receptor
antagonists
Creatinine and
electrolytes
- Before starting treatment, check electrolytes and renal function
- Recheck electrolytes and creatinine within 2 weeks of starting or increasing the dose
- A rise in serum creatinine concentration of more than 30% after initiation of therapy or a dose
increase should be followed by further measurements within 2 weeks
- Every 12 months
Notes
- If serum potassium levels rise to above 6.0 mmol/l stop nephrotoxic drugs, potassium-sparing
diuretics
British Columbia
Ministry of
Health Services
(2008)
ACE inhibitors, AT-
II receptor
antagonists
Creatinine and
electrolytes
- Before starting treatment, check creatinine, sodium and potassium
- If combining ACE inhibitor and AT-II receptor antagonist, monitor for hyperkalaemia and
worsening renal function
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Australian Heart
Foundation
(2008)
Antihypertensive
drugs
Biochemical tests - Initial tests of sodium, potassium and creatinine should be carried out.
- Monitor ACE inhibitors for hyperkalaemia, hyponatraemia
- Monitor AT-II receptor antagonists for hyperkalaemia
- Monitor thiazide diuretics for hyperkalaemia, hyponatraemia
Notes:
An initial rise in serum creatinine is commonly observed after initiation of ACE inhibitors or AT-II
receptor antagonists. An increase of 30% or less is acceptable. If creatinine increases by more than
30% from baseline, consider possible contributory factors (e.g. hypovolaemia, renal artery stenosis,
NSAIDs). If none present, consider ceasing treatment. Do not commence these agents if serum
potassium is > 5.0 mmol/L.
University of
Michigan Health
System (2009)
Antihypertensive
therapy
Creatinine and potassium - Consider tests of creatinine and potassium before therapy is initiated.
- Serum potassium and creatinine should be monitored at least 1–2 times/year.
Michigan Quality
Improvement
Consortium
(2009)
Antihypertensive
therapy
Creatinine and potassium - Measure potassium and creatinine prior to initiating therapy
Royal Infirmary
of Edinburgh
Renal Unit
(2009)
ACE inhibitor Creatinine - Before starting treatment
- Check at 4 and 10 days after initiating treatment in patients with peripheral vascular disease,
diabetes mellitus, old age, and pre-existing renal impairment
- Check at 7 days after initiating treatment in patients without the risk factors described above
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Potassium - Before starting treatment
- Check at 4 and 10 days after initiating treatment in patients with peripheral vascular disease,
diabetes mellitus, old age, and pre-existing renal impairment
- Check at 7 days after initiating treatment in patients without the risk factors described above
Specific guidance:
- If 5.0–5.5 mmol/l, recheck in 7 days; 5.6–6.0 mmol/l stop ACE inhibitor and check in 7 days; 6.1–
6.5 mmol/l stop ACE inhibitor and check immediately; >6.5 mmol/l stop ACE inhibitor and check
urgently
Sodium and urea - Before starting treatment
Canadian
Hypertension
Education
Program (2009)
Antihypertensive
drugs
Blood chemistry
(potassium, sodium, and
creatinine)
- Routine laboratory tests should be performed for the investigation of all patients with hypertension
- Monitor potassium and renal function of combining an ACE inhibitor with an AT-II receptor
antagonists
- Patients with non-diabetic chronic kidney disease place on an ACE inhibitor of an AT-II receptor
antagonist should have their serum creatinine and potassium carefully monitored
Japanese Society
of Hypertension
(2009)
Antihypertensive
drugs
Creatinine and potassium - Attention to hyperkalaemia is necessary while using AT-II receptor antagonists with a potassium-
sparing diuretic
- Caution is necessary in patients with renal dysfunction because hyperkalaemia is most likely
to occur 1–2 days after commencing treatment with ACE inhibitors.
ACE inhibitors should not be used in patients suggested to have bilateral renovascular hypertension
or renovascular hypertension with a functionally solitary kidney, as they may cause renal failure. If
they are used, monitoring of the serum creatinine and potassium levels is necessary.
Institute for
Clinical Systems
Improvement
(2010)
Antihypertensive
drugs
Creatinine and
electrolytes
- Initial laboratory tests prior to the initiation of therapy include: sodium, potassium, and creatinine
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NCQA (2010) ACE inhibitors, AT-
II receptor
antagonists, diuretics
Creatinine and potassium - Serum creatinine and potassium should be measured annually
In chronic kidney disease
National Kidney
Foundation
(2002)
ACE inhibitors, AT-
II receptor
antagonists, diuretics
Potassium - At initiation and increase in dose of ACE inhibitor, AT-II receptor antagonist or diuretic, the levels
of serum potassium should be measured to establish a "baseline" or "new baseline.” Follow-up
measurements should be undertaken as follows:
Time Baseline serum potassium
Every 4–12 weeks ≤4.5 mEq/L
Every 2–4weeks 4.6–5.0 mEq/L
≤2 weeks >5.0 mEqL
- After blood pressure is at goal and dose is stable , follow-up measurements should be made as
follows:
Time Baseline serum potassium
6–1months ≤4.5 mEq/L
3–6 months 4.6–5.0 mEq/L
1–3 months >5.0 mEq/L
- If hyperkalaemia develops, reduce the dose of ACE inhibitor or AT-II receptor antagonist by 50%
and reassess the serum potassium every 5 to 7 days until serum potassium has returned to baseline.
If serum potassium does not return to baseline within 2 to 4 weeks, discontinue the ACE inhibitor
or AT-II receptor antagonist and select an alternate antihypertensive agent.
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VA/DoD (2007) ACE inhibitors, AT-
II receptor
antagonists
Creatinine and potassium - Creatinine and potassium levels should be monitored one to two weeks after initiation or after a
change in dose of ACEI or AT-II receptor antagonist therapy and periodically to maintain a normal
range.
- After initiating an ACEI or AT-II receptor antagonist, it is recommended that the patient’s
potassium be checked within 2 weeks if baseline was > 5.0 mEq/L, at 2 to 4 weeks if baseline
potassium was 4.5–5.0 mEq/L, and at 4 to 12 weeks if baseline was < 4.5 mEq/L
- In most patients, an ACEI or AT-II receptor antagonist should be continued unless:
a. There is an acute GFR decline of > 30 percent within the first two weeks after initiation.
b. Serum potassium is > 6 mEq/L, despite appropriate treatment.
302
Guideline Drug class Monitoring test(s) Monitoring recommendations
NICE (2008) ACE inhibitors, AT-
II receptor
antagonists
Creatinine and potassium - Measure serum potassium and creatinine concentrations before starting ACE inhibitor/AT-II
receptor antagonist therapy.
- Repeat these measurements between 1 and 2 weeks after starting ACE inhibitor/ARB therapy and
after each dose increase.
Additional guidance:
- ACE inhibitor/AT-II receptor antagonist therapy should not normally be started if the pretreatment
serum potassium concentration is significantly above the normal reference range (typically more
than 5.0 mmol/litre).
- Concurrent prescription of drugs known to promote hyperkalaemia is not a contraindication to the
use of ACE inhibitors/AT-II receptor antagonists, but be aware that more frequent monitoring of
serum potassium concentration may be required.
- Stop ACE inhibitor/AT-II receptor antagonist therapy if the serum potassium concentration rises to
6.0 mmol/litre or more and other drugs known to promote hyperkalaemia have been discontinued.
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Treatment in heart failure
McMurray (2005) ACE inhibitors and
AT-II receptor
antagonists
Creatinine, potassium - Monitor creatinine and potassium 1–2 weeks after initiation and 1–2 weeks after final dose titration
- Some rise in creatinine and potassium is to be expected after initiation of an ACE inhibitor; if an
increase is small and asymptomatic no action is necessary
- An increase in creatinine of up to 50% above baseline, or 266 mmol/L (3 mg/dL), whichever is the
smaller, is acceptable
- An increase in potassium to ≤5.5 mmol/L is acceptable
- If creatinine or potassium do rise excessively consider stopping concomitant nephrotoxic drugs
(e.g., NSAIDs), other potassium supplements/retaining agents (triamterene, amiloride,
spironolactone/eplerenone) and, if no signs of congestion, reducing the dose of diuretic
- If greater rises in creatinine or potassium than those outlined above persist despite adjustment of
concomitant medications, the dose of the ACE inhibitor should be halved and blood chemistry
rechecked within 1–2 weeks; if there is still an unsatisfactory response specialist advice should be
sought
- If potassium rises to >5.5 mmol/L or creatinine increases by >100% or to above 310 ,mol/L (3.5
mg/dL) the ACE inhibitor should be stopped and specialist advice sought
- Blood chemistry should be monitored frequently and serially until potassium and creatinine have
plateaued
North East Essex
Medicines
Management
Committee
(2007)
ACE inhibitors Urea, creatinine,
electrolytes
- Check after one week.
- Review after one month
- Review at 6 months (or before if there is a dose change or patients become unwell)
- At annual review
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Wandsworth
Primary Care
Trust NHS
(2008)
ACE inhibitors Creatinine and
electrolytes
- Check baseline renal function (creatinine) and electrolytes
- Re-check renal function and electrolytes at week one, two, and four after initiation
- Once titrated, continue monitoring creatinine and electrolytes every 6 months
Notes
- Some rise in urea, creatinine and potassium is to be expected after initiation of an ACE inhibitor
(an increase in creatinine of up to 50% above baseline or up to 200 µmol/l and an increase in
potassium to ≤5.9 mmol/l is acceptable)
- If potassium rises ≥6.0 mmol/l or creatinine rises by >100% or to 350 µmol/l, stop ACE inhibitor
and seek advice
Eccles (1998) ACE inhibitors Creatinine and potassium - Serum creatinine and potassium should be tested before initiation of treatment, one week after the
start of treatment, and again one week after each significant increase in dosage
Lloyd and Mauro
(2000)
Spironolactone Creatinine and potassium - Serum creatinine and potassium concentrations should be monitored after 7 days of treatment and
the frequently (weekly–monthly) for the first few months, and routinely (every 3–6 months)
thereafter.
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Appendix 2 – Monitoring recommendations from SPCs for antihypertensive drugs
Drug class Drug Monitoring recommendations
Alpha blockers Doxazosin None
Indoramin None
Prazosin None
Terazosin None
ACE inhibitors Captopril - Careful titration and monitoring of renal function should be carried out in patients with bilateral renal artery stenosis;
- Routine monitoring of potassium and creatinine is part of normal medical practice in patients with renal impairment;
- Regular monitoring of serum potassium is recommended with concomitant treatment with potassium-sparing diuretics.
Cilazapril - Renal function in patients with renal impairment should be monitored during the first weeks;
- Routine monitoring of potassium and creatinine is part of normal medical practice for these patients;
- Potassium-sparing diuretics should be used with caution and serum potassium and renal function should be monitored frequently;
- Patients treated with concomitant NSAID should have monitoring of their renal function after initiation of concomitant therapy, and
periodically thereafter.
Enalapril - Renal function and serum potassium should be monitored in patients with hypertension.
- Renal function should be monitored closely both before and after starting treatment in patients with heart failure/asymptomatic left
ventricular dysfunction.
- Routine monitoring of potassium and creatinine are part of normal medical practice for patients with renal function impairment.
- Concomitant use of potassium-sparing diuretics and potassium supplements should be used with caution and with frequent
monitoring of serum potassium.
Fosinopril - Concomitant use of potassium-sparing diuretics should be used with caution and the patient's serum potassium should be monitored
frequently.
- Renal function should be assessed prior to initiation of therapy and during treatment where appropriate.
Imidapril - Close monitoring of renal function during therapy should be performed as deemed appropriate in patients with renal insufficiency.
- It is recommended that the renal function be monitored during the first weeks of therapy.
- Monitoring of renal function is recommended in patients with renovascular hypertension.
- Regular monitoring of serum potassium is recommended with the use of concomitant potassium supplements or potassium-sparing
diuretics.
- Consideration should be given to monitoring renal function after initiation of concomitant therapy with NSAIDs, and periodically
thereafter.
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Lisinopril - Renal function and serum potassium should be monitored in patients treated concomitantly with diuretics.
- In patients with renal failure, renal function should be monitored in the first weeks of therapy.
- Routine monitoring of potassium and creatinine is part of normal medical practice for patients with renal failure.
- Regular monitoring of serum potassium is recommended with concomitant use of potassium-sparing diuretics, potassium
supplements or potassium-containing salt substitutes.
Moexipril - Especially at the beginning of the ACE inhibitor therapy the blood pressure and the respective laboratory values must be monitored
carefully in patients with: impaired renal function (creatinine clearance 40-60 ml/min); renal hypertension; cardiac failure; salt
and/or fluid volume depletion; or age of more than 65 years.
- In hypertensive patients with renal artery stenosis in a solitary kidney or bilateral renal artery stenosis, renal function should be
monitored during the first few weeks of therapy.
- Concomitant use with potassium-sparing diuretics (e.g. spironolactone, triamterene, amiloride) potassium supplements or potassium-
containing salt substitutes should be given with caution and with frequent monitoring of serum potassium.
Perindopril - Renal function and serum potassium should be monitored.
- Patients at high risk of symptomatic hypotension e.g. patients with salt depletion with or without hyponatraemia, patients with
hypovolaemia or patients who have been receiving vigorous diuretic therapy should have these conditions corrected, if possible,
prior to therapy with perindopril.
- Blood pressure, renal function and serum potassium should be monitored closely, both before and during treatment with perindopril.
- Routine monitoring of potassium and creatinine are part of normal medical practice for patients with renal impairment.
- Frequent monitoring of serum potassium is recommended when the following drugs are used concomitantly: potassium-sparing
diuretics (e.g. spironolactone, eplerenone, triamterene, or amiloride), potassium supplements or potassium-containing salt
substitutes; or those patients taking other drugs associated with increases in serum potassium (e.g. heparin).
- Use of ACE-inhibitors and NSAIDs requires monitoring of renal function and serum potassium after initiation of concomitant
therapy, and periodically thereafter.
Quinapril - In patients with renal insufficiency, monitoring of renal function during therapy should be performed as deemed appropriate;
although in the majority renal function will not alter or may improve.
- Specifically, patients with a creatinine clearance of <40 ml/min require a lower initial dosage of quinapril and their renal function
should be closely monitored.
- In hypertensive patients with unilateral or bilateral renal artery stenosis, renal function should be monitored during the first few
weeks of therapy.
- Concomitant treatments with potassium-sparing diuretics, potassium supplements or potassium salts should be used with caution and
with appropriate monitoring of serum potassium.
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Ramipril - Patients concomitantly treated with diuretics should have their renal function and serum potassium monitored.
- Renal function should be assessed before and during treatment and dosage adjusted especially in the initial weeks of treatment.
- Particularly careful monitoring is required in patients with renal impairment.
- Regular monitoring of serum potassium is recommended in patients at risk for development of hyperkalaemia include those with
renal insufficiency, age (> 70 years), uncontrolled diabetes mellitus, or those using potassium salts, potassium retaining diuretics and
other plasma potassium increasing active substances, or conditions such as dehydration, acute cardiac decompensation, metabolic
acidosis.
Trandolapril - Patients with severe renal insufficiency may require reduced doses of trandalopril; their renal function should be closely monitored.
- Concomitant use with potassium-sparing diuretics (spironolactone, amiloride, triamterene) or potassium supplements requires
regular monitoring of serum potassium.
AT-II receptor
antagonists
Candesartan - Evaluation of patients with HF should always comprise assessment of renal function, especially in elderly patients 75 years or older,
including monitoring of serum creatinine and potassium.
- When used in hypertensive patients with renal impairment, periodic monitoring of serum potassium and creatinine levels is
recommended.
- During dose titration, monitoring of serum creatinine and potassium is recommended.
- Regular monitoring should be undertaken with used in combination with an ACE inhibitor in HF.
- Concomitant use with potassium-sparing diuretics, potassium supplements requires monitoring of potassium as appropriate.
- Concomitant treatment with a NSAID may increase risk of worsening renal function and consideration should be given to
monitoring renal function after initiation of concomitant treatment.
- In patients with renal impairment, periodic monitoring of serum potassium and creatinine levels is recommended.
Eprosartan - Regular monitoring for serum potassium levels is recommended with concomitant use of potassium supplements or potassium-
sparing diuretics.
- Monitoring of renal function after the initiation of concomitant NSAID, and periodically thereafter, is recommended.
- When eprosartan is to be used in patients with renal impairment, renal function should be assessed before starting treatment and at
intervals during the course of therapy. If worsening of renal function is observed during therapy, treatment with eprosartan should be
reassessed.
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Irbesartan - When irbesartan is used in patients with impaired renal function, a periodic monitoring of potassium and creatinine serum levels is
recommended.
- Close monitoring of serum potassium in patients at risk of hyperkalaemia (renal impairment, overt proteinuria due to diabetic renal
disease, and/or heart failure) is recommended.
- Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant
therapy with NSAIDs, and periodically thereafter.
Losartan - Plasma concentrations of potassium as well as creatinine clearance values should be closely monitored, especially patients with heart
failure and a creatinine clearance between 30–50 ml/ min should be closely monitored.
- Renal function should be regularly monitored during treatment with losartan as it may deteriorate. This applies particularly when
losartan is given in the presence of other conditions (fever, dehydration) likely to impair renal function.
- Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant
therapy with NSAIDs, and periodically thereafter.
Olmesartan - When olmesartan is used in patients with impaired renal function, periodic monitoring of serum potassium and creatinine levels is
recommended.
- Close-monitoring of serum potassium in patients at risk of hyperkalaemia is recommended: diabetes, renal impairment, age (> 70
years); combination with one or more other medicinal products that affect the renin-angiotensin-aldosterone system and/or
potassium supplements. Some medicinal products or therapeutic class of medicinal products may provoke a hyperkalaemia: salt
substitutes containing potassium, potassium-sparing diuretics, ACE inhibitors, angiotensin II receptors antagonists, non steroidal
anti-inflammatory drugs (including selective COX-2 inhibitors), heparin, immunosuppressor as ciclosporin or tacrolimus,
trimethoprim; or intercurrent events, in particular dehydration, acute cardiac decompensation, metabolic acidosis, worsening of renal
function, sudden worsening of the renal condition (e.g. infectious diseases), cellular lysis (e.g. acute limb ischemia, rhabdomyolysis,
extended trauma).
- Close monitoring of renal function is advised in hepatically-impaired patients who are already receiving diuretics and/or other
antihypertensive agents.
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Telmisartan - When telmisartan is used in patients with impaired renal function, periodic monitoring of potassium and creatinine serum levels is
recommended.
- Dual blockade of the renin-angiotensin-aldosterone system (e.g. by adding an ACE-inhibitor to an angiotensin II receptor antagonist)
is not recommended in patients with already controlled blood pressure and should be limited to individually defined cases with close
monitoring of renal function.
- Close monitoring of serum potassium in at patients at risk for hyperkalaemia: diabetes mellitus, renal impairment, age (>70 years);
combination with one or more other medicinal products that affect the renin-angiotensin-aldosterone system and/or potassium
supplements. Medicinal products or therapeutic classes of medicinal products that may provoke hyperkalaemia are salt substitutes
containing potassium, potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, non steroidal anti-
inflammatory medicinal products (NSAIDs, including selective COX-2 inhibitors), heparin, immunosuppressives (cyclosporin or
tacrolimus), and trimethoprim; or intercurrent events, in particular dehydration, acute cardiac decompensation, metabolic acidosis,
worsening of renal function, sudden worsening of the renal condition (e.g. infectious diseases), cellular lysis (e.g. acute limb
ischemia, rhabdomyolysis, extend trauma).
- Frequent monitoring of serum potassium is necessary with concomitant use of potassium-sparing diuretics e.g. spironolactone,
eplerenone, triamterene, or amiloride, potassium supplements, or potassium-containing salt substitutes may lead to a significant
increase in serum potassium.
- Concomitant use of NSAIDs requires that patients should be adequately hydrated and consideration should be given to monitoring of
renal function after initiation of concomitant therapy and periodically thereafter.
Valsartan - Other agents that affect the renin-angiotensin system may increase blood urea and serum creatinine in patients with unilateral renal
artery stenosis, therefore monitoring of renal function is recommended when patients are treated with valsartan.
- If a medicinal product that affects potassium levels (e.g. potassium-sparing diuretics, potassium supplements, salt substitutes
containing potassium and other substances that may increase potassium levels) is considered necessary in combination with
valsartan, monitoring of potassium plasma levels is advised.
- Monitoring of renal function and serum potassium at the beginning of the treatment is recommended with concomitant treatment
with NSAIDs, as well as adequate hydration of the patient.
Beta blockers Acebutolol No mention
Atenolol No mention
Betaxolol No mention
Bisoprolol No mention
Carvedilol - Renal function should be monitored during up-titration in patients with CHF and the drug discontinued or dosage reduced if
worsening of renal function occurs.
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Celiprolol - Close monitoring of elderly patients should be exercised, as renal and hepatic functions may be decrease in this population.
Metoprolol No mention
Nadolol No mention
Nebivolol No mention
Oxprenolol No mention
Pindolol No mention
Propranolol No mention
Sotalol - Potassium levels should be monitored and corrected appropriately during concomitant administration with other potassium-depleting
drugs: Amphotericin B (IV route), corticosteroids (systemic administration), and some laxatives.
Timolol No mention
Calcium channel
blockers
Amlodipine No mention
Diltiazem No mention
Felodipine No mention
Isradipine No mention
Lacidipine No mention
Lercanidipine No mention
Nicardipine No mention
Nifedipine No mention
Nimodipine No mention
Verapamil No mention
Loop diuretics Bumetanide - Regular checks of serum electrolytes, in particular sodium, potassium, chloride, and bicarbonate, should be performed.
Furosemide - Regular monitoring of creatinine and electrolyte balance is recommended.
- Frequent checks of the serum potassium level are necessary in patients with impaired renal function.
Torasemide - On long-term treatment with torasemide, regular monitoring of the electrolyte balance, glucose, uric acid, creatinine and lipids in the
blood, is recommended.
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Potassium-sparing
diuretics and
aldosterone
antagonists
Eplerenone - Renal function and serum potassium should be monitored in patients with hypertension.
- Renal function should be monitored closely both before and after starting treatment in patients with heart failure/asymptomatic left
ventricular dysfunction.
- Routine monitoring of potassium and creatinine are part of normal medical practice for patients with renal function impairment.
- Concomitant use of potassium-sparing diuretics and potassium supplements should be used with caution and with frequent
monitoring of serum potassium.
Potassium-sparing
diuretics with other
diuretics
Amiloride - Patients with increased in blood urea over 10 mmol/l, serum creatinine over 130 micromol/l, or with diabetes mellitus, should not
received amiloride without careful, frequent monitoring of serum electrolytes and blood urea levels.
- When administered concomitantly with an ACE inhibitor, ARB, trilostrane, ciclosporin or tacrolimus, frequent monitoring of serum
potassium is recommended.
- When used concomitantly with NSAIDs, renal function and serum potassium levels should be carefully monitored.
- When given with other diuretics, careful monitoring of serum electrolyte and blood urea levels should be carried out.
Spironolactone - Fluid and electrolyte status should be regularly monitored particularly in the elderly, in those with significant renal and hepatic
impairment.
- Hyperkalaemia may occur in patients with impaired renal function or excessive potassium intake and can cause cardiac irregularities
which may be fatal. Should hyperkalaemia develop, spironolactone should be discontinued, and if necessary, active measures taken
to reduce the serum potassium to normal.
- Concurrent administration of angiotensin-II receptor antagonists, e.g. valsartan, losartan, and spironolactone may result in an
increase in serum potassium levels. If concurrent use is necessary, monitor serum potassium levels.
- Avoid concurrent use of spironolactone and ciclosporin. If concurrent therapy is necessary, monitor serum potassium levels for
persistent elevations in patients.
- Co-administration of spironolactone with fludrocortisone may result in a paradoxical dose-related increase in urinary potassium
excretion. If concomitant administration is necessary, closely monitor serum potassium levels.
- Potassium supplements are contraindicated except in cases of initial potassium depletion. If potassium supplementation is considered
essential, serum electrolytes should be monitored.
Triamterene - It is advisable to monitor blood urea, serum potassium levels and electrolytes periodically. This is important in the elderly, those
with renal impairment and those receiving concomitant treatment with NSAIDs.
- It is advisable to monitor blood urea and serum potassium levels periodically in patients receiving concomitant treatment with
NSAIDs.
- Monitor serum potassium during first cycle of drospirenone.
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Thiazides and
related diuretics
Bendro-
flumethiazide
- Renal function should be continuously monitored during thiazide therapy. Serum electrolytes should be checked for abnormalities,
particularly hypokalaemia. Elderly patients and patients who are on long term treatment need regular blood tests to monitor
electrolyte levels.
- Bendroflumethiazide may enhance the nephrotoxicity of NSAIDs. Indometacin and ketorolac antagonise the diuretic effect of
bendroflumethiazide, this occurs to a lesser extent with ibuprofen, piroxicam and naproxen. The effects of concurrent use should be
monitored and the dose of bendroflumethiazide modified if necessary.
- There is an increased risk of hypokalaemia and a decrease in diuretic activity when carbenoxolone and bendroflumethiazide are
taken together. Patients should be monitored and given potassium supplements when required.
Chlortalidone - Periodic serum electrolyte determinations should be carried out.
- Monitoring of serum electrolytes is particularly indicated in the elderly, in patients with ascites due to liver cirrhosis, and in patients
with oedema due to nephrotic syndrome.
Indapamide - Plasma sodium must be measured before starting treatment, then at regular intervals subsequently.
- Any diuretic treatment may cause hyponatraemia. The fall in plasma sodium may be asymptomatic initially and regular monitoring
is therefore essential, and should be even more frequent in the elderly and cirrhotic patients.
- Plasma potassium should be first measured during the first week following the start of treatment.
- More frequent monitoring should be targetted at patients at high risk of hypokalaemia: elderly, malnourished and/or polymedicated,
cirrhotic patients with oedema and ascites, coronary artery disease and cardiac failure patients, individuals with a long QT interval.
Monitor renal function at the start of treatment with NSAIDs, baclofen, or ACE inhibitors used concomitantly. Monitor plasma
potassium if used concomitantly with amphotericin B, gluco- and mineralocorticoids, tetracosactide, stimulant laxatives, digitalis, or
potassium-sparing diuretics.
Metolazone - Fluid and electrolyte balance should be carefully monitored during therapy especially if metolazone is used concurrently with other
diuretics.
- In particular, metolazone may potentiate the diuresis produced by furosemide and, if the two agents are used concurrently, patients
should be carefully monitored.
- Prolonged therapy with metolazone may result in hypokalaemia. Serum potassium levels should be determined at regular intervals
and, if necessary, potassium supplementation should be instituted.
Xipamide No mention
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Appendix 3 – Medline and Embase search strategies used to identify monitoring
studies
Medline search strategy
Search term
1. *Angiotensin-Converting Enzyme Inhibitors/
2. *Angiotensin II Type 1 Receptor Blockers/
3. *Calcium Channel Blockers/
4. *Thiazides/
5. *Diuretics/
6. *Adrenergic alpha-Antagonists/
7. *Adrenergic beta-Antagonists/
8. *Aldosterone Antagonists/
9. *Antihypertensive Agents/
10. angiotensin converting enzyme inhibitors.ab,ti.
11. angiotensin receptor blockers.ab,ti.
12. angiotensin II receptor antagonists.ab,ti.
13. calcium channel blockers.ab,ti.
14. thiazide diuretics.ab,ti.
15. potassium sparing diuretics.ti,ab.
16. loop diuretics.ti,ab.
17. alpha adrenoceptor blocking drugs.ti,ab.
18. beta adrenoceptor blocking drugs.ti,ab.
19. alpha blockers.ti,ab.
20. beta blockers.ti,ab.
21. aldosterone antagonists.ti,ab.
22. potassium sparing diuretics.ti,ab.
23. antihypertensive drug$.ti,ab.
24. OR/1–23
25. *Drug Monitoring/
26. *Monitoring, Physiologic/
27. (laboratory adj5 monitoring).ti,ab.
28. (biochemical adj5 monitoring).ti,ab.
29. (sodium adj5 concentration).ti,ab. OR (potassium adj5 concentration).ti,ab. OR
(creatinine adj5 concentration).ti,ab. OR (urea adj5 concentration).ti,ab.
30. (sodium adj5 test).ti,ab. OR (potassium adj5 test).ti,ab. OR (creatinine adj5
test).ti,ab. OR (urea adj5 test).ti,ab.
31. (monitoring adj100 creatinine).ti,ab. OR
(monitoring adj100 electrolyte).ti,ab. OR (monitoring adj100 urea).ti,ab. OR
(monitoring adj100 potassium).ti,ab. OR (monitoring adj100 sodium).ti,ab. OR
(monitoring adj100 renal function).ti,ab.
32. OR/25–31
33. 24 AND 32
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Embase search strategy
Search term
1. *beta adrenergic receptor blocking agent/
2. *angiotensin 2 receptor antagonist/ OR *angiotensin 1 receptor antagonist/ OR
*angiotensin receptor antagonist/
3. *perindopril/ OR *captopril/ OR *enalapril/ OR *lisinopril/ OR *cilazapril/
4. *calcium channel blocking agent/
5. *diuretic agent/
6. *aldosterone antagonist/
7. *alpha adrenergic receptor blocking/ OR *alpha adrenergic receptor blocking
agent/ OR *alpha 2 adrenergic receptor blocking agent/ OR *alpha 1 adrenergic
receptor blocking agent/
8. *loop diuretic agent/
9. *potassium sparing diuretic agent/
10. *antihypertensive agent/
11. angiotensin converting enzyme inhibitors.ab,ti.
12. angiotensin receptor blockers.ab,ti.
13. angiotensin II receptor antagonists.ab,ti.
14. calcium channel blockers.ab,ti.
15. thiazide diuretics.ab,ti.
16. potassium sparing diuretics.ti,ab.
17. loop diuretics.ti,ab.
18. alpha adrenoceptor blocking drugs.ti,ab.
19. beta adrenoceptor blocking drugs.ti,ab.
20. alpha blockers.ti,ab.
21. beta blockers.ti,ab.
22. aldosterone antagonists.ti,ab.
23. potassium sparing diuretics.ti,ab.
24. antihypertensive drug$.ti,ab.
25. OR/1–24
26. *patient monitoring/
27. *drug monitoring/
28. *ambulatory monitoring/
29. (laboratory adj5 monitoring).ti,ab.
30. (biochemical adj5 monitoring).ti,ab.
31. (sodium adj5 concentration).ti,ab. OR
(potassium adj5 concentration).ti,ab. OR creatinine adj5 concentration).ti,ab. OR
(urea adj5 concentration).ti,ab.
32. (sodium adj5 test).ti,ab. OR (potassium adj5 test).ti,ab. OR (creatinine adj5
test).ti,ab. OR (urea adj5 test).ti,ab.
33. (monitoring adj100 creatinine).ti,ab. OR (monitoring adj100 electrolyte).ti,ab. OR
(monitoring adj100 urea).ti,ab. OR (monitoring adj100 potassium).ti,ab. OR
(monitoring adj100 sodium).ti,ab. OR (monitoring adj100 renal function).ti,ab.
34. OR/26–33
35. 25 AND 34
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Appendix 4 – Data extraction form for systematic review of monitoring studies
Study name
Year
Country
Patient
characteristics
Total number:
Setting:
Age:
Sex:
Study design
Audit  
Cross-sectional  
Prospective 
Retrospective 
RCT 
Other  ____________
Antihypertensive
drug class
Biochemical
tests monitored
Results Proportion of patients with:
Baseline testing:
Follow-up monitoring:
Patient factors associated with monitoring:
Frequency of monitoring:
Additional results presented:
Comments
(e.g. references to
other studies)
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Appendix 5 – Studies investigating the nature and frequency of laboratory monitoring of patients treated with antihypertensive drugs
Study Studydesign/description Drug class What to monitor? Results
Rhodes (1992)
UK
Cross-sectional review
of computerized patient
records from one general
practice
Diuretics Urea, electrolytes 76/330 (23%) patients had no record or urea or electrolyte during
treatment with a diuretic but not subsequently
36 (11%) had urea and electrolyte levels measured prior to starting
treatment with a diuretic
66 (20%) had results recorded within the past year
158 (48%) had results recorded within the past four years
Kalra (1999)
UK
Postal questionnaire to
400 GPs; audit of 1
general practice
ACE inhibitors Renal function (baseline
and follow-up monitoring)
Questionnaire results
GPs who usually monitored renal function:
- Before start of treatment* = 235/277 (85%)
- After start of treatment* = 93/277 (34%)
- At no stage of treatment = 42/277 (15%)
- GPs who would welcome guidelines for monitoring renal function =
234 (84%)
* Time frame not specified
Audit results
Patients who received renal function monitoring:
- Within 3 months before start of treatment = 55/122 (45%)
- At any stage before start of treatment = 60/122 (49%)
- Within 3 months after start of treatment = 35/122 (29%)
- At any stage after start of treatment = 76/122 (62%)
Renal dysfunction (increase of >10% in creatinine concentration) was
observed in 15/122 (12%) patients, of whom 11 (73%) continued
treatment without further monitoring or investigation
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Study Studydesign/description Drug class What to monitor? Results
Hoch (2003)
Israel
Retrospective review of
computerized medical
records pre- and post-
initiation of an electronic
alert for potassium
testing
Diuretics Potassium within 1 year Pre-intervention
78.5% of 34 284 patients had a record for at least one serum potassium
concentration test within one year of treatment
Post-intervention
81.5% of 35313 patients had a record for at least one serum potassium
concentration test within one year of treatment after the initiation of a
computer alert
Hurley (2005)
USA
Retrospective analysis of
databases from 2 HMOs
over 3 years
% of patients with at least 1 follow-up test within the year
1999 2000 2001
ACE inhibitors Creatinine 62% 66% 68%
Potassium 58% 61% 62%
Diuretics Creatinine 60% 65% 67%
Potassium 65% 67% 67%
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Simon (2005)
USA
Cross-sectional analysis
of databases from 10
HMOs over a 30-month-
period in patients aged
65 and older
ACE inhibitors,
AT-II receptor
antagonists,
Diuretics
Baseline creatinine or
potassium testing (defined
as a test 180 days before
prescription and up to 14
days after)
Patients treated with ACE inhibitors
- 6798/20 445 (33.3%, 95% CI 32.6–33.9) had no baseline creatinine
or potassium testing
- There was no sex difference in baseline testing (OR 1.05, 95% CI
0.99–1.11)
Patients treated with AT-II receptor antagonists
- 1 080/3 858 (28.0%, 95% CI 26.6–29.4) had no baseline creatinine or
potassium testing
- There was no sex difference in baseline testing (OR 0.98, 95% CI
0.84–1.14)
Patients treated with diuretics
- 11 777/35 707 (33.0%, 95% CI 32.5–33.5) had no baseline creatinine
or potassium testing
- Women were more likely to have no baseline testing (OR 1.25, 95%
CI 1.20–1.31)
- Those with no or one co-morbid condition were more likely to have
no baseline testing (OR 3.63, 95% CI 3.33–3.96)
Clayton
(2006b)
UK
Cross-sectional study of
the electronic prescribing
and laboratory records of
6 UK general practices
Thiazide diuretics Sodium and potassium
electronic records
- 488/2942 (16.6%) had a sodium and/or potassium record within 2
year prior to thiazide diuretic initiation
- 951/2942 (32.3%) had a sodium and/or potassium record in the two
year whilst prescribed a thiazide diuretic
- 140 (4.7% ) patients had electrolytes checked both prior to and
during treatment
- Patient covariates associated with monitoring during treatment were
male sex, age, and increasing number of prescriptions
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Sauer (2006)
USA
Retrospective analysis of
a large veterans’
database, identifying
patients who were
treated with an ACE
inhibitor or AT-II
receptor antagonist
ACE inhibitor or
AT-II receptor
antagonist
Potassium and creatinine - 569/2936 patients did not have a baseline serum potassium or
creatinine test
- The frequency of patients who were not monitored within the
recommended interval were:
- 12 weeks (50%), 4 weeks (67%), and 2 weeks (73%)
- Factors associated with lack of monitoring included: fewer than 6
outpatient encounters (OR 1.9, 95% CI 1.5–2.3), and driving
distance >30 miles (OR 1.19, 95% CI 1.03–1.4)
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Lafata (2007)
USA
Cluster-randomized
study of academic
detailing in primary care
practices
ACE inhibitors/
AT-II receptor
antagonists;
Diuretics
Baseline testing of
potassium (for diuretics)
or potassium and
creatinine during the 180
days before or 14 days
after first dispensing or
within 12 months after the
patient’s clinic’s initial
academic detailing visit
for continuing users
Rates of monitoring pre-intervention in control group only
ACE inhibitors/ AT-II receptor antagonists
For initial medication users: 59.2%
For continuing medication users: 76.4%
Diuretics
For initial medication users: 61.2%
For continuing medication users: 77.7%
Rates of monitoring post-intervention in control group only*
ACE inhibitors/ AT-II receptor antagonists
For initial medication users: 51.9%
For continuing medication users: 86.9%
Diuretics
For initial medication users: 62.8%
For continuing medication users: 86.9%
* adjusted for patients’ clinic preintervention laboratory monitoring, age, gender, insurance
sponsorship, Charlson Comorbidity Score, number of dispensings, number of visits to
primary care provided, number of visits to other primary care physicians, percent below
federal poverty line in residential census block, percent with less than high school education
in residential census block, and organization
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McAlister
(2007)
Canada
Retrospective analysis of
an administrative health
database over an eight-
year period
Antihypertensive
monotherapy (ACE
inhibitor, AT-II
receptor antagonist,
beta-blocker, Ca-
channel blocker,
thiazide diuretic)
Renal function,
electrolytes
- 67 879/164 413 (41%) had at least one laboratory test in 6 months
before initiation of treatment
- 79 985/164 413 (49%) had at least one laboratory monitoring test
during 1 year follow-up
In patients treated with thiazide diuretics
- 21% had electrolytes checked in 6 months before first prescription;
38% in 1 year after starting treatment
- 32% had renal function checked in 6 months before first prescription;
41% in 1 year after starting treatment
In patients treated with newer agents (ACE inhibitors, AT-II receptor
antagonists, Ca-channel blockers)
- 23% had electrolytes checked in 6 months before first prescription;
31% in 1 year after starting treatment
- 36% had renal function checked in 6 months before first prescription;
42% in 1year after starting treatment
Compared with patients treated with newer agents, thiazide diuretic-
treated patients were more likely to have their serum electrolytes
monitored (OR 1.38, 95% CI 1.35–1.41) and less likely to have renal
function monitored (OR 0.95, 95% CI 0.93–0.97) at least once during
follow-up
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Study Studydesign/description Drug class What to monitor? Results
Raebel (2007a)
USA
Retrospective analysis of
data from 10 HMO
databases
Spironolactone Creatinine and potassium
within 1 year
- Both serum creatinine and potassium were evaluated at least once in
1632/2257 (72.3%) patients
- 91/2257 (4.0%) patients underwent serum creatinine testing but not
potassium testing
- 111/2257 (4.9%) patients underwent serum potassium testing but no
creatinine testing
Characteristics associated with laboratory monitoring within 1 year:
Male sex (adjusted OR 1.25, 95% CI 1.01–1.54); age in increments of 10
years (OR 1.28, 95% CI 1.17–1.41); outpatient visits in increments of 5
(OR 1.31, 95% CI 1.19–1.44); ACE inhibitors/AT-II receptor antagonists
(OR 2.23, 95% CI 1.74–2.87); digoxin (OR 2.10, 95% CI 1.48–2.98);
other diuretics (OR 1.96, 95% CI 1.51–2.54); diabetes mellitus (OR 1.63,
95% CI 1.31–2.03)
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Study Studydesign/description Drug class What to monitor? Results
Raebel (2007b)
USA
Retrospective analysis of
data from 10 HMO
databases
ACE inhibitors,
AT-II receptor
antagonists
Creatinine and potassium
within 1 year
In patients treated with an ACE inhibitor:
- 31 909/47 291 (67.5%) had both tests evaluated within 1 year
In patients treated with an AT-II receptor antagonist
- 3063/1494 (74.3%) had both tests evaluated within 1 year
In all patients
- Both serum creatinine and potassium were evaluated at least once
in 36 185/52 096 (68.4%) patients
- 3117/52 906 (5.9%) patients underwent serum creatinine testing
but not potassium testing
- 1001/52 906 (1.9%) patients underwent serum potassium testing
but no creatinine testing
Characteristics associated with laboratory monitoring within 1 year for all
patients: Male sex (OR 1.06; 95% CI 1.02–1.11); age (80+ compared with
<50) (OR 2.10, 95% CI 1.93–2.28); outpatient visits (>9 compared to ≤9)
(OR 1.46, 95% CI 1.39–1.54); any hospitalization (OR 1.15, 95% CI 1.06–
1.25); digoxin (OR 1.15, 95% CI 1.01–1.30); potassium supplements (OR
2.01, 95% CI 1.84–2.20); diuretics (OR 1.54, 95% CI 1.47–1.61); diabetes
mellitus (OR 1.68, 95% CI 1.61–1.75); heart failure (OR 1.73, 95% CI
1.57–1.90); chronic kidney disease (OR 2.95, 95% CI 2.48–3.51)
Besançon
(2008)
France
Retrospective review of
anonymous
computerized healthcare
records from a health
insurance system
Spironolactone and
ACE inhibitor
Serum potassium and
creatinine
1083 (30%) of patients had at least one measurement of potassium or
creatinine in the six months prior to treatment
15% underwent either serum potassium or serum creatinine measurements
but not both
34% did not undergo any laboratory tests
Only 51% underwent the minimal biological monitoring defined in the
reference system.
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Study Studydesign/description Drug class What to monitor? Results
Géradin-Marais
(2008)
France
One-year retrospective
analysis of a national
health insurance
database in patients aged
75 and older
Diuretics (loop
diuretics, thiazide
diuretics,
potassium-sparing
agents,
combination
regimen)
Serum chemistry
monitoring (defined as
urea and creatinine
clearance; urea,
creatinine, potassium,
sodium, chloride
or carbon dioxide serum
levels, plasma proteins)
- A total of 11 315 patients, aged 75 years or more, were dispensed
at least 12 monthly diuretic prescriptions
- 8513/11 315 (75%) had at least one monitoring test within one
year of treatment
Patient characteristics associated with monitoring: Patient age ≥85 years
(OR 1.63, 1.36–1.97); female sex (OR 1.28, 95% CI 1.15–1.42); thiazide
diuretics (compared with loop diuretics) (OR 1.54, 95% CI 1.21–1.95);
serious disease (OR 1.70, 95% CI 1.55–1.87)
Raebel (2010)
USA
Retrospective analysis of
data from 3 HMOs in
diabetic patients aged 18
and older newly treated
with antihypertensive
therapy
ACE inhibitors,
angiotensin-II
receptor blockers,
spironolactone
Serum potassium 19 391/27 355 (71%) of patients had at least one serum potassium test
during treatment.
244/27 335 (0.9%) had a baseline potassium test within 30 days prior to
initiating treatment.
Patients who had at least one potassium test were less likely to experience
serious hyperkalaemia (≥6.0mmol/l), or hyperkalaemia-related adverse
events such as hospital admission, emergency department visit, or death.
Unadjusted RR 1.29, 95% CI 0.87–1.90
Adjusted RR* 0.50, 95% CI 0.37–0.66 (*adjusted for potential
confounders of monitoring)
In the subgroup of patients with chronic disease, monitoring further
reduced the risk of harm.
Unadjusted RR 0.28, 95% CI 0.14–0.57
Adjusted RR* 0.19, 95% CI 0.11–0.36 (*adjusted for potential
confounders of monitoring)
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Appendix 6 – Studies investigating the nature and frequency of laboratory monitoring excluded from the systematic review
Study Studydesign/description Drug class What to monitor? Results
Excluded because discrete data on only the antihypertensive medication could not be obtained
Feldstein
(2006) USA
Cluster-randomized trial
comparing 3
interventions to usual
care in 15 primary care
clinics in one HMO
ACE inhibitors,
AT-II receptor
antagonists,
diuretics (as well as
8 other drug
classes)
Baseline and follow-up
creatinine, potassium
Proportion of patients with baseline laboratory testing
Usual care 60.4%
Intervention 1 (electronic medical record) 59.7%
Intervention 2 (automated voice messaging) 53.2%
Intervention 3 (pharmacy team) 59.1%
Proportion of patients with follow-up laboratory testing within 25 days
Usual care 22.4%
Intervention 1 (electronic medical record) 48.5%
Intervention 2 (automated voice messaging) 66.3%
Intervention 3 (pharmacy team) 82.0%
Steele (2005)
USA
Pre- and post-
intervention analysis
ACE inhibitors,
thiazide diuretics
(and additional
non-
antihypertensive
drug classes)
Follow-up creatinine and
potassium
Monitoring following an intervention using an electronic alert
Intervention Pre-
intervention
Post-
intervention
P value
No message
displayed
17% 16.2% 0.38
Message displayed 38.5% 51.1% <0.001
Message displayed:
“Abnormal Labs”
33.8% 41.7% 0.077
Message displayed:
“No Labs
Available”
43.0% 62.0% <0.001
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Study Studydesign/description Drug class What to monitor? Results
Excluded because the denominator presented was the number of prescriptions and not the number of patients
Raebel (2005)
USA
Retrospective analysis of
patients from 10 HMOs
who were newly
prescribed treatment
ACE inhibitors,
AT-II receptor
antagonists,
diuretics
Baseline testing of
creatinine or potassium
(180 days before and 14
days after index
prescription)
ACE inhibitors
- 39.2% of 48 682 dispensings had no creatinine or potassium test
- 32.3% of dispensing had no creatinine test
AT-II receptor antagonists
- 34.1% of 8731 dispensings had no creatinine or potassium test
- 29.6% of dispensings had no creatinine test
Diuretics
- 39.5% of 78 903 dispensings had no creatinine or potassium test
- 34.4% of dispensing did had no creatinine test
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Study Studydesign/description Drug class What to monitor? Results
Palen (2006)
USA
Randomized intervention
study of a computerized
physician order entry
system in a US managed
care organization over 1
year
ACE inhibitors,
AT-II receptor
antagonists,
diuretics
Creatinine and potassium Control group
- 47.5% prescription orders had a creatinine and/or potassium record in
the 180 days prior to and 14 days after the initial ACE inhibitor
treatment
- 52.7% prescription orders had a creatinine and/or potassium record in
the 180 days prior to and 14 days after the initial AT-II receptor
antagonist treatment
- 45.6% prescription orders had a creatinine and/or potassium record in
the 180 days prior to and 14 days after the diuretic treatment
Intervention group (non-intrusive laboratory monitoring electronic alert)
- 47.0% prescription orders had a creatinine and/or potassium record in
the 180 days prior to and 14 days after the initial ACE inhibitor
treatment
- 52.0% prescription orders had a creatinine and/or potassium record in
the 180 days prior to and 14 days after the initial AT-II receptor
antagonist treatment
- 44.0%% prescription orders had a creatinine and/or potassium record
in the 180 days prior to and 14 days after the diuretic treatment
No significant differences were observed in the rates of monitoring in
group where electronic alerts reminded the physician of the need for
laboratory monitoring.
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Study Studydesign/description Drug class What to monitor? Results
Matheny
(2008) USA
Randomized study of
electronic reminders in a
cohort of patients
registered in a database
over 6 months
AT-II receptor
antagonists,
potassium-sparing
thiazide diuretics,
diuretics, ACE
inhibitors
Creatinine, potassium Control group
- 3.2% of GP visits of patients treated with an AT-II receptor
antagonist had no record of a creatinine test in the 365 days prior
- 3.2% of GP visits of patients treated with potassium-sparing
diuretic had no record of a potassium test in the 365 days prior
- 3.5% of GP visits of patients treated with a thiazide diuretic had
no record of a potassium test in the 365 days prior
- 2.9% of GP visits of patients treated with an ACE inhibitor had
no record of a potassium test in the 365 days prior
Intervention group (electronic reminders of laboratory monitoring)
- 4.1% of GP visits of patients treated with an AT-II receptor
antagonist had no record of a creatinine test in the 365 days prior
- 2.5% of GP visits of patients treated with potassium-sparing
diuretic had no record of a potassium test in the 365 days prior
- 3.1% of GP visits of patients treated with a thiazide diuretic had
no record of a potassium test in the 365 days prior
- 5.2% of GP visits of patients treated with an ACE inhibitor had
no record of a potassium test in the 365 days prior
No statistically significant improvement in any of the monitoring was
observed with the intervention
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Appendix 7 – Read/OXMIS codes for hypertension
Code Read/OXMIS name Code Read/OXMIS name
403 AH
RENOVASCULAR
HYPERTENSION 9OI..00
Hypertension monitoring
admin.
662B.00 O/E - initial high BP Y0601JA
HYPERTENSION CLINIC
ATTENDANCE
662G.00 Hypertensive treatm.changed 4000
MALIGNANT
HYPERTENSION
9OI..11 Hypertension clinic admin. 401 AR
HYPERTENSION
ARTERIOSCLEROTIC
G2...11 BP - hypertensive disease 662F.00 Hypertension treatm. started
G201.00 Benign essential hypertension 9OIA.11 Hypertension monitored
G232.00
Hypertensive heart&renal dis wth
(congestive) heart failure G20z.00 Essential hypertension NOS
G241z00 Secondary benign hypertension NOS G210100
Malignant hypertensive
heart disease with CCF
Y060 JA HYPERTENSION CLINIC G211z00
Benign hypertensive heart
disease NOS
Y100 NH
NURSE HYPERTENSION
ASSESSMENT G222.00
Hypertensive renal disease
with renal failure
401 P
HYPERTENSION ARTERIAL
PRIMARY G240z00
Secondary malignant
hypertension NOS
9N1y200 Seen in hypertension clinic G24zz00
Secondary hypertension
NOS
G210z00
Malignant hypertensive heart disease
NOS G672.11 Hypertensive crisis
Gyu2000 [X]Other secondary hypertension 403 AA
RENAL HYPERTENSIVE
DISEASE
L0010EM
REFERRED TO HYPERTENSION
CLINIC 9OI2.00
Refuses hypertension
monitor.
4003AA
HYPERTENSIVE RENAL
DISEASE 9OIA.00
Hypertension monitor.chck
done
401 R HYPERTENSION CRISIS G202.00 Systolic hypertension
6627.00 Good hypertension control G20z.11 Hypertension NOS
9OI1.00 Attends hypertension monitor. G21zz00
Hypertensive heart disease
NOS
G210000
Malignant hypertensive heart disease
without CCF G23..00
Hypertensive heart and renal
disease
G211100
Benign hypertensive heart disease
with CCF G2z..00 Hypertensive disease NOS
G21z100
Hypertensive heart disease NOS
with CCF Gyu2100
[X]Hypertension secondary
to other renal disorders
G221.00 Benign hypertensive renal disease 401 A HYPERTENSION
G24z.00 Secondary hypertension NOS 401 AB
HYPERTENSION
BORDERLINE
G2y..00 Other specified hypertensive disease 401 AW HIGH BLOOD PRESSURE
Gyu2.00 [X]Hypertensive diseases 401 BN
HYPERTENSION
BENIGN
L0010AM
SEEN IN HYPERTENSION
CLINIC 401 C
HYPERTENSION
ESSENTIAL
403 NC
HYPERTENSION IMPAIRED
RENAL FUNCTION 401 DC
HYPERTENSION
DIASTOLIC
2466.00 O/E - BP reading raised 403 RENAL HYPERTENSION
662O.00 On treatment for hypertension 401 AC
HYPERTENSION
ACCELERATED
662P.00 Hypertension monitoring 401 AK
OBSERVATION ONLY
HYPERTENSION
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Code Read/OXMIS name Code Read/OXMIS name
8B26.00 Antihypertensive therapy G240.00
Secondary malignant
hypertension
G2...00 Hypertensive disease 2465.00 O/E - BP borderline raised
G20..11 High blood pressure G200.00
Malignant essential
hypertension
G210.00 Malignant hypertensive heart disease G21..00 Hypertensive heart disease
G21z.00 Hypertensive heart disease NOS G211.00
Benign hypertensive heart
disease
G231.00
Benign hypertensive heart and renal
disease G22..00 Hypertensive renal disease
G240000
Secondary malignant renovascular
hypertension G230.00
Malignant hypertensive
heart and renal disease
G241000
Secondary benign renovascular
hypertension G244.00
Hypertension secondary to
endocrine disorders
4003
HYPERTENSIVE
NEPHROPATHY 401
BENIGN
HYPERTENSION
G220.00 Malignant hypertensive renal disease 401 EL
HYPERTENSION
ARTERIAL SYSTEMIC
G22z.00 Hypertensive renal disease NOS 402 C
HYPERTENSION
CONGESTIVE HEART
FAILURE
G233.00
Hypertensive heart and renal disease
with renal failure 403 NG
HYPERTENSIVE
GLOMERULOSCLEROSIS
G23z.00
Hypertensive heart and renal disease
NOS 8HT5.00
Referral to hypertension
clinic
G241.00 Secondary benign hypertension 9N03.00 Seen in hypertension clinic
G24z000
Secondary renovascular
hypertension NOS 401 BM
HYPERTENSION ON
TREATMENT
G672.00 Hypertensive encephalopathy 401 S
HYPERTENSION
SYSTOLIC
3055CE
HYPERTENSIVE SPASM
CARDIAC SPHINCTER 402
HYPERTENSIVE HEART
DISEASE
401 AT
HYPERTENSION
ATHEROSCLEROTIC 9N4L.00
DNA - Did not attend
hypertension clinic
401 PA HYPERTENSION PRIMARY 662d.00 Hypertension annual review
2467.00 O/E - BP reading very high 662c.00
Hypertension six month
review
6628.00 Poor hypertension control 662b.00
Moderate hypertension
control
G20..00 Essential hypertension 8BL0.00
Patient on maximal tolerated
antihypertensive therapy
G21z000
Hypertensive heart disease NOS
without CCF 66b2.00
Hypertension monitoring
not required
G22z.11 Renal hypertension 1JD..00 Suspected hypertension
G24..00 Secondary hypertension 8CR4.00
Hypertension clinical
management plan
401 E HYPERTENSION ARTERIAL G8y3.00
Chronic peripheral venous
hypertension
403 NF
HYPERTENSION RENAL
INSUFFICIENCY G21z011
Cardiomegaly -
hypertensive
662..12 Hypertension monitoring 8I3N.00
Hypertension treatment
refused
662C.00 O/E - check high BP G211000
Benign hypertensive heart
disease without CCF
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Appendix 8 – Read/OXMIS codes for baseline smoking
Code Read/OXMIS name Code Read/OXMIS name
1373.00 Light smoker - 1-9 cigs/day 9OO2.00 Refuses stop smoking monitor
137Q.11 Smoking restarted T5113 SMOKER (15 PER DAY)
137R.00 Current smoker T512 SMOKER PIPE
9OO1.00 Attends stop smoking monitor. 1377.00 Ex-trivial smoker (
T5091HS EX HEAVY SMOKER 1379.00 Ex-moderate smoker (10-19/day)
T5115M SMOKER MILD (5 OR LESS PER
DAY)
137A.00 Ex-heavy smoker (20-39/day)
T5117 SMOKER (30 PER DAY) 9OO5.00 Stop smoking monitor 2nd lettr
T513 SMOKER CIGARS 9OO6.00 Stop smoking monitor 3rd lettr
L5091S SMOKING STARTED 9OO7.00 Stop smoking monitor verb.inv.
T5093N SMOKED NEVER 9OO9.00 Stop smoking monitoring delete
Y060 J1 STOP SMOKING GROUP T509 SMOKER
Y060 JJ CLINIC ANTI-SMOKING T510 SE SMOKING EXCESSIVE
137B.00 Ex-very heavy smoker (40+/day) T5114 SMOKER (10 PER DAY)
H310100 Smokers' cough 1371.00 Never smoked tobacco
T5091ES FORMER SMOKER 1372.00 Trivial smoker - < 1 cig/day
T5092 SMOKING ADVISED TO STOP 1376.00 Very heavy smoker - 40+cigs/d
T5093 SMOKER NON 137H.00 Pipe smoker
T510 EXCESSIVE SMOKING 137K.00 Stopped smoking
T5112 SMOKER (20 PER DAY) 9OO..11 Stop smoking clinic admin.
5020M SMOKERS' THROAT 9OO..12 Stop smoking monitoring admin.
137..11 Smoker - amount smoked T509 SR SMOKING RESTARTED
1371.11 Non-smoker 137C.00 Keeps trying to stop smoking
137F.00 Ex-smoker - amount unknown 137P.11 Smoker
137L.00 Current non-smoker 9OOA.00 Stop smoking monitor.chck done
9OO..00 Anti-smoking monitoring admin. T5090XC SMOKER CIGARETTES
T5092SA SMOKING WANTS TO STOP T510 HS HEAVY SMOKER (20-PLUS
PER DAY)
137M.00 Rolls own cigarettes T5115 SMOKER (LESS THAN 10 PER
DAY)
137N.00 Ex pipe smoker 8CAL.00 Smoking cessation advice
13WF400 Passive smoking risk 8HTK.00 Referral to stop-smoking clinic
9OO8.00 Stop smoking monitor phone inv 137V.00 Smoking reduced
T5090OR SMOKER OWN ROLLED 13p..00 Smoking cessation milestones
T5092S SMOKING WISHES TO STOP 137X.00 Cigarette consumption
T511 SMOKER MODERATE (LESS
THAN 20 PER DAY)
13p1.00 Smoking status at 4 weeks
Y0601KA SMOKING CLINIC
ATTENDANCE
137Y.00 Cigar consumption
5287MK SMOKERS' MOUTH PATCHES 13p0.00 Negotiated date for cessation of
smoking
1372.11 Occasional smoker 13p2.00 Smoking status between 4 and 52
weeks
1375.00 Heavy smoker - 20-39 cigs/day 137b.00 Ready to stop smoking
1378.00 Ex-light smoker (1-9/day) 137c.00 Thinking about stopping smoking
137J.00 Cigar smoker 13p4.00 Smoking free weeks
137Q.00 Smoking started 9N4M.00 DNA - Did not attend smoking
cessation clinic
137T.00 Date ceased smoking 8H7i.00 Referral to smoking cessation
advisor
9OO4.00 Stop smoking monitor 1st lettr 13p3.00 Smoking status at 52 weeks
9OOZ.00 Stop smoking monitor admin.NOS 13p5.00 Smoking cessation programme
start date
T5091 STOPPED SMOKING 137g.00 Cigarette pack-years
137P.00 Cigarette smoker 137d.00 Not interested in stopping smoking
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Code Read/OXMIS name Code Read/OXMIS name
T510 SH SMOKER HEAVY (20-PLUS PER
DAY)
9N2k.00 Seen by smoking cessation advisor
T5116 SMOKER(OCCASIONAL) 137e.00 Smoking restarted
1374.00 Moderate smoker - 10-19 cigs/d 137f.00 Reason for restarting smoking
137G.00 Trying to give up smoking 67H1.00 Lifestyle advice regarding
smoking
137O.00 Ex cigar smoker ZRh4.00 Reasons for smoking scale
137S.00 Ex smoker 13WK.00 No smokers in the household
8I6H.00 Smoking review not indicated 745H.00 Smoking cessation therapy
ZRh4.11 RFS - Reasons for smoking scale ZRaM.00 Motives for smoking scale
333
Appendix 9 – Read/OXMIS codes for baseline diabetes mellitus
Code Read/OXMIS name Code Read/OXMIS name
R054200 [D]Gangrene of toe in diabetic L2500GC DIABETES - GOOD CONTROL
R054300 [D]Widespread diabetic foot
gangrene
C10yz00 Diabetes mellitus NOS with other
specified manifestation
ZV65312 [V]Dietary counselling in diabetes
mellitus
C107z00 Diabetes mellitus NOS with
peripheral circulatory disorder
Cyu2.00 [X]Diabetes mellitus C10zz00 Diabetes mellitus NOS with
unspecified complication
Kyu0300 [X]Glomerular disorders in diabetes
mellitus
C107.11 Diabetes mellitus with gangrene
Cyu2100 [X]Malnutrit-relat diabetes mellitus
with other spec comps
C102.00 Diabetes mellitus with
hyperosmolar coma
Cyu2200 [X]Malnutrit-related diabetes mellitus
with unspec complics
C101.00 Diabetes mellitus with
ketoacidosis
Cyu2000 [X]Other specified diabetes mellitus C103.00 Diabetes mellitus with
ketoacidotic coma
Cyu2300 [X]Unspecified diabetes mellitus
with renal complications
C106.00 Diabetes mellitus with
neurological manifestation
250 AB ABSCESS DIABETIC C106.12 Diabetes mellitus with neuropathy
F372000 Acute painful diabetic neuropathy C100.00 Diabetes mellitus with no mention
of complication
8H2J.00 Admit diabetic emergency C105.00 Diabetes mellitus with ophthalmic
manifestation
F420300 Advanced diabetic maculopathy C10y.00 Diabetes mellitus with other
specified manifestation
F420500 Advanced diabetic retinal disease C107.00 Diabetes mellitus with peripheral
circulatory disorder
TJ23z00 Adverse reaction to insulins and
antidiabetic agents NOS
C106.13 Diabetes mellitus with
polyneuropathy
66AT.00 Annual diabetic blood test C104.00 Diabetes mellitus with renal
manifestation
F372200 Asymptomatic diabetic neuropathy C10z.00 Diabetes mellitus with unspecified
complication
9NM0.00 Attending diabetes clinic C106100 Diabetes mellitus, adult onset, +
neurological manifestation
F171100 Autonomic neuropathy due to
diabetes
C105100 Diabetes mellitus, adult onset, +
ophthalmic manifestation
F420000 Background diabetic retinopathy C10z100 Diabetes mellitus, adult onset, +
unspecified complication
M037200 Cellulitis in diabetic foot C100100 Diabetes mellitus, adult onset, no
mention of complication
250 M CHARCOT'S DIABETIC
ARTHROPATHY
C102100 Diabetes mellitus, adult onset,
with hyperosmolar coma
F372100 Chronic painful diabetic neuropathy C101100 Diabetes mellitus, adult onset,
with ketoacidosis
250 H COMA DIABETIC C103100 Diabetes mellitus, adult onset,
with ketoacidotic coma
66AN.00 Date diabetic treatment start C104100 Diabetes mellitus, adult onset,
with renal manifestation
250 AN DIABETES C107200 Diabetes mellitus, adult with
gangrene
C10y100 Diabetes mellitus, adult, + other
specified manifestation
66A..00 Diabetic monitoring
250 JE DIABETIC ACETONAEMIA 66Al.00 Diabetic monitoring - higher risk
albumin excretion
250 JA DIABETIC ACIDOSIS 66Ak.00 Diabetic monitoring - lower risk
albumin excretion
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250 AT DIABETIC AMYOTROPHY 66AZ.00 Diabetic monitoring NOS
F381311 Diabetic amyotrophy F345000 Diabetic mononeuritis multiplex
C106.11 Diabetic amyotrophy F35z000 Diabetic mononeuritis NOS
66AS.00 Diabetic annual review F3y0.00 Diabetic mononeuropathy
F464000 Diabetic cataract C104.11 Diabetic nephropathy
250 CT DIABETIC CATARACT 250 N DIABETIC NEPHROPATHY
N030100 Diabetic Charcot arthropathy F372.12 Diabetic neuropathy
N030000 Diabetic cheiroarthropathy 66A3.00 Diabetic on diet only
N030011 Diabetic cheiropathy 66A5.00 Diabetic on insulin
2500W DIABETIC CLINIC 66AV.00 Diabetic on insulin and oral
treatment
8A12.00 Diabetic crisis monitoring 66A4.00 Diabetic on oral treatment
250 DR DIABETIC DIARRHOEA 9OLD.00 Diabetic patient unsuitable for
digital retinal photography
13B1.00 Diabetic diet G73y000 Diabetic peripheral angiopathy
66AY.00 Diabetic diet - good compliance 66Ac.00 Diabetic peripheral neuropathy
screening
66Aa.00 Diabetic diet - poor compliance F372.11 Diabetic polyneuropathy
68AB.00 Diabetic digital retinopathy screening
offered
6761.00 Diabetic pre-pregnancy
counselling
66AG.00 Diabetic drug side effects F420.00 Diabetic retinopathy
66Ab.00 Diabetic foot examination 8HBG.00 Diabetic retinopathy 12 month
review
8I3W.00 Diabetic foot examination declined 8HBH.00 Diabetic retinopathy 6 month
review
8I6G.00 Diabetic foot examination not
indicated
F420z00 Diabetic retinopathy NOS
66AW.00 Diabetic foot risk assessment 68A7.00 Diabetic retinopathy screening
250 LG DIABETIC
GLOMERULOSCLEROSIS
8I6F.00 Diabetic retinopathy screening not
indicated
13AB.00 Diabetic lipid lowering diet 8I3X.00 Diabetic retinopathy screening
refused
F420400 Diabetic maculopathy 8A13.00 Diabetic stabilisation
66AH.00 Diabetic treatment changed 250 HC HYPOGLYCAEMIC COMA
DIABETIC
13AC.00 Diabetic weight reducing diet 250 ED HYPOGLYCAEMICS ORAL
DIABETES
66AL.00 Diabetic-uncooperative patient 9999DM IATROGENIC DIABETES
MELLITUS
8HLE.00 Diabetology D.V. done C108.11 IDDM-Insulin dependent diabetes
mellitus
8HKE.00 Diabetology D.V. requested 66AA.11 Injection sites - diabetic
9N4p.00 Did not attend diabetic retinopathy
clinic
C108900 Insulin dependent diabetes
maturity onset
ZC2C800 Dietary advice for diabetes mellitus C100011 Insulin dependent diabetes
mellitus
ZC2C900 Dietary advice for type I diabetes C10E.12 Insulin dependent diabetes
mellitus
ZC2CA00 Dietary advice for type II diabetes C108.00 Insulin dependent diabetes
mellitus
250 DC DIETARY CONTROL DIABETES C10E812 Insulin dependent diabetes
mellitus - poor control
9N4I.00 DNA - Did not attend diabetic clinic C108800 Insulin dependent diabetes
mellitus - poor control
2G5C.00 Foot abnormality - diabetes related C108H00 Insulin dependent diabetes
mellitus with arthropathy
2G51000 Foot abnormality - diabetes related C108F00 Insulin dependent diabetes
mellitus with diabetic cataract
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250 GA GANGRENE DIABETIC C108600 Insulin dependent diabetes
mellitus with gangrene
44V3.00 Glucose tol. test diabetic C108E00 Insulin dependent diabetes
mellitus with hypoglycaemic coma
14F4.00 H/O: Admission in last year for
diabetes foot problem
C108B00 Insulin dependent diabetes
mellitus with mononeuropathy
1434.00 H/O: diabetes mellitus C10E312 Insulin dependent diabetes
mellitus with multiple complicat
66A8.00 Has seen dietician - diabetes C108300 Insulin dependent diabetes
mellitus with multiple complicatn
42W..00 Hb. A1C - diabetic control C108D00 Insulin dependent diabetes
mellitus with nephropathy
42WZ.00 Hb. A1C - diabetic control NOS C108C00 Insulin dependent diabetes
mellitus with polyneuropathy
42c..00 HbA1 - diabetic control C108700 Insulin dependent diabetes
mellitus with retinopathy
F420800 High risk non proliferative diabetic
retinopathy
C108500 Insulin dependent diabetes
mellitus with ulcer
F420700 High risk proliferative diabetic
retinopathy
C109J11 Insulin treated non-insulin
dependent diabetes mellitus
250 NH HYPEROSMOLAR DIABETIC
STATE
C109J00 Insulin treated Type 2 diabetes
mellitus
C10FK00 Hyperosmolar non-ketotic state in
type 2 diabetes mellitus
C10FJ00 Insulin treated Type 2 diabetes
mellitus
C109K00 Hyperosmolar non-ketotic state in
type 2 diabetes mellitus
C109J12 Insulin treated Type II diabetes
mellitus
250 E HYPOGLYCAEMIA IN DIABETES
MELLITUS
C10FJ11 Insulin treated Type II diabetes
mellitus
C108200 Insulin-dependent diabetes mellitus
with neurological comps
M271200 Mixed diabetic ulcer - foot
C108100 Insulin-dependent diabetes mellitus
with ophthalmic comps
F381300 Myasthenic syndrome due to
diabetic amyotrophy
C108000 Insulin-dependent diabetes mellitus
with renal complications
K01x100 Nephrotic syndrome in diabetes
mellitus
C108A00 Insulin-dependent diabetes without
complication
M271100 Neuropathic diabetic ulcer - foot
M271000 Ischaemic ulcer diabetic foot 250 F NEUROPATHY DIABETIC
250 JK KETOACIDOSIS DIABETIC C109.11 NIDDM - Non-insulin dependent
diabetes mellitus
250 JL KETOSIS DIABETIC 250 AA NIDDM (NON-INSULIN
DEPENDENT DIABETES)
2500AH LATENT DIABETES F420600 Non proliferative diabetic
retinopathy
C10M.00 Lipoatrophic diabetes mellitus C109E00 Non-insulin depend diabetes
mellitus with diabetic cataract
8HME.00 Listed for Diabetology admissn C109700 Non-insulin dependant diabetes
mellitus - poor control
C10A.00 Malnutrition-related diabetes mellitus C100112 Non-insulin dependent diabetes
mellitus
C10A000 Malnutrition-related diabetes mellitus
with coma
C109G00 Non-insulin dependent diabetes
mellitus with arthropathy
C10A100 Malnutrition-related diabetes mellitus
with ketoacidosis
C109500 Non-insulin dependent diabetes
mellitus with gangrene
C10A600 Malnutrition-related diabetes mellitus
with multiple comps
C109D00 Non-insulin dependent diabetes
mellitus with hypoglyca coma
C10A200 Malnutrition-related diabetes mellitus
with renal complicatn
C109A00 Non-insulin dependent diabetes
mellitus with mononeuropathy
C10A700 Malnutrition-related diabetes mellitus
without complications
C109C00 Non-insulin dependent diabetes
mellitus with nephropathy
336
Code Read/OXMIS name Code Read/OXMIS name
C10A400 Malnutrition-related diabetes mellitus
wth neuro complicatns
C109B00 Non-insulin dependent diabetes
mellitus with polyneuropathy
C10A500 Malnutritn-relat diabetes melitus wth
periph circul complctn
C109400 Non-insulin dependent diabetes
mellitus with ulcer
C10AX00 Malnutrit-relat diabetes mellitus with
other spec comps
C109.00 Non-insulin-dependent diabetes
mellitus
C10AW00 Malnutrit-related diabetes mellitus
with unspec complics
C109300 Non-insulin-dependent diabetes
mellitus with multiple comps
C10A300 Malnutrit-related diabetes mellitus
wth ophthalmic complicat
C109200 Non-insulin-dependent diabetes
mellitus with neuro comps
C100111 Maturity onset diabetes C109100 Non-insulin-dependent diabetes
mellitus with ophthalm comps
250 AM MATURITY ONSET DIABETES
(MELLITUS)
C109000 Non-insulin-dependent diabetes
mellitus with renal comps
C10C.11 Maturity onset diabetes in youth C109600 Non-insulin-dependent diabetes
mellitus with retinopathy
C10D.11 Maturity onset diabetes in youth type
2
C109900 Non-insulin-dependent diabetes
mellitus without complication
250 AK MATURITY ONSET DIABETES
MELLITUS INSULIN
8H3O.00 Non-urgent diabetic admission
250 AL MATURITY ONSET
DIABETES(MELLITUS) NON-IN
2BBL.00 O/E - diabetic maculopathy
present both eyes
2G5W.00 O/E - left chronic diabetic foot ulcer C105y00 Other specified diabetes mellitus
with ophthalmic complicatn
2G5L.00 O/E - Left diabetic foot - ulcerated C10yy00 Other specified diabetes mellitus
with other spec comps
2G5K.00 O/E - Left diabetic foot at high risk C107y00 Other specified diabetes mellitus
with periph circ comps
2G5I.00 O/E - Left diabetic foot at low risk C104y00 Other specified diabetes mellitus
with renal complications
2G5J.00 O/E - Left diabetic foot at moderate
risk
C10zy00 Other specified diabetes mellitus
with unspecified comps
2G5B.00 O/E - Left diabetic foot at risk 7276.00 Pan retinal photocoagulation for
diabetes
2BBQ.00 O/E - left eye background diabetic
retinopathy
93C4.00 Patient consent given for addition
to diabetic register
2BBX.00 O/E - left eye diabetic maculopathy 9360.00 Patient held diabetic record issued
2BBS.00 O/E - left eye preproliferative
diabetic retinopathy
679R.00 Patient offered diabetes structured
education programme
2BBV.00 O/E - left eye proliferative diabetic
retinopathy
8BL2.00 Patient on maximal tolerated
therapy for diabetes
2BBl.00 O/E - left eye stable treated prolif
diabetic retinopathy
ZRbH.00 Perceived control of insulin-
dependent diabetes
2G5V.00 O/E - right chronic diabetic foot ulcer F372.00 Polyneuropathy in diabetes
2G5H.00 O/E - Right diabetic foot - ulcerated 250 HP PRECOMA DIABETIC
2G5G.00 O/E - Right diabetic foot at high risk L180500 Pre-existing diabetes mellitus,
insulin-dependent
2G5E.00 O/E - Right diabetic foot at low risk L180600 Pre-existing diabetes mellitus,
non-insulin-dependent
2G5F.00 O/E - Right diabetic foot at moderate
risk
L180X00 Pre-existing diabetes mellitus,
unspecified
2G5A.00 O/E - Right diabetic foot at risk L180700 Pre-existing malnutrition-related
diabetes mellitus
2BBP.00 O/E - right eye background diabetic
retinopathy
F420200 Preproliferative diabetic
retinopathy
2BBW.00 O/E - right eye diabetic maculopathy 8HVU.00 Private referral to diabetologist
2BBR.00 O/E - right eye preproliferative
diabetic retinopathy
F420100 Proliferative diabetic retinopathy
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2BBT.00 O/E - right eye proliferative diabetic
retinopathy
250 PR PRURITUS DIABETIC
2BBk.00 O/E - right eye stable treated prolif
diabetic retinopathy
8H7r.00 Refer to diabetic foot screener
2BBo.00 O/E - sight threatening diabetic
retinopathy
8Hl1.00 Referral for diabetic retinopathy
screening
C103y00 Other specified diabetes mellitus with
coma
ZL62500 Referral to diabetes nurse
C101y00 Other specified diabetes mellitus with
ketoacidosis
8HTk.00 Referral to diabetic eye clinic
C108y00 Other specified diabetes mellitus with
multiple comps
8HHy.00 Referral to diabetic register
C106y00 Other specified diabetes mellitus with
neurological comps
8H4F.00 Referral to diabetologist
8HTi.00 Referral to multidisciplinary diabetic
clinic
C10EN00 Type 1 diabetes mellitus with
ketoacidotic coma
L0010EI REFERRED TO DIABETIC CLINIC C10EB00 Type 1 diabetes mellitus with
mononeuropathy
9OL2.00 Refuses diabetes monitoring C10E300 Type 1 diabetes mellitus with
multiple complications
2BBF.00 Retinal abnormality - diabetes related C10ED00 Type 1 diabetes mellitus with
nephropathy
250 C RETINOPATHY DIABETIC C10E200 Type 1 diabetes mellitus with
neurological complications
C10N.00 Secondary diabetes mellitus C108212 Type 1 diabetes mellitus with
neurological complications
C10G.00 Secondary pancreatic diabetes
mellitus
C108J12 Type 1 diabetes mellitus with
neuropathic arthropathy
C10G000 Secondary pancreatic diabetes
mellitus without complication
C10EJ00 Type 1 diabetes mellitus with
neuropathic arthropathy
9N2d.00 Seen by diabetologist C10E100 Type 1 diabetes mellitus with
ophthalmic complications
L0010AI SEEN IN DIABETIC CLINIC C10EG00 Type 1 diabetes mellitus with
peripheral angiopathy
9N1v.00 Seen in diabetic eye clinic C10EL00 Type 1 diabetes mellitus with
persistent microalbuminuria
9N1i.00 Seen in diabetic foot clinic C10EK00 Type 1 diabetes mellitus with
persistent proteinuria
250 A SUGAR DIABETES C10EC00 Type 1 diabetes mellitus with
polyneuropathy
8CP2.00 Transition of diabetes care options
discussed
C10E000 Type 1 diabetes mellitus with
renal complications
C108.12 Type 1 diabetes mellitus C108012 Type 1 diabetes mellitus with
renal complications
C10E.00 Type 1 diabetes mellitus C108712 Type 1 diabetes mellitus with
retinopathy
C10E800 Type 1 diabetes mellitus - poor
control
C10E700 Type 1 diabetes mellitus with
retinopathy
C108812 Type 1 diabetes mellitus - poor
control
C10E500 Type 1 diabetes mellitus with
ulcer
C10E900 Type 1 diabetes mellitus maturity
onset
C10EA00 Type 1 diabetes mellitus without
complication
C10EH00 Type 1 diabetes mellitus with
arthropathy
C109.12 Type 2 diabetes mellitus
C10EF00 Type 1 diabetes mellitus with
diabetic cataract
C10F.00 Type 2 diabetes mellitus
C10EP00 Type 1 diabetes mellitus with
exudative maculopathy
C109712 Type 2 diabetes mellitus - poor
control
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C10E600 Type 1 diabetes mellitus with
gangrene
C10F700 Type 2 diabetes mellitus - poor
control
C10EQ00 Type 1 diabetes mellitus with
gastroparesis
C109G12 Type 2 diabetes mellitus with
arthropathy
C10EE00 Type 1 diabetes mellitus with
hypoglycaemic coma
C10FG00 Type 2 diabetes mellitus with
arthropathy
C108E12 Type 1 diabetes mellitus with
hypoglycaemic coma
C10FE00 Type 2 diabetes mellitus with
diabetic cataract
C10EM00 Type 1 diabetes mellitus with
ketoacidosis
C109E12 Type 2 diabetes mellitus with
diabetic cataract
C10FQ00 Type 2 diabetes mellitus with
exudative maculopathy
C109412 Type 2 diabetes mellitus with
ulcer
C10F500 Type 2 diabetes mellitus with
gangrene
C10F900 Type 2 diabetes mellitus without
complication
C10FR00 Type 2 diabetes mellitus with
gastroparesis
C108.13 Type I diabetes mellitus
C109D12 Type 2 diabetes mellitus with
hypoglycaemic coma
C10E.11 Type I diabetes mellitus
C10FD00 Type 2 diabetes mellitus with
hypoglycaemic coma
C108811 Type I diabetes mellitus - poor
control
C10FN00 Type 2 diabetes mellitus with
ketoacidosis
C108911 Type I diabetes mellitus maturity
onset
C10FP00 Type 2 diabetes mellitus with
ketoacidotic coma
C108H11 Type I diabetes mellitus with
arthropathy
C10FA00 Type 2 diabetes mellitus with
mononeuropathy
C108F11 Type I diabetes mellitus with
diabetic cataract
C10F300 Type 2 diabetes mellitus with
multiple complications
C108E11 Type I diabetes mellitus with
hypoglycaemic coma
C10FC00 Type 2 diabetes mellitus with
nephropathy
C10EM11 Type I diabetes mellitus with
ketoacidosis
C109C12 Type 2 diabetes mellitus with
nephropathy
C10EN11 Type I diabetes mellitus with
ketoacidotic coma
C10F200 Type 2 diabetes mellitus with
neurological complications
C108B11 Type I diabetes mellitus with
mononeuropathy
C109212 Type 2 diabetes mellitus with
neurological complications
C108D11 Type I diabetes mellitus with
nephropathy
C109H12 Type 2 diabetes mellitus with
neuropathic arthropathy
C108211 Type I diabetes mellitus with
neurological complications
C10FH00 Type 2 diabetes mellitus with
neuropathic arthropathy
C108C11 Type I diabetes mellitus with
polyneuropathy
C10F100 Type 2 diabetes mellitus with
ophthalmic complications
C108011 Type I diabetes mellitus with renal
complications
C109112 Type 2 diabetes mellitus with
ophthalmic complications
C108711 Type I diabetes mellitus with
retinopathy
C109F12 Type 2 diabetes mellitus with
peripheral angiopathy
C108511 Type I diabetes mellitus with ulcer
C10FF00 Type 2 diabetes mellitus with
peripheral angiopathy
C10EA11 Type I diabetes mellitus without
complication
C10FM00 Type 2 diabetes mellitus with
persistent microalbuminuria
C10F.11 Type II diabetes mellitus
C10FL00 Type 2 diabetes mellitus with
persistent proteinuria
C109.13 Type II diabetes mellitus
C10FB00 Type 2 diabetes mellitus with
polyneuropathy
C10F711 Type II diabetes mellitus - poor
control
C109012 Type 2 diabetes mellitus with renal
complications
C109711 Type II diabetes mellitus - poor
control
C10F000 Type 2 diabetes mellitus with renal
complications
C109G11 Type II diabetes mellitus with
arthropathy
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C109612 Type 2 diabetes mellitus with
retinopathy
C109E11 Type II diabetes mellitus with
diabetic cataract
C10F600 Type 2 diabetes mellitus with
retinopathy
C109511 Type II diabetes mellitus with
gangrene
C10F400 Type 2 diabetes mellitus with ulcer C10F511 Type II diabetes mellitus with
gangrene
C109D11 Type II diabetes mellitus with
hypoglycaemic coma
C10E412 Unstable insulin dependent
diabetes mellitus
C109A11 Type II diabetes mellitus with
mononeuropathy
C108400 Unstable insulin dependent
diabetes mellitus
C10F311 Type II diabetes mellitus with
multiple complications
C10E400 Unstable type 1 diabetes mellitus
C109C11 Type II diabetes mellitus with
nephropathy
C108411 Unstable type I diabetes mellitus
C10FC11 Type II diabetes mellitus with
nephropathy
C10E411 Unstable type I diabetes mellitus
C109211 Type II diabetes mellitus with
neurological complications
66AJ.11 Unstable diabetes
C109H11 Type II diabetes mellitus with
neuropathic arthropathy
250 NT UNSTABLE DIABETIC
C109111 Type II diabetes mellitus with
ophthalmic complications
C10F611 Type II diabetes mellitus with
retinopathy
C10FF11 Type II diabetes mellitus with
peripheral angiopathy
C109411 Type II diabetes mellitus with
ulcer
C109F11 Type II diabetes mellitus with
peripheral angiopathy
C109911 Type II diabetes mellitus without
complication
C10FL11 Type II diabetes mellitus with
persistent proteinuria
C10F911 Type II diabetes mellitus without
complication
C109B11 Type II diabetes mellitus with
polyneuropathy
250 G ULCER DIABETIC
C10FB11 Type II diabetes mellitus with
polyneuropathy
9NND.00 Under care of diabetic foot
screener
C109011 Type II diabetes mellitus with renal
complications
9NN8.00 Under care of diabetologist
C10F011 Type II diabetes mellitus with renal
complications
66A9.00 Understands diet - diabetes
C109611 Type II diabetes mellitus with
retinopathy
C108z00 Unspecified diabetes mellitus with
multiple complications
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Appendix 10 – Read/OXMIS codes for biochemical ADRs
Code Read/OXMIS name Code Read/OXMIS name
C367.00 Hyperkalaemia C361.11 Hyponatraemia
7886K HYPERKALAEMIA 7886N HYPONATRAEMIA
C368.00 Hypokalaemia
7887K HYPOKALAEMIA
Appendix 11 – Read/OXMIS for death codes
Code Read/OXMIS name Code Read/OXMIS name
9234 FP22-death 9413 Med A given to family
94D..00 Hospital notified of death T053z00 Killed by rolling stock -
unspecified person
945..00 Hospital death discharge notif T053000 Killed by rolling stock - railway
employee
945Z.00 Hospital death disch. NOS T140 FP DEATH IN HOSPITAL
T0y0z00 Found dead on railway unspecified -
unspecified person
T053300 Killed by rolling stock - pedal
cyclist
T0y0200 Found dead on railway unspecified –
pedestrian
T053y00 Killed by rolling stock - other
specified person
9499 Found dead at accident site 22J3.00 O/E - dead - unattended death
22J..13 Died ZV68011 [V]Issue of death certificate
8HG..00 Died in hospital 9433 Coroner report - paid for
T1400M DIED L0010GP CORONER REFERRED TO
T0y0y00 Found dead on railway unspecified -
other spec person
94B..11 Condition fatal-cause of death
T0y0.00 Found dead on railway right-of-way
unspecified
941..11 Certificate - death
949..13 Died - place patient died 947..00 Cause of death clarif. SD17/18
T053200 Killed by rolling stock - pedestrian 94B..00 Cause of death
7962 FOUND DEAD 9452 Await hosp death disch letter
795 DR DROPPED DEAD 9454 Ask for hosp death disch lett.
T0y0100 Found dead on railway unspecified -
passenger
94...11 Administration after pat. died
22J4.00 O/E - dead - sudden death TGyz400 Accidentally killed NOS
949B.00 Patient died in community hospital RyuC100 [X]Other sudden death, cause
unknown
9491 Patient died at home 946..00 Death notif.- non.hosp source
949..00 Patient died - to record place RyuC.00 [X]Ill-defined and unknown
causes of mortality
T400 PATIENT DIED 9441 Coroner's PM report awaited
22J..14 Patient died R213z00 [D]Unattended death NOS
236..12 O/E - respiratory death R213.00 [D]Unattended death
2329 O/E - death rattle R21z.00 [D]Sudden death, cause unknown
NOS
22JZ.00 O/E - dead NOS R21..00 [D]Sudden death, cause unknown
22J1.00 O/E - dead - unexpected R2...12 [D]Mortality, cause unsure
T053100 Killed by rolling stock - passenger R211.00 [D]Instantaneous death
22J6.00 O/E - dead - suspicious death R213100 [D]Found dead
T053.00 Killed by rolling stock R213000 [D]Found after death, unknown
cause of death
22J2.00 O/E - dead - expected R212100 [D]Died, with no sign of disease
22J..11 O/E - dead - condition fatal R212000 [D]Death, not instantaneous cause
unknown
22J..00 O/E - dead R212z00 [D]Death less than 24 hours from
onset of illness NOS
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9414 Med A not signed-coroner case R212.00 [D]Death less than 24 hours from
onset of illness
RyuC200 [X]Other ill-defined and unspecified
causes of death
948..11 Stat B,C and F cremation certs
9498 Dead on arrival at hospital G575100 Sudden cardiac death, so described
949C.00 Patient died in GP surgery 795 N SUDDEN DEATH
NONVIOLENT
9451 Death notif. from hospital 7963 UNKNOWN CAUSE DEATH
9492 Patient died in part 3 accom. 94A..00 Unexpected death-Coroner told
8HG..11 Death in hospital 9495 Patient died in hospital
941..00 Death certificate form Med A 949A.00 Patient died in hospice
9412 Death cert. Med A signed 9471 SD17/18 received-death clarif.
941Z.00 Death cert. Med A NOS 9494 Patient died in resid.inst.NOS
9411 Death cert. Med A due T4001 VIOLENT DEATH
T140 FH DEATH AT HOME 9493 Patient died in nursing home
9681D DEATH ANAESTHETIC T4002 SUDDEN DEATH
94Z..00 Death administration NOS L0010GN REFERRED TO CORONER
94...00 Death administration 949Z.00 Patient died in place NOS
9431 Coroner report - requested 9497 Patient died in publ.place NOS
22J..12 Death 9496 Patient died in street
9432 Coroner report - sent off L 917PM POST MORTEM REPORT
RECEIVED
949..11 Dead - place patient died 949..14 Place of death
94E..00 Date of death 94A..11 Referral to coroner
948Z.00 Cremation certification NOS 94C..00 Post mortem report
948..00 Cremation certification 94C0.00 Post mortem report received
9484 Crem. form part C completed 9481 Patient for cremation
9483 Crem. form part C arranged 9453 Receiv hosp death disch letter
9482 Crem. form part B completed 7L1M000 Preoperative anaesthetic death
944..00 Coroner's post-mortem report TK55.00 Suicide and selfinflicted injury by
explosives
9442 Coroner's PM report requested TKx3.00 Suicide and selfinflicted injury by
extremes of cold
9443 Coroner's PM report received TK5..00 Suicide and selfinflicted injury by
firearms and explosives
944Z.00 Coroner's PM report NOS TK30.00 Suicide and selfinflicted injury by
hanging
949..12 Deceased - place patient died TK50.00 Suicide and selfinflicted injury by
handgun
T140 F DEATH TKx4.00 Suicide and selfinflicted injury by
electrocution
947..12 SD18 - cause of death clarif TKx5.00 Suicide and selfinflicted injury by
crashing motor vehicle
943Z.00 Report for Coroner NOS TK30.00 Suicide and selfinflicted injury by
hanging
L 917WD REPORT RECEIVED FROM
CORONER
TK5z.00 Suicide and selfinflicted injury by
firearms/explosives NOS
947..11 SD17 - cause of death clarif TK4..00 Suicide and selfinflicted injury by
drowning
947Z.00 SD17/18 cause of death NOS TK6z.00 Suicide and selfinflicted injury by
cutting and stabbing NOS
9472 SD17/18 completed TK6..00 Suicide and selfinflicted injury by
cutting and stabbing
943..00 Report for Coroner TK60.00 Suicide and selfinflicted injury by
cutting
9473 SD17/18-no details, returned TKx6.00 Suicide and selfinflicted injury by
crashing of aircraft
TKx1.00 Suicide and selfinflicted injury by
burns or fire
TKx7.00 Suicide and selfinflicted injury
caustic subst, excl poison
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TKx1.00 Suicide and selfinflicted injury by
burns or fire
TKx0100 Suicide + selfinflicted injury-lying
before moving object
TK52.00 Suicide and selfinflicted injury by
hunting rifle
TK05.00 Suicide + selfinflicted poisoning
by drug or medicine NOS
TK21.00 Suicide and selfinflicted poisoning by
other carbon monoxide
TK05.00 Suicide + selfinflicted poisoning
by drug or medicine NOS
TK60.00 Suicide and selfinflicted injury by
cutting
TK1z.00 Suicide + selfinflicted poisoning
by domestic gases NOS
TK61.00 Suicide and selfinflicted injury by
stabbing
TK07.00 Suicide + selfinflicted poisoning
by corrosive/caustic subst
TK70.00 Suicide+selfinflicted injury-jump
from residential premises
TK01.00 Suicide + selfinflicted poisoning
by barbiturates
TK71.00 Suicide+selfinflicted injury-jump
from oth manmade structure
TK01.00 Suicide + selfinflicted poisoning
by barbiturates
TK72.00 Suicide+selfinflicted injury-jump
from natural sites
TK08.00 Suicide + selfinflicted poisoning
by arsenic + its compounds
TK7z.00 Suicide+selfinflicted injury-jump
from high place NOS
TK00.00 Suicide + selfinflicted poisoning
by analgesic/antipyretic
TK1y.00 Suicide and selfinflicted poisoning by
other utility gas
TK0z.00 Suicide + selfinflicted poisoning
by solid/liquid subst NOS
TK2y.00 Suicide + selfinflicted poisoning by
other gases and vapours
TK06.00 Suicide + selfinflicted poisoning
by agricultural chemical
TKz..00 Suicide and selfinflicted injury NOS TK1..00 Suicide + selfinflicted poisoning
by gases in domestic use
TK...00 Suicide and selfinflicted injury TKx0000 Suicide + selfinflicted injury-
jumping before moving object
TKz..00 Suicide and selfinflicted injury NOS TKx0.00 Suicide + selfinflicted injury-
jump/lie before moving object
TK61.00 Suicide and selfinflicted injury by
stabbing
TK31.00 Suicide + selfinflicted injury by
suffocation by plastic bag
U2...13 [X]Suicide TK3..00 Suicide + selfinflicted injury by
hang/strangulate/suffocate
TK51.00 Suicide and selfinflicted injury by
shotgun
TKx0z00 Suicide + selfinflicted inj-jump/lie
before moving obj NOS
TK51.00 Suicide and selfinflicted injury by
shotgun
TK3y.00 Suicide + selfinflicted inj oth
mean hang/strangle/suffocate
TKx2.00 Suicide and selfinflicted injury by
scald
TK3y.00 Suicide + selfinflicted inj oth
mean hang/strangle/suffocate
TKxy.00 Suicide and selfinflicted injury by
other specified means
TK3z.00 Suicide + selfinflicted inj by
hang/strangle/suffocate NOS
TKxz.00 Suicide and selfinflicted injury by
other means NOS
3009D SUICIDE
TKx..00 Suicide and selfinflicted injury by
other means
TK00.00 Suicide + selfinflicted poisoning
by analgesic/antipyretic
TK54.00 Suicide and selfinflicted injury by
other firearm
TK0..00 Suicide + selfinflicted poisoning
by solid/liquid substances
TK53.00 Suicide and selfinflicted injury by
military firearms
TK01500 Suicide and self inflicted injury by
Quinalbarbitone
TK01400 Suicide and self inflicted injury by
Phenobarbitone
TK02.00 Suicide + selfinflicted poisoning
by oth sedatives/hypnotics
TK01300 Suicide and self inflicted injury by
Pentabarbitone
TK20.00 Suicide + selfinflicted poisoning
by motor veh exhaust gas
TK01200 Suicide and self inflicted injury by
Butabarbitone
TK11.00 Suicide + selfinflicted poisoning
by liquified petrol gas
TK01z00 Suicide and self inflicted injury by
barbiturates
TK...00 Suicide and selfinflicted injury
TK01100 Suicide and self inflicted injury by
Barbitone
TK03.00 Suicide + selfinflicted poisoning
tranquilliser/psychotropic
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TK01000 Suicide and self inflicted injury by
Amylobarbitone
TK0..00 Suicide + selfinflicted poisoning
by solid/liquid substances
TK...14 Suicide and self harm TK2..00 Suicide + selfinflicted poisoning
by other gases and vapours
TK...14 Suicide and self harm TK04.00 Suicide + selfinflicted poisoning
by other drugs/medicines
TK10.00 Suicide + selfinflicted poisoning by
gas via pipeline
TK04.00 Suicide + selfinflicted poisoning
by other drugs/medicines
TK03.00 Suicide + selfinflicted poisoning
tranquilliser/psychotropic
TK02.00 Suicide + selfinflicted poisoning
by oth sedatives/hypnotics
TK2z.00 Suicide + selfinflicted poisoning by
gases and vapours NOS
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Appendix 12 – Read/OXMIS codes for hospital admission
Code Read/OXMIS name Code Read/OXMIS name
8Hd..00 Admission to hospital ZLF2.00 Discharge from hospital
8H2Q.00 Admit cardiology emergency 8HE..00 Discharged from hospital
8H2O.00 Admit cardiothoracic emergency 8HE2.00 Discharged from inpatient care
8H2R.00 Admit COPD emergency 8HE4.00 Discharged from private hosp'l
8H2D.00 Admit dermatology emergency 8H23000 Emerg psychiatric admiss MHA
8H2J.00 Admit diabetic emergency T927 E EMERGENCY ADMISSION
8H29.00 Admit ENT emergency 8H2P.00 Emergency admission, asthma
8H24.00 Admit geriatric emergency 8H2..00 Emergency hospital admission
8H26.00 Admit gynaecological emergency T927 HOSPITAL ADMISSION
8H2H.00 Admit haematology emergency Y1190AC HOSPITAL ADMISSION
MENTAL HEALTH ACT
8H2S.00 Admit heart failure emergency 9b0K.00 Hospital admission note
8H2Z.00 Admit hospital emergency NOS T932 HOSPITAL DISCHARGE
8H21.00 Admit medical emergency unsp. 13F8.11 Hospital inpatient
8H2E.00 Admit neurology emergency 9b0L.00 Hospital inpatient report
8H2N.00 Admit neurosurgical emergency 8CO..00 Inpatient care
8H27.00 Admit obstetric emergency Z177800 Inpatient care
8H2B.00 Admit ophthalmological emerg. T927 AA INPATIENT HOSPITAL
8H2K.00 Admit oral surgical emergency 13F8100 Long stay hospital inpatient
8H28.00 Admit orthopaedic emergency 13FS.00 Long stay hospital inpatient
8H2I.00 Admit plastic surgery emergenc T927 L LONG-STAY HOSPITAL
PATIENT
8H23.00 Admit psychiatric emergency T306 HA MEDICAL CERT FOR
HOSPITAL ADMISSION
8H2L.00 Admit psychogeriatric emergency 8H3V.00 Non-urgent cardiological
admission
8H2G.00 Admit radiotherapy emergency 8H3T.00 Non-urgent cardiothoracic
admission
8H2M.00 Admit renal medicine emergency 8H3I.00 Non-urgent dermatology admisn.
8H2C.00 Admit rheumatology emergency 8H3O.00 Non-urgent diabetic admission
8H22.00 Admit surgical emergency unsp. 8H3E.00 Non-urgent ENT admission
8H15.00 Admit to burns unit 8H39.00 Non-urgent geriatric admission
8H11.00 Admit to cardiac ITU 8H3B.00 Non-urgent gynaecol.admission
8H1..11 Admit to I.T.U. 8H3M.00 Non-urgent haematology admisn.
8H1Z.00 Admit to intensive c.u. NOS 8H31.00 Non-urgent hosp.admission unsp
8H1..00 Admit to intensive care unit 8H3..00 Non-urgent hospital admission
8H14.00 Admit to metabolic ITU 8H36.00 Non-urgent medical admission
8H13.00 Admit to neurological ITU 8H3J.00 Non-urgent neurology admission
8H12.00 Admit to respiratory ITU 8H3S.00 Non-urgent neurosurgical
admission
8H2A.00 Admit trauma emergency 8H3C.00 Non-urgent obstetric admission
8H2F.00 Admit urology emergency 8H3G.00 Non-urgent ophthalmolog.admisn
T927 MT ADMITTED MENTAL HOSPITAL 8H3U.00 Non-urgent oral Surg.admission
T9270AC COMPULSORY ADMISSION TO
HOSPITAL
8H3D.00 Non-urgent orthopaedic admisn.
8H3D.00 Non-urgent orthopaedic admisn. 8HJ..00 Self-referral to hospital
8H3N.00 Non-urgent plastic surg.admisn 8BAR.00 Specialist palliative care treatment
- inpatient
8H38.00 Non-urgent psychiatric admisn. 8HF..12 Transferred from hospital
8H3Q.00 Non-urgent psychogeriatric
admission
9N1B.00 Seen in hospital ward
8H3L.00 Non-urgent radiotherapy admisn 8H3Z.00 Other hospital admission NOS
8H3R.00 Non-urgent renal medicine admission 9144 Patient in hospital
8H3P.00 Non-urgent respiratory admission 8H3K.00 Non-urgent urology admission
8H3H.00 Non-urgent rheumatology admisn 8H3F.00 Non-urgent trauma admission
8H37.00 Non-urgent surgical admission
345
Appendix 13 – Stata® codes for propensity score matching
use "C:\Users\Sarah\Documents\PhD\Propensity score analysis -
baseline monitoring.dta", clear
**** Run psmatch2 based on pscore1009 ****
gen u = uniform()
sort u
psmatch2 anybaselinetesting6mos, pscore(pscore1009) caliper (0.001)
descending noreplacement common
gen casecontrolpscore1009 = 1 if _treated==1 & _weight==1
replace casecontrolpscore1009 = 0 if _treated==0 & _weight==1
tab casecontrolpscore1009
*** Create matching ID for conditional LR analysis ***
gen matchpscore1009 = _id if _treated==0 & _weight==1
replace matchpscore1009 = _n1 if _treated==1 & _weight==1
*** Assess balance on variables ***
pstest ageatevdate
pstest Diabetesstatuscorrected
pstest evyear2000
pstest evyear2001
pstest evyear2002
pstest evyear2003
pstest Smokingbinary
pstest gender
pstest SESscore
pstest BMI
pstest unitsweek
pstest SystolicBP
pstest DiastolicBP
pstest hypothyroidism
pstest PVD
pstest carbamazepinebaseline
pstest nsaidbaseline
pstest SSRIbaseline
pstest tricyclic
pstest trimethoprimbaseline
pstest aceibaseline
pstest alphabaseline
pstest at2baseline
pstest betabaseline
pstest cabaseline
pstest loopbaseline
pstest mixedbaseline
pstest thiazidebaseline
pstest gpvisits8plus
pstest rx1year10plus
pstest elecdisturb
*** compare 2 groups in matched cohort ***
ttest ageatevdate, by(casecontrolpscore1009)
tab gender casecontrolpscore1009, chi column
ttest SESscore, by(casecontrolpscore1009)
ttest BMI, by(casecontrolpscore1009)
ttest unitsweek , by(casecontrolpscore1009)
ttest SystolicBP, by(casecontrolpscore1009)
ttest DiastolicBP, by(casecontrolpscore1009)
tab Diabetesstatuscorrected casecontrolpscore1009, chi column
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tab Smokingbinary casecontrolpscore1009, chi column
tab hypothyroidism casecontrolpscore1009, chi column
tab PVD casecontrolpscore1009, chi column
tab aceibaseline casecontrolpscore1009, chi column
tab at2baseline casecontrolpscore1009, chi column
tab betabaseline casecontrolpscore1009, chi column
tab cabaseline casecontrolpscore1009, chi column
tab mixedbaseline casecontrolpscore1009, chi column
tab loopbaseline casecontrolpscore1009, chi column
tab thiazidebaseline casecontrolpscore1009, chi column
tab carbamazepinebaseline casecontrolpscore1009, chi column
tab nsaidbaseline casecontrolpscore1009, chi column
tab SSRIbaseline casecontrolpscore1009, chi column
tab tricyclic casecontrolpscore1009, chi column
tab trimethoprimbaseline casecontrolpscore1009, chi column
tab evyear2000 casecontrolpscore1009, chi column
tab evyear2001 casecontrolpscore1009, chi column
tab evyear2002 casecontrolpscore1009, chi column
tab evyear2003 casecontrolpscore1009, chi column
tab rx1year10plus casecontrolpscore1009, chi column
tab elecdisturb casecontrolpscore1009, chi column
tab gpvisits8plus casecontrolpscore1009, chi column
*** Q-Q plots ***
qqplot pscore1009base pscore1009nobase if pscore1009q==1
qqplot pscore1009base pscore1009nobase if pscore1009q==2
qqplot pscore1009base pscore1009nobase if pscore1009q==3
qqplot pscore1009base pscore1009nobase if pscore1009q==4
qqplot pscore1009base pscore1009nobase if pscore1009q==5
** Boxplot of quintiles ***
graph box pscore1009 if drugsonevdate==1,
//over(anybaselinetesting6mos) over(pscore1009q)
*** Draw kensity plots to demonstrate whether matching has been
successful ***
kdensity pscore1009 if anybaselinetesting6mos==1, addplot((kdensity
//pscore1009 if anybaselinetesting6mos==0))
kdensity pscore1009 if casecontrolpscore6==1, addplot((kdensity
//pscore1009 if casecontrolpscore6==0))
*** Run clogit with matchpscore1009 as a matching id ***
clogit HospAdmCode6mos anybaselinetesting6mos, group(matchpscore1009)
or
clogit AnyADRCode6mos anybaselinetesting6mos, group(matchpscore1009)
or
clogit DeathCode6mos anybaselinetesting6mos, group(matchpscore1009)
or
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